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“From a physician standpoint the Holy Grail of COPD disease 
modification is to halt, or at least slow down, the rate of decline of 
FEV1.  However, from a patient perspective the Holy Grail is simply 
to be able to breathe easier.”(1) 
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Abstract 
The broad aim of this thesis on ‘Health Economic aspects in the management of Chronic 
Obstructive Pulmonary Disease’ (COPD) was to study the natural history of the disease in 
order to inform the conceptualisation and development of a new economic model. 
Existing economic evaluations for COPD were critiqued and information on the natural 
history of the disease gathered though literature searches and analyses of two large datasets, 
a COPD randomised controlled trial called TORCH and a general population observational 
dataset called the Renfrew/Paisley (MIDSPAN) study.  Particular attention was paid to 
identifying the COPD population using different diagnostic criteria.  The elicitation of 
utility estimates under a number of circumstances was considered.  A regression based 
prediction model was conceptualised and developed. 
Significant contributions of this thesis include, but are not limited to:  a NICE COPD 
cohort were identified who were found to be at higher risk of all-cause and COPD mortality 
than a GOLD defined cohort; a mapping equation was successfully developed that predicts 
the EQ-5D from the SGRQ; and an entirely new concept for modelling COPD was 
developed that uses a series of regression equations to predict cost and effect based on lung 
function, symptoms and exacerbations and weighted by survival probability in order to 
generate a model with one arm representing current treatment and a second arm 
representing a comparator treatment. 
The thesis successfully combined information gathered throughout the period of research 
on the natural history of COPD with treatment effects in a novel way in order to 
conceptualise and develop a new economic model for COPD.  
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Chapter 1.  Introduction 
The broad aim of this thesis on Health Economic aspects in the management of chronic 
obstructive pulmonary disease (COPD) is to gain an in-depth understanding of the 
respiratory disease, COPD though literature searches and analyses of a number of datasets 
containing COPD patients, with the ultimate goal of using this information to inform the 
design and build of an economic model that represents the disease over time, so that the 
costs and effects of treatment on a defined COPD population can be assessed.   
COPD is a chronic condition with a high prevalence in the older population.  As the disease 
worsens over time, there is an increasing, detrimental impact upon health related quality of 
life and an increase in the cost burden to the health care provider.  Advice on the treatment 
and management of COPD has been available since the 1980s and has evolved over time.  
There are currently a number of published guidelines advising on best practice.  
The UK National Health Service (NHS) provides health care free at the point of delivery, 
based on clinical need, with a general aim of maximising population health, subject to the 
budget constraint for health care.  With the emergence of high cost pharmaceuticals for the 
treatment of COPD over recent years, it is important to know whether these treatments 
demonstrate value for money.  That is, do the benefits (or effectiveness) of the new 
treatment warrant the additional cost, compared to current treatment?  The National 
Institute for Health and Clinical Excellence (NICE) makes reimbursement decisions about 
treatments on behalf of the UK NHS based on all available and relevant evidence.  To date, 
no treatment for COPD has been analysed by NICE in terms of its cost effectiveness but 
new treatments for the disease are emerging and a formal appraisal is expected in the near 
future.  
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There are a number of published studies that demonstrate the cost effectiveness of current 
treatments for COPD, but there are inconsistencies between the methodologies employed 
and comparisons between studies are therefore difficult.  There is a need for a common 
approach, which can be used to assess different treatments on the same platform. 
Economic modelling of disease is a response to the need for making informed decisions 
about the cost effectiveness of treatment based on all the available and relevant evidence. 
Economic models are frequently developed based on existing models and structures, and 
tend to focus on the mechanism of action of the drug of interest, and in doing so important 
aspects of the natural history of the disease may be ignored.  In developing an 
understanding of the epidemiology of disease, in addition to the synthesis of results from 
literature searches, data from clinical trials and observational datasets are useful to explore.  
Clinical trials generally contain information on the effect of treatment over a short period of 
time and often contain detailed data relating to the health related quality of life of the 
diseased population and on costs arising to the health care provider.  Observational studies 
on the other hand can provide information on the natural history of disease over a longer 
period of time but in less detail than clinical trials, and may provide an opportunity for 
raising and answering questions on the natural history of the disease, such as how the 
disease progresses over time.   
Economic models represent a simplification of reality so that only key events or aspects, 
which impact upon health related quality of life and/or costs are captured.  For example, 
people with COPD tend to have the disease for a long duration of time, often running into 
several decades.  During that time, some events may occur which have a large detrimental 
effect on health related quality of life and/or may increase health care costs, such as 
exacerbations requiring hospitalisation.  It is important to represent such events within an 
economic model.  Some other events that occur during the person’s life may have little or 
   
 15 
no bearing on health related quality of life and/or health care costs and are therefore 
irrelevant for the purpose of economic modelling and should not be included.   
It is of interest to identify ‘who’ the COPD population are and within that, those at 
differential risk of disease related events, using data containing information on the natural 
history of COPD.  Published guidelines on COPD recommend different ways of diagnosing 
the disease with potentially large differences in prevalence and ultimately, the identification 
of ‘who’ the population in the model are.  Different populations are likely to lead to 
different cost effectiveness estimates.  Therefore in developing an economic model, a sound 
understanding of the disease is required.  Frequently economic models use specific groups 
of people that move through the model, such as those with mild, moderate and severe 
disease and have limited flexibility to incorporate further heterogeneity at the patient level.  
However some people are at higher risk of certain events than others.  For example, people 
with a history of heavy smoking are more likely to be at risk of mortality than non-smokers 
or those with a light smoking history and people with respiratory symptoms may have 
different outcomes than those without respiratory symptoms.  Age is also a consideration, 
for as people age they are more likely to die from any cause than younger counterparts and 
people who are older may be at increased risk of respiratory events such as exacerbations.  
Because of differences in risk between potential study populations, the cost effectiveness of 
treatment may differ by subgroup, and the ability of a model to identify subgroups in which 
treatment might be particularly cost effective would be a useful feature of a new economic 
model. 
The thesis is split into six main chapters: Chapters 2 to 7.  Chapter 2 provides background 
information on COPD, Chapter 3 introduces the subject of health economics and describes 
in detail key concepts of economic evaluation.  Within Chapter 4, a literature review on the 
economic evaluations published for COPD is described, with reference to key concepts 
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within economic evaluation.  Chapter 5 presents results of several analyses conducted on an 
observational longitudinal dataset, and Chapter 6 contains results from analyses using data 
from a COPD clinical trial.  Based on all the information gathered on the disease within the 
preceding chapters, in Chapter 7, an economic model for COPD is conceptualised and 
developed, incorporating further analyses on both the longitudinal and clinical trial data.  
The rest of this introductory chapter presents information on the specific chapters.   
The purpose of Chapter 2 is to provide background details on COPD and begins by 
introducing the disease and describing the associated health and financial burdens that 
arise, for: the patient; to the health care system; and to society at large.  The clinical 
management of the disease is discussed and the changing pattern of management and 
treatment for COPD and the associated costs to the NHS are detailed.  A section that 
describes the current and historical COPD diagnostic criteria and a review of how these 
criteria affect prevalence estimates is presented.   
Within Chapter 3, the need for economic analysis in health care is discussed before 
exploring the branch of health economics, economic evaluation, which is focussed 
specifically on the evaluation of different treatments and can be used to inform health care 
providers about the relative value of competing courses of treatment action.  In developing 
an economic evaluation, it is important to fully understand the disease under study, 
including: how the disease presents itself, how the disease changes over time and how 
treatment affects the disease.  The chapter on health economics presents information on the 
key elements required for the economic evaluation of any treatment or intervention and 
these key concepts are drawn upon throughout the thesis.  Topics explored include: a 
general overview of economic evaluation, the types of evaluation available, different 
structural models that can be used to develop an evaluation, costs and cost data, outcome 
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measures including utility and issues around uncertainty.  Specific interest is paid to 
outcome measures and in the measurement of utility. 
Chapter 4 contains a literature review of the published economic evaluations for COPD.  
The focus is on treatments where competing interventions exist for COPD patients and 
includes pharmacological and surgical treatment.  The review is split into two sections: the 
first section focuses on economic evaluations that have been conducted either alongside a 
clinical trial or an observational study and is structured around the key concepts of 
economic evaluation identified in Chapter 3: perspective, patient group, comparators, 
outcome measures, extrapolation, the results of the evaluations and the handling of 
uncertainty.  The second section examines in further detail those economic evaluations that 
develop an economic model and include, in addition to those key concepts mentioned 
above, a description of the model structure, design of the study, sources of input data and 
assumptions used within the model.   
In developing economic models for COPD, often researchers have searched the literature or 
consulted clinical experts for data on the natural history of disease, rather than directly 
exploring primary data sources.  The analyses within Chapter 5 are aimed at examining the 
natural history of COPD in a British population and makes use of the Renfrew/Paisley 
(MIDSPAN) dataset, a Scottish prospective cohort followed since the early 1970s, with 
ongoing linked hospitalisation and mortality records, with a view to using the information 
gathered to inform an economic model for the disease.  The analyses conducted on the 
dataset are split into four sections, each containing section specific methods, results and a 
summary or discussion.  Within the first section, summary statistics of the MIDSPAN 
dataset are presented, by COPD disease severity, including: mortality rates, survival curves 
and the major causes of mortality.  The second analysis replicates and updates a 1996 study 
conducted by Hole et al, who published a paper on the link between reduced lung function 
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and subsequent mortality.  The third analysis examines the diagnostic criteria for COPD 
and challenges the assumption that COPD is best diagnosed using lung function alone.  The 
effect of including a risk factor such as smoking history and respiratory symptoms in the 
diagnostic criteria for COPD is investigated.  The final analysis investigates the number of 
hospital admissions and length of stay in hospital, before determining hospitalisation rate 
by disease severity for the Renfrew/Paisley population. 
Within economic evaluations of health technologies, decision makers use quality adjusted 
life years (QALYs) in order to compare treatments in different disease areas on the same 
scale.  Because of the importance of utility and ultimately the QALY as an outcome 
measure, analyses within Chapter 6 are focused on utilities and on deriving values for the 
QALY from a large, multinational, multi-site randomised controlled trial called the 
Towards a Revolution in COPD Health (TORCH) trial.  Summary utility values are derived 
from the TORCH trial by disease severity and QALYs by treatment group are calculated.  
Multivariate regression models are developed to predict utility scores and to predict 
QALYs.  The final section of the chapter develops a mapping equation, which generates 
EQ-5D utility scores, for use when a utility-based measure is not collected within a clinical 
trial, and from which QALYs can be estimated. 
Economic models combine information on the natural history of a disease, specifically 
relating to components that quantify the major drivers of cost and effect within the disease, 
with the effect of treatment, so that decision makers can make reimbursement decisions 
based on all the available and relevant information.  Chapter 7 presents the development 
and results of a new concept in economic modelling for COPD.   In the first section of the 
chapter, a conceptual framework for an economic model of COPD is developed in which 
key components affecting cost and effect for COPD patients are considered.  The rationale 
for selecting the chosen economic structure, a regression based model, is explained.  The 
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second section presents details relating to the development of regression equations that are 
used to construct the economic model for COPD; equations predicting individually: lung 
function, exacerbations, symptoms, EQ-5D utility, cost and survival.  The development of 
each regression equation was considered with attention given to the dataset within which 
the equations were developed, choice of explanatory variables and the type of regression 
analysis used.  When combined, these regression equations form an economic model that 
represents current treatment.  The final section of Chapter 7 considers different treatment 
effects and gives a worked example of a treatment effect applied to the model in order to 
develop the comparator arm and to generate cost effectiveness values. 
The overriding purpose of this thesis is to aid better decision-making, by developing a 
generic disease model that can be used to appraise COPD therapies on the same platform.  
The model is built from the bottom up, based by an understanding of the epidemiology of 
the disease as a result of analyses conducted on a wealth of data.  The methods and 
principles used in this thesis are generalisable to modelling other disease areas.    
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Chapter 2. COPD  
The purpose of this chapter is to provide background details on chronic obstructive 
pulmonary disease (COPD) and begins by introducing COPD and the associated health and 
financial burdens that arise as a result of the disease, for the patient, to the health care 
system and to society at large.  Treatment for the disease is discussed and the changing 
pattern of treatment and associated costs to the National Health Service (NHS) are detailed 
and is followed by an overview of the clinical management of the disease and how this has 
changed over time.  A section that describes the current and historical COPD diagnostic 
criteria and a review of how these criteria affect prevalence estimates is presented.   
2.1 The disease 
COPD is a lung disease that principally affects older people with a history of smoking.  
People with COPD initially complain of breathlessness and may also have cough and 
increased sputum production, which tend to worsen over time.   
COPD is defined by the Global initiative for chronic Obstructive Lung Disease (GOLD) as: 
“…a preventable and treatable disease…characterised by airflow limitation that 
is not fully reversible.  The airflow limitation is usually progressive and 
associated with an abnormal inflammatory response of the lung to noxious 
particles or gases.”(2) 
COPD is an umbrella term that covers both parenchymal destruction (emphysema) and 
small airways disease (obstructive bronchiolitis).  Small airways disease is caused by 
structural changes following inflammation which cause the thickening of the bronchial 
walls and the narrowing of the airways and results in irreversible airflow obstruction.  
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Small airway diseases include bronchiectasis and bronchiolitis obliterans.  As the damage 
to the airways increases, the patient is likely to suffer from breathlessness and because the 
body is more susceptible to infection, phlegm and cough may be produced in response.  
Parenchymal destruction or emphysema refers to the permanent enlargement of the alveoli 
to inflammation.  The walls of the alveoli are stretched beyond repair, leading the alveoli to 
merge into larger sacs, reducing the surface area for gas exchange and to airflow limitation. 
Lung function is a key indictor of disease and disease severity.  Lung function naturally 
decreases over time with age and the decline has been found to occur faster in smokers than 
non smokers.(3)  Lung function is measured using spirometry and is frequently used to 
derive values of forced vital capacity (FVC) and forced expiratory volume in one second 
(FEV1).  From this, the ratio of FEV1 to FVC (FEV1/FVC) is calculated.  Most guidelines 
for COPD agree that COPD is present in patients where FEV1/FVC < 0.7,(2;4-7) (discussed 
in detail in section 2.4.3).   
FEV1 prediction equations based on age and sex and developed within a healthy population 
are used to predict FEV1 values for each patient (details of developing a prediction equation 
are described in Chapter 5, section 5.2.2).  The observed FEV1 value is divided by the 
predicted FEV1 value to give a lung function value called FEV1 % predicted which gives a 
relative lung function score compared to a healthy person of the same age and sex.  FEV1 
% predicted is employed in order to determine COPD disease severity.   
Within guidelines for diagnosing COPD, disease severity is categorised based on lung 
function.  Different guidelines categorise disease severity in different ways.  For instance, 
as illustrated in table 2.1, disease severity in the GOLD guidelines is categorised in terms of 
mild, moderate, severe and very severe according to the degree of respiratory 
impairment.(2)  COPD is diagnosed based solely on a lung function FEV1/FVC score <0.7 
plus FEV180% predicted for mild, 50%FEV1<80% predicted for moderate, 
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30%FEV1<50% predicted for severe and FEV1<30% predicted or FEV1<50% predicted 
plus chronic respiratory failure for very severe disease.  This is in contrast to the National 
Institute for Health and Clinical Excellence (NICE) diagnostic criteria where COPD is 
based on FEV1/FVC<0.7 plus evidence of a risk factor (principally smoking), and 
symptoms such as breathlessness, cough, regular sputum,(8) and where disease severity is 
based on FEV1 % predicted score which can be either: mild (50%FEV1<80% predicted), 
moderate (30%FEV1<50% predicted) or severe (FEV1<30% predicted).  The comparison 
is made between the GOLD and the NICE criteria as the GOLD criteria are frequently used 
in many types of study, in observational datasets and in clinical trials, and as this thesis is 
primarily focussed in the United Kingdom (UK), the NICE guidelines for COPD represent 
current thinking on the disease within the UK.  Details of these and other diagnostic criteria 
for COPD are presented towards the end of this chapter in section 2.4.3. 
Table 2.1 Diagnostic criteria for COPD according to the GOLD and NICE guidelines.(2;7)  
GOLD Mild Moderate Severe Very severe 
 FEV1/FVC<0.7 
FEV180%  
FEV1/FVC<0.7 
50%FEV1<80%  
FEV1/FVC<0.7 
30%FEV1<50%  
FEV1/FVC<0.7 
FEV1<30% or  
FEV1<50% + chronic 
respiratory failure 
NICE  Mild Moderate Severe 
  Risk factor 
Resp symptoms 
FEV1/FVC<0.7 
50%FEV1<80%  
Risk factor 
Resp symptoms 
FEV1/FVC<0.7 
30%FEV1<50%  
Risk factor 
Resp symptoms 
FEV1/FVC<0.7 
FEV1<30%  
FVC= Forced Vital Capacity.  FEV1= Forced Expiratory Volume in one second  
 
Exposure to cigarette smoke is the most common risk factor for COPD, however other risk 
factors do exist, including occupational dusts and chemicals, and indoor air pollution as a 
result of cooking/heating using biomass fuels in homes with poor ventilation (particularly 
problematic for women in developing countries).(2) 
Exacerbations are a characteristic of the disease, particularly in more severe COPD 
patients.(9)  Exacerbations have been said to occur when there is a worsening of respiratory 
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symptoms requiring treatment with oral corticosteroids and/or antibiotics.(10)  Severe 
exacerbations occur where worsening of symptoms requires that the subject is hospitalised.  
Reductions in quality of life occur as a direct result of exacerbations.  Recovery periods can 
be protracted and during this period, Health Related Quality of Life (HRQoL) will be less 
than normal.  The duration of recovery periods can vary substantially between individuals. 
COPD and asthma often present with similar symptoms making differentiation potentially 
difficult, however there are differences and these are described in table 2.2.  For example 
symptoms are rare in the under 35’s for COPD but are common in asthma patients.  The 
use of spirometry can aid differentiation between the two conditions.  Administration of a 
short-acting bronchodilator prior to spirometry should cause reversibility for asthma 
sufferers whereas for COPD sufferers, the airflow obstruction is largely irreversible.  
Table 2.2 Clinical features differentiating COPD and asthma, reproduced from the NICE 
guidelines.(7) 
 COPD Asthma 
Smoker or ex-smoker Nearly all  Possibly 
Symptoms under age 35 Rare Common 
Chronic productive cough Common Uncommon 
Breathlessness Persistent and 
progressive 
Variable 
Night time waking with breathlessness and/or 
wheeze 
Uncommon Common 
Significant diurnal or day to day variability of 
symptoms 
Uncommon Common 
 
2.2 Burden of COPD 
COPD is a major cause of morbidity and mortality worldwide and is the only major cause 
of morbidity that is increasing.  A substantial increase in the global burden of COPD is 
expected for the future.  The health burden of COPD including: mortality, morbidity, the 
effects of age, gender and smoking, together with the financial burden of the disease, with 
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particular emphasis on the key drivers of cost: disease severity, exacerbation frequency and 
severity, are outlined in this section.  
2.2.1 Health Burden  
Current estimates of COPD prevalence in the general population of Europe are large and 
variable at between 4 and 10%.(11)  The difference in prevalence estimates is attributable 
to the population under study and the different diagnostic criteria used in epidemiological 
studies; this issue is covered in section 2.4.3 and in detail in 5.6 within Chapter 5.  The 
population of diagnosed COPD cases within primary and secondary care is much lower and 
is approximately 1% in the UK,(12) and evidence suggest that COPD is heavily under 
diagnosed worldwide.(12-14)  It is likely that a substantial number of people are unaware 
of having COPD (especially so in mild to moderate stages) and who, rather than seek help, 
may attribute problems such as breathlessness and fatigue to old age rather than on any 
underlying cause.  Figure 2.1 shows the reported breakdown, by disease severity, of a 
known COPD population (Mediplus UK, see section 5.1 for details of this dataset).(15)  
17% of the population had mild COPD compared to 48% with moderate and 27% with 
severe disease.  The true breakdown of COPD within the general population is likely to be 
different from this pattern because it is assumed that the majority of COPD patients are in 
the mild group.  These data support the viewpoint that COPD is under diagnosed 
worldwide,(12-14;16) particularly among mild cases of COPD. 
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Figure 2.1 Proportion of COPD patients, by disease severity 
 
COPD causes an accelerated depreciation of lung function over time compared to the 
average or predicted level for a healthy person, and is further accentuated by smoking.(3)  
Calverley et al suggest that around 20% of smokers are susceptible to some form of 
progressive lung disease,(12) but it may be larger than this: a different study reports that the 
absolute risk of developing COPD in smokers is at least 25%.(17)  In China where COPD 
represents a major public health problem, smoking rates are very high: it was estimated that 
67 % of the men in China smoke (approximately 300 million).(18)  Approximately 15% of 
people in China who have ever smoked and 5% of people who have never smokers, are 
thought to have COPD.(14)  
Smoking cessation has been shown to effectively slow the deterioration in FEV1 and return 
the trajectory of lung function to one consistent with that of a non smoker.(3)  The Lung 
Health study, at five years, found significantly lower all-cause mortality rates in a ‘special 
intervention’ group where smoking cessation was actively encouraged, compared to the 
non intervention group.(19)  
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Worldwide Burden of COPD 
The World Health Organisation found global COPD deaths to be the fifth largest cause of 
death, accounting for 4.5% of deaths worldwide.(20)  The proportion of deaths attributable 
to COPD varies between regions of the world.  Of particular concern is the Western Pacific 
region (including China, Malaysia, the Philippines and Vietnam) where COPD accounts for 
13.8% of all deaths and where COPD is ranked as the second leading cause of death, as 
shown in table 2.3 in the final row.  
Table 2.3 Worldwide mortality burden of COPD 
WHO region % of deaths 
from COPD 
Relative ranking 
of COPD mortality 
African   1.1 15 
Americas 3.5 6 
Eastern Mediterranean 1.4 15 
European 2.8 5 
South East Asia 2.2 9 
Western Pacific 13.8 2 
% Percentage of total deaths attributable to COPD in each region.  Rank for COPD deaths within region, compared 
to all other diseases/illnesses    
 
Data from Europe suggest a lesser impact of the disease than in other regions; nevertheless, 
COPD was found to account for 2.8% (table 2.3, row 4) of all deaths and was ranked as the 
fifth cause of death within this region. 
COPD prevalence increases with age and is generally a disease that occurs in an older 
population.  Data from both the US and the UK show that the prevalence of COPD is 
comparatively small among the under 45’s but increases markedly throughout later 
years.(21)  In the UK, about 1% of the general population is diagnosed with COPD 
increasing with age to around 5% of men between 65 and 74 and rising to 10% in men aged 
75 years and over.(12)  
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Gender specific mortality for COPD seems to be country specific.  In Canada and in 
Northern Europe, there is little difference between death rates by gender.(11)  In other 
countries there are notable differences.  Many more men than women die of COPD in 
Eastern and Southern European countries.(14)  Mortality rates for Europe as a whole 
suggest that two to three times as many men die from COPD as women.(11)  In Singapore, 
female hospitalisation and mortality from COPD is significantly less than for male 
counterparts.(14)  These differences are most probably attributable to historical reasons 
where smoking rates amongst men have been higher than for women.  In recent years and 
in some countries, women now smoke as much as their male counterparts.  Where smoking 
prevalence rates are equal, and have been for some time, similar mortality rates for COPD 
are expected.  In countries where smoking rates have increased, the burden of COPD is 
expected to increase in the future.    
2.2.2 Financial Burden  
Within the UK, chronic conditions such as COPD place a major burden upon the NHS.  
Approximately 80% of all General Practitioner (GP) consultations are related to chronic 
disease, 60% of all hospital bed days are used by patients with chronic disease and two 
thirds of medical emergencies are either a result of an exacerbation of a chronic disease, or 
by the disease itself.(22)  Total costs to the NHS for COPD have been estimated 
somewhere between around £486 million (23;24) and £848 million (25;26) per year.  The 
major drivers of COPD burden are disease severity and exacerbations. 
Disease Severity 
Costs increase substantially as disease severity (measured by FEV1% predicted) moves 
from moderate to severe (with a smaller increase between mild and moderate 
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groups).(24;27-32)  Britton et al estimated that the direct cost for the three groups was €232 
(£209) for mild disease, €477 (£430) for moderate and €2026 (£1826) for severe 
disease.(24)  Total cost doubled with the inclusion of productivity costs, which was defined 
in the study as time lost from work for those under retirement age (see section on 
productivity costs below for more on this type of cost).  Productivity cost was found to be 
€399 (£331) for mild, €202 (£168) for moderate and €2331 (£1934) for severe disease.(24)  
As FEV1 deteriorates, a general shift from outpatient care to hospitalisation, an increase in 
the use of oxygen therapy and a subsequent increase in total costs, especially in the most 
advanced stages of the disease has been shown to occur.(33)  
Exacerbations 
Exacerbations are the leading driver of cost in COPD.  A serious exacerbation leads to 
hospitalisation; indeed an exacerbation is the main reason why a COPD patient would 
attend hospital.  COPD is responsible for approximately 1 million hospital bed days per 
year.(34)  Mean  unit cost was £1109 for a length of stay of four days for an admission with 
no complications and £1516 for a six day stay with complications,(35) or a total cost of 
approximately £142 million for non-elective inpatient COPD hospital admissions alone.  
The cost of exacerbations has been found to increase in line with the severity of the 
exacerbation; a Swedish study reports: SEK 120 (£11) for mild, SEK 354 (£31) for 
mild/moderate, SEK 2111 (£185) moderate and SEK 21 852 (£1919) for severe 
exacerbations.  Exacerbations account for between 35-40% of the total per capita health 
care costs for COPD.(36)   
In the UK, the cost arising from acute exacerbations has been estimated to be £45 million at 
1994 prices for a COPD population of 233 000.(37)  Treatment which acts to reduce or 
prevent disease progression and or an exacerbation (particularly severe exacerbations) will 
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have a direct effect on the total cost for COPD.(38)  In England and Wales, McGuire 
calculated that for every exacerbation related hospital admission avoided a total saving of 
approximately £1200 would be made.(37) 
Productivity Costs 
Productivity costs represent lost output/productivity within the economy due to ill health 
and mortality.(39)  Productivity costs for COPD represent a burden on society as COPD is 
a cause of absenteeism from work.(24;40) People with COPD have a ‘substantially 
shortened’ work life compared to the population average.(41)  Between 1994 and 1995 it 
was estimated that 24 million lost work days were attributable to COPD within the UK 
alone.(42)  Within the 15 ‘original’ EU member states, COPD was estimated to account for 
41 300 lost work days per 100 000 people and productivity losses of around €28.5 (£25.7) 
billion per year.  In Central and Eastern Europe, the number of lost work days was found to 
be 10% of this value; with a rate of 4300 per 100 000 people.(11) 
In one UK study, 44% of COPD patients were below retirement age and because of the 
disease, 24% were completely prevented from working and 5% of patients’ carers missed 
work. (24)  Around 12 days were missed from work, per patient per year.  Productivity 
costs were found to be almost equivalent in size to direct costs, imposing an additional 
£820 per patient per year upon the economy.(24)  Whilst productivity costs can represent a 
considerable burden on both the individual and on society, their use in economic evaluation 
is an area of debate and will be discussed in detail in Chapter 3. 
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Treatment and Management Costs 
In 2002, Britton et al estimated mean drug costs for COPD to be £152.84 per person per 
year.(24)  Costs, especially drug costs, have increased significantly since then because of 
the change in the mix of prescribing and is shown in detail in section 2.3.1.  
The cost impact arising from the change in the management of COPD (see section 2.4 for 
details on this change) is much harder to quantify, though it is anticipated that costs have 
increased: greater awareness of COPD, routine spirometry, the Hospital at Home guidelines 
(which are explained in section 2.4.2) and the other more general trends seen within COPD 
all demand additional resources.  The British Lung Foundation (BLF) has met some costs 
pertaining to the “Hospital at Home” guidelines (Malcolm Shepherd, personal 
communication), however, extra nurses and respiratory specialists, numerous equipment 
costs, including nebulisers and improved prescribing of domiciliary oxygen therapy are 
required nationwide and this implies additional costs.  No references were found that report 
the change in management costs for the UK over recent years. 
2.3 Treatment of COPD 
The aim of treatment for COPD, in the absence of a disease cure, is to prevent and control 
symptoms, reduce the frequency and severity of exacerbations, improve health status and 
improve exercise tolerance.(2)  COPD, by definition, is a chronic condition, lasting over the 
course of a patient’s life.  There is no cure, patients symptoms may be managed in order to 
maximise quality of life, subject to resource limitations.   
Treatment is dependent upon disease severity as previously described and disease 
management is additive.  As the disease progresses through the stages, more treatments are 
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added, for example, in the European market in 2006 on average, mild patients (GOLD 
classified) were prescribed 1.4 products, moderate 1.8, severe 2.6 and very severe patients, 
3 products.(43)  Because COPD is a progressive disease, treatment must be continued 
throughout the lifetime of the patient.(38) 
Table 2.4 Pharmacological classes and drugs used for treating COPD 
Drug class Generic name (commercial) 
Inhaled Corticosteroids (ICS): Beclomethasone 
 Budesonide 
 Triamcinolene 
 Fluticasone 
Short acting Bronchodilators:  
Short acting 2 agonist (SABA) Salbutamol (Albuterol) 
 Terbutaline 
Short acting anticholinergic (AC) Ipratropium 
Long acting bronchodilators:  
Long acting 2 agonist (LABA) Formoterol 
 Salmeterol 
Long acting anticholinergic  Tiotropium (Spiriva) 
Combination products:  
 SABA + AC Salbutamol/Ipratropium  
 LABA +ICS Formoterol/Budesonide (Symbicort) 
 Salmeterol/Fluticasone (Seretide) 
Methylxanthines:  
 Theophylline 
 
As seen in table 2.4, there are five broad classes of drug treatments for COPD: inhaled 
corticosteroids (ICS), short acting bronchodilators, long acting bronchodilators, 
combination products (where two different substances have been combined in the same 
device) and methylxanthines.  Table 2.4 above contains the major pharmacological 
treatment options available for COPD and provides the generic names of commonly used 
therapies for COPD within each class, together with some of the commercial names (in 
brackets) of new entrants.   
Current treatment guidelines for the treatment of COPD as suggested by GOLD are 
outlined in table 2.5 and are similar to those proposed by NICE.(7)  Both guidelines 
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approve of the use of smoking cessation programmes, rehabilitation and the administration 
of the influenza and pneumococcal vaccinations from early stages of the disease.  
Table 2.5 Treatment guidelines for COPD, adapted from GOLD.(2) 
 Mild Moderate Severe Very severe 
Lung 
function 
criteria 
FEV1/FVC<0.7 
FEV180% 
predicted 
FEV1/FVC<0.7 
50%FEV1<80% 
predicted 
FEV1/FVC<0.7 
30%FEV1<50% 
predicted 
FEV1/FVC<0.7 
FEV1<30% predicted or  
FEV1<50% + chronic 
respiratory failure 
Treatment Influenza vaccination 
Short acting bronchodilator added when necessary: 
1) Short acting 2 agonists: fenoterol, salbutamol, terbutaline. 2) Short acting 
anticholinergic: ipratropium 
  Add rehabilitation 
Add regular treatment with one or more long acting 
bronchodilators if needed: 
1) Long acting 2 agonists: formoterol, salmeterol. 2) Long 
acting anticholinergic: tiotropium 
   Add inhaled corticosteroids if exacerbations 
are repeated: fluticasone, beclomethasone, 
triamcinolone, Budesonide 
    Add long term oxygen if 
chronic respiratory 
failure. Consider 
surgical treatments: lung 
volume reduction 
surgery, lung 
transplantation, 
bullectomy. 
FVC= Forced Vital Capacity.  FEV1= Forced Expiratory Volume in one second 
 
Smoking cessation is important in stemming the progression of COPD because quitting 
smoking has been shown to return subsequent decline in lung function to a normal rate, 
consistent with that of a non-smoker.(3)   
“Smoking cessation is the single most cost effective way to reduce exposure to 
COPD risk factors.”(2) 
Interventions to assist individuals in quitting smoking include: counselling, nicotine 
replacement products (gum, patches, spray, lozenges) and drug therapies: bupropion, 
nortriptyline and varenicline.  Smoking cessation programmes are widely available in both 
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primary and secondary care settings and in some cases, through the pharmacy as well as via 
telephone and online support. 
Rehabilitation is a multifaceted approach which incorporates a wide range of programs to 
improve quality of life and functional independence and to reduce symptoms and disability 
for the patient.  Areas within the rehabilitation program can include exercise and physical 
training, psychological, social interactions, education around the disease, and about 
nutrition.(44)  Rehabilitation usually occurs within secondary care. 
NICE is less explicit about when treatments should be added in terms of stage of disease 
severity: nonetheless both guidelines suggest the initial use of short-acting bronchodilators 
for patients and then inhaled treatment should be intensified by adding a long-acting 
bronchodilator or combined therapy with a short-acting beta2 (2)-agonist and a short-
acting anticholinergic, in patients who remain symptomatic, as seen in table 2.5. 
With regards to the use of inhaled corticosteroids, the GOLD guidelines recommend usage 
in patients with an FEV1  50% predicted, or severe and very severe patients as illustrated 
in table 2.5, where exacerbations are repeated.  NICE recommends combination therapies if 
the patient remains symptomatic on monotherapy.   
Both guidelines suggest the patient be assessed for oxygen therapy when FEV1 is less than 
30 % predicted and it is used to increase the partial pressure of oxygen in the arterial blood 
(PaO2) with a view to: relieve dyspnea, aid oxygen intake during exercise and for long 
term, continuous treatment.(2)  Portable oxygen therapy is available to enable greater 
mobility of the advanced COPD patient.  Oxygen therapy forms a high proportion of 
outpatient costs for COPD patients.(45)  
   
 34 
Lung surgery can be considered in some patients with advanced stages of the disease.  
There are three types of surgery: lung volume reduction surgery (LVRS), lung 
transplantation and bullectomy.  LVRS involves cutting away around 30% of the diseased 
lung tissue in order to increase the effectiveness and efficiency of the remaining lung and 
surrounding muscle.  With lung transplantation either a single or both lungs are replaced.  
Bullectomy may be an option when a large air filled bulla exists that fills half of the 
thoracic volume and compresses the relatively normal adjacent parenchyma.(46)  Surgery 
for COPD patients is rare and is very expensive with variable outcomes.  Suitable 
candidates must satisfy strict criteria,(2) to ensure that only patients likely to benefit and 
least likely to have associated complications, are selected.  For example, to be eligible for a 
bullectomy under the NICE guidelines, patients must have a lung function of FEV1 30–49% 
predicted, have breathlessness as a symptom and have a single large bulla on a CT scan. 
A substantial part of the treatment and management for COPD occurs in the primary care 
setting; including diagnosis, prescription of appropriate pharmacotherapy, vaccination, 
smoking cessation programmes and repeat prescription oxygen therapy. 
As the severity of the patient’s COPD intensifies, there is an increased probability that the 
patient will be admitted to secondary care, primarily due to exacerbations.  Other reasons 
why the patient would be admitted into hospital include surgery for COPD, rehabilitation, 
the prescription of oxygen therapy and any other co-morbid conditions that require 
hospitalisation.  Patients may also be sent to hospital to confirm a diagnosis or to be tested 
for COPD, though increasingly first diagnosis is shifting away from secondary care into the 
primary care setting. 
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2.3.1 The Changing Face of Treatment for COPD 
Since 2000 there has been an emergence of new treatments for COPD including long-acting 
bronchodilator drugs, respiratory rehabilitation services, and non-invasive ventilation in 
respiratory failure.  Two combination products (combining a long acting 2 agonist and an 
inhaled corticosteroid) entered the market; the first in 2000 was Seretide, and the second, in 
2001 was Symbicort.  A third product, tiotropium (Spiriva), a long acting anticholinergic, 
entered the market in 2002.  Clinical trials providing evidence on these new products are 
briefly described below, in order to provide information on the trials supporting these new 
treatments, the size of the patient population and the outcome measures used within the 
trial. 
The TORCH (Towards a Revolution in COPD Health) (GlaxoSmithKline (GSK)) trial was 
published in early 2007, and followed a cohort of over 6000 patients for 3 years.  The study 
compared the product Seretide with its component products, fluticasone and salmeterol and 
with placebo.  The primary outcome measure was mortality.  Other outcome measures 
included the St George’s Respiratory Questionnaire (SGRQ),(47) and the EuroQoL-
5D,(48) rate of exacerbations and post bronchodilator FEV1.(49)  
TRISTAN was a multi-centre, multi-national randomised controlled trial (RCT) of 1974 
COPD patients followed for 12 months (GSK).  The study was designed to compare the 
efficacy of salmeterol/fluticasone with salmeterol alone, fluticasone alone and placebo with 
primary endpoints including pre bronchodilator FEV1, rate of exacerbations, and the 
SGRQ.(50)  
UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) was a 
four year study of 6000 COPD patients, published in 2008, comparing tiotropium to 
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placebo (Boehringer Ingelheim).  Outcome measures included lung function: FEV1, FVC, 
and slow vital capacity (SVC), health status as measured by the SGRQ and rate of 
exacerbations.(51) 
The tiotropium trials were two one-year trials that were run simultaneously in different 
countries to evaluate the efficacy and safety of tiotropium compared to ipratropium 
(Boehringer Ingelheim) in COPD patients.  Outcome measures included: FEV1, dyspnea 
using the transition dyspnea index (TDI) and the baseline dyspnea index (BDI).  HRQoL 
was assessed using both the SGRQ and the short form 36 (SF-36).  COPD exacerbations 
were also monitored.(52) 
INSPIRE (53) followed 1270 patients from 20 countries who were randomised to either 
salmeterol/ fluticasone or to tiotropium over 104 weeks (GSK).  The primary outcome was 
rate of exacerbations and secondary outcomes included post dose FEV1, SGRQ, and all-
cause mortality. 
The OPTIMAL trial was a 52 week Canadian trial developed and implemented by the 
Canadian Thoracic Society Clinical Trials group (an academic group) in a sample 
population of 432 COPD patients, randomised to one of three treatments:  tiotropium plus 
placebo, tiotropium plus salmeterol or tiotropium plus Seretide.  The trial was designed to 
answer a question about which combination of products is the best for treating COPD 
patients.  The primary outcome measure was the proportion of patients in each arm 
experiencing an exacerbation, secondary endpoints included the SGRQ, changes in dyspnea 
as measured by the BDI, the TDI and the dyspnea domain of the chronic respiratory disease 
questionnaire (CRQ), number of exacerbations and hospitalisations, time to first 
exacerbation, FEV1 and FVC.(54) 
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The recent trials in COPD formed a considerable evidence base which supported the 
introduction of Seretide, Symbicort and tiotropium onto the market.  Of all the trials, 
TORCH contained the most participants at over 6000 people, over the longest duration of 
follow up.  All of the trials included measures of lung function, exacerbations and HRQoL.  
Economic evaluations from the literature which use the results from these trials are 
presented in Chapter 4.   
Since 2000, on the basis of the trial results, Seretide, Symbicort and Spiriva have entered 
the market.  The entrance of each product is clearly illustrate in figure 2.2 where the % of 
COPD patients taking the medication increased from 0 over time as the new products 
caused a change in prescribing, away from the more established treatments and towards the 
newer treatments.   
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Figure 2.2 Therapy class shares (%) of the total market over time 
Europe COPD market 2000-2006.(43) 
 
Seretide, Symbicort and Spiriva were successfully adopted within the European market and 
by the second quarter of 2006, therapy class shares of the total patient market were 30% for 
Seretide, 29% for Tiotropium and 19% for Symbicort as seen on the right hand side of the 
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graph in figure 2.2.  In response, as illustrated in figure 2.2, there was a gradual decline in 
the separate prescribing of ICS, LABAs and ACs (43) from approximately 43%, 30% and 
18% down to 16%, 16% and 6% respectively and a fall in the use of ICS and LABA used 
together (but not in a combination product) from 20% to 8%.(43)  Clinical trials assessing 
the efficacy and effectiveness of triple combination products are emerging,(55-57) and if 
found to be successful, further changes to the COPD market for treatments are expected in 
the future.  
A clinical expert estimated the mix of treatments that would generally be prescribed to a 
moderate/severe patient in the year 2002 and then again for (March) 2009 (Malcolm 
Shepherd, personal communication).  Using the British national formulary (BNF53),(58) 
the cost of each drug was determined (in 2009 prices) and is presented in table 2.6.  Costs 
for these drugs are not assumed to have changed significantly over the period.  In the 2009 
prescription, it was assumed that a moderate/severe patient would be prescribed an inhaled 
corticosteroid, a 2 agonist, an anticholinergic and additionally, tiotropium. 
Table 2.6 The changing treatment mix and corresponding cost increase of COPD drug 
prescriptions: 2002-2009 
 Prescription  N doses      
pe day  
Unit 
cost 
30 day 
cost 
2002     
Beclomethasone 100mcg 100 dose 4 £5.58 £6.70 
Ipratropium 20mcg 200 dose 8 £4.21 £5.05 
Salbutamol 100mcg 200 dose 8 £2.88 £3.46 
 Total 30 day cost £15.21 
2009 
Seretide 250 120 dose 4 62.29 62.29 
Tiotropium inhaler 18mcg 30 dose 1 37.62 37.62 
Salbutamol 100mcg 200 dose 8 £2.88 £3.46 
 Total 30 day cost £103.37  
 
Between 2002 and 2009, table 2.6 shows that there were significant increases associated 
with the cost of prescriptions for COPD due to the availability of newer and more 
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expensive treatments.  The yearly prescription cost for moderate to severe patients, based 
on the assumptions used was £182.52 in 2002 compared to £1240.44 in 2009.  That is, in 
2009 prices, treatment costs are estimated to be almost seven times that of in 2002.  Future 
treatment costs are expected to increase further still, if and when, triple therapy 
combination products are launched. 
2.4 Management of COPD 
Since the late 1980s, there has been a significant shift in the awareness and management of 
COPD.  Prior to this period, COPD was largely ignored because of the widely held opinion 
that little could be done to treat COPD patients.(7)  This section describes recent changes to 
the management of COPD. 
 “Good chronic disease management offers real opportunities for improvements 
in patient care and service quality, and reductions in costs…and enabling 
people living with chronic conditions to attain the best possible quality of 
life.”(59) 
2.4.1 Routine Spirometry 
Since 2003 there has been a move towards routine collection of spirometry data by GP’s 
from those patients deemed ‘at risk’ of developing COPD.  Within the general medical 
services contract (GMSC), clinical practices are rewarded payments for having records of 
COPD patients, an initial diagnosis of COPD (where diagnosis is confirmed by spirometry) 
and ongoing management of COPD.(60)  
Little research has been published on the uptake of spirometry in routine practice. The 
earliest paper (published in 1999), a study around the uptake of spirometry in North 
Staffordshire, reported that while 21% of the general practices surveyed (88% response 
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rate) owned a spirometer, 12% were using it and two users out of 84 practices had received 
specific training in the use of spirometry.(61)  Another study surveyed general practices in 
Leicestershire between January to March 2002 and found that very few practices within the 
area had sufficient resources to provide high quality care for COPD (65% response rate).  
54% of those surveyed owned one or more spirometer(s) and 15% had one or more people 
with current training in spirometry.(62)  A study using a similar survey, sent three years 
later (February 2005), after the introduction of the GMSC, to general practices within 
Grampian, Scotland revealed widespread use of spirometry (89% response rate): 93% of 
the practices had at least one spirometer and at least one person was trained in the use of 
spirometry in 92% of the responding practices.(63)  As yet evidence is lacking as to 
whether the extensive use of spirometry as found in Grampian is a widespread trend across 
the country, emerging from the introduction of incentives offered by the GMSC, or whether 
it is location specific.  However, expert opinion (Malcolm Shepherd, personal 
communication) supports the initial evidence that the pattern of first diagnosis of COPD is 
shifting away from secondary care and into primary care.  
Concerns have been raised about the validity of spirometry results in general practice due to 
insufficient training and knowledge around the use and administration of spirometry.(61-
65)  The British Thoracic Society has issued a practical guide to encourage the use of 
spirometry amongst doctors and nurses in order to try and address this problem.(66) 
2.4.2 Early Discharge  
Guidelines from the British Thoracic Society (2007) recommend support of patients once 
they return home by way of the ‘Hospital at Home’ strategy.  This is a process whereby 
treatment is delivered by specialist respiratory professionals (including nurses, occupational 
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therapists and physiotherapists) who visit the patient at home and treat the patient over a 
finite period, known as early supported discharge.(67) 
Evidence from one study suggests that patients with uncomplicated acute exacerbations of 
COPD may be discharged earlier than is current practice provided that they are visited by a 
respiratory specialist.(68)  The study found that hospital stay was reduced by almost a half, 
from 6.1 to 3.2 days, and found no associated increases in either re-admission or mortality 
rates.(68)  Potentially large cost savings arising from a reduction in consumed resources 
could be achieved, for example by bed days avoided.  A reduction in the number of bed 
days used would directly reduce costs to the NHS associated with COPD and in time, the 
resulting available beds would be redeployed for use in other disease areas.   In order to 
determine if this is a cost saving strategy, the additional costs associated with the “Hospital 
at Home” strategy such as the employment of a respiratory nurse to conduct the “Hospital 
at Home” visits, would need to be weighed against the cost saving of less time spent in 
hospital for the patient.  
2.4.3 Guidelines: Diagnostic Criteria  
Many guidelines advising on the diagnosis and treatment of COPD have been published 
and the effects of applying these criteria to the same population have often been examined, 
using prevalence statistics.  This section describes some of the most frequently used 
diagnostic criteria and reports on studies that have compared criteria using prevalence 
statistics.   
The first COPD guidelines were published in 1986 by the American Thoracic Society 
(ATS), and the British Thoracic Society (BTS) published the first UK guidelines for COPD 
in 1997.  These guidelines resulted in significant improvements in the recognition and care 
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of COPD patients,(7) as they increased awareness of the disease, and for the first time 
presented a way of managing and treating people with COPD, as described above in section 
2.4.  Since then and on the back of these guidelines, numerous other guidelines have been 
developed, most notably, that of the Global initiative for chronic Obstructive Lung Disease 
(GOLD).  From 2001, GOLD has produced, in collaboration with the US National Heart, 
Lung and Blood Institute (NHLBI) and the World Health Organisation, guidelines on the 
diagnosis and management of COPD.  A total revision of the GOLD guidelines were 
published in 2006, and an update was published in 2007.(2)  NICE produced their own 
guidelines for COPD in 2004.(7)  Details of these criteria are described below. 
It is important to consider the diagnostic criteria because differences in the definition of 
COPD can have large effects in terms of estimating the prevalence of COPD within a given 
population.(69)  Different definitions of obstruction for diagnosing COPD could lead to 
estimates of prevalence that vary from one another by greater than 200%.(70) 
Global Initiative for Obstructive Lung Disease (GOLD) 
The GOLD guidelines state that “COPD is characterized by airflow limitation”,(2) defined 
as FEV1/FVC<0.7.  Symptoms and risk factors are mentioned but are not explicitly 
included within the diagnostic criteria.  In recent years there has been some consensus over 
the use of the criteria published in the GOLD guidelines and the GOLD criteria are 
frequently employed to identify COPD.  This definition is based solely upon lung function; 
however it is widely known that the clinical diagnosis of COPD takes into account more 
information than lung function alone. 
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European Respiratory Society (ERS) 
The European Respiratory Society state that the main risk factors for COPD are cigarette 
smoking and occupational exposure.  The two main symptoms are breathlessness and 
cough, sometimes accompanied by wheezing or sputum production. Chronic cough is 
present in most patients.  Patients with COPD are usually aged over 40 years and have 
functional evidence of moderate or severe airflow limitation.  Airflow limitation is 
identified by a reduction in the ratio of FEV1 to vital capacity (VC) or FVC: 
FEV1/VC<88% in men, FEV1/VC <89% in women and FEV1/FVC<70%.(6) 
American Thoracic Society (ATS)  
The American Thoracic Society produced standards for the diagnosis and care of patients 
with COPD in 1986.(71)  The standards state that COPD is characterised by airflow 
obstruction with exposure to tobacco smoke being the primary cause of the disease.  COPD 
patients have at least 20 pack years (20 cigarettes per day for 20 years) before symptoms 
develop and the symptoms commonly present from ages 50 with productive cough or an 
acute chest illness.  Dyspnea on effort usually does not occur until the 60’s or 70’s.  
Sputum production is gradual and increases over time.  Chest illness is characterised by 
increased cough, purulent sputum, wheezing, dyspnea and occasionally fever.(71)  
Spirometry values for diagnosis of COPD were published in a later paper, and were 
reported as FEV1/FVC<75%.(72)   
More recently (2004), the ATS and the ERS issued a joint statement on diagnosis and 
treatment of COPD 
   
 44 
ATS/ERS  
The ATS/ERS guidelines state that a diagnosis of COPD should be considered in any 
patient who has the following: symptoms of cough, sputum production, dyspnoea; or 
history of exposure to risk factors for the disease.  The diagnosis requires spirometry (post-
bronchodilator) FEV1/FVC < 0.7 and that the airflow limitation is not fully reversible.  
Spirometry should be obtained in all persons with the following history: exposure to 
cigarettes; and/or environmental or occupational pollutants; and/or presence of cough, 
sputum production or dyspnoea.(5)  
British Thoracic Society (BTS) 
The British Thoracic Society produced guidelines for COPD in 1997 and defined COPD as 
a chronic, slowly progressive disorder characterised by airways obstruction (FEV1 <80% 
predicted and FEV1/VC ratio <70%), with most COPD cases being caused by smoking.(4)  
The guidelines state that a diagnosis of COPD is normally suggested by symptoms but can 
only be established by an objective measure, preferably using spirometry.  Treatment can 
improve symptoms and measured airflow limitation.  
Symptoms and signs were thought to vary with the severity of the disease. In mild disease 
(FEV1 60-80 % predicted), no abnormal signs would be present, a smoker’s cough may 
occur and there would be little or no breathlessness.  In moderate disease (FEV1 40–59 % 
predicted) patients would generally be breathless (with or without wheeze) on moderate 
exertion and have a cough (plus or minus sputum).  Some abnormal signs would present 
(general reduction in breath sounds and presence of wheeze).  In severe disease (FEV1 <40 
% predicted) breathlessness on any exertion and/or at rest could occur and wheeze and 
cough are often prominent.  Signs include lung over-inflation, cyanosis, peripheral oedema 
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and polycythemia in advanced disease, especially during exacerbations.(4)  The BTS 
guidelines were superseded by the NICE guidelines in 2004. 
National Institute for Health and Clinical Excellence (NICE) 
The NICE guidelines recommend that a diagnosis of COPD should be considered in 
patients: aged over 35, with a risk factor (principally smoking), who present with one or 
more of the symptoms: exertional breathlessness, chronic cough, regular sputum 
production, frequent winter ‘bronchitis’ or wheeze, and who have airflow obstruction, 
considered present when both FEV1/FVC<0.7 and FEV1<80% predicted.(7)  
Comparison of Prevalence Using Different Diagnostic Criteria 
A study compared the ATS criteria (spirometry values) to those from the ERS (spirometry 
values) and used data on symptoms to validate the criteria in terms of overall accuracy, 
predictive value, sensitivity and specificity.(73)  Prevalence rates (aged  46 years) were 
14.5% (12.0%) for the men (women) with ERS, 33.1% (22.2%) using a clinical definition 
(symptoms) and 60.7% (53.4%) using the ATS criteria.  The authors found that age, height 
and number of pack years were statistically significant in the prediction of prevalence of 
COPD.  Prevalence of COPD was found to be dependent upon the definition used.(73) 
The GOLD criteria (spirometry values) was compared to the BTS criteria (spirometry 
values) in a random population sample (aged  46 years).  The prevalence of COPD was 
8% using BTS and 14% using the GOLD criteria.  Using the BTS criteria and stratifying by 
age, gave prevalence rates of: 1% (46-47 years), 2% (62-63 years) and 16% (76-77 years) 
compared to rate of: 5%, 24% and 45% respectively when employing the GOLD criteria. 
94% of those diagnosed with COPD using BTS guidelines were symptomatic compared to 
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88% with the GOLD criteria.  Age and smoking history were found to be important risk 
factors for the disease.(74) 
In a study that employed five different diagnostic criteria in a random population sample 
(aged  40 years) COPD prevalence ranged from 8.2% to 26% for the males and 6.6% to 
28% for the women.(75)  Criteria assessed were: 1) based upon the symptoms of chronic 
bronchitis1 and no spirometry, 2) the symptoms of chronic bronchitis plus FEV1/FVC70% 
(old GOLD guidelines) 3)  FEV1/FVC<70% and 50<FEV1<80% (old GOLD guidelines) 4) 
FEV1/FVC70% 5) FEV1/FVC<88% predicted (males) and FEV1/FVC<89% (females) 
(ERS).(75)  
A more recent study (2007) compared the criteria using the Lower Limit of Normal (LLN) 
as suggested by the ATS/ ERS Task Force, to the GOLD criteria in a general population 
study (aged  40 years). (76)  The LLN uses a cut-off value for the FEV1/FVC ratio set at 
the fifth percentile of the normal distribution.  The prevalence of COPD using the GOLD 
defined criteria was 14.2% compared to prevalence of 9.0% using the LLN criteria.(76) 
In a general population study that recruited participants with a smoking history of greater 
than 100 cigarettes (aged  36years), COPD was diagnosed based upon lung function 
measured by spirometry.(77)  By taking into account smoking history, the authors found 
that the prevalence rates were lower than expected: 11.6% for men and 4.8% for 
women.(77) 
In a meta-analysis of prevalence statistics, COPD was stated as being between 4 and 
10%.(78).  However the values reported within the study are conservative with higher 
estimates of prevalence of over 20%,(73) being reported in at least one of the studies that 
                                                 
1  Cough with phlegm, on most days for three months of the year, over not less than two years. 
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was reported on within the meta-analysis.  In all the studies that make use of the GOLD 
definition, the COPD prevalence estimate was up to 28% of the over 40 population: a value 
that is much larger than reported in the meta-analysis.(78) 
BOLD 
The Burden of Obstructive Lung Disease (BOLD) study was set up to measure the 
prevalence of COPD and its risk factors, in order to determine the burden of COPD, in 
various countries around the world using standardised techniques.(79)  
BOLD employed the GOLD diagnostic criteria to identify COPD cases, however in the 
reporting that followed, GOLD stages II and above (FEV1/FVC<0.7 and FEV1<80% 
predicted) were frequently used to identify disease.  Doing so reduced disease prevalence 
estimates by about a half.(80;81)  The first group to publish, reporting on COPD prevalence 
in Salzburg, Austria, found that overall prevalence in a random sample of the general 
population (aged  40 years) was 26.1%,(82) but prevalence was 10.3% when criteria of 
GOLD stages II and above were applied.(80)  This compares to a doctors diagnosis of 
COPD for 5.6% of the participants.(82) 
2.5 Summary 
COPD is a chronic respiratory disease that principally affects lung function.  Lung function 
impairment is used to identify the disease and to define disease severity.  The disease is 
manifested with respiratory symptoms such as breathlessness and wheeze and also through 
exacerbations where major exacerbations end in hospitalisation.  Smoking is an important 
risk factor for COPD.   
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COPD prevalence estimates for Europe are between 4 and 10% of the population but the 
prevalence of physician diagnosed COPD is less and represents approximately 1% of the 
population, leading to the opinion that there is under diagnosis of the disease.  Compared to 
all other illnesses/disease, within Europe, COPD mortality accounts for the fifth largest 
cause of death and in the Western Pacific region COPD is responsible for a larger 
proportion still, with COPD as the second highest cause of death and 14% of deaths being 
attributable to the disease.  The high proportion of deaths attributable to the disease within 
the Western Pacific region are largely explained by smoking patterns, and with smoking 
rates in this region continuing to be high, the considerable burden of the disease looks set to 
continue. 
COPD represents a large and increasing health and financial burden on both the individual 
and on the health care provider as the disease worsens over time.  Exacerbations in 
particular cause cost implications for the provider, particularly major exacerbations where 
the patient is hospitalised.   
Current guidelines are largely in agreement over treatment for the disease and recommend 
an additive approach as the disease worsens and to treat specific elements of the disease 
including respiratory symptoms and exacerbations. 
Until recently there has been little hope for COPD patients because of the widespread belief 
that nothing could be done for these patients.  Clinical trials that have been published over 
the past ten years have brought evidence on new treatments which have been shown to 
bring benefits to this population.  The licensing of these new products, particularly 
combination products, has caused a changing mix of treatments.   
These new pharmacological products successfully entered the market and currently enjoy 
large market shares, to the detriment of market share for older drugs.  This changing mix of 
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pharmacotherapy caused an increase in costs for treatment for COPD, with a potential 
seven times increase in drug costs over a seven year timeframe.  Costs of other forms of 
care are more difficult to quantify.  Hospitalisation costs will increase with increasing 
prevalence of COPD.  Nevertheless, costs of care at the patient level, particularly in 
secondary care, might be expected to decrease with improved pharmacotherapy; because of 
a potential reduction in the incidence of exacerbations.  The benefit of a new drug treatment 
relative to its cost is of particular relevance within this thesis.  Details of methods to 
evaluate treatments are discussed in further detail within Chapters 3 and 7. 
The development of a number of COPD guidelines, each with their own diagnostic criteria 
for the disease, have contributed to the changing pattern of care for COPD as the clinical 
community seeks to define appropriate care for this challenging patient group.  However, 
prevalence estimates fluctuate heavily depending upon the diagnostic criteria employed to 
identify COPD cases.  For example, spirometry alone is often used to identify COPD cases, 
resulting in large prevalence estimates, yet many descriptions of the disease describe it as 
resulting from smoking and presenting via respiratory symptoms.  However, no studies 
were identified that compared prevalence from a spirometry based diagnostic criteria of 
COPD, with that of a diagnostic criteria based on spirometry and symptoms and a risk 
factor (such as smoking history), such as that proposed by NICE.  A disparity in the 
identification and diagnosis of COPD therefore exists because criteria based upon lung 
function, symptoms and smoking history is likely to be the approach used by a physician, 
yet a diagnosis based upon spirometry alone dominates the literature.  In the one study that 
compared doctors’ diagnoses to the GOLD diagnostic criteria, prevalence estimates were 
five times higher applying GOLD criteria compared to the doctors’ diagnoses (26.1% vs 
5.6%).  In reality the actual prevalence is probably somewhere in between these two values.  
However, taken with the finding that the GOLD definition always produced the highest 
estimates of COPD prevalence in the papers reviewed, it may be the case that applying 
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GOLD criteria overestimates prevalence of COPD in the general population from the 
perspective of the health provider.  This question is raised and examined in detail within 
Chapter 5. 
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Chapter 3. Health Economics 
In this chapter, the use and need for economic analysis within health care is discussed 
before the branch of health economics, economic evaluation, which is focussed 
specifically on the evaluation of different treatments, in order to inform health care 
providers about the relative value of competing courses of action, is explained.   
In developing an economic evaluation for a treatment, it is important to fully understand 
the disease under study including how the disease presents itself, how the disease 
changes over time and how treatment affects the disease.  The purpose of the previous 
chapter was to ascertain information from the published literature around the natural 
history of COPD and on treatments for the disease in order to begin the 
conceptualisation around an economic evaluation for COPD; this chapter on health 
economics presents information on the key elements required for the economic 
evaluation of any treatment or intervention and these key concepts are drawn upon 
throughout the thesis. 
Specific topics are explored including a general overview of economic evaluation, the 
types of evaluation available, different structural models that can be used in which to 
develop an evaluation, costs and cost data, outcome measures and issues around 
uncertainty.  Specific interest is paid to outcome measures and in particular, the 
measurement of utility. 
3.1 Introduction 
When the UK NHS was founded in 1948 it was built upon three core principles: the 
NHS would aim to meet the needs of everyone, be free at the point of delivery and be 
based on clinical need, not ability to pay.(83)  These founding principles still apply 
today.  Every year the NHS is allocated a sum of money and it is up to budget holders to 
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allocate this money in an appropriate way in order to fulfill the founding principles.  
Because resouces are finite, difficult decisions are constantly being made including 
which treatments or procedures to finance (and to whom) and which treatments should 
be replaced.   
The budget holders seek to maximise population health, represented by the notion of 
utility (a measure of the relative satisfaction or quality of life gained), subject to the 
budget constraint for health care.  In a world of perfect information, the combination of 
goods and services that results in the highest utility gain for society is selected subject to 
the fixed budget.  However perfect information is a notion of the text books and in 
reality decisions must be made based on available, imperfect information.  These 
choices have to be made, and have in the past been made based on ‘gut feeling’, ‘what 
we did last time’ and ‘educated guesses’.(84)   
Economists can assist decision makers with these difficult decisions via the use of 
economic evaluation where the value of one treatment in terms of its costs and effects is 
compared to the costs and effects of another treatment, usually current practice.  
economic evaluation has been described as:   
‘the comparative analysis of alternative courses of action in terms of both 
their costs and consequences’.(84 p9)    
Hence the concept of opportunity cost, which is the cost of foregoing the next best 
choice, is of fundamental importance within economic evaluation.  The true cost of 
something is what is given up to get it.  This includes not only the money spent in 
buying the something (treatment/procedure), but also the economic benefits (utility) 
foregone because of buying that particular something and one can therefore no longer 
buy something else.  Everything has an opportunity cost.  Where one drug is accepted 
for use within the NHS, other drugs or treatments within the system are displaced.  
When a treatment is evaluated in an economic evaluation, the opportunity cost is often 
considered to be the value of the current treatment. 
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Economists seek to make explicit one set of criteria that can be used to decide between 
different uses for scarce resources.(84)  In this way, decisions about which treatments to 
accept and/or reject are made based on criteria of value rather than on a value 
judgement. 
Many countries around the world include a role for the incorporation of economic 
evidence into the decision making process for health, including many European 
countries, Australia and Canada.(85)  In England & Wales, the relevant decision making 
agency is NICE who is an organisation independent from Government, responsible for 
providing guidance on the use of health technologies and the implementation of public 
health programmes.  In the process of developing guidance, NICE brings together all 
the available clinical and economic evidence in order to decide whether the adoption of 
the technology (drug or treatment) represents good value for the NHS.(86) 
The broad content of an economic evaluation should be similar regardless of the disease 
of interest and the treatment(s) under study.  A number of different checklists have been 
proposed for assessing economic evaluations.(84;87;88)  Most well known within the 
field of health economics is the ten point checklist proposed by Drummond et al which 
is reproduced below in table 3.1.(84)  The checklist ensures the researcher ascertains 
whether various desirable elements have been included within the economic evaluation 
including, that the aim of the evaluation is clearly stated, the inclusion of a statement 
about which treatments are to be compared, that the costs and effects of the different 
treatments under study are established from appropriate data sources and a comparative 
analysis has been made, and that consideration has been given to uncertainty in the 
parameter estimates.  
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Table 3.1 Ten point checklist.(84) 
Questions 
1) Was a well defined question posed in answerable form? 
2) Was a comprehensive description of the competing alternatives given? (that is, can you tell 
who did what to whom, where and how often?) 
3) Was the effectiveness of the programmes or services established? 
4) Were all the important and relevant costs and consequences for each alternative identified? 
5) Were costs and consequences measured accurately in appropriate physical units (for 
example, hours of nursing time, number of physician visits, lost work days, gained life 
years)? 
6) Were costs and consequences valued credibly? 
7) Were costs and consequences adjusted for differential timing? 
8) Was an incremental analysis of costs and consequences of alternatives performed? 
9) Was allowance made for uncertainty in the estimates of costs and consequences? 
10) Did the presentation and discussion of study results include all issues of concern to users? 
  
NICE has defined a ‘reference case’ in which submissions to the Institute should follow 
to ensure consistency of health technology assessments (HTA)/economic evaluations 
and for these to be in keeping with the NHS objective of health maximisation under a 
limited budget,(87) and is reproduced in table 3.2. 
Table 3.2 NICE reference case.(87) 
Element of HTA Reference Case 
Defining the decision problem The scope developed by the Institute 
Comparator Therapies routinely used in the NHS, inc technologies 
regarded as best practice 
Perspective on costs NHS and Personal Social Services 
Perspective on outcomes All health effects on individuals 
Type of economic evaluation Cost effectiveness analysis 
Evidence on outcomes Based on a systematic review 
Measure of health effects QALYs 
Source for HRQoL  Reported directly by patients and/or carers 
Source for valuing HRQoL Representative sample of the public 
Discount rate An annual rate of 3.5% on costs and QALYs 
 
NICE is concerned with comparisons across studies and as described in table 3.2, 
normally requires that outcome measurements are in terms of Quality Adjusted Life 
Year (QALYs) (discussed in detail in section 3.2.5).  The source for valuing QALYs 
should be that of the general population (rather than the patient population), since the 
NHS is acting on behalf of the general population in allocating resources for health.  
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Whilst the ten point checklist and the NICE reference case were designed with different 
uses in mind, they are both used to assess economic evaluations.  Of note is how the 
focus has shifted between the older ten point check list and the NICE reference case.  A 
basic methodological focus is apparent within the ten point check list that concentrates 
on where costs and outcomes come from and how the outcome and costs were elicited 
and valued.  These issues are less of a focus in the NICE reference case as 
methodologies used to assess costs and effects have become increasingly established.  
The focus within the NICE reference case ensures comparisons across disease areas can 
be made.   
3.2 Key Concepts within Economic Evaluation 
Within the rest of this chapter, the subject of economic evaluation is explained and 
specific topics explored, including: the decision problem, different types of evaluation, 
economic evaluation structures, cost, outcome measures including utility and issues 
around uncertainty, in order to introduce topics and concepts that will be drawn upon 
throughout the thesis.   There is a specific interest in outcome measurements and in the 
measurement of utility.  The subheadings of the NICE reference case are loosely 
followed so as to provide a framework for describing the important concepts within 
economic evaluation.   
3.2.1 The Decision Problem and Comparators 
An economic evaluation should begin with a clear statement of the decision 
problem.(87) Including details on the technologies to be compared and the relevant 
patient population. The statement could read along the lines of:  
“The aim of the study was to compare the cost effectiveness of drug X to 
drug Y in a COPD population from the perspective of the UK NHS”  
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An economic evaluation may look at different populations or subpopulations depending 
on the aim of the study.  It is important to consider any subgroups in order to permit, 
where evidence allows, the identification of any specific group of patients to whom the 
technology is particularly cost-effective.  
Most published guidelines for economic evaluations assert that the comparator of 
interest is current treatment.(89)  It is important to choose an appropriate comparator 
because the comparative nature of economic analysis means that an inappropriate 
comparator can bias an analysis and render it of little value for decision making.  A 
significant issue in economic evaluation is that because the primary endpoint of RCTs 
(to which economic evaluations are frequently piggybacked onto) is drug registration, 
trials often provide relative treatment effects compared to placebo only.  This is 
potentially a fundamental problem of conducting economic analyses alongside clinical 
trials.(90)  
3.2.2 Types of Economic Evaluation 
An economic evaluation can either be cost effectiveness, cost utility analysis, cost 
minimisation or cost benefit analysis.  A cost benefit analysis measures the value of an 
intervention by a monetary value such as the dollar, or the Euro, and compares it to the 
costs of providing the treatment.  The decision criterion as to whether or not to adopt the 
technology is based upon whether the benefits are greater than the costs subject to 
budget limitations.  Where the alternatives under consideration have equal benefit or 
effect, then it is possible to choose the optimal treatment based only upon their cost; this 
method is known as cost minimisation.  However, this scenario occurs infrequently 
because more often than not, different treatments will cause different effects and unless 
this is the case, cost minimisation is inappropriate.(91)  More useful are cost 
effectiveness and cost utility analyses, where cost utility is a special case of cost 
effectiveness analysis.  This type of analysis allows a full economic evaluation to take 
place where both the costs and outcomes are analysed.  The main difference between 
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them lies in the outcome measure. Cost effectiveness studies present results in terms of 
natural units such as the cost per exacerbation avoided,(92) or improvement in health 
status.(93)  A cost utility evaluation identifies the change in health status measured by 
cost per unit of utility (usually the QALY).  Utilities and the QALY concept are 
described in detail in section 3.2.5.  The terms cost effectiveness and cost utility are 
used interchangeably within the thesis.  
Presenting cost-effectiveness analysis in natural units, such as cost per exacerbation 
avoided, will potentially limit the scope for decision-making on the efficient allocation 
of resources between COPD and other diseases.  Therefore, in order to inform the 
choice of whether to allocate more health care resources to the treatment of one disease 
compared to another disease area, a generic outcome using cost utility analysis is 
required, as this enables a comparison both within and across disease areas to be made.  
Both NICE and the US Public Health Service via the US panel, recommend cost-utility 
analyses as the appropriate way to make comparative assessments of value for money 
within a health system.(93-95)  Nevertheless, the US tends to make decisions on the use 
of drugs based on ‘medical appropriateness’ without taking into account cost.  For 
example, Medicare does not consider costs when making decisions about coverage.   
3.2.3 Economic Evaluation Structures 
Economic evaluation can take a number of different structures including: alongside a 
clinical trial and within a modelling framework: a decision tree, a Markov model, a 
simulation model and regression modelling.  Economic evaluation alongside a clinical 
trial is used to evaluate the cost effectiveness of different treatments within the clinical 
trial itself whereas a modelling structure aims to represent the disease under study and 
the effects of treatment on the disease in an appropriate way.  These structures can also 
be combined, for example regression equations can be used to predict values for an 
economic evaluation alongside a clinical trial or could be used within a Markov model 
to inform a specific parameter of the model.   
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There are at least two ways of developing an economic evaluation alongside a clinical 
trial.  The first method is, for each treatment group, to calculate the area under the curve 
(AUC) in order to derive the mean QALY score (described in detail in Chapter 6), and 
then calculate mean costs for each treatment group.  The difference in costs divided by 
the difference in effects can be calculated in order to derive a cost effectiveness statistic.  
This method does not allow for patient heterogeneity such as differences in age and sex, 
which may influence subgroup cost effectiveness.  The second method uses regression 
equations to fit models in order to predict the HRQoL score (usually QALYs) with 
explanatory variables including patient characteristics and treatment group.  The same 
method is used to derive a prediction equation for costs.  Cost effectiveness can be 
predicted by treatment group but also for different patient subgroups.  Whilst included 
here for completeness, economic evaluation alongside a clinical trial is not the same as 
economic modelling for several reasons.  Whilst there are benefits to conducting 
economic evaluation alongside clinical trials due to the substantial amount of patient 
level data on costs, effects and key outcomes,  there is a lack of external generalisability 
because the trial participants and treatment may not be representative of those found in 
a ‘real life’ setting.  Importantly the timeframe of the economic evaluation is restricted 
by the length of the clinical trial, which usually runs for one year or less.  Health 
outcomes typically take longer to manifest than the duration of the trial allows. 
More useful for decision makers is the use of economic models.  Health Economists use 
economic models to represent the real system in a simplified way.  Disease processes 
can be highly complex and economic modelling provides a way in which key 
information on the natural history of the disease and on the effect of treatment can be 
combined in a potentially useful and meaningful way so that decision makers can make 
reimbursement decisions based on all the available and relevant information.   
“The purpose of a model structure is to characterise the consequences of 
alternative options in a way that is appropriate for the stated decision 
problem and boundaries of the model”(96) 
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The different model structures that can be used for conducting economic evaluations are 
described below together with some pros and cons of selecting that type of modelling 
structure. 
Decision Tree 
Decision trees offer one approach to modelling a disease.  A decision tree represents 
individuals’ possible prognoses following an intervention, by way of different 
pathways,(84) as shown in figure 3.1.  The tree is characterised by decision nodes (the 
square boxes in figure 3.1) representing the decision being addressed in the model such 
as treat/no treat and chance nodes (the circles in figure 3.1) representing uncertainty.  
Connecting the various nodes to outcomes are branches.  The branches have 
probabilities attached that represent how likely it is that the event of interest occurs.  
Each way through the tree represents a pathway.  In figure 3.1 there are 7 pathways.  
Each pathway has a probability attached to it, a cost and an effect value and from these, 
expected values for each decision can be determined. 
Outcome 1
Outcome 2
Outcome 3
Outcome 4
Outcome 5
Outcome 6
Outcome 7
Decision Uncertainty
 
Figure 3.1 An example of a decision tree 
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Popular in the past, decision trees are rarely used nowadays in favour of other methods. 
The trees can become very bushy particularly in modelling chronic diseases, making 
them unwieldy and complex to programme and analyse.(84)  In addition, and perhaps 
more importantly, the decision tree cannot incorporate time dependency.  Time 
dependency is often a feature with modelling disease, particularly chronic conditions 
such as COPD where the disease tends to worsen over time.  Another related problem is 
that the change in age related mortality cannot be modelled in this framework, nor can 
discounting occur (which is described in section 3.2.8).  Sometimes decision trees are 
used within a Markov framework.(97) 
Markov Model 
Markov models have frequently been used in the economic evaluation of COPD.  
Markov modelling forces the characterisation of a disease into a number of discrete 
health states through which the disease will progress.  The classification into a 
particular state is dependent on the natural history of a disease.  In COPD, patients are 
frequently classified into a particular state depending upon FEV1 % predicted.  
Movement between the states is dependent on decline in lung function and can be 
estimated in a number of ways such as with data from clinical trials or using a 
regression equation to predict the transition.  
Markov models have cycles with durations that might last one day, one week, one 
month or one year, depending on the nature of the disease.  At the beginning, middle or 
end of each cycle (subject to the modellers approach) the patient cohort moves through 
the model.  The subjects being modelled move through the model in a number of ways, 
typically they either stay in the same state, move to a worse state (or a state in which a 
specific event occurs), or they die.  The models extrapolate these cycles for a certain 
timeframe ie 30 yrs after which time the cohort is expected to have all but died and the 
marginal costs and effects are negligible.  Costs and utilities are attached to each disease 
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state within the model.  Events occurring within disease states such as exacerbations can 
be modelled by attaching (dis)utilities and costs, weighted by event rates. 
A particular feature of the Markov model is that it is memory-less.  That is, once a 
person has entered a state, the model cannot distinguish between them and others who 
were and remain in that state.  A problem with this is that time, especially with chronic 
diseases, is often strongly correlated to worsening disease and that through the Markov 
approach, this way this correlation is ignored.   
Discrete Event Simulation 
Discrete Event Simulation (DES) contains three components: entities, events and time.  
Entities are usually the patients and are assigned attributes such as age, sex, type of 
disease.  An event is something that occurs during the simulation, such as an 
exacerbation, and events can occur sequentially and/or simultaneously.  The rate at 
which the event occurs can change and be dependent on any of the attributes of the 
entity.  Time is an explicit element of a DES simulation and the model can be run for as 
long as is necessary.(98)  DES has been described as: 
“…discrete event simulation models the pathway of an individual by 
sampling probabilities from an a priori distribution.”(98)   
DES is most successfully applied to processes such as modelling the introduction of 
new equipment within the setting of a GP clinic or for queuing.  Another situation 
where DES is typically used is in infectious disease modelling where people with the 
disease infect others through interactions with them.  DES explicitly allows for this 
interaction between patients. 
A problem with DES is that the processes can get very complex, whilst the fundamental 
idea behind economic modelling is to present the disease in a simplified format and at 
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the same time, capturing the important elements that drive cost and effect: caution needs 
to be made to ensure that the model does not over-complicate the processes involved.  
Regression Equation 
Regression equation modelling can take a number of forms but principally involves the 
use of one or more prediction equations that predict the value of a dependent variable 
from a range of independent variables using patient level data such as a RCT or an 
observational dataset.  Some authors have used a prediction equation for one parameter 
within a Markov model, for instance, cost, the probability of survival over time and 
transition probabilities (see Chapter 4 for details of these models).  Glick et al have 
proposed the use of prediction equations for cost and effect based on patient level data 
within RCT data that when combined give a cost effectiveness statistic.(99)  The use of 
regression equations to depict cost and effect, albeit outside of a modelling framework, 
dates back to at least 1977 where Weinstein and Stason represented net health care costs 
by the following expression: 
LERXMorbSERX CCCCC ΔΔ+Δ−Δ+Δ=Δ  
Where RXCΔ  includes all direct medical and health care costs, such as the cost of 
hospitalisation, medications and physician time, SECΔ  comprises all health care costs 
associated with side effects occurring as a result of treatment, MorbCΔ−  is comprised of 
the savings from preventing or alleviating disease by improvements in morbidity and 
LERXC ΔΔ  is the cost of treating disease or illness that occur with the patient living for 
longer than otherwise. Weinstein and Stason represented the effectiveness parameter by: 
SEMorb YYYE Δ−Δ+Δ=Δ  
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which essentially represents a QALY, where YΔ represents the unadjusted number of 
life years gained following treatment, MorbYΔ  representing the adjustment to take into 
account quality of life and  SEYΔ−  factors in side effects of treatment.(100) Regression 
based modelling can be used to inform part of the economic evaluation or it can be used 
to inform the entire economic evaluation, if the model is built as a series of related 
regression equations that when combined give cost and effectiveness values for 
different treatments.   
The main benefits of using a regression based model are that patient level heterogeneity 
(described in section 3.2.9) can be captured in much more detail compared to a Markov 
model and a regression based model allows for greater flexibility in the structure of the 
model.  The main limitation of an economic model based on regression equations is the 
necessity for good quality data, with a large sample size that can be used to study the 
natural history of the disease.  However, if good quality data are obtained, the use of a 
regression based structure makes better use of the available data than other modelling 
structures as the regression equations used to develop the model are developed from the 
data.  The ultimate choice of model structure should be based on the natural history of 
the disease and the aim of the study.  
3.2.4 Cost 
The choice of perspective on cost depends upon the target audience for the study.(88)  
There are several perspectives: a specific provider/provider institution (ie the NHS), the 
patient/patient group, a third party payer (ie an insurer) or the perspective of 
society.(84)  The perspective used will determine the costs employed and these must be 
appropriate and as comprehensive as required.  
A societal perspective would typically include productivity costs due to absence 
from/inability to work, cost of and to carers and additional costs of the illness to 
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patients, but could exclude productivity costs.  Whilst productivity costs can represent a 
considerable burden on both the individual and on society, their use in cost 
effectiveness analyses is an area of controversy.  This is partly due to methodological 
uncertainty concerning the appropriate method of measuring productivity losses, 
especially where significant unemployment is evident.(101)   
The US Panel on cost-effectiveness analysis recommends a societal perspective which 
can include productivity losses.(94)  In contrast, NICE limits its perspective to the 
health service and personal social services perspective and explicitly excludes the use of 
productivity costs in its evaluations.  It is often argued however, that economic studies 
should include all relevant costs associated with the illness,(102) and several countries 
including Sweden and the Netherlands suggest the use of a societal perspective. 
3.2.5 Outcomes  
The outcome of interest in an economic evaluation for health care is the effectiveness 
parameter which is usually described in terms of a utility measurement.  NICE advise 
that all health effects should be accounted for within an economic evaluation.  Where 
there is a belief that other non-utility based measures capture health effects that are not 
captured within the utility measure, the effectiveness of treatment on these measures can 
also be presented and there are a number of non-utility based HRQoL measures which 
are routinely measured in COPD patients.   
Evidence on outcomes should ideally come from a RCT.  If a clinical trial is unavailable 
or where or alternative options have not been looked at, then evidence should come 
from a meta-analysis or an indirect treatment comparison analysis.  To be of use, a RCT 
should be externally valid, so that the results of the study are applicable to the intended 
treatment population in a real life setting.  
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In valuing outcomes, the aim is to capture the benefit of treatment to the patient 
population and this is achieved through the administration of a tool directly to the 
patients that can capture these HRQoL benefits.  For utility based measures, for 
example with the EQ-5D questionnaire (which is discussed in detail in Chapter 6, 
section 6.2) the utility values attributable to each patient are based on previously 
collected scores elicited from the values that a representative sample of the population 
place on different states of health.  The use of patient level data weighted by the views 
of the general population is recommended by NICE and represents the idea that the 
NHS is acting on behalf of the UK general population to allocate resources in its 
collective best interest.  
There are a number of non-utility measures of COPD health effects including: hard 
endpoint data, clinical measures, and health outcome measures from health outcome 
questionnaires.  Hard endpoint data consist of: mortality (survival), hospitalisations, and 
number of exacerbations.  Clinical measures such as FEV1 and FEV1 % predicted, and 
exercise tolerance are limited in their scope to address questions of health benefit to 
patients and may only be weakly correlated to actual health benefit as experienced by 
the patient.  Health outcome questionnaires on the other hand, specifically lend 
themselves to monitor health benefit as perceived by the patient.  
Health outcome questionnaires fall into two groups, generic questionnaires and 
condition specific measures. Over the last twenty or so years, both generic and 
condition specific measures have increasingly been used within clinical and 
observational studies,(103) in order to capture health benefits to patients, usually as a 
result of treatment or an intervention. 
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Generic Questionnaires 
Generic questionnaires were first developed during the 70s in an attempt to capture the 
HRQoL of different people in different health states.  Many generic questionnaires have 
been applied to COPD patients, of which the following list captures the most common.  
• Euroqol instrument (EQ-5D).(48) 
• Health utilities index (HUI).(104) 
• Short form 36 questionnaire (SF-36).(105) 
• SF-12.(106) 
• SF-6D.(107) 
• General health questionnaire (GHQ).(108) 
• Dartmouth COOP charts.(109) 
• Nottingham health profile.(110) 
• Quality of well being (QWB).(111) 
• Sickness impact profile (SIP).(112) 
 
Of these, the EQ-5D, SF-6D and HUI can be used to derive a utility score.  Generic 
measures can be used on a variety of disease areas or health problems and can be used 
to compare HRQoL across disease areas.  Generic measures can pick up important 
changes in HRQoL in all spheres of the patient’s health: representing quality of life 
ideals that are common to all, regardless of age, disease or treatment, and measure the 
functional and mental well being.(113)  However generic measures may be insensitive 
to small changes in specific components of COPD such as breathlessness or dyspnea 
(which may cause significant impact on HRQoL for COPD patients) because of the 
breadth of health areas they cover: particularly over shorter time periods.(114)  In 
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addition, they may not pick up on  the specific limitations experienced by COPD 
patients.(114)  
HRQoL Measures Specific to COPD 
Condition specific measures for COPD were developed in order to address the issue of 
the HRQoL specific to the COPD patient.  There are many condition specific measures.  
In addition, there are questionnaires that target specific aspects of COPD such as 
dyspnea and breathlessness.  The most frequently used questionnaires are listed below 
• St George’s respiratory questionnaire (SGRQ). (47)  
• Chronic respiratory disease questionnaire (CRQ).(115) 
• Breathing problems questionnaire (BPQ).(116) 
• Seattle obstructive lung disease questionnaire (SOLG).(117) 
• Sino-Nasal outcomes test.(118)  
• Changes in dyspnea: 
o MRC dyspnea scale.(119) 
o Baseline Dyspnea Index (BDI).(120) 
o Transitional dyspnea index (TDI).(120) 
 
Disease specific measures may be more sensitive than generic measures because the 
content is directly relevant to COPD patients.(121)  However, the results are not easily 
generalisable or comparable across different diseases.  In addition, disease specific 
instruments cannot be used on populations who do not have the disease and they may 
not pick up on co-morbidities or health problems that are associated with unexpected 
effects from treatment.(122)  Most Health Economists prefer the use of a generic tool 
for outcome measurement from which utility scores can be derived, such as the EQ-5D, 
the SF-6D or the HUI. 
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Utility 
As previously stated, utility is a measure of the relative satisfaction or quality of life 
gained.  In economics, the notion of utility is frequently used to compare goods or 
services against one another in terms of preference.  This could be the consumption of 
an orange over an apple. If the consumer prefers oranges to apples, they will place a 
higher value on the consumption of an orange than an apple; utilities are used to 
quantify this preference.  However not all consumption gives enjoyment, goods give the 
user a degree of enjoyment but they may also fill a human need or may even be a 
negative experience.  Within the economic evaluation of different treatments, analyses 
are conducted that determine the cost effectiveness of one drug treatment compared to 
one or several comparators.  In the same way that utilities can be used to value the 
consumption of oranges and apples, so too can they be used to value outcomes from 
drug treatment.  
In order to measure preferences in health economics, cardinal preferences are measured, 
that is a number needs to be attached to the effectiveness or outcome from the treatment 
so that the strength of preference for the treatment can be measured.  These numbers 
should be measured onto an interval scale which has equal intervals, so that a move 
from a value of 0.3 to 0.4 has the same worth to the individual as a move from 0.8 to 
0.9. 
Measuring Utilities  
Two methods are used to derive cardinal utilities from the patient population: standard 
gamble (SG) and time trade off (TTO).  Generic utility based questionnaires were 
developed using either the SG or the TTO method and offer an indirect meausurement 
of HRQoL in a convenient and time saving format. 
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Standard Gamble 
The SG technique has its foundations in von Neumann utility theory.(123)  Within the 
SG, the subject is presented with a health state describing a particular condition and 
what it is like to be in that state.  They are offered two choices.  Either they can stay in 
the state with certainty, or they can take a treatment which involves an element of risk.  
The treatment is said to work immediately and either returns the subject to full health 
with a probability of p, or the subject dies with a probability of 1-p.  The probability is 
varied until the subject is indifferent between the two alternatives. 
Time Trade Off 
Within the TTO technique, the participant is presented with a health state and they are 
again given two choices.  This time the choice is between remaining in the state with 
certainty for a period of time t, such as ten years, followed by immediate death, or they 
are offered the choice of fewer years of life y in which they live in a state of full health, 
such that y<t, follwed by immediate death.  The time y is varied until the subject is 
indifferent bewtween the two alternatives.  
Generic Utility-Based Questionnaires 
Generic health-related questionnaires are used to derive utilities and include the EQ-5D, 
the SF-6D and the HUI.  These questionnaires are most freqently used to derive utilities 
because they are comparatively easy to administer and the results are easily 
generalisable across disease areas. 
Quality Adjusted Life Years (QALYs) 
In order to make resource allocation decisions across disease areas, a generic form of 
outcome measure that is measured over time is useful.  The QALY is grounded in utility 
theory.  In essence, a new treatment that leads to improved quality of life over a time 
period, compared to existing treatment, will generate greater utility than if the patient 
continued to take the existing treatment.  The QALY quantifies changes in utility over  
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the life of the patient.  The QALY has two components; quality and quantity of life.  
NICE recommends the use of QALYs within cost effectiveness analysis: 
Measures that capture both quantity (duration) of life and quality of life… 
are best suited for use in a reference case analysis.”(94) 
Quality adjusted 
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Figure 3.2 QALY profiles for a hypothetical patient with and without treatment  
Profiles weight length of life by quality of life on a zero-one scale where one represents 
perfect health and zero death. In a chronic disease such as COPD, exacerbations might 
result in reduced quality of life for a period of time with incomplete recovery. 
 
In figure 3.2 intervention 1 is associated with a higher quality of life (the curve is above 
the other) and, greater life expectancy (quantity) than the treatment with intervention 2.  
The shaded area between the two curves represents the difference in the number of 
QALYs between the treatments.  
For example, a treatment may improve quality of life over the remainder of the patient’s 
life by 0.03 QALYs, from 0.6 to 0.63 and extend the life of the patient from 10 years to 
11. This will give: 
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New treatment     Existing treatment 
10 years at 0.63 = 6.3    10 years at 0.6 = 6 
Plus one extra year of life = 0.63 
QALYs = 6.93    QALYs = 6 
The new treatment will add a total of 0.93 QALYs compared to the existing treatment.  
The QALY is by far the most accepted health-related utility measure and is the 
preferred outcome measure in many countries including Canada, New Zealand, Sweden, 
England and Wales (NICE HTA guidelines), the Netherlands and the US(85). 
3.2.6 Incremental Cost Effectiveness Ratio (ICER) 
The cost effectiveness statistic derived within economic evaluations is the incremental 
cost effectiveness ratio (ICER).  The ICER represents the difference in costs and 
benefits between a new therapy (x) compared to current treatment (y).  The ICER is 
calculated using the following formula: 
ICER = Cx – Cy 
             Bx – By 
 
Using the previous example of a gain of 0.93 QALYs following treatment with 
intervention 1, with a treatment cost of £15 000 over the remainder of the patient’s life, 
compared to the cost of the existing treatment at £1000, gives an ICER of:  
              15 000-1 000 = £15 054 
6.93-6 
 
The ICER quantifies the additional cost of an extra QALY by taking the new treatment 
rather than the existing one: the new treatment can provide one extra QALY for a cost 
of £15 054. 
Because the reimbursement of one treatment will displace monies spent from other 
treatments within the health system, it is important to ensure that the treatment 
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reimbursed provides sufficient value for money.  A ‘guide price’ or a threshold from 
which to decide whether or not any one treatment should be reimbursed by the health 
care system is required.  In the UK, NICE have a threshold of between £20,000 and £30 
000 per QALY, but this can vary.  Below £20,000 per QALY there is a high probability 
of the technology being accepted and above £30 000 per QALY there is less chance of 
the technology being accepted.(87)  
3.2.7 Timeframe 
Economic evaluations attached to clinical trials are naturally constrained by the 
timeframe of the trial to which they are connected.  Economic models have an 
advantage in that through applying adequate and transparent assumptions, the results 
can be extrapolated into the future, up to a lifetime timeframe.  The timeframe of a 
study is crucial because the full benefit of treatment may not occur within the period of 
the trial: the timeframe of the model should extend far enough into the future so that the 
key differences between the comparators in the analysis can be established.(88)  
Restricting the timeframe may yield un-meaningful results: 
“There is no natural interpretation for life-years gained during a finite period 
of time, and the CE ratios that result from using different time horizons, 
such as one year and five years, cannot be compared in any meaningful 
way…researchers who truncate their analyses have made, perhaps 
unwittingly, the implausible alternative assumption that study subjects 
experience neither the costs nor the benefits of living beyond the period of 
study”.(124 p191-192) 
3.2.8 Discount Rate 
A discount rate is often applied to cost effectiveness analyses in order to represent the 
fact that immediate health (or financial) gains are more highly valued in the present than 
in the future.  The discount rate is currently set at 3.5% by NICE for both costs and 
effects though this value has not always been applied and there is still uncertainty 
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around the absolute value of the discount rate.  It is common to see scenario analysis 
around the discount rate in order to assess the effect of different rates on the cost 
effectiveness result. 
3.2.9 Uncertainty 
Five different types of uncertainty exist in economic modelling: patient to patient 
variability, parameter uncertainty, structural uncertainty, heterogeneity, and decision 
uncertainty.  
Of these, heterogeneity refers to differences between individuals that can be explained 
and as such, is a source of uncertainty that it is possible to reduce to some degree by 
accounting for patient level characteristics such as age and gender.  Variability on the 
other hand, refers to differences between patients occurring for reasons that are 
unknown or that can not be captured, and within analyses, variability is covered within 
the error term. 
Parameter uncertainty occurs around inputs into the model such as utilities, resource 
use, costs, event rates, and so on.  Models have in the past used data deterministically, ie 
one value (usually the mean) is employed within the analysis and the uncertainty around 
the mean values was not accounted for.  The use of Probabilistic Sensitivity Analysis 
(PSA) addresses the issue of parameter uncertainty by placing distributions around the 
parameter.  Usually Beta distributions are applied to transition probabilities and to 
utilities, and gamma distributions are applied to cost parameters.  The Cholesky 
decomposition can be used to keep the covariance structure between regression results 
in place whilst accounting for uncertainty in the model parameters.   
The decision around the type of modelling structure to employ (or which mixture) is 
largely informed by the natural history of the disease in question.  For instance 
infectious diseases are more successfully modelled using DES, whereas for chronic 
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conditions, Markov models are used to the same effect.  Regression based modelling for 
cost effectiveness can be applied so that key drivers of the disease can be explicitly 
modelled. Often the chosen modelling structure is informed by historical models, 
carried out in the same disease area and this is an important starting point to building a 
new economic model, however this may lead to inflexibility in structure.  It is often 
therefore useful to look to models carried out in other (similar) disease areas to 
investigate alternative approaches to model structure. 
Where analyses are conducted using patient level data, a statistical analysis of the data 
should incorporate measures of uncertainty around cost-effectiveness results.  If the 
study uses a modelling framework, sensitivity analysis, ideally PSA should be 
employed,(125) this allows the combined uncertainty of all the parameters in the model 
to be included,(126) by using the full probability distributions of each input into the 
model, rather than just the point estimates.  A number of best practice guidelines (eg the 
BMJ, NICE and US Panel) state that the uncertainty surrounding estimates of cost 
effectiveness needs to be explored when presenting economic evaluation results.(95)  
PSA is now a formal requirement for cost effectiveness models submitted to NICE.(95) 
Sponsorship 
Industry sponsored studies represent a major source of funding for economic 
evaluations, however, concerns have been raised regarding potential biases arising as a 
result of this alliance because studies have found an association between pharmaceutical 
sponsorship and the probability of a favourable result.(127-129) 
3.3 Summary 
This chapter introduced the subject of health economics together with specific details 
about economic evaluation.  Economic evaluation consists of a number of key concepts 
and within this chapter a focus has been given to: the types of economic evaluations, the 
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structure of model employed, cost, outcomes and utility, the ICER and the issue of 
uncertainty.  
The aim of the economic evaluation should be clearly stated and the comparators 
considered should include current practice. There are a number of model structures that 
can be employed including Markov models and regression based models and it is 
important to select a structure that is appropriate for the disease under study and the 
question or aim of the economic evaluation.  In estimating costs, all relevant costs 
should be considered and from the UK perspective this should represent all costs to the 
NHS and social services.  The measuring of utility is a key component of economic 
evaluation and the QALY has been proposed as the appropriate measure of HRQoL for 
valuing treatments.  Costs and QALYs from two different treatments can be combined 
in order to generate a cost utility value, the ICER.  Decision rules exist where treatments 
are accepted if the ICER value falls below, between or above a documented threshold.  
Uncertainty is present in a number of forms including within parameter estimates, in the 
choice of model structure and between patient heterogeneity.  Uncertainty should be 
considered in all economic evaluations, preferably using PSA.  The timeframe of the 
study should be extended to lifetime in order to capture the full benefits of treatment. 
In the following chapter these key concepts of economic evaluation are considered with 
reference to published economic evaluations in COPD, in order to assess the extent to 
which existing models meet current standards. 
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Chapter 4. Literature Review of Economic 
Evaluations in COPD 
This chapter presents a review of the published literature on economic evaluations for 
COPD treatments.  The focus is on treatments where competing courses of interventions 
exist for COPD patients and includes pharmacological and surgical treatment.   
The review is split into two sections with the first section focusing on economic 
evaluations that have been conducted either alongside a clinical trial or an observational 
study, and is structured around the key concepts of economic evaluation identified in 
chapter 3: perspective, patient group, comparators, outcome measures, extrapolation, 
the results of the evaluations and the handling of uncertainty.  The economic 
evaluations that develop an economic model are examined further in the second section 
and include, in addition to those key concepts mentioned above, a description of the 
model structure and design, sources of input data and assumptions used within each 
model.  First the search strategy is presented. 
4.1 Search Strategy  
The focus of the search was on pharmacological therapies that are routinely used in the 
treatment of COPD, as described in table 2.5.  Surgical interventions were included 
because surgery represents an alternative course of action to continued treatment.  Other 
treatments such as smoking cessation, antibiotics, vaccinations and oxygen therapy are 
prescribed in addition to routine pharmacological treatment and as such would not be 
expected to affect the place in the treatment pathway of a routine pharmacological 
treatment.  As such, these treatments are excluded from the scope of this chapter. 
Four databases were used to search the literature for economic evaluations on 
interventions for COPD: MEDLINE, EMBASE, the Centre for Reviews and 
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Dissemination (CRD) and the Health Economics Evaluations Database (HEED) and 
restricted from 1990 until 2007.  The search strategy was designed for MEDLINE and 
also applied to EMBASE.  Included terms were: “Lung diseases, obstructive/ or 
bronchitis/ or pulmonary disease, chronic obstructive” or “COPD”, and “costs and cost 
analysis”/ or “cost benefit analysis”/ or “cost of illness”/ or “health care costs”/ or 
“health expenditures” and “quality adjusted life years/ or cost utility” or “health adj4 
utili#ation” or “economic$ or economics.”  
For CRD and HEED – where this type of search strategy was not possible to apply –  
“cost” or “effectiveness” and “chronic” or “COPD” and the names of individual drugs 
were used: “fluticasone”, “salbutamol”, “ipratropium”, “formoterol”, “tiotropium” etc.  
MEDLINE gave 732 hits; EMBASE = 159; CRD = 235 and HEED = 53.  Removing 
duplicates, a total of 918 papers were found (March 2007).  Reference lists from key 
papers were also searched for studies and papers: relevant papers were selected by first 
reviewing the abstracts and then if deemed appropriate, the papers were obtained.  
Papers satisfying the inclusion and exclusion criteria were selected.  Inclusion criteria 
were: economic evaluations of pharmacotherapy or surgery for COPD and in the 
English language.  Exclusion criteria included papers where the focus was upon: cost 
alone, antibiotics, smoking cessation, vaccinations and oxygen therapy.  Fifteen 
pharmacoeconomic evaluations of COPD were identified and five papers evaluating 
surgical interventions.  The search was updated in October 2009 and identified a further 
six pharmacological studies and three surgical studies, totalling 29 economic 
evaluations. 
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Table 4.1 Summary of COPD economic evaluations 
First author Ref Yr Type Structure Outcome measure 
 
 
 UA EA RCT Obs 
Mod 
el 
QA
LY 
Sur
v 
SG
RQ 
Exa
c 
FE
V1 
Jubran  (97) 93                     
Ramsey (130) 95            
Rutten-v M  (131) 95                     
Al  (132) 98           
Friedman  (129) 99                     
Van den 
Boom 
(133) 01                    
Anyanwu (134) 02           
NETT (135) 03           
Ayres (136) 03                     
Hogan (137) 03                     
Jones (93) 03                     
Borg (138) 04           
Groen (139) 04           
Oostenbrink (140) 04                     
Sin  (141) 04                     
Gagnon  (142) 05                     
Lofdahl  (143) 05                     
Oostenbrink  (92) 05                     
Spencer (144) 05                     
Briggs (145) 06                     
Maniadakis  (146) 06                     
Ramsey (147) 07           
Rutten-v M (148) 07                     
Chuck (149) 08           
Earnshaw  (150) 08                     
Najafzadeh  (151) 08                     
Blough (152) 09           
Briggs (153) 09           
Oba  (154) 09                     
UA=cost utility analysis. EA=cost effectiveness analysis. RCT=randomised controlled trial. Obs= observational. QALY=quality adjusted life year. Surv=survival. SGRQ=St 
George’s respiratory questionnaire. Exac=exacerbation. FEV1= Forced Expiratory Volume in one second  
 
Table 4.1 provides a summary of the features of each of the 29 economic evaluations, 
including the type of study (cost utility analysis or cost effectiveness), the structure of 
the study (RCT/observational or model) and the main outcomes measures used (QALY, 
survival, change in SGRQ, rate of exacerbations and of change in FEV1 score.  
Approximately half of the evaluations were conducted alongside clinical trials (13/29); 
three used data from observational studies and thirteen used an economic model.  
Evaluations were either cost utility (19/29) or cost effectiveness analyses (10/29).   
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The QALY was the most frequently used outcome measure but there were others, 
including: survival, reduction in rate of exacerbations, improvement in SGRQ and 
improvement in FEV1.  There has been a rapid increase in the number of economic 
evaluations published within the disease area over recent years, with 22/29 studies being 
published within the past six years, and in which an increasing focus on modelling and 
the use of the QALY as an outcome measure was seen.   
4.2 Review of the Non-Modelling Papers 
In total, sixteen economic evaluations were non-modelling papers, of which thirteen 
were conducted alongside a RCT and three used data from an observational study.  Of 
these studies, five assessed the cost effectiveness of lung surgery, three of which were 
based on the national emphysema treatment trial (NETT) RCT.  A summary of each of 
these studies is described within this section and each subheading refers to information 
contained in table 4.2.  
As described previously in section 3.1, there are a number of different checklists for 
assessing economic evaluations.(84;87;88)  A review that strictly followed one of these 
checklists was not used for a number of reasons including that in the health economics 
community, there is no consensus over which checklist should be used and the use of a 
checklist often turns into a box ticking exercise without getting to the heart of the issue 
of whether the study is of sufficient quality.  As in Chapter 3, within this chapter, the 
NICE reference case was loosely followed so as to provide a framework for assessing 
whether the important concepts within economic evaluation have been captured, 
namely: perspective, patient population, size of the evidence base and extrapolation, 
comparators, outcomes, uncertainty and discounting. 
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4.2.1 Perspective 
Three different perspectives were used: the provider (ie the NHS),(136;145;151) 
societal, (134-136;140;147;152) and the payer.(93;137;142;143)  In three cases no 
reference to perspective was made.(129;130;133) 
4.2.2 Patient Group 
In order to compare patient severity for COPD, the patient population used within each 
study was classified into disease severity groups as defined by GOLD (mild, moderate, 
severe and very severe as previously described in Chapter 2).  However, often scarce 
reporting within some papers around inclusion and exclusion criteria as well as 
heterogeneous classifications made it difficult to accurately convert the disease 
severities into GOLD severity groups.  All the pharmacological studies included severe 
COPD patients with most focussing upon moderate to 
severe.(129;131;136;140;145;151)  The cost effectiveness analysis alongside the 
observational study,(142) included COPD patients in each severity category, as did the 
study by Van den Boom et al.(133)  No reference to patient severity was made in Hogan 
et al paper,(137) and so the original trial publication was searched for this 
information.(155)   
Within the cost effectiveness analyses on surgical interventions, the patient population 
had either severe emphysema or end stage lung disease.  Whilst FEV1 % predicted 
values were not presented, this patient population represents very severe COPD as 
defined by GOLD. 
4.2.3 Patient Numbers and Duration of the Study 
Patient numbers in each of the studies varied substantially from 52,(130) to 1067 
participants.(129)  Most studies tended to have upwards of 500 participants, usually 
  81 
equally distributed between the treatment arms.  The shortest study durations were 3 
months,(129;137) four studies were for 12 months and two were for 36 
months.(142;145)  The surgical analyses used data collected within a 3yr, 4yr or 5yr 
study.  
4.2.4 Comparators 
Perhaps due to the very nature of the RCT and the complexities that doing so would 
demand, none of the pharmacological studies used the preferred comparator of ‘current 
treatment’.  Conversely, all of the surgical cost effectiveness studies used current 
treatment as comparator defined as either being on the waiting list for surgery,(130;134) 
or a group receiving medical treatment.(135;147;152)   
Placebo was a comparator in eight of the pharmacological studies.  In five out of the 
sixteen studies the main point of interest was the cost effectiveness of a combined drug 
compared to its component parts and sometimes placebo.(129;131;142;143)  However 
the more recent studies compared a number of different drugs such as one comparing 
tiotropium with combinations of salmeterol and/or fluticasone,(151) the study by 
Lofdahl compared the cost effectiveness of placebo, Budesonide, Formoterol and the 
combination Budesonide and Formoterol and finally Oostenbrink et al measured the 
effects of replacing the short acting anticholinergic, Ipratropium with the long acting 
equivalent, Tiotropium.  Where two different dosages were examined, the dominated 
treatment was dropped from further study.(93;137)  
4.2.5 Outcome Measures 
A wide range of outcome measures were used within the studies.  All of the surgical and 
four pharmacological cost effectiveness studies used QALYs.  Other outcomes assessed 
were: survival, change in SGRQ, reduction in number of exacerbations and 
improvement in FEV1.  In addition to this there were others, including: proportion of 
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patients remaining free of exacerbations after six months,(136) number of symptom free 
nights,(93) a daytime symptom card of less than 2,(93) avoided 
exacerbation,(140;143;151) and improvement in dyspnea.(140)   
4.2.6 Extrapolation 
Four of the five surgical studies extrapolated to a longer time frame: either 10 years, 
(135;147) 15years,(134) or to a lifetime,(130) and used regression based models to 
predict survival.(130;134;135;147)  These models were then used to calculate survival 
weighted costs and effects via the Kaplan-Meier Sample Estimator,(156) so that a cost 
effectiveness statistic could be calculated.  One study also developed a regression 
equation to predict costs past the duration of follow up.(147)  
4.2.7 Results 
All the pharmacological studies reported a favourable outcome compared to the 
comparator(s) except for the Najafzadeh et al study.  Six found the study drug cost 
effective compared to the comparator(s).(133;136;140;142;143;145)  The other four 
reported improvements in outcome associated with the study drug compared to the 
comparator(s).(93;129;131;137)  The results from the surgical economic evaluations 
were more conservative with all studies reporting that surgery was expensive but over 
time ICERs were shown to reduce.  
4.2.8 Handling of Uncertainty 
Five of the studies used probabilistic sensitivity analysis.(140;142;143;145;151)  Five 
studies used univariate sensitivity analysis around the underlying assumptions such as 
adjusting the value for the cost per day,(136) and inflating/deflating the cost of 
treatment drugs and rescue medication by 50%.(137)  Two studies used bootstrapping 
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of the results.(135;147)  Four made no mention of the uncertainty surrounding the 
economic evaluation.(93;129;131;133)  
4.2.9 Sponsorship 
Most of the papers were sponsored by industry: five fully 
sponsored.(129;136;140;143;145)  The paper by Jones et al,(93) did not state any 
information on financial support, though one of the authors was working for 
GlaxoSmithKline.(GSK)  Three papers were partially supported by the 
industry.(131;137;142)  GSK supported most of the studies (n=6) Boehringer Ingelheim 
(BI) (2) and Astra Zeneca (AZ) and Novartis sponsored one each.  None of the 
economic evaluations for surgery were sponsored by industry. 
4.2.10 Summary 
The non-modelling papers were of mixed quality with the surgical evaluations tending 
to be of better quality in terms of duration of follow up, comparator, use of the QALY 
and extrapolation.  For decision making the economic evaluations for pharmacological 
treatments would have limited use as the duration of these studies was too short 
(maximum three years), none of the studies used ‘current treatment’ as the comparator 
and a range of disparate outcome measures were used, only occasionally the QALY.  
The QALY and the effect of uncertainty on the ICER were increasingly seen in the 
more recent studies.    
  
Table 4.2 Key features of the economic evaluations for COPD 
  Pers
pecti
ve 
Cou
ntry 
a 
Cost 
year  
Duration               
(mths) 
Patient 
group b 
Interventions c                                                                                             
(n by study arm) 
Outcome measure Outcome +ve  (d) 
outcome  
Uncert
ainty 
Spons
or 
Ramsey. 
(130) 
(1995)  
/ USA /($) 3yrs life-
time 
emphys
ema 
patients 
Post transplant n=28 
Waiting list n=24 
Cost per QALY ICER $176 817 per QALY mixed One 
way 
Acade
mic 
Rutten-
van 
Molken. 
(131) 
(1995) 
Soci
etal 
NL 1989 
($) 
30 II, III Combined 2 agonist 
& corticosteroid n=91        
Combined 2 agonist & 
anticholinergic n=92                                                    
2 agonist & placebo 
n=91 
Improvement in 
FEV1(10%).                                    
Hyper-responsiveness.                            
Restricted activity days.                               
Symptom free days. 
Cost per relevant improvement in FEV1: 
Co vs Pl = $200 and $5.35 per symptom 
free day.
 None Partly 
by 
GSK 
Friedma
n.(129) 
(1999) 
/ USA 1998 
($) 
3 II, III Ipratropium n=362                                                 
Albuterol n=347                                         
Ipratropium & 
albuterol n=358 
Peak change in FEV1.                                                  
Area under the FEV1 
response time curve from 
time 0 to 4 hrs  
ICER not calculated: Combination product 
striclty dominated albuterol 
 None BI 
Van den 
Boon. 
(133) 
(2001) 
/ NL 1999 
($) 
12 I, II, III, 
IV 
Placebo n=41                                                                                                   
Fluticasone 250µg (x2 
daily) n=33 
Improvement in FEV1.           
Quality adjusted life years  
ICER $13 016. Early detection and 
treatment: ICER $33 921 (direct costs) $14 
031 (direct and productivity costs). 
 None Variou
s 
Partly 
by 
GSK 
Anyanw
u. (134) 
(2002) 
Soci
etal 
UK 1999 
(£) 
4yrs 
15yrs 
extrap 
End 
stage 
lung 
disease 
Single transplant n=260 
Double transplant n=199 
Waiting list n=1030 
Cost per QALY 
Life years 
£29 415 single lung 
£20 002 double lung 
mixed One 
way 
Gover
nment 
Ayres. 
(136) 
(2003) 
NHS 
Soci
etal 
UK 1998 
(£) 
6 I,II,III Placebo n=139                                                    
Fluticasone n= 142 
Improvement in FEV1 
Proportion of patients 
remaining exacerbation 
free (moderate/ severe 
and mild)  
Per patient per day: Cost per relevant 
improvement in FEV1= £0.25 (NHS 
perspective) = -£3.39 (societal). Cost per 
relevant proportion of patients remaining 
free of moderate & sev exacerbations = 
£0.25 (NHS) and £-3.28 (Societal).  
 One 
way 
GSK 
Hogan. 
(137) 
(2003) 
Pay
er 
USA 2002 
($) 
3 II, III* Placebo n=200                                                                                                          
Ipratropium n=194                                                  
Formoterol 12µg n=194                                        
Formoterol 24µg n=192* 
Change in FEV1.
Change in Quality of life 
as assessed via the
SGRQ. 
Cost per relevant improvement in FEV1: Pl 
vs Ip = $273.03. Ip vs Fo 12µg = 
$1611.32. Cost per relevant improvement 
in QoL: pl vs Fo 12µg = $25.20. 
 One 
way 
Partly 
by 
Novart
is 
Jones. 
(93) 
(2003) 
Pay
er 
UK /(£) 4 II Placebo  n=227                                                                                                
Salmeterol 50mcg 
n=229                                          
Salmeterol 100mcg 
n=218 
Improvement in FEV1                                
% of symptom free nights.                                                                          
Improvement in SGRQ 
((-)4 points).  
Per patient per day: Cost per relevant 
improvement in FEV1= £4.62. Cost per 
symptom free night = £5.67. Cost per 
daytime symptom card of<2 = £12.33. 
Cost per relevant increase in health status 
= £4.44. 
 None One 
author 
workin
g for 
GSK 
  
NETT. 
(135) 
(2003) 
Soci
etal 
USA 2002 
($) 
3yrs 
5yrs 
10yrs 
Severe 
emphys
ema 
LVRS n=531 
Medical treatment n=535 
Cost per QALY $190 000 per QALY at 3yrs 
$53 000 per QALY at 10 yrs 
mixed Bootst
rap 
Acade
mic 
Oostenb
rink. 
(140) 
(2004) 
Soci
etal 
NL  
BE 
2001(
€) 
12 II, III Tiotropium n=344                                                          
Ipratropium n=175 
Reduction in 
exacerbations.                                              
Improvement in SGRQ 
((-)4 points).                                                                    
Improvement in trough 
FEV( 12%).  
Improvement in the 
transitional dyspnoea 
index (1 unit). 
Per patient per year: Cost per: 
exacerbation avoided = €667; 
improvement in health status = €1084; 
improvement in dyspnea = €1259; relevant 
improvement in FEV1 =  €796. At a 
threshold of €2000, probability of being 
cost effective to avoid one exacerbation is 
80%.  
 One 
way 
BI 
Gagnon. 
(142) 
(2005) 
Pay
er 
USA 2001 
($) 
36 I, II, III, 
IV 
 No ICS, no LABA 
(placebo) n=274                                                   
Inhaled corticosteroid 
(ICS) n=538                                    
B2 agonists (LABA) 
n=130                                 
LABA & ICS n=212 
Life expectancy 3 yr: ICER: LABA vs ICS/LABA = $91 430. 
Lifetime: ICER: placebo vs LABA= $6110. 
ICER: LABA vs comb= $27 570. 
Discounted gain in life expectancy in days 
(within study/lifetime respectively) No ICS 
and no LABA = 2.41/3.88, LABA and ICS 
= 2.70/6.14.  
 PSA Partly 
by 
GSK 
Lofdahl. 
(143) 
(2005) 
Pay
er 
SE 2001 
(€) 
12 III, IV Placebo n=228                                                                                             
Budesonide n=243                                                           
Formoterol n=235                                                           
Budesonide & 
Formoterol n=245 
Avoidance of an 
exacerbation requiring
medical intervention.
Comb is cost effective vs placebo if a 
decision maker is willing to pay about €2 
per day per avoided exacerbation.  
 PSA AZ 
Briggs. 
(145) 
(2006) 
NHS UK 1998 
(£) 
36 II, III Placebo n=370                                                                                             
Fluticasone n=372 
Quality adjusted life
expectancy over three 
years.                                                                                  
Life expectancy. 
Cost per additional life year gained = £17 
700. Cost per QALY gained £9500. Gain in 
Life expectancy = 23 days
 PSA GSK 
Ramsey. 
(147) 
(2007) 
Soci
etal 
USA /($) 5yrs  
10yrs 
Severe 
emphys
ema 
LVRS n=538 
Medical treatment n=540 
Cost per QALY ICER $140 000, 5yrs & $54 000, 10 yrs 
More CE for patients with predominantly 
upper lobe emphysema & low exercise 
capacity 
mixed Bootst
rappin
g 
Acade
mic 
Najafzad
eh. (151) 
(2008) 
Heal
thca
re 
syst
em 
CAN 2006 
($) 
12 II, III Tiotropium n=449/3            
Tiotropium + salmeterol  
n=449/3                          
Tiotropium + 
salmeterol/fluticasone  
n=449/3     
Cost per exacerbation 
avoided                             
Cost per QALY 
Treble combination vs monotherapy was 
$243 180 per QALY and $6510 per 
exacerbation avoided. 
 X  PSA Resea
rch 
Blough. 
(152) 
(2009) 
Soci
etal 
USA ($) 3yrs Severe 
emphys
ema 
LVRS n=531 
Medical treatment n=535 
Cost per QALY ICER: $178 000 to $331 000 depending on 
imputation method for missing data 
mixed imputa
tion of 
missin
gness 
Acade
mic 
a NL stands for the Netherlands and BE for Belguim. b Patient grouping standardised in line with the GOLD guidelines. c Bold type corresponds to the primary drug of interest d Positive outcome for the primary drug of interest. QALY=quality adjusted life year. ICER=incremental cost 
effectiveness ratio. FEV1= Forced Expiratory Volume in one second. SGRQ=St George’s respiratory questionnaire. BI=Boehringer Ingelheim. GSK=GlaxoSmithKline. AZ=Astra Zeneca 
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4.3 Review of the Economic Models 
In this section, the thirteen economic evaluations that were developed around a 
modelling framework were examined.  The models were taken individually and are 
described below by way of the methodology/characteristics employed and some of the 
inputs used.  Table 4.3 presents key elements of each study.   
4.3.1 Jubran et al (1993, (97))  
The Jubran paper is the earliest example of an economic model applied to COPD.  The 
study compares the costs and cost effectiveness of theophylline vs ipratropium over one 
year from a societal perspective, based on three observational data sets, totalling 600 
people with a diagnosis of moderate to severe COPD in three US practice based sites.  
Resource use was extracted from the data sets to include: the number and type of visits 
made, drug treatments, lab tests, consultations and toxic events.  From this data, 
estimates for labour, non-labour and overhead costs were made.  The datasets were 
uneven in duration (theophylline: 7.1 months and ipratropium: 5.9 months) but the 
results were extrapolated to one year.   
Jubran et al incorporated a decision tree into the Markov framework.  There were seven 
states within the model: stable; clinic visit, consult, ER visit, hospital, major toxicity 
and minor toxicity and during these cycles, any one of five outcomes could occur: 
exacerbation, toxicity, routine clinic visit, routine consultation and no event, from which 
a number of other possible outcomes could arise.  The model assumed that the patient 
was in one of the states at any one time and transitions between these states took place 
at the end of a one month cycle.  There were 12 cycles in total and the study was limited 
to a one-year framework.  The Jubran et al model was focused on toxic outcomes for 
COPD treatments.  Within the analysis, toxic events accounted for 8% of hospitalisation 
for those taking Theophylline compared to 0% of patients taking Ipratropium.  
 87 
No ICER was calculated since ipratropium was found to be both less costly and more 
cost effective than theophylline.  Univariate sensitivity analysis was used to represent 
the uncertainty around costs and probabilities into the model.  The study was sponsored 
by Boehringer Ingelheim.  
4.3.2 Al et al (1998, (132)) 
The model by Al et al compared the cost effectiveness of a situation with and without a 
lung transplantation programme from the perspective of society for up to 40 years using 
a simulation model that mirrored the movement of patients through the Dutch lung 
transplant program.  The simulation modelled 100 patients and 17 donor lungs entering 
the program each year and consisted of 7 phases: outpatient screening, inpatient 
screening, pre-transplantation, waiting list, transplantation, inpatient follow up and 
outpatient follow up.  The model predicted duration of stay for each patient within each 
of these phases using survival analysis.  During each phase: death, referral to the next 
phase, rejection or contact lost with the team could occur.  For the comparator analysis, 
only movement to the waiting list was permitted.  For the treatment arm, each cycle 
(which was one year in duration) when the 17 lungs become available, the model checks 
the waiting list to match the donor lung to the person with the longest wait and with the 
appropriate body and blood type and the corresponding person moves through to the 
next phase of the model, to the transplant.  Once the patient history of each patient has 
been simulated, costs and effects were added and were weighted by the probability of 
survival, which was predicted based on a Weibull parametric model.  Sensitivity 
analyses were conducted using scenario analyses.  The ICER for surgery compared to 
no surgery was calculated as G167 000 (£68 477). 
4.3.3 Groen et al (2004 (139)) 
Groen et al employed the same model as Al et al, described above, in order to answer a 
question about the relationship between diagnosis and the cost effectiveness of lung 
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transplantation.  In this model, the patients were split into seven categories, of which 
one was COPD and individual survival curves were fit based on diagnosis.  Cost and 
utility data were the same as in the earlier model.  The ICER for COPD patients was 
$118 200 compared to no transplant when a 3% discount rate was applied. 
4.3.4 Borg et al (2004 (138)) 
This model aimed to evaluate new medicines to satisfy various payer requirements.  The 
model was a two dimensional Markov model as shown in figures 4.1 and 4.2, and was 
comprised of two factors: irreversible decline in lung function and periods of 
exacerbations.  Disease states were based on lung function, categorised according to 
GOLD guidelines by FEV1 % predicted, split into four groups: 1) FEV180%, IIA) 
50% FEV1<80%, IIB) 30% FEV1<50% and III) FEV1<30% predicted.  Transition 
between disease severities was based on a decline in FEV1.  
 
Figure 4.1 The first part of the disease model, Borg et al 
 
The first part of the model was updated weekly as seen in figure 4.1, according to 
exacerbation activity and was based on current disease severity.  Within each disease 
state Borg et al allowed any of four different events (exacerbation free, mild 
exacerbation, moderate exacerbation, severe exacerbation) to occur. 
Mild exac 
Moderate exac 
Severe exac 
Exac free 
risk of moving to a 
worse health state 
risk of death 
Current disease severity 
Move to a worse state 
 89 
 
Figure 4.2 The second part of the Borg et al model 
The normal progression was from 1, 2, 4, 6 then 7.  It was also possible to regress one 
step (to 1, 3, 5) but no further 
 
As shown in figure 4.2, the second part of the model was updated mid-yearly and within 
this part of the model, the patient could move: to the next state, remain in the same 
state, die or return to a previous health state.  
4.3.5 Sin et al (2004, (141)) 
A societal perspective was adopted by Sin et al,(141) for their Markov Model which 
examined the effects of adding ICS to treatment for three groups; all COPD patients; 
patients with stage 2 or 3 disease and stage 3 disease.  The model was three years in 
duration with twelve cycles; each cycle was for three months.  Transitions between the 
states could occur after each cycle.  Shown in figure 4.3, the model was split into three 
stages based on lung function: stage 1: FEV150%, stage 2: 35% FEV1<50% and stage 
3: FEV1<35%.  A final state of death was not explicitly included, though was inferred.  
I 
III 
IIB 
IIA 
Death 
1 
2 3 
5 
6 
4 
7 
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Figure 4.3 The Sin et al Markov model 
 
FEV1 was assumed to decline over time (47ml per year in each severity group) and from 
this the probability of progressing to the next stage was calculated and applied to all 
groups.  Treatment was not assumed to affect the transition probabilities between states.  
Data from the third National Health and Nutritional Examination survey were used to 
estimate the proportion of patients in each state.(157)  All-cause mortality was 
estimated from published data; risk increased subject to disease severity and varied 
between those treated with ICS compared to those who were not treated.  
The rate and severity of exacerbations increased according to COPD stage, with the 
proportion of severe exacerbations, (compared to mild and moderate exacerbations) 
increasing as the disease severity worsened.  Treatment with ICS was assumed to 
reduce the rate of exacerbations by 30%.  Assumptions used in the model: 
• Lung function decline was 11.75 ml per cycle regardless of disease severity 
group. 
• QALY values applied were: 1.00 for stage 1, 0.92 for stage 2 and 0.84 for stage 
3. 
• From baseline, a reduction of 0.32 QALYs per exacerbation was applied 
regardless of exacerbation severity. 
Death 
Stage 3 
Stage 1 
Stage 2 
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• The estimated duration of effect was 1 week (mild), 2 weeks (moderate) and 4 
weeks (severe).  
• The rate and severity of exacerbations increased according to COPD stage.  
Whilst the viewpoint was that of society, direct marginal costs were included within 
primary analysis and an estimation of the productivity costs associated with work loss 
during exacerbations for those 65 years or younger was only conducted during a 
secondary analysis.  Sin et al found that treatment was cost effective when given to 
patients with stage 2 or 3 disease.  PSA was performed to account for the uncertainty 
around the inputs of the model.  
4.3.6 Oostenbrink et al (2005, (92)) 
Oostenbrink et al developed an economic model for COPD in 2005.  Since then this 
model has been adapted to different county settings in two subsequent studies, the first 
by Maniadakis et al in 2006,(146) and the second by Rutten-van Molken.(148)  As these 
models are slightly different to the original they will be described later in this section. 
The 2005 Oostenbrink et al (92) model was a one year Markov model around disease 
severity states (moderate, severe and very severe) and exacerbations, to compare the one 
year cost effectiveness of tiotropium compared to ipratropium and to salmeterol in the 
Netherlands and in Canada.  The perspective of the model was the local health care 
reimbursement authorities in the Netherlands and in Canada.  The Markov model had 
three health states: moderate (50% FEV1<80% predicted), severe (30% FEV1<50% 
predicted) and very severe (FEV1<30% predicted) and did not include a mild state or a 
death state. The model had cycle lengths of one month.  Within each state, non severe 
and severe exacerbations could occur and movement between states could be either: 
forwards, backwards or to remain in the same state.  Effectiveness data for the 
tiotropium arm came from six RCTs and for the salmeterol and ipratropium arms, from 
the relative difference to tiotropium seen during the individual trials.  
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Tiotropium was assumed to improve symptoms and HRQoL and lead to fewer 
exacerbations in comparison to ipratropium and to placebo, and improvements in lung 
function in comparison to salmeterol.  Exacerbations rates (severe and non severe) were 
dependent upon the treatment group and on disease severity. 
• The length of the first cycle was 8 days. 
• All subsequent cycles were one month.   
• Only one exacerbation was allowed during any one cycle.  
• Transitions between states were assumed to take place halfway through the 
cycle. 
• Treatment was assumed to affect the transition probabilities; the average 
ipratropium patient was found to have a probability of 2.7 times more than the 
average tiotropium for movement from a moderate to severe state. 
• Mean EQ-5D index scores used were: moderate=0.755; severe=0.748 and very 
severe= 0.549.   
During a cycle in which an exacerbation occurred, utility was assumed to decrease (for 
the whole cycle) by 15% for a non severe exacerbation and 50% for a severe 
exacerbation.  
In the Netherlands and in Canada, tiotropium was found to be associated with maximum 
expected net benefit for plausible values of the ceiling ratio. 
To account for the uncertainties in the evaluation, Oostenbrink et al used PSA to test for 
the robustness of the result to changes in the baseline values of the model.  PSA was 
employed by applying appropriate distributions around mean input values (for transition 
probabilities the Dirichlet (as proposed by Briggs et al, (158)), for rate of exacerbations 
and utilities the Beta, and for resource use, the Gamma distribution).  Scenario analysis 
was employed to assess the impact on the model to different transition probabilities, 
utility values and around the cost of adding oxygen therapy. 
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4.3.7 Spencer et al (2005, (144))  
The model by Spencer and et al (144)  employed a Markov model in order to compare 
the cost effectiveness of the combination drug salmeterol/fluticasone, to usual care in 
patients with COPD.  The model consisted of four disease states: mild COPD, 
FEV150%, moderate: 35% FEV1<50%, severe: FEV1<35% and death as illustrated in 
figure 4.4.  The cycles were three months in duration and a maximum time horizon of 
25 years was applied.  Treatment for COPD was assumed to affect the risk of 
exacerbations, the risk of disease progression, risk of mortality and patient health status.  
 
Figure 4.4 The Spencer et al Markov model 
 
Baseline values for the model were sourced from GSK clinical trial data 
(TRISTAN),(159) published medical literature and from expert opinion.  Estimates of 
health status by disease stage were mild: 0.81, moderate: 0.72 and severe: 0.67.  
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Transitions between states were based on decline in FEV1.  A regression equation was 
developed to predict disease progression based on FEV1 at baseline, height, age and sex.  
Movement between states was unidirectional.  Smoking status was assumed to affect the 
rate of decline of lung function and so affect the transition probability, which was 
calculated separately for smokers than ex-smokers.  Smokers and ex-smokers were 
found to have increased FEV1 rates of decline: 62ml and 31ml respectively.   
Exacerbations were considered as a function of the disease state and were split into 
minor (contacts with primary care) and major (hospitalisation).  Using the EQ-5D score, 
estimates for health status during an exacerbation were obtained from 27 respiratory 
physicians who completed the questionnaire from the perspective of their patients.  For 
a minor exacerbation, health status was assumed to drop to 0.61 (mild), 0.61 (moderate) 
and 0.05 (severe).  For a major exacerbation, health status fell to -0.26 regardless of 
disease severity.  The study assumed a non linear recovery from the ‘low point’ to a 
position of 0.03 utility points below those of others in the study who did not have an 
exacerbation.  
Routine/maintenance costs for each disease state were estimated and applied to the 
model.  Costs associated with exacerbations for each disease state were estimated and 
included in the model by weighting by the rate of minor/major exacerbations in each 
disease state.  
The study found that the combination therapy may represent a cost effective treatment 
in those patients who have a history of frequent exacerbations and poorly reversible 
COPD.  A PSA was performed around the discount rate, exacerbation rate and the 
mortality benefit.  The study was sponsored by GSK.  
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4.3.8 Maniadakis et al (2006 (146)) 
Maniadakis et al applied the model that was developed by Oostenbrink et al, to a Greek 
setting with the aim of comparing tiotropium to salmeterol over a one year time frame 
from the perspective of the Greek National Health Service.  The probabilities and 
utilities applied to the model were the same as in the Oostenbrink et al model.  New cost 
data were derived using resource utilisation obtained from the medical records at a 
Greek hospital and to this, unit costs were applied.  Tiotropium was concluded to be 
cost effective, however there was no statistically significant difference found between 
the treatments.  PSA was performed around the baseline values.  As with the 
Oostenbrink et al paper, the study was supported financially by Boehringer Ingelheim. 
The same issues around limitations of the Oostenbrink et al paper apply to this study, 
namely that there was no dead state applied to the model and that the model had only a 
one year time frame.    
4.3.9 Rutten-van Molken et al (2007 (148))  
The model by Rutten-van Molken et al expanded upon the earlier Oostenbrink et al 
model. The aim of the study was the same as in the Oostenbrink et al study, which was 
to examine the cost effectiveness of bronchodilator therapy with tiotropium, salmeterol 
or ipratropium for COPD, but from the perspective of the Spanish NHS. 
The time frame was extended from one year in the earlier model to five years.  The 
Markov model added the disease state of ‘dead’ compared to its predecessor, giving 
four disease states based on FEV1 % predicted: moderate (50% FEV1<80% predicted), 
severe (30% FEV1<50%), very severe (FEV1<30%) and dead.  In each state, subjects 
were at risk of experiencing an exacerbation (moderate or severe) as illustrated in figure 
4.5.  Movements between states were based on the annual decline in FEV1 derived from 
the trial data.  Cycles were one month in duration.  Backwards and forwards transitions 
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were allowed during the first year, and for subsequent years only forward transitions 
were permitted.  
 
Figure 4.5 The Rutten-van Molken et al Markov model 
 
Within the clinical trial, treatment with tiotropium was found to delay progression to the 
next disease state and to reduce the number of exacerbations and was applied to the 
model using scenario analysis.  The base case scenario was that after the first year, the 
mean FEV1 decline was the same for each treatment group (52ml per year).  
Exacerbation probabilities were based on first year rates.  The second scenario applied 
transition and exacerbation probabilities from the first year throughout the five year 
model.  The third scenario assumed that neither disease progression or exacerbation 
frequency/intensity was affected by treatment after the first year.  Assumptions 
included: 
• Movement between states was based on an annual decline in FEV1 informed by 
trial data. 
• The relative mortality rate (where severe mortality rate =1) was 3.754 for very 
severe COPD patients and 0.248 for moderate COPD patients.   
• No differences in mortality risk were assumed between treatments. 
• Mean (SE) utilities were 0.809 (0.008) for moderate disease, 0.762 (0.009) for 
severe disease and 0.655 (0.024) for very severe disease. 
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• Utility decreased by 15% for a moderate exacerbation and 50% for a severe 
exacerbation. 
• The cost of a non severe exacerbation was EUR83 (£74) for a non severe 
exacerbation and EUR 2176 (£1941) for a severe exacerbation.   
 
The ICER for tiotropium compared to salmeterol was EUR 4118 (£3787) and the ICER 
for salmeterol vs ipratropium EUR 348 971 (£320 896) in base case analyses.  The 
research was financially supported by BI and by Pfizer. 
4.3.10 Chuck et al (2008 (149)) 
Chuck et al developed a Markov model to determine the cost effectiveness of using 
combination therapy (long acting beta 2 agonists and inhaled corticosteroids) in 
different groups of COPD patients and was based on data from the literature.  The 
model had three disease stages and a death state.  Stage 1 was defined as FEV150% 
predicted, stage 2 35 FEV1<50 % predicted and stage 3, <35 % predicted.  Cycle 
lengths were three months and were extrapolated to a lifetime horizon. 
FEV1 was assumed to decrease at a constant rate of 47ml per patient year and from this 
a transition probability for moving between states was calculated.  Exacerbations were 
assumed to occur at each stage and were split into three types: mild, moderate and 
severe.  The rate and severity of exacerbations increased in line with disease severity so 
that the total number of exacerbations per person per year was 0.17 for stage 1, 0.59 for 
stage 2 and 0.83 for stage 3.  All-cause mortality rates increased with disease severity 
and were 3.92% for stage 1 disease, 6.16% for stage 2 disease and 9.24% for stage 3 
disease.   
Utility scores and costs were attached to exacerbations and utility was modelled as 
disutility where a QALY reduction would occur following an exacerbation: -0.17 for a 
mild exacerbation, -0.47 for a moderate and severe exacerbation.  
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Combination therapy for stages 2 and 3 over a lifetime perspective gave an ICER of 
CAN $50 571 (£29 455) and restricting therapy to stage 3, an ICER of CAN $25 333 
(£14 755) per QALY.  Including stage 1 patients was unlikely to be cost effective.  The 
study was sponsored by GSK. 
4.3.11 Earnshaw, S (2008 (150)) 
This Markov model was developed in order to examine the cost effectiveness of treating 
COPD patients with a combination of fluticasone and salmeterol compared to 
fluticasone alone, salmeterol alone and placebo, from the perspective of a third party US 
payer.  The model had four states: moderate, severe, very severe and dead.  Within each 
state the patient could either have no exacerbation, a mild exacerbation or a severe 
exacerbation.  Annual cycle lengths were applied and the timeframe of the model was 
lifetime. 
Transitions probabilities between states were based on data from the Lung Health Study 
(and were previously used in the model by Sin et al).  Input data for exacerbation and 
for mortality risk were derived from the TORCH dataset.  Utility values were taken 
from a study by Borg et al.  The cost data were obtained from a range of sources. 
The results from the model show that the ICER for the combination product compared 
to placebo was $33 865 (£20 766).  PSA was conducted to explore uncertainty around 
the parameters.  The study was sponsored by GSK. 
4.3.12 Oba. Y (2009 (160)) 
Oba developed a Markov model, designed to assess the cost effectiveness of inhaled 
medication (salmeterol, fluticasone and Seretide (salmeterol and fluticasone) compared 
to placebo) use in COPD from the third party payer’s perspective in the US healthcare 
system. The model was based on four health states: stable, exacerbation requiring a 
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physician visit, severe exacerbation requiring hospitalisation, and death as illustrated in 
figure 4.6.  Cycle lengths were three months and the total model duration was three 
years.  
 
Figure 4.6 The Oba Markov model 
 
Input data were derived from the TORCH clinical trial.  Inputs into the model included: 
frequency of exacerbations requiring a physician visit, frequency of exacerbations 
requiring hospitalisation, all-cause mortality rates and utility scores (derived from the 
SGRQ and mapped to the EQ-5D).  The three monthly all-cause mortality rate was 
modelled using an exponential approximation.  A 3% discount rate was applied to costs 
and effects.  
Compared to placebo, the ICER was $56 519 (£34 657) for salmeterol, $62 833 (£38 
529) for fluticasone and $52 046 (£31 914) for the combination product.  None of the 
arms were found to clearly dominate the other.  One way sensitivity analysis was 
conducted.  The study was developed within an academic setting and was not funded by 
the pharmaceutical industry.  
4.3.13 Briggs et al (2009 (153)) 
Briggs et al developed an economic model using data from the TORCH trial to inform 
regression models to predict study medication cost, other medical cost, EQ-5D and 
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survival.  The model compared the cost effectiveness of four treatments: salmeterol, 
fluticasone and the combination product salmeterol plus fluticasone to placebo. 
Costs were inflated to a 2007 base year where necessary.  Explanatory variables within 
the models included: age, body mass index, race, gender, count of items in medical 
history at baseline, count of pre randomised exacerbations requiring hospitalisation, 
baseline FEV1 % predicted, Medical Research Council (MRC) dyspnea score, the 
SGRQ, smoking and region.  The regression equation on survival was fit using a 
parametric Weibull survival model.  A Generalised Linear Models (GLM) was used to 
estimate cost and an OLS regression equation was used to model EQ-5D scores. 
Cost and QALY scores were weighted by the probability of surviving at the time of the 
visit.  The method of recycled predictions was used to estimate costs and QALYs and 
ICERs.  A discount rate of 3% was applied for both costs and effects.  Bootstrapping 
was carried out to generate 95% confidence intervals (CIs) around the ICER results.  
Compared to placebo, the combination product had an ICER of $43 600 (£26 735), 
compared to salmeterol an ICER of $26 500 (£16 250) and to fluticasone, an ICER of 
$27 000 (£16 556).    
4.4 Discrepancies in utility values  
It is evident that there are many similarities in the approach adopted in the development 
of an economic model for COPD.  COPD has been modelled using stages of the disease 
and at each stage; an exacerbation causes a drop in HRQoL for the modelled patient.  
The studies all used a utility measure in their analysis but there were sometimes large 
discrepancies around the inputs into the model, some of which have been described 
elsewhere.(161)  Table 4.4 illustrates the differences between the utility values used in 
the papers by Sin et al, Oostenbrink et al, Rutten-van Molken et al and Spencer et al.  
The disease severity groupings were reported as per GOLD: FEV1>50% (GOLD 
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moderate); 35%< FEV150% (approximate GOLD severe); and FEV1<35% 
(approximate GOLD very severe). 
Table 4.4 Health status by disease severity and the impact of an exacerbation 
  Moderate Severe Very Severe 
Baseline 0.81 0.76 0.66 
 to (minor exac) 0.69 0.65 0.56 
to (major exac) 0.41 0.38 0.33 
Rutten van 
Molken (2007) 
Duration of effect 1 month 1 month 1 month 
Baseline 0.76 0.75 0.55 
 to (minor exac) 0.64 0.64 0.47 
to (major exac) 0.38 0.37 0.27 
Oostenbrink 
(2005) 
Duration of effect 1 month 1 month 1 month 
Baseline 1.00 0.92 0.84 
 to (exac) 0.68 0.60 0.52 
Sin (2004) 
Duration of effect 1 week 2 weeks 4 weeks 
Baseline 0.81 0.72 0.67 
 to (minor exac) 0.61 0.61 0.05 
 to (major exac) -0.26 -0.26 -0.26 
Spencer (2005) 
Duration of effect Recovery over six months 
 
Differences between the utility values by disease state differed between studies.  For 
example, within table 4.4, utility values for very severe COPD were: 0.76 (Rutten-van 
Molken),0.55 (Oostenbrink), 0.84 (Sin) 0.67 (Spencer) as seen in the last column.  In 
the same way, health state and duration of effect assigned to an exacerbation also 
differed.  These differences exist due to the general lack of RCTs in COPD that have 
been designed to collect a generic HRQoL measure such as the EQ-5D and the 
subsequent need to derive utility estimates from elsewhere: from experts, from other 
studies or from mapping from a disease specific measure to the generic measure (none 
of these studies used mapping).  Using expert opinion is unlikely to accurately capture 
utilities values and if other studies are used then there is a danger that the populations 
are different to one another.  As described earlier in section 3.2.5, utility estimates for 
people with COPD are best obtained from RCT data using a generic HRQoL measure 
such as the EQ-5D. 
The cost effectiveness analysis by Chuck et al applied dis-utilities to the model 
following an exacerbation: -0.17 for a mild exacerbation and -0.47 for a moderate or 
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severe exacerbation.  Within the models, the reduction in HRQoL following a major 
exacerbation for a very severe patient was presumed to be: 0.33 (Rutten-van Molken), 
0.27 (one month) Oostenbrink, 0.52 (one month) Sin and Spencer -0.26 (six months 
recovery time) as shown in table 4.4.  The Spencer model assumed a non-linear 
recovery following an exacerbation to a position of 0.03 utility points below those of 
others in the study that did not have an exacerbation.  Modelling recovery from an 
exacerbation in this way was novel and more likely to match the natural history of 
exacerbations compared to other approaches.  Nevertheless, the approach taken by the 
authors of deriving utility estimates for health status during an exacerbation from the 
opinions of 27 respiratory physicians, is a major limitation of the Spencer study.  
4.5 Discussion  
The output of an economic evaluation is to inform and assist the decision maker in 
allocating scarce health care resources, but how far does the existing literature go in 
fulfilling this role?   
Fundamental is the design of the study; RCT, observational study based or employing a 
model: this decision is all-important.  Economic evaluations based entirely upon RCTs, 
such as those within the non-modelling section of the chapter, with tight inclusion and 
exclusion criteria may have limited generalisabilty to a wider population which may: 
“seriously restrict their relevance for policy making”(162 p450) 
The validity of alternative data sources, such as observational studies, depends upon the 
extent to which the study populations are representative and the conclusions of such 
studies may need supporting evidence from RCTs.  It is suggested that modelling and 
the addition of observational data can enhance the external validity of the cost 
effectiveness study based on RCTs,(162) so that the study is generalisable to a wider 
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population than are contained in the RCT, and may be a useful avenue for future 
economic evaluations of COPD. 
Within an RCT based study, efficacy data are confined to the length of the trial.  To be 
of most value to clinicians and health care funding agencies, the costs and benefits 
should be considered over a period that reflects the longevity of the effects of the 
intervention.(163)  All of the economic evaluations (with the exception of the surgical 
CE analyses) and almost half of the economic models had a duration of five years or 
fewer.  A cost effectiveness ratio based solely upon the duration of the trial may fail to 
capture the longer-term effects of treatment, such as the extended life of study patients.  
This is important as there is currently an ongoing debate as to the impact of treatment 
on survival: recent evidence from trials such as TRISTAN,(50) UPLIFT,(51) and 
TORCH,(49) have suggested a survival effect of therapy in COPD patients following 
treatment with a combination product of salmeterol and fluticasone.  Incorporation of a 
mortality effect into economic evaluations using models to extrapolate from trial 
evidence, may result in dramatic reductions of the resulting ICER.(141;144)  
Extrapolation is essential within surgical interventions because large costs in the short 
run lead to large HRQoL gains for those receiving successful treatment and so a long 
term follow up is necessary to capture all the benefits of treatment.  
Several of the economic evaluations incorporated regression modelling, either for a 
particular variable, most predominantly survival, but also used for cost and for 
transition probabilities.  Briggs et al used regression modelling within a clinical trial for 
their cost utility analysis.  Several of the studies used a mapping equation to predict 
utility from a non-utility based HRQoL questionnaire, where utility data from an RCT 
was unavailable.  
There is a clear and continuing role for the use of modelling in economic evaluation of 
COPD therapies.  A modelling framework can produce externally valid studies (based 
on internally valid evidence of treatment effects), capturing the long-term effects of 
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treatment, thereby being useful in assisting the decision maker in allocating resources.  
Economic models in all their forms need to be methodologically sound, have relevant 
and valid inputs and to be well described and explained.  In addition, the sensitivity 
analysis needs to be executed with care, distributions around the inputs explained and 
reasoned, and extrapolation needs to be adopted and presented with caution.  It has been 
seen that within pharmacoeconomics for COPD, there has been a recent surge in the 
number of economic models for COPD.  Economic evaluations in the future should 
ideally be based on sufficiently long RCT study durations and on modelling, so as to 
capture the relevant costs and effects so that results are useful and relevant for decision 
makers. 
Results of economic evaluations are likely to vary according to the perspective 
employed.  The perspective should be clearly stated within the paper and the results 
presented should be based upon the adopted perspective.  Four evaluations did not 
mention perspective.(92;129;133) 
RCTs for drug treatments were principally developed for the purposes of drug efficacy 
and more often than not an economic evaluation is piggybacked onto a RCT.  As a 
result there are often problems when conducting cost effectiveness analyses where 
incremental effects and benefits arising from treatment are taken from the RCT, when 
the comparator(s) does not include ‘current treatment’.  If the comparator is not a real 
life existing/usual treatment or mix of treatment, the results have little value for the 
decision maker on which to base a decision.  Only two of the pharmacological 
studies,(141;144) and all of the analyses for surgical interventions, included a range of 
relevant alternatives, including existing treatment.  Decision makers need to know the 
full impact of the introduction of a new therapy to a disease or treatment area and this 
can best be achieved by using usual care as a comparator.  
‘Decisions on cost effectiveness should be based on the comparison of a  
new intervention with current practice, rather than with a placebo.’(164 
p711) 
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Earlier versions of the Oostenbrink 2005 model omitted the death state.  Modelling a 
chronic condition longitudinally necessarily involves mortalities and death should 
always be modelled explicitly for COPD economic evaluations and in the case of the 
Oostenbrink et al model, was corrected in later versions.  
A wide range of outcome measures have been used in economic evaluations of COPD.  
Although it may be the case that: 
“…it is neither known nor generally agreed which outcomes are most 
relevant”(165 p41) 
A range of outcome measures causes a problem for the decision maker if they are faced 
with the problem of making a judgement based on disparate results which are not 
directly comparable.  For example, to what extent is the avoidance of an exacerbation 
equivalent to an annual improvement in FEV1 of 20ml?  The economists’ solution is the 
QALY.  Within England and Wales, NICE has stated  
‘the QALY is considered to be the most appropriate generic measure of 
health benefit that reflects both mortality and HRQoL.’(95 p22).   
As was described in Chapter 3, the QALY is a particularly useful outcome measure for 
economic evaluations.  The strength of cost utility analyses based on QALYs depends 
upon the robustness of the derivation of the utility values.  In each of the three 
modelling studies that used QALYs, the utility weights applied to different COPD states 
and to the impact of exacerbations varied quite considerably.  The most likely reason 
behind these differences in utility values is the different methods of elicitation (and the 
population surveyed).  The decrement in utility (from baseline) associated with each 
exacerbation and length of time to which this decrease is applied (duration of 
exacerbation), differs considerably between studies.  It would be valuable to undertake 
further research into the derivation of utility values for COPD patients, and in particular, 
further research needs to be conducted in order to determine the effect of an 
exacerbation on utility. 
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An assessment of uncertainty should be included within an economic evaluation to 
reflect the uncertainty in the cost and health outcome results obtained from the study.  
In the case of modelling studies, there are further uncertainties, such as in the design of 
the model itself and the extrapolation of study data to a time horizon that extends 
beyond the life of the trial.  PSA is preferred for assessing uncertainty in Markov 
models because it allows the combined uncertainty surrounding all of the parameters 
within the model to be assessed.(126) 
Whilst all of the surgical interventions were developed and funded within academic 
settings, the majority of the pharmacological studies were sponsored to some extent by 
the pharmaceutical industry and the study drugs in each of these papers were reported to 
have a favourable cost-effectiveness result.  Concerns about the outcomes of these 
studies, because of issues around: selection of study design, patient population and the 
potential for bias in the outcome and in the publication, are often raised.  Nevertheless, 
the industry is an important provider of cost effectiveness data, especially to support 
submission for reimbursement in particular countries.  In addition, the industry, because 
of tight regulating standards, may pay closer attention to quality control than academic 
institutes.  Whatever the pros and cons are, industry-financed studies will continue to be 
a valuable source of data.  However there is a gap for non-industry sponsored 
evaluations of pharmacotherapy in COPD and efforts should be made to provide the 
resources necessary in order to support non-industry bodies in producing such studies.   
4.6 Conclusion 
Within this chapter the published economic evaluations for COPD treatments were 
reviewed and critically appraised.  The use of published economic evaluations in 
informing and assisting the decision maker to allocate scarce health care resources was 
then discussed.   
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The development of the reference case as discussed in Chapter 3 and recent 
methodological advances within the subject have gone some way to standardise the 
economic evaluations, as authors have increasingly: adopted the QALY as an outcome 
measure and used an economic model to carry out the evaluation.  
Consistency between evaluations is necessary in order for comparisons to be made 
between different treatments over time,(95) however observed differences within the 
reviewed studies in terms of: study design, comparators, interventions, outcome 
measures and the analysis of uncertainty, make meaningful comparison between the 
studies very difficult.  For the decision maker and for the clinician, it is of utmost 
importance that interventions are directly comparable.  Decisions must be made as to 
the most suitable treatment; informed decisions, based upon and supported by all 
available knowledge and evidence of substitute or alternative treatments are most likely 
to be appropriate.   
Efforts should be made for future economic evaluations to harmonise study design and 
methods, particularly towards adopting a universal modelling framework, using current 
treatment as comparator and adopting an effectiveness measure such as the QALY in 
order to produce results that are comparable across interventions and disease areas, and 
that are useful to a decision maker. 
A generic model where an ICER could be derived in order to compare different 
treatments for COPD would be desirable.  To maximise internal and external validity, 
combining different data including RCT and observational data is ideal within a 
modelling structure.  The following two chapters investigate different data sources with 
the ultimate objective of developing an economic model.  An observational dataset is 
studied to learn more about the natural history of COPD and from this assists the 
identification of an appropriate structure for an economic evaluation of the disease, and 
a RCT is analysed with a particular focus on utilities. 
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Chapter 5. Natural History of COPD in a 
British Population 
The analyses within this chapter are aimed at examining the natural history of COPD in 
a British population, using the Renfrew/Paisley (MIDSPAN) dataset, a Scottish 
prospective cohort followed since the early 1970s, with ongoing linked hospitalisation 
and mortality records.  It is guided by the importance of appropriately modelling the 
disease within the context of economic evaluation. 
The process of evaluating COPD treatments for disease through economic evaluation, 
particularly decision analytic modelling, requires an understanding of the disease itself.  
Initially, what is the disease and how is it defined?  How does the disease progress for 
the individual and more generally within the COPD population?  Are number of 
hospitalisations influenced by disease severity and how many hospitalisations do COPD 
patients have?  How frequent are hospitalisations and what is the length of hospital 
stay?  Which factors are important for mortality risk?  In other words, what is the 
natural history of the disease?  In Chapter 4, it was seen that when developing economic 
models for COPD, researchers have often searched the literature or consulted clinical 
experts for answers to these questions rather than fully explore primary data sources.  
The purpose of this chapter is to analyse the natural history of COPD using a large 
longitudinal dataset from which the answers to these questions can be ascertained using 
primary evidence and four different analyses were conducted for this purpose.   
Within the first analysis, summary statistics of the MIDSPAN dataset are presented. 
Prevalence of COPD in the dataset is reported.  Particular attention is given to disease 
severity, and mortality rates, survival curves and the major causes of mortality are 
determined.  
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The second analysis replicates a previous study conducted by Hole et al,(166) who 
published a paper on the link between reduced lung function and subsequent mortality 
using the Renfrew/Paisley dataset with linked mortality records.  One of the features of 
the dataset is that the follow-up of hospitalisations and mortality records is ongoing.  
The analysis in this chapter validates and updates the original analysis using all 
available data (up until December 2005). 
The third analysis examines the diagnostic criteria for COPD.  COPD is frequently 
identified based on impaired lung function and within this section the assumption that 
COPD is best diagnosed using lung function alone is questioned.  The effect of 
including a risk factor such as smoking history and symptoms in the diagnostic criteria 
for COPD is investigated. 
The final analysis investigates the number of hospital admissions and length of stay in 
hospital, before determining hospitalisation rates (or severe exacerbations) by disease 
severity for the Renfrew/Paisley population. 
First, the benefits of using the Renfrew/Paisley (MIDSPAN) dataset compared to other 
datasets are explored before the MIDSPAN dataset is described.  A section on 
epidemiology and statistics follows, explaining general concepts that are used 
throughout this chapter. 
5.1 Datasets for Investigating the Natural History 
of COPD 
Within this section, an overview of available datasets within the UK that have potential 
for study of the natural history of COPD is presented. 
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The MIDSPAN studies are comprised of three distinct large-scale epidemiological 
studies within the Scottish population and were designed to be used for researching 
issues of public health.  At the time of conception in the 1960s, the development and 
use of such large population based studies was a novel concept.  The importance of the 
MIDSPAN studies is not to be underestimated, with over 160 scientific papers written 
on findings from the studies.  Of these three studies, of particular use for examining the 
natural history of COPD is the Renfrew/Paisley (MIDSPAN) study.  Renfrew/Paisley 
was the last of the three studies to be operationalised and was the largest in terms of 
numbers recruited with 15 402 participants, of whom, 7048 were men and 8354 were 
women.  The studies were originally developed in order to provide  
“…an evidence base for the detection and control of cardio-respiratory risks 
and diseases in whole populations in addition to improving the detection and 
control of tuberculosis.”(167) 
Nevertheless, the nature of the questions asked and data collected at the time of 
recruitment lend the dataset well to the investigation of COPD, with data collected on 
lung function, smoking history and respiratory symptoms.  In addition, the study 
followed a general population with an appropriate age range for the study of COPD (45-
64 years) in a UK population.  
Other studies exist within the UK that could be used to investigate the natural history of 
COPD, including datasets based in primary care and secondary care: 
The General Practice Research Database (GPRD) is based upon 3.4 million ‘active’ 
patients from approximately 450 primary care practices around the UK.  GP Practices 
are not tied in to participating and may move into and out of providing data.  The GPRD 
aims to provide continuous information on morbidity in primary care.  In operation 
since 1988, it is said to be the largest computerised database of primary care medical 
records over time of its kind.(168)  The GPRD records include: prescriptions (acute and 
repeat), adverse drug reactions, all consultations with medical personnel, family history, 
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diagnoses, symptoms, referrals (outpatient and emergency), hospital admissions, 
hospital diagnoses, operations, surgery, tests and investigations (such as FEV1), 
contraception,  pregnancies, births, deaths (cause and date) and patient lifestyle 
including smoking history, height and weight.(168)   
The QRESEARCH database holds records for 3.3 million current and 4 million past, 
UK patients throughout 525 general practices, dating back to 1988.  It is an anonymous 
database of GP records.(169)  The database is similar to the GPRD database.  
The Health Improvement Network (THIN) database contains anonymous patient 
information from over 400 general practices around the UK.  The database is used for 
studies in: drug safety, epidemiology and health outcomes.  THIN has been in operation 
since 1988.(170)  
The Mediplus database is held by IMS.  More than 500 GP’s take part and it is regarded 
as being broadly representative of the GP population within the UK.  Information 
available for analysis includes: patient age and sex, diagnoses (International 
Classification of Disease 10 (ICD-10)) and diagnoses linked to treatment, treatment 
linked with cost, test results linked with diagnosis and referrals.(171) 
Secondary care based databases include the Scottish Morbidity Record (SMR1) and the 
Hospital Episode Statistics (HES).  The SMR1 holds data on all patients admitted to 
Scottish hospitals since 1961,(172) a total of 6 million patients and 25 million 
individual episodes of care (to the end of 2006).(173)  Each SMR1 episode (a single 
consultant in-patient episode) has an ICD-9, now ICD-10 code, recorded and for 
surgical operations, at least one operative code.  The SMR1 data have been used to 
inform a wide range of decisions: to plan trust budgets, monitor year on year trends, to 
plan hospital bed numbers, for annual reports of individual consultants/ trusts and also 
for research purposes.(172)  The SMR1 can be linked with corresponding mortality data 
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from the General Register Office (GRO) and to other Scottish datasets.  The 
Renfrew/Paisley (MIDSPAN) dataset is linked to the SMR1 dataset. 
The HES database collects information on all admitted patients treated within the 
English NHS.  The range of data that the HES gathers is similar to that collected within 
the SMR1 with information on the care and treatment a patient receives whilst in 
hospital and coded using the ICD-10.  Longitudinal data are available on patients’ 
admissions.  HES data are available since 1989, and currently approximately 12 million 
records are taken per year (approximately 150 million episodes of care had been 
reported by the end of 2003).(174)  The HES data are said to be useful for a range of 
settings from developing, monitoring and evaluating departmental policies, identifying 
public health issues, monitoring improvements in public health, and for research 
purposes.(175)  HES could be used to examine COPD hospitalisations (rates and 
frequency), length of hospital stay and survival for a COPD population (mortality data 
could be obtained from the Office of National Statistics).  HES can be linked to other 
datasets.   
Other databases available for examining the natural history of COPD include: the 
Health Survey for England and the Scottish Health Survey.  The Health Survey for 
England has been running since 1991 and is an annual survey of a random sample of 
individuals from private households in England.  The sample is thought to be 
representative of the general population.  The Health Survey for England collects data 
on a range of socio-demographic, lifestyle, behavioural and biological variables.  The 
data are collected via interview and physical examination.  Key variables such as height, 
weight, smoking, drinking, blood pressure and general health are collected annually.  In 
addition, each year sees a new focus for the survey, of particular interest is:  asthma, 
accidents and disability in 1995, asthma, accidents and special measures of general 
health (including measurement of EQ-5D and SF-36) in 1996, and respiratory disease 
and atopic conditions, disability and non-fatal accidents in 2001.  In the years, 1995, 
1996, 1997, 2001 and 2002, several respiratory related questions were included as well 
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as lung function measurement (FEV1).  Analysis of this dataset would allow an 
estimation of the prevalence and incidence of COPD in relation to socio-demographic, 
lifestyle and behavioural factors.  However there are limitations which exist because of 
the cross sectional nature of this survey, in particular, that the same people are not 
followed up at each survey.  
The Scottish Health Survey aims to assess a representative sample of health and health 
related behaviours within private households in Scotland.  It has been carried out three 
times: in 1995, 1998 and 2003.  To date, more than 25 000 individuals have participated 
in the SHS.  The survey involves two stages for each participant: an interview and a 
nurse visit.  The interview covers a wide range of questions, including self assesed 
health and disability, health service utilisation, respiratory disease, smoking, drinking 
and socio-economic status.  The nurse collects additional information including the use 
of prescribed medicine and takes clinical measures: blood pressure, lung function and 
collects blood and saliva samples.(176)  It is possible to link the Scottish Health Survey 
to data from the SMR1 and the SMR4 (acute psychiatric hospital admissions), cancer 
registers and mortality data from the GRO. 
Whilst it can be seen that there are a number of other databases available within the UK 
that could be used to study the natural history of COPD, the Renfrew/Paisley study is 
unique and is ideal for analyses around the natural history of COPD.  The 
Renfrew/Paisley study provides a wealth of information on a sizeable population who 
have been continuously followed since the start of the study in the early 1970’s until the 
end of 2005 in terms of both hospitailsation records and mortality.  One particualar 
merit of the study is that follow up is either ongoing or complete for the majority of 
participants.  Study participants continually residing within the UK had or will have 
complete follow up on mortality within the dataset.  For participants continuously 
residing in Scotland, there is complete/ongoing follow up on both mortality records and 
hospitalisations.  The time period and geographical location in which this study 
operated meant that few left the study location of Renfrew/Paisley, let alone the UK so 
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follow up is particularly strong.  Added to that the high participation rate at the 
beginning of the study (78% of the general population in the two towns) and the result 
is an impressive and potentially highly informative UK general population study.  The 
following section provides more detail on the Renfrew/Paisley (MIDSPAN) study. 
5.2 Renfrew/Paisley (MIDSPAN) Study 
The Renfrew/Paisley (MIDSPAN) study recruited from the general population of two 
towns, Renfrew and Paisley, located near Glasgow in Scotland between 1972 and 1976.  
All residents within the towns aged between 45 and 64 were invited to participate and 
asked to complete a self-reported questionnaire.  They were then called for a screening 
examination.  The total study population comprised 15 402 participants, representing 
78% of the eligible population.  
The self reported questionnaire asked a broad range of demographic and health 
questions, including: date of birth, sex, marital status, occupation, smoking history, the 
presence of phlegm and/or cough, breathlessness, wheeze, MRC bronchitis, angina, 
stroke symptoms and asthma.  An example of the record card is reproduced in the 
appendix.  The clinical examination measured, amongst other things: height, weight, 
blood pressure, plasma cholesterol and respiratory function (FEV1 and FVC).  Each 
participant had a chest x-ray.  Details on occupation were used to determine 
occupational social class.  Carstairs deprivation scores were derived based on the 
postcode of home address.  BMI and FEV1 % predicted were derived from the clinical 
examination data. 
Since the start of the study in 1972, the MIDSPAN cohort have been linked to 
information held by the GRO for Scotland on all UK deaths,(177) and more recently, to 
all acute hospital discharges in Scotland through the SMR1 recording scheme.(178)  
Each hospitalisation and mortality is coded using ICD codes.  Record linkage is on 
going and is set to continue until the study population has died out.  The most recent 
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dataset available for analysis contains all mortality and hospitalisation records until the 
31st December 2005 and is the dataset that is used within this chapter to conduct all 
analyses in order to investigate the natural history of COPD in a British population.  
5.2.1 Missing Data  
Two percent (n=368) of the participants were excluded from the analyses within this 
chapter, including participants who had data missing on any of: lung function (FEV1 
and FVC), respiratory symptoms (identified using the questions described in figure 5.3), 
height, age at starting smoking for current and ex-smokers and age at stopping smoking 
for ex-smokers.  Other missing values by sex, were replaced by the mean value for 
diastolic blood pressure (n=8) and cholesterol (125), and by the modal value for social 
class (406).  Participants who moved outside the UK were censored at the date of 
embarkation.(115)  Twenty three participants were lost to follow-up and were also 
excluded. 
Because there are only small amounts of missingness within the dataset, considering the 
patterns of missingness and appropriate responses is less important than if there were 
significant amounts of missing data.  More space is given to discussions around 
missingness in Chapter 6. 
5.2.2 Reference Values for Lung Function  
As described earlier in Chapter 2, FEV1 % predicted is used in diagnosing COPD and in 
stratifying by disease severity.  Calculating a subject’s FEV1 % predicted is done by 
dividing that person’s observed FEV1 by a predicted FEV1.  The predicted FEV1 
represents the expected lung function value for a ‘healthy’ person, with the same age 
and gender as the person under study.  
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Many equations have been developed that calculate predicted FEV1 within various 
populations, usually with age and height as the independent variables,(179) and split by 
gender.  The extent to which any of these equations relate to the Renfrew/Paisley 
(MIDSPAN) population is questionable as reference values are ideally calculated from 
measurements observed in a representative sample of healthy subjects within a general 
population.(180)  A ‘healthy’ person can be identified as one with no respiratory disease 
or systematic disease and a lifelong non smoker (or who has no more than incidental 
smoking experience).(181)  In order to produce representative % predicted lung 
function values for participants within MIDSPAN, equations for predicting FEV1 were 
developed within the study population using only those subjects who met the ‘healthy’ 
criteria.  Predicted FEV1 for each subject was determined by a linear regression on age 
and height by sex using the healthy participants in the cohort.  Those who answered 
‘yes’ to questions on presence of wheeze, breathlessness, asthma, phlegm and the 
weather affecting their health as well as a smoking history were excluded.  The 
remaining healthy participants comprised 870 men and 2792 women.  The resulting 
regression equations with standard errors (SE) (R2 = 0.26) for men and women were: 
FEV1 (l) in men = -1.859 (0.532)- 0.029 (0.003) x age(yrs) + 0.037 (0.003) x height(cm) 
FEV1 (l) in women = -0.225 (0.230)- 0.029 (0.001) x age(yrs) + 0.024 (0.001) x 
height(cm) 
 
FEV1 % predicted was calculated for each subject using actual FEV1 divided by 
predicted FEV1.  These equations slightly differ from previously published equations 
from the same dataset,(166) due to improved data recording in the dataset (details of 
which are described in section 5.5.1).  STATA v10,(182) was used in all analyses. 
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5.3 Epidemiology and Statistics 
Disease prevalence is defined as how much of a disease is present in a population at a 
point in time.  Prevalence is calculated by dividing the number of people with a 
particular disease by the total number of people in the study at that time point.  For 
example, if 500 people are diagnosed with COPD from a study population of 10 000 
then disease prevalence would be equal to 500/10 000.  Prevalence is usually expressed 
as a percentage, so in this case COPD prevalence would be 5%.  Prevalence data can be 
used to compare prevalence between groups, for example it is probable that smokers are 
more likely than non smokers to have COPD, also that older people are more likely to 
have the disease than those who are younger.  
Another measure that is frequently used in epidemiology studies is incidence.  Incidence 
measures the rate of occurrence of new cases of a disease.  It is calculated by dividing 
the number of new cases of a disease by the size of the disease free population.  
Because the Renfrew/Paisley dataset only contained information on patient 
characteristics from one time point, it is not possible to calculate incidence within the 
dataset.  
Mortality rates are a measure of the number of deaths in a specific population, scaled to 
the size of the population, per unit of time.  Mortality could be from either all-cause or 
disease specific causes.  Mortality rates are given here per 10 000 individuals per year. 
5.3.1 Survival Analysis 
Survival analysis is used throughout this chapter for analysing time to event data.  Some 
basic terminology is presented here, together with a discussion around the appropriate 
time frame to use within longitudinal studies.  
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Unique to the analysis of longitudinal data where time to event is of interest, is the 
notion of censored data.  This concept was brought to light widely in the paper by 
Kaplan and Meier in 1958.(183)  Within survival data, participants will either: 1) 
participate in the study until the event of interest 2) leave the study before the event of 
interest has occurred or 3) remain in the study until the study completion date and not 
have the event of interest.  Survival analysis allows for censoring to occur.  
An example of a longitudinal dataset with 10 participants, lasting for 25 years is 
presented below in table 5.1 and facilitates the explanation of some of the key concepts 
used within survival analysis.  The event of interest is mortality and the dataset focuses 
around age at entry and age at exit, the rationale for which is described in the following 
section. 
Within table 5.1, the age when each participant entered the study (column 2) and the age 
when they exited the study is recorded (column 3), together with information on if they 
were: alive, dead or whether they left the study before the end of the study (column 4).  
For example, participant A entered the study at age 45 and left the study 25 years later, 
aged 70 and alive, participant B entered the study at age 49 and died 30 years into the 
study, aged 79 and participant D entered the study at age 54 and exited just 3 years later.  
All participants who died have a value of one in the event column, or else zero (column 
5), and all those who were either alive at the end of the study, or exited before study 
completion, have a value of one in the censored column, or else zero (column 6). 
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Table 5.1 Survival data for a hypothetical study  
 Age enter 
study 
Age exit 
study 
Outcome Event Censored 
A 45 70 Alive 0 1 
B 49 79 Dead 1 0 
C 51 76 Alive 0 1 
D 54 57 Left study  0 1 
E 56 69 Dead 1 0 
F 58 83 Alive 0 1 
G 60 85 Dead 1 0 
H 60 72 Dead 1 0 
I 62 87 Alive 0 1 
J 63 81 Dead 1 0 
 
Another way of presenting these data is shown in figure 5.1 where age is placed along 
the x axis and for each participant (represented by a bar), age of entry into the study, age 
of exit and outcome and events of interest are plotted.  This way, the number of 
participants left in the study following an outcome can easily be established.  
 
At each time point at which an event (mortality) occurs, a survival probability, S(t) is 
calculated and for the above cohort, given in table 5.2.  S(t) is defined as:  
( ) ( )
t
tt
n
dntrtS −=−=1  
where r(t) represents the estimated risk of mortality at the exact time of the event and is 
calculated by dividing the number of events, dt by the total number at risk nt.  For 
example the risk of mortality for patient E, when that patient died at time t was 
calculated in table 5.2 by: 
r(t) = dt/nt = 1/9 = 0.11 
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Figure 5.1 Visual representation of time in study and events, participants in a hypothetical study  
Vertical lines represent outcomes of interest (A=alive, D=dead, C=censored) 
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If an event does not occur (for instance where censoring occurs) s(t) is always equal to 
1.  The survivor function is calculated by multiplying S(t) in the previous time point by 
s(t) at the current time point, and is formally described below: 
( ) ( )( ) ( ) ( ) ( ) ( )jjjj tststststStS ...211 ××=×= −  
The survival probability S(t) is the probability that an individual survives until at least 
time t.(184)  Because the survival probability only changes when there is an event, the 
value of the survival function, S(t), is constant between events and the estimated 
probability is a step function.(185)  For example, for the time point at which the first 
person (who is censored) leaves the study, the S(t) remains at 1.00, this compares to the 
S(t) for the second observation which was calculated as: 
S(t) = 1.00 x 0.89 = 0.89 
The values for r(t), s(t), S(t) based on nt, dt and ct (censored at time t) for the ten 
participants are shown below in table 5.2 
Table 5.2 Calculation of the survival function  
Age (yrs) nt dt ct r(t) s(t) S(t) 
57 5 0 1 0.00 1.00 1.00 
69 9 1 0 0.11 0.88 0.88 
70 8 0 1 0.00 1.00 0.88 
72 7 1 0 0.14 0.86 0.76 
76 6 0 1 0.00 1.00 0.76 
79 5 1 0 0.20 0.80 0.61 
81 4 1 0 0.25 0.75 0.46 
83 3 0 1 0.00 1.00 0.46 
85 2 1 0 0.33 0.66 0.30 
87 1 0 1 0.00 1.00 0.30 
 
Survival data are usually described and modelled in terms of two rates: survival as 
previously described, and hazard.  The hazard function, h(t) describes the event rate at 
time t conditional on survival up until time t, or beyond.  The cumulative hazard, H(t) is 
the total hazard experienced up to time t and is estimated by the sum of the risks at each 
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time point at which an event occurs.  S(t) is related to H(t) as described by the formula 
below: 
)()( tHetS −=  
5.3.2 Kaplan-Meier Curves 
The Kaplan-Meier survival curve is essentially a plot of the survival probability S(t) 
against time.  It is easy to compare the survival probabilities in different groups using 
this visual method and also to determine the median survival time if applicable.  Within 
this chapter, Kaplan-Meier curves are used to compare survival in different COPD 
severity groups and between groups identified using different diagnostic criteria. 
The time frame to use within survival analysis is debated.  Time in the study has often 
been used, however age, rather than time in the study has been recommended as the 
appropriate time scale within a longitudinal study.(186;187)  This is because for some 
outcomes, such as COPD, it is expected that the hazard would change more as a 
function of age than as a function of time in the study.(186;187)  To illustrate this point 
within the MIDSPAN study, it is argued that it is reasonable to assume that a participant 
who entered the study at 45 would have a lower hazard of mortality than a participant 
aged 65.  Using the traditional method of time in the study as the time scale, there is an 
assumption that any two participants have the same hazard after a certain amount of 
time in the study (five years, ten years etc), however, it seems logical that in general, a 
fifty year old would, ceteris paribus, have a lower hazard compared to a seventy year 
old.  For other studies, particularly clinical trials, time in study is likely to be a more 
appropriate timeframe because RCTs are looking for differences in treatment groups.  
As each treatment group is usually randomised, there should be no differences in the 
age distribution between groups and it is the time on treatment and subsequent effects of 
treatment that are of interest and which are studied through the use of time in study as 
the time frame.  Using age as the time scale allows the median age of survival (at death) 
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to be read from the survival curve.  The median age is found by reading off the x axis 
when the survival curve/function is equal to 0.5.  The equivalent when using the 
traditional method is median time to event from the start of the study, the interpretation 
of which is less informative. 
Note that at the start and at the end of the study, the numbers at risk are small.  In 
standard survival analysis, precisely because the right hand tail of the Kaplan-Meier 
curve is based on comparatively fewer participants data than at other points on the 
curve, it is advised that when the number of observations is low (approximately five) 
either these values are omitted entirely from the analysis or that any interpretation is 
dismissed for these points.  For the same reason, when using age along the x axis: 
because values at the left hand side of the curve are also based upon fewer observations, 
it is advised that interpretations of these areas are not made (discussed and illustrated in 
section 5.4.2). 
A limitation of using age as the time variable, is that a person with moderate COPD 
entering the study aged 65 is treated the same a person with moderate COPD aged 45 on 
entry to the study, who survives for 20 years.  This is problematic because after 20 years 
the person with moderate COPD at baseline may have worse disease severity such that 
they would be in the severe COPD group.    
The corresponding survival curve for the data described in the previous section is shown 
in figure 5.2.  With age on the x axis, the first event at age 69 causes a corresponding 
drop in the survival curve.  Events occurring in the dataset at different ages are clearly 
shown using this method.  Median survival is shown where the dotted line meets the 
survival curve, at approximately 80 years of age.  
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Figure 5.2 An example of a survival curve with age on the x axis  
 
5.3.2.1 Cox Proportional Hazards Model 
The Cox proportional hazards model is the most commonly used model for conducting 
survival analysis.  The model describes the relationship between the event of interest 
(usually mortality) and the covariates, by way of Hazard Ratios (HR).  
The Cox model is expressed as: 
}{ qqxbxbxbthth +++×= ...exp)()( 22110  
where the hazard function, h(t) is dependent upon a set of q covariates ( )qxxx ,, 21  and 
whose impact is measured by the size of the coefficients ),,,( 21 qbbb  on those 
covariates. (188)  The equation gives the hazard for the exposed group (h1(t)).  The 
hazard of the unexposed group, ho(t)is equal to the value of the hazard if all of the x’s 
are equal to 0 (which when exponentiated gives a value of 1).   
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The HR from comparing the exposed group to the unexposed group at time t is given by 
the equation below and provides a measure of the relative survival experience between 
the two groups.(185)    
( ) ( )
( )
( ) ( )
( )
( )1
0
10
0
1 expexp ββ =×== th
th
th
thtHR  
Because h0(t) appears in the top and bottom of the equation, they cancel one another 
out, and the HR is equal to the exponential of the linear equation.  A HR with a value of 
one corresponds to the groups having equal hazards.  A HR that is greater than one 
means that an explanatory variable is positively associated with the event of interest and 
conversely, if the HR is below one, that the explanatory variable is negatively 
associated with the event of interest. 
One of the benefits of the Cox regression model is that because it is estimated non-
parametrically, the model does not assume or impose any particular distribution on the 
dataset, however an important assumption of the model is that of proportional hazards: 
that the ratio of the hazards in the exposed group to the hazards in the unexposed group 
remains constant over time, as illustrated in the equation below.(189) 
( )
( )
=th
th
0
1 constant 
Fulfilling the proportional hazards assumption is important when it is the absolute 
magnitude of effect of the independent variables that is of interest.  If instead it is the 
relationship between variables that is of interest, then the assumption may be considered 
as having a secondary role.(190)  If the assumption of proportional hazards is violated 
then the corresponding risk estimates may be inaccurate,(190) and the associated p 
values and CIs may be misleading.(191) 
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The assumption of proportional hazards can be tested either graphically or by using 
Schoenfeld residuals.(192)  The graphical method involves plotting the log of the 
cumulative hazards function for each group against the log of time, which should give 
parallel lines.(193;194)  With the graphical method, for the assumption to hold, the 
hazard curves for the groups should not cross and they should be proportional.  The 
Schoenfeld residual is defined as the explanatory value for the individual that failed 
minus its expected value, and calculates separate residuals for each explanatory 
variable.(192)  The Schoenfeld residuals are independent of time and as a result, the 
proportional hazards assumption can be assessed by testing the association between 
residuals and time.(193)  A non-significant relationship between the residuals and time 
supports the proportional hazards assumption whereas a significant relationship 
suggests the proportional hazards assumption has not been met.  Options to address the 
problem of violation of the Proportional Hazards assumption if it arises include: 
conducting the analysis stratified by the variable in question,(190) and including 
previously omitted variables or interaction terms into the model,(194) (if known). 
5.4 Exploratory analysis 
Within this section, exploratory analyses are conducted within the Renfrew/Paisley 
dataset in order to obtain information on the disease, such as prevalence of COPD in the 
general population, survival duration and mortality rates by disease severity, and causes 
of mortality for people with COPD. 
5.4.1 Methods 
COPD cases were identified using the NICE diagnostic criteria for COPD (which were 
outlined previously in Chapter 2 and the rationale for adopting these criteria is discussed 
later in detail in section 5.6), NICE suggest that a diagnosis of COPD should be 
considered in patients aged over 35 with airflow obstruction (FEV1/FVC<0.7 and 
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FEV1<80% predicted), a risk factor (principally smoking) and who present with one or 
more of: exertional breathlessness, chronic cough, regular sputum production, frequent 
winter ‘bronchitis’ or wheeze).(7)  Assumptions were made to identify NICE COPD 
cases within the dataset:  
• Airflow obstruction: FEV1/FVC<0.7 and FEV1<80% predicted. 
• Respiratory symptom(s): one or more of breathlessness, wheeze, phlegm, 
identified using the questions listed in figure 5.3. 
• Risk factor: either a smoking history of ten pack years or more, or being a 
pipe/or cigar smoker.  
Disease severity was applied to the COPD cases according to FEV1 % predicted.  Mild 
COPD was identified in subjects with 50 FEV1< 80% predicted, moderate COPD 
where 30 FEV1< 50% predicted and severe COPD where FEV1<30% predicted. 
 
Figure 5.3 Inclusion criteria for respiratory symptoms within the NICE COPD diagnostic 
criteria 
 
All analyses were conducted by disease severity groups and by sex.  Prevalence of 
COPD was determined.  Kaplan-Meier survival curves (with age on x axis) were 
produced to illustrate the impact of COPD and COPD disease severity on survival.  
Presence of a self-reported respiratory symptom was considered if the 
participant answered positively to one or more of: 
 
“Do you get short of breath walking with people of your own age on 
level ground?” 
OR 
“Does your chest sound wheezy or whistling on most days (or nights)?” 
OR 
“Do you usually bring up any phlegm from your chest first thing in the 
morning in the winter?” plus, yes to either: “do you bring up phlegm like 
this on most days for as much as three months in the winter each 
year?” or “in the past three years have you had a period of increased 
cough and phlegm lasting for three weeks or more?”  
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Mortality rates were calculated for all-cause mortality and for COPD mortality using 
person-years at risk.  COPD mortality was identified where mortality records contained 
any of the following codes: ICD-9: 490-492 and 496 and ICD-10 J40-J44, in any 
position. 
In a secondary analysis, first cause of death was identified in order to establish the 
degree of co-morbidity for COPD patients.  The focus was on cardiovascular disease, 
respiratory disease and cancers as these three causes represent a high proportion of 
cause of mortality in the general population.  ICD codes were: ICD-9 460-519 and ICD-
10 J00-J99 for respiratory disease, ICD-9 140-208 and ICD-10 C00-C99 for cancer and 
ICD9 390-459 and ICD-I0 I00-I99 for cardiovascular disease.  The proportion of deaths 
from these three causes of mortality was presented by disease severity. 
5.4.2 Results 
The Renfrew/Paisley (MIDSPAN) general population study comprised 15 034 
participants of whom 46% were men and 54% were women.  The majority of the 
participants have died: 78% of the men and 66% of the women.  Most of the 
participants were smokers or had smoked, 77% of men and 46% of women had ten or 
more pack years (where one pack year is defined as 20 cigarettes smoked per day for 
one year).  The participants tended to be from a working class background with the 
modal social glass group of III manual (IIIM) for men and IV for women.  The mean 
BMI values show that on average both men and women were slightly overweight. 
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Table 5.3 Baseline characteristics of the study population 
 Men Women 
Participants, n 6861  8173  
Deceased, n (%) 5381 (78) 5378 (66) 
Years of follow up, mean (SD) 
 
19.8(9.6) 23.2(8.9) 
Years of follow-up (range)  0-34 0-34 
Age, mean (SD) 54.6(5.6) 54.9(5.6) 
Social Class (mode) IIIM IV 
Body Mass Index, mean (SD) 25.9(3.4) 25.8(4.5) 
Smoking  10yr pack yrs, n (%)  5264 (77) 3757 (46) 
 
Prevalence 
COPD prevalence was lower for women than for men with overall COPD prevalence in 
the study of 12.4% (n=854) for men and 4.7% (n=388) for women.  Of those diagnosed 
with COPD, the majority had mild rather than moderate or severe COPD.  This is 
clearly illustrated in table 5.4, which shows that 8.5% of the men in the study and 3.3% 
of the women were diagnosed with mild COPD compared to 4% of men and 1.5% of 
women who were diagnosed with moderate or severe COPD at baseline.  
Within the COPD cases, the proportion of subjects in each disease severity group was 
similar for men and women.  As seen in table 5.4, 67.9% of the men were in the mild 
group compared to 68.8% of women, 23.9% of the men and 24.7% of the women were 
in the moderate group and 8.2% of the men and 6.4% of women were in the severe 
COPD group. 
Table 5.4 Prevalence of COPD disease severity (%)  
within: 1) the general population study and 2) COPD cases, men (left) and women (right) 
 N in 
group 
General 
pop 
(n=6861) 
COPD 
cases 
(n=854) 
 N in 
group 
General 
pop 
(n=8173) 
COPD 
cases 
(n=388)  
Mild 580 8.5  67.9  267 3.3 68.8 
Moderate 204 3.0  23.9  96 1.2 24.7 
Severe 70 1.0  8.2  25 0.3 6.4 
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Survival 
The survival curves shown in figure 5.4 for all-cause mortality showed clear separation 
by disease severity.  The severe COPD group had the lowest survival probability in men 
and women and the no COPD group, the highest survival probability.  The median age 
of survival was associated with disease severity.  On average, participants with severe 
disease had a life expectancy of 20 years fewer than the no COPD group for all-cause 
mortality. 
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Figure 5.4 Survival curves for all-cause mortality for men (top) and women (bottom) by 
COPD disease severity 
 
The large jumps at the start of these curves illustrate the point that was previously made 
in section 5.3.1.  Because few subjects entered the study aged 46 and 47 (the youngest 
members of the study), when a 46 year old died within the first year of the study, this 
caused a large jump in the Kaplan-Meier curve because the number at risk, n(t) was low 
and the corresponding event risk, r(t) was high so the effect on S(t) was large.  This 
contrasts to other age groups such as age 65 where thousands of subjects were in the 
number at risk group and where one person dying would have a small impact on the 
S(t).  Therefore, for the youngest ages in the study, large drops in the S(t) curve impact 
on the shape of the survival curves at the left hand side.  Therefore when using this 
approach, for ages where there are only small numbers at risk, curves representing 
survival at these ages should be ignored.  Adjustment methods can be used to limit the 
impact at the left hand side of these curves, and an approach for this is developed in the 
analysis comparing NICE to GOLD diagnostic criteria. 
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Mortality 
Within this section, the effects of COPD disease severity on mortality rates for all cause 
and COPD mortality are described. 
All-Cause Mortality Rates 
All-cause mortality rates were seen to increase with disease severity, with a higher 
mortality rate by disease severity in men than in women.  Table 5.5 shows that all-cause 
mortality rates in the no COPD group for men (women) were 372 (276) per 10 000 
person years for men, this compares to 559 (417) deaths in every 10 000 person years at 
risk in the mild COPD group, 733 (582) in the moderate group and 1318 (634) deaths in 
every 10 000 person years at risk in the severe group.  
Table 5.5 Mortality rates by disease severity, men and women 
  
N in 
group 
N 
deceased 
Person 
yrs at risk 
Rate p/10 
000 person 
yrs 
No COPD 13792 9635 305742 315 
mild 847 750 14733 509 
moderate 300 281 4148 677 
Men & 
women 
severe 95 93 902 1031 
No COPD 6007 4588 123209 372 
mild 580 532 9511 559 
moderate 204 192 2619 733 Men 
severe 70 69 523 1318 
No COPD 7785 5047 182533 276 
mild 267 218 5222 417 
moderate 96 89 1529 582 Women 
severe 25 24 378 634 
 
COPD Mortality 
The impact of disease severity on COPD related mortality is illustrated in table 5.6.  The 
proportion of people with COPD related mortality rose as disease severity increased.  In 
table 5.6 it can be seen that compared to 4% of the no COPD population, 21% of the 
mild group, 44% of the moderate group and 51% of the severe COPD population had 
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COPD recorded on their death certificate.  This pattern was observed in both men and 
women. 
Table 5.6 Percentage of the study with COPD coded mortality, by disease severity  
  N COPD mortality    
N (%) 
No COPD 13 792 557 (4) 
Mild 847 180 (21) 
Moderate 300 132 (44) 
Men & 
women 
Severe 95 48 (51) 
No COPD 6007 285 (5) 
Mild 580 123 (21) 
Moderate 204 93 (46) Men 
Severe 70 40 (57) 
No COPD 7785 272 (3) 
Mild 267 57 (21) 
Moderate 96 39 (41) Women 
Severe 25 8 (32) 
 
Major Causes of Mortality 
Primary causes of death for the study participants were compared by disease severity 
with a focus on cardiovascular disease, cancer and respiratory disease.  Of the men and 
women, 70% and 56% respectively died from one of these three causes of mortality: 
39% of the men died of cardiovascular disease compared to 32% of the women, 23% of 
men died from cancer compared to 18% of the women and 8% of the men died from 
respiratory disease and 6% of the women. 
The three primary causes of mortality (cardiovascular disease, cancer and respiratory 
disease) accounted for 34% of deaths in the no COPD group, 45% of mild, 48% of 
moderate and 67% of severe COPD deaths and which is illustrated in figure 5.5.  Cause 
of death changed with disease severity: over 50% of those in the severe COPD group 
died of respiratory disease which is represented in the final column in figure 5.5, 
compared to 6% in the no COPD group which is shown in the first column in figure 5.5.  
Mortality attributable to cancer was proportionally less for severe COPD patients 
compared to the no COPD group with 13% of deaths as a result of cancer within a 
severe COPD group compared to 20% in the no COPD group, though the absolute 
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number of people with cancer was small in the severe group, n= 12 compared with 
n=2735 in the no COPD group.  The proportion of deaths due to cardiovascular disease 
was also less for the severe COPD group than the no COPD group with 2% of 
cardiovascular mortalities in severe COPD compared to 8% in no COPD participants. 
 
Figure 5.5 Cause of death by disease severity 
 
5.4.3 Summary 
People with COPD are at higher risk of all-cause mortality than the general population 
without COPD.  This risk increases with disease severity and severe COPD patients 
have a mortality risk approximately three times that of the no COPD group.  Increased 
risk affects survival duration and the data show that, adjusted for age, people with 
increasing disease severities have on average, a shorter life expectancy, such that for the 
severe group, life expectancy was as much as 20 years fewer than in the no COPD 
population.  Survival curves for COPD by disease severity, presented as shown in this 
section with lengthy follow up of mortality data, have not previously been seen before 
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within the published literature.  An economic model would need to factor in this 
increased risk of mortality by disease severity (which is directly related to FEV1 % 
predicted) and take into account that it would be inappropriate to model a COPD 
population as having the same mortality risk as a non COPD population.  
The proportion of people with COPD recorded on their death certificate was seen to 
increase in line with disease severity and was recorded in over 50% of death certificates 
for those people who had severe disease.  Conducting analyses where COPD mortality 
is identified based on COPD coding in any diagnostic position on the death certificate is 
likely to overestimate the significance of COPD as cause of death.  This is because the 
disease may have been recorded on the death certificate without actually playing a 
direct part in final cause of death.  Thus it is more conservative to use primary cause of 
death on which to conduct analyses for diseases and because of this, subsequent 
analyses on mortality data focus on the principal cause of death.  
The three primary causes of death investigated (cardiovascular disease, cancers and 
respiratory disease) represent a significant proportion of cause of death for people with 
COPD, indicating the degree of co morbidities present in COPD cases and the range of 
causes of death that the COPD population may suffer.  When designing an economic 
model for COPD it is important to consider the causes of death within the analyses.  The 
analyses conducted within this section have shown that it would be unwise to focus 
exclusively on COPD related mortality for a COPD population as this only represents a 
proportion of cause of death.  More appropriate would be to consider all-cause 
mortality.  
5.5 Impaired Lung Function and Mortality Risk 
One of the most influential analyses of the Renfrew/Paisley (MIDSPAN) dataset was by 
Hole et al and was published in 1996.  The study assessed the relationship between 
impaired FEV1 and mortality.(166)  As described in Chapter 2, impaired lung function 
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is a key factor within COPD and is an indicator of disease severity.  As shown in the 
previous section, as disease severity (which is defined by FEV1 % predicted alone) 
worsens, mortality risk increases.  This section analyses the extent to which impaired 
lung function affects mortality risk, away from disease severity, by replicating and 
extending the Hole et al study.  The duration of available follow up between the original 
study and 2005 has increased from a mean of 15 years and now contains mean follow 
up duration of approximately 20 years.   
Over recent years, some of the original coding of sex within the dataset was found to be 
incorrect and the total number of participants in the current version is slightly fewer 
than previously reported (15 402 vs 15 411).  Therefore study numbers differ in the 
most recent version as previously described compared to those reported in the Hole et al 
paper.  Most importantly there are now 7049 men compared to the 7058 as was reported 
in the Hole et al paper. The number of women has stayed the same.   
The degree to which impaired lung function affects mortality risk (represented by HRs) 
within a general population for all-cause, respiratory and COPD mortality was 
calculated.  The original study is described below before the updated analysis is 
presented in section 5.5.2.  Secondary analyses investigated the extent to which having 
age on the x axis within the survival analysis as opposed to time, affected HR estimates. 
5.5.1 Review of the 1996 Hole et al Paper 
The aim of the Hole et al study was to assess the relationship between baseline FEV1 % 
predicted and subsequent mortality using the MIDSPAN population with 15 years of 
linked mortality data.  The main outcome measure was all-cause mortality.  Secondary 
analyses were carried out for other causes of death however the focus in this section is 
on all-cause and respiratory mortality in line with the themes of the thesis. 
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Methods 
The dataset contained an average of 15 years of follow up of mortality.  Variables of 
interest within the study included mortality, FEV1 % predicted, age at screening, history 
of cigarette smoking, diastolic blood pressure, cholesterol concentration, BMI and 
social class.  Analyses were conducted based on FEV1 % predicted.  
Predicted FEV1 for each subject was obtained from linear regressions on age and height 
on 878 men and 2796 women, classified as ‘healthy’ using the same method as 
described earlier in section 5.2.2.  The resulting predicted FEV1 equations for men and 
women are reproduced below and were used to determine FEV1 % predicted (observed 
FEV1 divided by % FEV1).  The prediction equations slightly differ in the constant term 
from those reported in section 5.2.2 because of differences in the dataset as previously 
described. 
FEV1 (l) in men = -1.9302 – (0.0290 x age(yrs)) + (0.0373 x height(cm)) 
FEV1 (l) in women = -0.2662 – ( 0.0289 x age(yrs)) + (0.0238 x height(cm)) 
 
Participants were split into five groups according to FEV1 % predicted.  Those with the 
lowest 20% FEV1 % predicted values went in group 1 and those with the highest (least 
impaired) FEV1 % predicted values went into group 5.  All other participants went into 
groups 2, 3 and 4 depending upon degree of lung function impairment. 
The association between FEV1 % predicted and mortality (adjusted for age, cigarette 
smoking, diastolic blood pressure, cholesterol concentration, BMI and social class) was 
examined using Cox’s proportional hazards models, by group.  Group 5, the least 
impaired group, was the base case. 
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Results 
At the start of the study there were 15 411 participants of which 7058 were men and 
8353 were women.  After the follow up period, 4439 of the participants had died, 2454 
of the men and 1844 of the women.  Five equally sized groups (quintiles) were derived 
based on FEV1 % predicted values.  For men, FEV1 % predicted values <73 meant that 
they were in group 1, values between 73 and 86 placed participants in group 2 , 87-98 
scores went into group 3, 97-107 values into group 4 and a FEV1 % predicted score of  
108 placed participants in group 5, which was the base case and represented those with 
the least impairment.  For women, the corresponding FEV1 % predicted values were 
<75 for group 1, 75group 2<90, 90group 3<101, 101group 4<113 and participants 
with FEV1 % predicted values 113 went into group 5. 
Table 5.7 HRs by mortality from all-cause, respiratory and lung cancer  
and by lung function group, in men and women. Adapted from Hole et al.(166)  
HRs (95%CI) vs group 5(HR=1) Cause 
of death 
Sex N 
dead Group 1 Group 2 Group 3 Group 4 
M 2545 1.92(1.68-2.20) 1.51(1.31-1.74) 1.45(1.26-1.68) 1.28(1.1-1.48) All-
cause W 1894 1.89(1.63-2.20) 1.52(1.30-1.77) 1.21(1.03-1.42) 1.17(0.99-1.38) 
M 198 9.35(4.87-17.97) 2.02(0.96-4.25) 1.45(0.65-3.32) 1.12(0.48-2.60) Respira
tory W 115 6.47(3.17-13.19) 2.95(1.38-6.29) 1.00(0.40-2.54) 1.04(0.41-2.61) 
Groups were split by FEV1 % predicted. For men: <73=group 1, 73group 2<87, 87group 3<97, 97group 4<108 and 108 = 
group 5. For women: <75=group 1, 75group 2<90, 90group 3<101, 101group 4<113 and 113 = group 5.  
 
As seen within table 5.7, those participants with FEV1 % predicted values  <108 in men 
(groups 1-4) and <101 in women (groups 1-3) were found to have a significantly 
increased mortality risk for all-cause mortality compared to those in group 5.  The HR 
for all-cause mortality in group 1 was 1.9 for men and women.  For deaths from 
respiratory disease, group 1 for men and women and group 2 for men were found to 
have increased mortality risk, table 5.7 shows that the HRs for group 1 were 9.35 for 
men and 6.47 for women. 
Increased mortality risk was identified in subjects whose FEV1 was moderately lower 
than the FEV1 % predicted, regardless of group.  The authors found that participants 
smoking fifteen or more cigarettes daily, with low cholesterol, placed in low social class 
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groups and who had reduced FEV1 % predicted, had the highest mortality risk.  Fifteen 
year all-cause mortality was: 48% (29%) in men (women) smoking 20 cigarettes a day 
with poor FEV1 % predicted; 28% (17%) for those smoking 20 a day and with good 
FEV1 % predicted and 15% (10%) for non smokers and in summary, the authors found 
that: 
“Impaired lung function is a major clinical indication of mortality risk in 
men and women for a wide range of diseases(166).” 
5.5.2 Update of the Hole et al Paper, 1996 
This section describes the methods and results for the updated analysis that built on and 
extended analyses conducted in the Hole et al paper, with follow up of mortality until 
31st December 2005. 
Methods 
The methods described in the review of the Hole et al paper were largely replicated.  To 
identify quintiles of impaired lung function, the same cut off limits as in the Hole et al 
study were used.  All analyses were run with the least impaired group (FEV1 108 % 
(113) predicted for the men (women)) as the base case. 
Cox proportional hazards models were used to investigate the impact of lung function 
on all-cause, respiratory and COPD mortality (adjusted for age at start of study, 
cigarette smoking, diastolic blood pressure, cholesterol concentration, body mass index 
and social class).  
The primary analysis was conducted using time in study for the Cox model (as was used 
within the Hole et al study).  A secondary analysis examined the effect of changing the 
time frame of the survival analysis to age in study for reasons explained in section 5.3.1. 
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The linked follow-up mortality data employed in the Hole et al study was coded using 
the ICD-9, which was the only classification system used for mortality during that 
period.  The current ICD codes, known as ICD-10 were introduced in 1994 and enter 
the dataset from then on.  The ICD codes used to identify different causes of mortality 
were: ICD-9 460-519, ICD-10 J00-J99 for respiratory mortality and ICD-9 490-492 and 
496, ICD-10 J40-J44) for COPD mortality. 
Results 
Of the 15 402 participants in the study, 368 were excluded (as previously described) 
because of missing data.  The study cohort consisted of 6861 men and 8173 women, of 
whom 10 759 had deceased: 5381 men and 5378 women. 
As in the Hole et al paper, group 1 contained those with the most impaired lung 
function, group two the second most impaired and so.  Group 5 was the base case group 
and comprised those people with the greatest FEV1 % predicted.  
Table 5.8 Percentage of group deceased, men and women by FEV1 group (n) 
Group Men Women 
1 89 (1303) 78 (1299) 
2 83 (1152) 69 (1204) 
3 78 (1029) 64 (1030) 
4 74 (1023) 59 (950) 
5 67 (874) 58 (895) 
 
Table 5.8 illustrates how the proportion of deceased participants increased in relation to 
the degree of lung impairment, with the highest proportion of deceased participants in 
the group with the lowest FEV1 % predicted values.  These results suggest that there is 
an increased risk of mortality for those in group 1 compared to those in group 5.  
The results from the primary analysis with time in study as the time horizon are 
presented in table 5.9, and table 5.10 contains the results of the survival analysis in 
which age as the time horizon was employed.
  
 
Table 5.9 HRs by cause of death and group, in men and women (time in study)  
HRs (95%CI) vs group 5(HR=1) Cause  Sex Dead (n) 
Group 1 Group 2 Group 3 Group 4 
Men 5381 1.77(1.62-1.93) 1.45(1.33-1.59) 1.34(1.23-1.47) 1.24(1.13-1.36) All-cause 
Women 5378 1.77(1.62-1.93) 1.40(1.28-1.53) 1.24(1.14-1.36) 1.12(1.02-1.23) 
Men 542 5.48(4.02-7.45) 2.25(1.61-3.15) 1.45(1.01-2.10) 1.38(0.96-1.99) Respiratory 
Women 535 3.64(2.76-4.81) 1.78(1.32-2.40) 1.22(0.88-1.69) 1.03(0.74-1.44) 
Men 425 27.97(12.29-63.66) 7.41(3.15-17.41) 2.68(1.04-6.92) 2.14(0.81-5.64) COPD 
Women 180 19.34(8.45-44.24) 5.00(2.10-11.93) 2.95(1.18-7.41) 1.28(0.44-3.69) 
Groups were split by FEV1 % predicted. For men: <73=group 1, 73group 2<87, 87group 3<97, 97group 4<108 and 108 = group 5. For women: <75=group 1, 75group 2<90, 90group 
3<101, 101group 4<113 and 113 = group 5.  
 
Table 5.10 HRs by cause of death and group, in men and women (age in study) 
HRs (95%CI) vs group 5(HR=1) Cause  Sex Dead (n) 
Group 1 Group 2 Group 3 Group 4 
Men 5381 1.81(1.66-1.98) 1.46(1.33-1.60) 1.34(1.22-1.47) 1.24(1.13-1.36) All-cause 
Women 5378 1.78(1.63-1.94) 1.40(1.28-1.53) 1.24(1.13-1.35) 1.11(1.01-1.22) 
Men 542 5.64(4.15-7.66) 2.26(1.61-3.15) 1.44(1.00-2.08) 1.37(0.96-1.98) Respiratory 
Women 535 3.63(2.75-4.79) 1.77(1.32-2.39) 1.22(0.88-1.69) 1.04(0.74-1.45) 
Men 425 28.68(12.62-65.20) 7.38(3.14-17.33) 2.65(1.03-6.84) 2.12(0.81-5.59) COPD 
Women 180 19.11(8.37-43.66) 5.05(2.12-12.05) 2.99(1.19-7.50) 1.32(0.46-3.80) 
Groups were split by FEV1 % predicted. For men: <73=group 1, 73group 2<87, 87group 3<97, 97group 4<108 and 108 = group 5. For women: <75=group 1, 75group 2<90, 90group 
3<101, 101group 4<113 and 113 = group 5 
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Tables 5.9 and 5.10 show that regardless of method adopted, participants with FEV1 % 
predicted values of <108 for men and <113 for women (or groups 1 to 4) were found to 
have a statistically significant, increased mortality risk for all-cause mortality compared 
to those in group 5, the base case.  The HRs for all-cause mortality were 1.8 in group 1 
for both men and women.  This compares to a slightly larger HR of around 1.9 for men 
and women in the Hole et al study.  
Participants with FEV1 % predicted of <97 in men and <101 in women (groups 1 to 3) 
had significantly larger HRs for COPD mortality than those in group 5.  Those 
participants whose lung functions placed them in group 1 (FEV1 % predicted <73 for 
men and <75 for women) had very large HRs for COPD mortality with HRs of 28.68 
for men and 19.11 for women, compared to those in group 5.  The size of the HRs for 
COPD mortality illustrates the importance of impaired lung function on COPD 
mortality.   
The HRs for each quintile were found to be similar when analysing the data using time 
in study for the survival analysis compared to using age in study.  The CIs were almost 
identical.  This finding supports those presented elsewhere, that using time in study 
rather than age, yields approximately unbiased proportional hazards regression 
coefficients.(186) 
There is a clear difference in hazards between men and women.  The men tended to 
have larger HRs compared to the women in each of the groups and this manifests itself 
as a higher percentage of deceased men in the study compared to deceased women for 
COPD, respiratory and all-cause mortality.  
The conclusions of the Hole et al study, that impaired lung function was found to be a 
major clinical indication of mortality risk for a wide range of diseases in men and 
women,(166) is as true today as it was in 1996 and is backed up by an even greater 
amount of evidence. 
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5.5.3 Summary 
An updated version of the study by Hole et al was presented that replicated the previous 
analysis, but with a longer follow up period.  With 2/3 (n=10 759) of the original 
population deceased in the current version of the dataset as opposed to 1/3 (4439) at the 
time when Hole et al analysed the data, the HRs had changed.  For all-cause mortality, 
the HR in group 1 was lower than the same group using the shorter follow up period.  
Within the other groups, the HRs all differed slightly to those previously reported: 
either larger or smaller than those published in the original paper.  Nevertheless, in all 
cases, the HRs calculated using the current version of the dataset lay within the 95% CI 
of those reported in the original paper.  
The use of time in study rather than age as the time frame for the survival analysis 
produced almost identical results, indicating that if time in study were used, it would 
produce approximately unbiased estimators of the hazard ratios.   
Analysing the data by sex found that men and women have different mortality risks, 
especially for respiratory and for COPD mortality.  Therefore it would be useful to 
conduct analyses on men and women separately when building a cost effectiveness 
model.  Whilst policy makers are unlikely to differentiate provision of treatments 
according to gender if a treatment was found to be cost effective in females and not in 
males, or vice versa, because of ethical and political implications, it is nonetheless of 
interest to examine the impact of cost effectiveness by sex because of the differences in 
the natural history of the disease between men and women.  The aim when building an 
economic model is to simplify reality whilst still maintaining the fundamental elements 
of the disease.  Gender seems to play an important role and so it would be appropriate to 
model men and women separately where possible.  In addition, if certain groups of the 
population can be identified at higher risk than others, then preventative treatment and 
awareness campaigns can be targeted to these populations.   
 146 
The findings from this study entirely support those published a decade earlier, namely 
that there is an important link between impaired lung function and mortality.  The 
extension to the original work confirmed the link between impaired lung function and 
COPD mortality with large and highly significant HRs particularly for group 1, which 
were much larger than any for other diseases replicated here or published by Hole et al 
in their paper.  Group 1 are likely to closely match a COPD population, diagnosed based 
on impaired lung function.  However it is known that a COPD case may be identified 
based on more than impaired lung function, and some guidelines for diagnosing COPD 
(as presented in Chapter 2), explicitly include other elements for inclusion within the 
diagnosis of COPD.  The mortality risk for subjects with impaired lung function along 
with other risk factors is investigated in detail in the following section.  
5.6 NICE vs GOLD  
It has been previously stated (in Chapter 2) that between 4 and 10% of the adult 
population worldwide have COPD,(78) with population estimates varying considerably 
according to the age group under study and the diagnostic criteria used,(69;73) and 
there is no clear agreement over which criteria are most appropriate.  As seen in Chapter 
2 most international guidelines agree on the central importance of the ratio of FEV1 to 
FVC, however sole reliance on this measure is believed to under-diagnose in the young 
and over-diagnose the disease in the elderly.(195)  GOLD diagnoses COPD on the basis 
of airflow limitation alone (FEV1/FVC<0.7).(2)  Reporting of disease prevalence from 
the BOLD study (see Chapter 2), a large study on the burden of COPD worldwide, used 
GOLD stage II and above, defined as airflow obstruction (FEV1/FVC<0.7 and 
FEV1<80% predicted).(79;81)  NICE in the UK suggests that identification of disease 
be based on airflow obstruction, a risk factor and respiratory symptoms.(7)   
NICE and GOLD have different remits which may explain the differences in criteria, 
GOLD is “to raise awareness of COPD and to improve prevention and treatment”,(196) 
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and NICE is to provide recommendations on appropriate treatment and care for people 
with specific diseases (such as COPD) within the UK NHS, based upon ‘best’ available 
evidence.(86) 
Previous studies have compared COPD prevalence under different COPD diagnostic 
criteria,(70;73-76;78;82;197;198) but none have compared the GOLD, GOLD II+ and 
NICE criteria.  Some studies have used respiratory symptoms to identify COPD either 
alone or in combination with airflow limitation/obstruction,(78;199) but a COPD 
diagnostic criteria incorporating a risk factor, in particular smoking history, has not 
previously been investigated.  In addition, while the impact of airflow limitation on 
mortality has been demonstrated by Hole et al,(166) and again in the previous section, 
the effect of FEV1/FVC<0.7 and FEV1<80% predicted, in combination with smoking 
history and respiratory symptoms is unknown.  
Diagnostic criteria for COPD are difficult to validate, partly due to the chronic nature of 
the disease.  The Renfrew/Paisley study offers a unique opportunity to compare GOLD, 
GOLD II+ and NICE diagnostic criteria because of the data gathered at baseline and the 
lengthy follow-up of mortality.  
When conducting an economic evaluation of a treatment it is important to correctly 
identify the patient population before any modelling of the disease gets underway.  
Within this section an analysis to compare NICE criteria to the most frequently used 
diagnostic criteria, the GOLD diagnostic criteria, is presented.  The principal aim of the 
analysis was to determine how diagnosing COPD based on a smoking history and 
respiratory symptoms in addition to airflow limitation and/or airflow obstruction, 
impacts upon prevalence estimates and mortality risk for all-cause and COPD mortality, 
compared to a diagnosis based only on lung function.  A secondary aim was to 
determine if smoking history, respiratory symptoms, FEV1/FVC<0.7 and FEV1<80% 
predicted are independently predictive of all-cause and COPD mortality risk in the 
Renfrew/Paisley (MIDSPAN) dataset.  
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5.6.1 Methods 
Three different diagnostic criteria for COPD were applied to subjects in the dataset.  
These have previously been stated, but are reproduced here to enable comparisons 
between the criteria to be made: 
GOLD:“COPD is characterized by airflow limitation”(2) defined as FEV1/FVC<0.7.  
GOLD II+:  COPD is characterised by airflow obstruction (FEV1/FVC<0.7 and 
FEV1<80% predicted). 
NICE: a diagnosis of COPD should be considered in patients aged over 35 with airflow 
obstruction (FEV1/FVC<0.7 and FEV1<80% predicted), a risk factor (principally 
smoking) and who present with one or more of: exertional breathlessness, chronic 
cough, regular sputum production, frequent winter ‘bronchitis’ or wheeze.(7)  
Assumptions were made to identify NICE COPD cases within the dataset:  
• Airflow obstruction: FEV1/FVC<0.7 and FEV1<80% predicted. 
• Respiratory symptom(s): one or more of breathlessness, wheeze, phlegm (see 
figure 5.3).  
• Risk factor: either a smoking history of ten pack years or more, or being a 
pipe/or cigar smoker. 
All subjects were aged 45 and over, therefore the age criterion was satisfied.  As all 
three diagnostic criteria require airflow limitation (FEV1/FVC<0.7), the more restrictive 
NICE criteria form a subgroup within the GOLD groups.  It was of interest to follow 
those subjects who had airflow limitation/obstruction but who did not fulfil all 
requirements to enter the NICE COPD group.  These subjects are referred to as the ‘low 
risk’ group. 
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Statistical Analysis 
Comparisons were made between the NICE and GOLD and the NICE and GOLD II+ 
COPD diagnostic criteria.  All analyses were carried out on men and women separately. 
Prevalence estimates were calculated by age group and diagnostic criteria.  Kaplan-
Meier curves were produced for the full follow-up period for the ‘no COPD’ vs ‘low 
risk’ vs NICE groups only (as GOLD=‘low risk’+NICE), with age along the time scale.  
As previously described with reference to figure 5.4, where the denominator is small (in 
the dataset at the extremes of age), small numbers of events can cause large effects on 
the Kaplan-Meier curve.  To avoid this, the graphs were started from age 46 years 
onwards.  Kaplan-Meier curves were used to compare mortality risk using the different 
diagnostic criteria, by disease severity. 
Cox proportional hazards models were used, adjusted for risk factors (age, diastolic 
blood pressure, cholesterol, BMI, social class and ex-smoker).  The assumption of 
proportional hazards was violated when using the full follow-up period, therefore the 
data were analysed in two time periods ( 20years and >20 years follow-up).  The split 
represents the point at which half of all the COPD deaths occurred.  Entrance to the 2nd 
period was conditional on surviving/remaining in the study for the first 20 years.  All 
Cox regressions were run in both time periods.  The proportionality assumption (tested 
using Schoenfeld residuals) was found to perform better following the split.   
Analyses were run using both methods of time scale within the survival analysis.  
Employing time in study was found to meet the proportionality assumption more times 
over all the analyses in the study than employing age in study as the time scale.  
Analyses with age in study were therefore conducted to represent the survival profile 
visually.  All other analyses were conducted with time in study as the time scale and 
adjusted for age. 
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Two sets of Cox proportional hazards models were run, the first set used GOLD and 
NICE to identify a ‘low risk’ group and compared 1) ‘no COPD’ vs GOLD and 2) ‘no 
COPD’ vs ‘low risk’ vs NICE.  The second set used GOLD II+ and NICE to identify a 
different ‘low risk’ group and compared 1) ‘no COPD’ vs GOLD II+ and 2) ‘no COPD’ 
vs ‘low risk’ vs NICE. 
An analysis was carried out on the components of the NICE diagnostic criteria using a 
Cox proportional hazards model to predict all-cause and COPD mortality with 
FEV1/FVC<0.7,  FEV1<80% predicted, smoking history and respiratory symptoms as 
independent variables and adjusted for risk factors.  Statistical significance was defined 
at the p=0.05 level.  
5.6.2 Results 
The general population study comprised of 6861 men and 8173 women and is 
summarised in table 5.11.  As can be seen in the table, of the men and women 77% and 
46% respectively had 10 or more pack years and a substantial minority, 39% of men 
and 29% of women, had one or more respiratory symptom.  Compared to the women, 
the men were more likely to suffer from phlegm and wheeze and less likely to report 
breathlessness.  Of the study population, 3542 of the men and 5518 of the women 
remained in the study after 20 years of follow-up and these formed the dataset for the 
second period of follow-up.  
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Table 5.11 Baseline characteristics of the study population, Renfrew/Paisley (MIDSPAN) 
 Men Women 
Participants, n (%) 6861 (46) 8173 (54) 
Participants >20yrs follow up, n (%) 3542 (39) 5518 (61) 
Years of follow up, mean (SD) 
 
19.8(9.6) 23.2(8.9) 
Years of follow-up (range)  0-34 0-34 
Age, mean (SD) 54.6(5.6) 54.9(5.6) 
Social Class (mode) IIIM IV 
Body Mass Index, mean (SD) 25.9(3.4) 25.8(4.5) 
Smoking  10yr pack yrs, n (%)  5264 (77) 3757 (46) 
Presence of symptoms, n (%) 2644 (39) 2389 (29) 
Presence of phlegm, n (%)  2107 (31) 1382 (17) 
Presence of breathlessness, n (%) 920 (13) 1332 (16) 
Presence of wheeze, n (%)  1206 (18) 961 (12) 
 
Prevalence 
The prevalence of COPD in the study population was high.  Overall the prevalence of 
COPD was 25% using the GOLD diagnostic criteria, 15% with the GOLD II+ and 8% 
with the NICE criteria.  Prevalence of COPD was higher in men than in women and this 
is clearly shown in table 5.12.  COPD prevalence generally increased with age and was 
highest in men aged 60-64.  
Table 5.12 COPD prevalence by diagnostic criteria and age, men and women 
                     Prevalence, % (n) 
 
Age 
category 
Total 
number GOLD GOLD II+ NICE 
 45-49 1774 25(441) 16(282) 9(156)  
 50-54 1934 28(546)  18(346) 10(197) 
Men 55-59 1641 34(554)  23(385) 13(217)  
 60-64 1512 41(622)  29(437) 19(284)  
 Overall 6861 32(2163)  21(1450) 12(854)  
 45-49 1997 17(338)  12(238) 5(94)  
 50-54 2249 19(431)  13(300) 5(107)  
Women 55-59 1997 23(463)  16(320) 6(127)  
 60-64 1930 21(401)  13(243) 3(60)  
 Overall 8173 20(1633)  13(1101) 5(388)  
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Figure 5.6 illustrates diagrammatically how the COPD population is affected by the 
diagnostic criteria.  The ‘no COPD’ population is dependent upon the criteria used and 
is larger when applying the NICE criteria than either the GOLD II+ or GOLD criteria.   
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Figure 5.6 COPD prevalence applying the GOLD, GOLD II+ and the NICE diagnostic 
criteria to the Renfrew/Paisley dataset in men and women, n 
The ‘low risk’ group is smaller when using the GOLD II+ criteria in conjunction with 
the NICE criteria in both men and women, as opposed to applying the GOLD criteria in 
conjunction with the NICE criteria as illustrated in figure 5.6.  The ‘low risk’ population 
shown in the top column for the men and the top column for the women of figure 5.6 is 
made up of study participants with airflow obstruction but without both respiratory 
symptoms and a smoking history.  Because of the high proportion of the dataset with a 
smoking history: 77% of men and 46% of women had 10 or more pack years as 
described in table 5.12, it is likely that the majority of those in this ‘low risk’ group 
would have airflow obstruction and a smoking history, but no respiratory symptoms.    
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The ‘low risk’ population shown in the bottom column in figure 5.6 for men and the 
bottom column for women, potentially contains any subject who has an FEV1/FVC<0.7 
but not all of: FEV1<80% predicted plus a smoking history and respiratory symptoms.  
The difference between the top and bottom columns is that lung function must be 
FEV1<80% predicted in the top columns.  Therefore it can be seen that the addition of 
this lung function criteria is highly influential in the diagnosis of COPD.  
Survival 
Survival curves for all-cause, and COPD mortality, which are shown below in figures 
5.7 to 5.10 showed clear separation between the NICE, ‘low risk’ and ‘no COPD’ 
groups (log rank p<0.001) in men and women.  This is important because it clearly 
illustrates that the groups are different from one another in terms of survival probability 
with the NICE COPD group having the lowest survival probabilities.  The ‘low risk’ 
group is separated from the no COPD group, highlighting the increased mortality risk 
relative to the ‘no COPD’ group of those within this ‘low risk’ classification.    
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Figure 5.7 Survival curves for all-cause mortality (men) 
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Figure 5.8 Survival curves for all-cause mortality (women) 
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Figure 5.9 Survival curves for COPD mortality (men) 
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Figure 5.10 Survival curves for COPD mortality (women) 
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The median age of survival can be read off the x axis when the survival curve is equal 
to 0.05 (where the dotted horizontal line meets the dotted vertical line).  The horizontal 
line running through the 0.50 survival probability for all-cause mortality gives a median 
age of survival for men of 68 years if they are categorised in the NICE COPD group, 74 
if they are in the ‘low risk’ group and 76 for those with ‘no COPD’.  For women, the 
median age was higher at 72 years, 80 years and 82 years respectively. 
Because the survival curves for COPD mortality incorporates censoring as a result of 
death from causes other than COPD, these curves illustrate the degree of co-morbidity 
within COPD patients who often die from causes other than COPD (as previously 
shown in figure 5.5).  Survival probability for the ‘no COPD’ is close to 1 throughout 
the observed period. 
All-Cause Mortality 
Table 5.13 below presents the results from four separate Cox proportional hazards 
models, comparing HRs between the different diagnostic criteria in terms of all-cause 
and COPD mortality.  Compared to ‘no COPD’ (where the HR=1) HRs for men 
(women) were 1.41 (1.47) for GOLD and 1.48(1.64) for GOLD II+ in 20 years of 
follow-up, suggesting a slightly higher mortality risk in the GOLD II+ group than 
GOLD. 
As shown in table 5.13, the ‘low risk’ group (GOLD) and the ‘low risk’ (GOLD II+) 
had statistically significant but lower HRs for mortality than the HRs in the NICE 
groups for follow up 20yrs.  In men (women) HRs were 1.19 and 1.81 (1.24 and 2.42) 
for ‘low risk’ (GOLD) and NICE respectively compared to ‘no COPD’, and 1.15 and 
1.76 (1.32 and 2.40) for ‘low risk’ (GOLD II+) and NICE.  In both time periods, the 
HRs for the NICE group were considerably larger than the HRs in the 'low risk' group, 
suggesting that participants with airflow obstruction, respiratory symptoms and risk had 
a higher all-cause mortality risk than those with airflow limitation and/or obstruction 
 156 
alone. The low risk group from the GOLD II+ versus NICE analysis with follow up >20 
years in men had a mean value of 1.11 (95%CI: 0.95-1.30) and confidence interval that 
included 0, implying that this group cannot be considered significantly different to the 
no COPD group.  
 
  
Table 5.13 HRs from four separate Cox PH regression models:  
1) ‘no COPD’ vs GOLD 2)‘no COPD’ vs ‘low risk’ vs NICE (GOLD=‘low risk’+NICE) 3) ‘no COPD’ vs GOLD II+ 4)‘no COPD’ vs ‘low 
risk’ vs NICE (GOLD II+=‘low risk’+NICE), follow-up  20 years (n=6861 men and 8173 women) and > 20 years (n=3542 men and 
5518 women) for all-cause and COPD mortality, men (top) and women (bottom) 
GOLD Hazard Ratios (95%CI) GOLD II+ Hazard Ratios (95%CI) Cause of death/ 
follow-up 
Dead 
%(n) GOLD ‘low risk’ NICE GOLD II+ ‘low risk’ NICE 
All-cause        
20 yrs 48 (3275) 1.41(1.31-1.51) 1.19(1.09-1.30) 1.81(1.65-1.99) 1.48(1.37-1.60) 1.15(1.03-1.30) 1.76(1.61-1.93) 
>20 yrs 59 (2106) 1.34(1.22-1.48) 1.26(1.12-1.40) 1.58(1.36-1.84) 1.29(1.15-1.45) 1.11(0.95-1.30) 1.52(1.31-1.77) 
COPD        
20 yrs 2 (139) 20.57(11.02-38.41) 6.69(3.27-13.67) 48.81(25.87-92.10) 22.03(13.30-36.50) 7.67(3.97-14.80) 35.08(20.98-58.66) 
>20 yrs 3 (106) 6.14(4.03-9.34) 4.58(2.87-7.31) 10.94(6.63-18.05) 5.41(3.64-8.04) 3.72(2.22-6.23) 7.83(4.96-12.37) 
All-cause        
20 yrs 32(2593) 1.47(1.34-1.60) 1.24(1.12-1.38) 2.42(2.10-2.80) 1.64(1.48-1.81) 1.32(1.16-1.50) 2.40(2.08-2.77) 
>20 yrs 50(2785) 1.27(1.15-1.39) 1.16(1.04-1.28) 1.95(1.62-2.36) 1.44(1.29-1.61) 1.29(1.13-1.47) 1.95(1.62-2.35) 
COPD        
20 yrs 1 (73) 8.87(5.25-15.00) 4.38(2.34-8.20) 27.73(15.54-49.51) 9.86(6.05-16.07) 4.28(2.19-8.34) 22.45(13.17-38.26) 
>20 yrs 2 (107) 5.22(3.55-7.67) 3.83(2.47-5.93) 12.86(7.67-21.56) 5.91(3.99-8.76) 4.10(2.51-6.68) 11.22(6.79-18.55) 
Regressions were adjusted for age, blood pressure, cholesterol, body mass index, social class and ex-smoker . 
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COPD Mortality 
Of those deceased, COPD mortality was the cause of death for 17% (16%) of men 
(women) in the NICE group, 6% (6%) of the ‘low risk’ (GOLD) and 11% (9%) of those 
diagnosed with COPD by GOLD.  This compared to 8% (7%) of the ‘low risk’ (GOLD 
II+) group and 13% (10%) of the GOLD II+ group. 
HRs in both GOLD groups for COPD mortality were large and comparable and were 
smaller for women than men as seen in table 5.13.  The HR for GOLD men (women) 
was 20.57 (8.87) and for GOLD II+ was 22.03(9.86) compared to ‘no COPD’. 
Splitting participants diagnosed with COPD according to the GOLD/GOLD II+ criteria 
into a 'low risk' group and a NICE group resulted in a clear trend of increasing risk with 
increasing disease severity.  The ‘low risk’ groups had statistically significant but 
smaller HRs for COPD mortality than the HRs for NICE in follow up 20yrs for men 
and in both time periods for the women.  In men (women) HRs were 6.69 and 48.81 
(4.38 and 27.73) for ‘low risk’ (GOLD) and NICE respectively, and 7.67 and 35.08 
(4.28 and 22.45) for ‘low risk’ (GOLD II+) and NICE.  These results illustrate that 
participants meeting NICE criteria had a higher COPD mortality risk than those with 
airflow limitation and/or obstruction alone.  
Individual Components of the NICE Diagnostic Criteria 
The regression model on mortality (all-cause and COPD) identified that in general, 
smoking history (10 pack years), respiratory symptoms, FEV1/FVC <0.7 and predicted 
FEV1<80% were found to independently predict all-cause and COPD mortality in men 
and women with large and significant HRs.  Results from the analysis are presented in 
table 5.14. 
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Table 5.14 HRs from a Cox PH regression model on the individual components of the 
NICE criteria:  
FEV1/FVC, FEV1<80% predicted, smoking history and respiratory symptoms and with 
follow-up split into   20 years and > 20 years for all-cause and COPD mortality, men (top) 
and women (bottom) 
Hazard Ratios (95%CI)  Cause of 
death/ follow-
up 
FEV1/FVC<0.7 FEV1<80% 
predicted 
 10 pack years Respiratory 
symptoms 
All-cause     
20 years 1.10(1.01-1.20) 1.26(1.16-1.37) 1.71(1.55-1.89) 1.30(1.20-1.40) 
>20 years 1.16(1.03-1.30) 1.08(0.96-1.22) 1.49(1.34-1.65) 1.29(1.17-1.42) 
COPD     
20 years 5.65(2.92-10.95) 6.13(3.26-11.55) 1.78(0.92-3.44) 6.86(3.83-12.28) 
>20 years 3.22(1.96-5.29) 2.02(1.25-3.24) 7.10(2.85-17.72) 1.75(1.17-2.63) 
All-cause     
20 years 1.13(1.02-1.25) 1.35(1.23-1.48) 1.64(1.51-1.78) 1.37(1.26-1.50) 
>20 years 1.02(0.92-1.14) 1.33(1.21-1.46) 1.63(1.50-1.76) 1.21(1.11-1.32) 
COPD     
20 years 3.01(1.70-5.32) 5.00(2.53-9.88) 3.62(1.85-7.09) 5.24(2.87-9.56) 
>20 years 2.52(1.62-3.92) 2.59(1.65-4.07) 6.02(3.54-10.23) 1.93(1.29-2.88) 
The regressions were adjusted for age, blood pressure, cholesterol, BMI, social class and ex-smoker 
FEV1 = forced expiratory volume in one second, FVC= forced vital capacity 
 
Larger HRs for the individual components of the NICE criteria were seen in the first 
period of follow-up (20 years) than in the second (>20 years), except for the HRs 
relating to smoking history for COPD mortality where a smoking history was seen to 
have a stronger relationship with mortality in the second period of follow up compared 
to the first.  Results presented in table 5.14 show that in the first 20 years the HR for 
smoking history in men was not statistically significant: HR:1.78 (95%CI:0.92-3.44) yet 
for follow-up of over 20 years, the HR was large and highly significant at 7.10 
(95%CI:2.85-17.72).  The table also provides evidence showing an increase in hazards 
for women with a smoking history, where the HR was seen to increase over time from 
3.62 to 6.02.   
5.6.3 Discussion 
This study assessed how the presence of respiratory symptoms and a risk factor in 
addition to airflow limitation and/or airflow obstruction impacts upon disease 
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prevalence and mortality risk for all-cause and COPD mortality within a general 
population cohort whose survival was followed from the 1970s.  
Prevalence of COPD was heavily dependent on the diagnostic criteria used and was 
found to be anywhere between 8% (NICE) and 25% (GOLD).  In terms of estimates of 
burden of disease and subsequent resource allocation, the implications of potentially 
treating an additional 17% of the population are substantial.  Misclassified cases with 
people free from the disease are likely and treating false positives may result in quality 
of life decrements to the individuals involved and unnecessary resource use for the 
payer.  Nevertheless, in treating any disease it is important to identify those most at risk 
of key events such as hospitalisations and disease specific mortality, which would not 
only lead to a drop in quality of life or ultimately a premature end to life for the 
individual, but also to a financial burden for the NHS.  
The implications of splitting a GOLD COPD diagnosed population into a NICE group 
and a ‘low risk’ group were examined and it was found that doing so identified groups 
that are statistically significantly different.  The NICE group contained participants 
meeting the NICE diagnostic criteria who had respiratory symptoms, smoking histories 
of >10 pack years and airflow obstruction (FEV1/FVC<0.7 and FEV1<80% predicted), 
and were found to be at high risk from all-cause and COPD mortality compared to a 
‘low risk’ group.  The ‘low risk’ group contained subjects with either airflow limitation 
(FEV1/FVC<0.7) (GOLD) or airflow obstruction (GOLD II+), without both of 
respiratory symptoms and a smoking history.  Thus it is the inclusion of respiratory 
symptoms and smoking history that identifies those at highest risk.  The ‘low risk’ 
group is of interest and raises the question, to what extent, if any, should clinical 
management for the ‘low risk’ group differ from the approach pursued for the NICE 
COPD group?  The answer to this question lies with the clinical experts and should be 
debated given the evidence presented here.  
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The components of the NICE criteria: respiratory symptoms, smoking history, 
FEV1/FVC<0.7 and FEV1<80% predicted, were identified as independent predictors of 
all-cause and COPD mortality within a Cox proportional hazards model.  
A substantial number of the study population were diagnosed with COPD using GOLD 
criteria but ‘no COPD’ with GOLD II+, 10% (n=713) of men and 7% (n=532) of 
women (representing those with FEV1/FVC<0.7 and FEV180% predicted).  Applying 
GOLD II+ instead of GOLD reduced prevalence estimates from 25% to 15%.  HRs for 
those meeting GOLD criteria to ‘no COPD’ in terms of mortality remained similar to 
HRs for GOLD II+ compared to ‘no COPD’. 
Strengths and Limitations 
GOLD criteria stipulate the use of post bronchodilator spirometry to measure lung 
function but this method was not standard procedure at the time of the study.  This may 
have some impact on the absolute numbers diagnosed with COPD but is unlikely to 
affect the key messages from the study. 
The diagnostic criteria used here are based on an interpretation of the NICE guidelines 
with specialist input from a respiratory clinician (Malcolm Shepherd), firstly around the 
assumption that smoking history is the only risk factor and additionally that it should be 
set at 10 pack years.  Secondly that evidence of respiratory symptom(s), set by the 
inclusion criteria applied, was limited by the questions asked within the study.  
This comparative analysis is the first to use NICE diagnostic criteria in a general 
population cohort and has shown that these are practical to employ in a large 
prospective study.  The information necessary to diagnose based upon the NICE criteria 
are readily available to the clinician and there is evidence that the NICE diagnostic 
criteria reflect physician diagnosed COPD more closely than GOLD criteria.(200)  In 
particular, fewer false positive diagnoses will be made using NICE criteria than with 
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GOLD, especially in the elderly who are most at risk of misclassification.(195)  The 
problem of false negatives may arise but the recognition of a ‘low risk’ group would 
resolve this issue.    
The organisations behind these guidelines arguably succeed in their respective remits.  
GOLD adopts a blanket approach and flags up a large population of COPD cases, thus 
raising awareness of the disease as a substantial issue.  NICE on the other hand is 
focused on providing recommendations on appropriate treatment and care, so 
identifying those most in need of treatment is important.  However by restricting COPD 
cases to those identified using NICE criteria ignores a group at ‘low risk’ but 
nonetheless higher mortality risk than those with ‘no COPD’.  Recognising higher 
mortality risk in those identified by NICE whilst recognising increased risk in those at 
‘low risk’, bridges the gap between the GOLD and the NICE diagnostic criteria. 
5.6.4 Conclusion 
More restrictive COPD criteria identify subjects at higher risk of all-cause and COPD 
mortality than using the GOLD criteria alone.  Diagnosing COPD based upon airflow 
obstruction, respiratory symptoms and smoking history as opposed to airflow 
limitation/airflow obstruction splits the COPD population as diagnosed by 
GOLD/GOLD II+, into two, one at ‘high risk’ and another at ‘low risk’.  These two 
groups have statistically significant mortality risks and may benefit from different 
clinical management strategies.  
5.7 Hospital Admissions  
The major drivers of costs to the NHS arising from COPD are disease severity and 
severe exacerbations, for example as described in Chapter 2, COPD patients have been 
found to occupy approximately one million bed days annually.(201)  Severe 
exacerbations have been described as when the patient (or caregiver) recognises an 
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obvious and/or a rapid deterioration in their condition and requires hospitalisation.(202)  
They are typified by one or more of: increased shortness of breath; increased volume 
and purulence of sputum; increased cough and shallow/rapid breathing.(202)  An 
exacerbation is the main reason why a COPD patient would attend hospital. 
Reducing or preventing disease progression and/or hospital admission would have a 
direct effect on the total cost burden for COPD,(38) and on quality of life for patients.  
Therefore, reducing or preventing disease progression and/or hospital admission are 
often principal outcome measures for clinical trials in COPD. 
As seen in Chapter 4, due to the physical detriment and economic cost associated with 
exacerbations, exacerbations are often modelled within cost effectiveness analyses of 
COPD.  In brief, exacerbations are predominantly built into the disease states (usually 
mild, moderate and severe).(92;141;144;146;203)  Each health state has an exacerbation 
(usually mild and severe) probability attached which varies by disease state and by 
treatment group.(92;141;144;146;203)  To date all information on COPD exacerbations 
used within decision analytic models have come from clinical 
trials.(92;141;144;146;203) 
As previously explained in section 5.2, the Renfrew/Paisley dataset with its sizeable 
COPD population has been linked to hospitalisation data as well as to death records.  
Within this section the feasibility of using observational data to study the course of 
severe hospitalisation for COPD patients was investigated, for the purpose of informing 
an economic model.  The rate of hospitalisation, length of stay in hospital and number 
of hospitalisations per participant were studied. 
5.7.1 Methods 
All linked respiratory coded hospital discharges for the MIDSPAN dataset (SMR1 
recording scheme) occurring in Scotland between 1972 and December 1995 were 
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obtained.  All COPD coded hospital admissions within the dataset were regarded as 
severe exacerbations on the grounds that an exacerbation is the main reason why a 
COPD patient would attend hospital (clinical opinion - Malcolm Shepherd, personal 
communication).  
COPD hospital admissions (ICD-8 491-492, ICD-9 490-492 & 496, ICD-10 J40-J44) 
were identified, in any diagnostic position (in any of the principal or secondary (up to 
five) diagnostic coding positions).  Hospital admission stays of more than 200 days 
(n=11) were removed from the dataset as these were unlikely to represent (acute) COPD 
hospital exacerbations.  COPD cases and corresponding disease severity were identified 
within the dataset according to NICE guidelines, as previously described in section 5.4. 
Statistical Analysis 
Missing data was dealt with as outlined in section 5.2.1.  The percentage of participants 
in each COPD severity group at baseline, with a COPD hospitalisation at any point 
within the follow up period was identified from the data.  The percentage of participants 
within each COPD severity group with a COPD coded death was also determined. 
Hospitalisation rates were calculated by first summing the frequency of hospitalisations 
in each severity group and then dividing this value by the number of person years at risk 
for the severity group.  The number of times each participant was hospitalised over the 
duration of follow up was determined and depicted in a histogram.  Length of stay in 
hospital was derived from the data and also illustrated using a histogram.  Length of 
stay was calculated by subtracting the date of discharge from the admission date (once 
any transfers had been accounted for).  A value of one was added to all length of stay 
values to adjust for day cases, because the admission date is equal to the discharge date 
and otherwise, the length of stay would have been 0 days.   
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5.7.2 Results 
Of the study population, 10% of men and 8% of women had a COPD hospital 
admission.  The proportion of study participants with a COPD hospital admission was 
shown to increase in line with baseline disease severity.  COPD hospitalisation was 
proportionally higher in women than in men, regardless of disease severity.  Table 5.15 
shows that 33% of the women with mild COPD at baseline had a COPD coded hospital 
admission in comparison to 25% of the men in the same group, this compares to 42% of 
the women in the moderate group and 36% of men, and in the severe group, 56% and 
49% respectively had a hospitalisation. 
Table 5.15 Percentage of participants with a COPD coded hospital admission  
in any diagnostic position by COPD disease severity at baseline   
  N % (N) with COPD 
hosp admission(s) 
No COPD 13 792   7  (915) 
Mild 847 27  (232) 
Moderate 300 38  (114) Men & women 
Severe 95 51  (48) 
No COPD 6007   7  (441) 
Mild 580 25  (144) 
Moderate 204 36  (74) Men 
Severe 70 49  (34) 
No COPD 7785   6  (616) 
Mild 267 33  (88) 
Moderate 96 42  (40) Women 
Severe 25 56  (14) 
 
COPD hospitalisation rates were seen to increase with disease severity as shown in table 
5.16, in both men and women.  In the male (female) group, for every 10 000 person 
years at risk in the severe COPD group, there were 1452 (1163) hospitalisations, 
compared to 373 (458) for every 10 000 person years at risk in the mild group and 89 
(73) in the no COPD group. 
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Table 5.16 COPD hospitalisation rates by disease severity, men and women 
  
N in 
group 
N 
hospitalisations 
Person yrs 
at risk 
Rate per 10 000 
person yr 
No COPD 13792 2426 305742 79 
mild 847 594 14733 403 
moderate 300 392 4148 945 
Men & 
women 
severe 95 120 902 1331 
No COPD 6007 1093 123209 89 
mild 580 355 9511 373 
moderate 204 227 2619 867 Men 
severe 70 76 523 1452 
No COPD 7785 1333 182533 73 
mild 267 239 5222 458 
moderate 96 165 1529 1079 Women 
severe 25 44 378 1163 
 
Of those hospitalised with COPD, the modal number of hospital admissions in both men 
and women was one, as seen in figures 5.11 and 5.12: 51% of men and 47% of women 
had one hospital admissions over the follow up period.  The distribution around number 
of hospitalisations was positively skewed in men and women.  The largest number of 
COPD hospital admissions was seen in the female group, with one woman having 39 
admissions compared to one man having 34 admissions.  Nevertheless, most of the 
participants (98%) had eleven or fewer hospital admissions over a maximum follow up 
period of 34 years.  The mean number of COPD hospitalisations was three for both men 
and women, in those people hospitalised for COPD. 
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Figure 5.11 Number of times hospitalised, men 
 
0
10
20
30
40
50
Pe
rc
en
t
0 10 20 30
Number of hospitalisations
 
Figure 5.12 Number of times hospitalised, women  
 
Figures 5.13 and 5.14 illustrate the length of hospital stay for men and women over the 
study period, for those hospitalised with COPD.  Of the men (women), 50% had a 
length of stay of 8 (9) days or fewer and 90% of hospital admissions were less than or 
equal to 28 (27) days.  The distribution around duration of stay was positively skewed.  
Less than 4% of hospital stays in both men and women were for more than 50 days.    
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Figure 5.13 Length of stay in hospital, men  
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Figure 5.14 Length of stay in hospital, women 
 
5.7.3 Summary 
Hospitalisation rates increased with disease severity in both men and women.  Most of 
those hospitalised during the follow up period had one hospitalisation, and length of 
stay in hospital was found to be nine days or fewer for 50% of those with a COPD 
hospitalisation.  A significant proportion of participants diagnosed with COPD did not 
experience a hospital admission.   
Whilst this dataset has value in studying the pattern of hospitalisation over a longer time 
frame, a limitation of using the data within economic evaluation is that only severe 
exacerbations could be studied.  Often in economic models it is of interest to study the 
impact of treatment on both minor and major exacerbations.  Whilst data on severe or 
major hospitalisations could be obtained using the MIDSPAN dataset, data on minor 
exacerbations would have to be sourced from elsewhere.  Another limiting factor is that 
because there is no information on HRQoL or FEV1 values, other than at baseline, the 
relationship between these variables and hospitalisation could not be modelled.  The 
other option with regards to obtaining data on exacerbations is from a RCT.  The 
hospitalisation rates reported in this chapter are likely to be lower than those reported in 
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a RCT because of the design of each type of study.  The extent to which this is the case 
would be of interest for further study.  The use of COPD coding in any position for a 
hospitalisation may have led to the over reporting of hospitalisation rates, however 
because the linked hospitalisation data obtained included information on respiratory 
coded hospitalisation only, the degree to which this is the case is less than otherwise.   
5.8 Discussion 
The MIDSPAN dataset with over 30 years of follow-up is among the longest and largest 
yet available for studying the natural history of COPD in a general population.  COPD 
is by definition a chronic condition and most mortality studies are limited by the 
duration of follow-up.  This study reports on 425 COPD deaths from a deceased 
population of 10 759 (72%) compared to a previously published longitudinal cohort 
study reporting on 242 of 6709.(204)  
Since follow-up began in 1972, all mortality records and (Scottish) hospitalisations for 
the MIDSPAN cohort who remained in the UK have been linked to the dataset, however 
coding errors and under-reporting of the disease may exist, particularly in older 
mortality records as recent shifts in the awareness of COPD may have led to increased 
recording of the disease on death certificates. 
The use of age as the time scale produced mixed results.  The proportionality 
assumption proved to be more difficult to fulfil when using age compared to time in 
study.  The reason behind this is unclear and additional research into this would be 
beneficial in order to understand this further.  Nonetheless, in presenting survival 
analysis visually via graphs such as Kaplan-Meier curves, the use of age along the x 
axis is more intuitive than time in study for displaying the survival history of 
participants within an observational based study design. 
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One of the biggest issues with the dataset is that information on the participants was 
only collected at one time point.  Therefore as the study population grew older, lung 
function was bound to deteriorate and a proportion was likely to develop respiratory 
symptoms. The extent to which any participant with no COPD went on to develop 
COPD is unknown, but is likely to, in part, explain the no COPD population with 
COPD coded mortality and the 7% of the no COPD group with a COPD hospitalisation.  
Of those with mild or moderate COPD at baseline, the proportion developing more 
severe disease is unknown and is a limitation of the study and the extent to which this 
impacted on subsequent mortality and hospitalisations is unknown. 
5.9 Conclusion 
Analyses conducted within this chapter have uncovered useful information on the 
natural history of disease that can be used to inform an economic model.  The data and 
analyses on mortality are of particular value because of the length of follow up and the 
size of the study population.  The breakdown of cause of death by disease severity 
revealed a range of causes of death that the COPD patient may face.  It is not the case 
that people with COPD all tend to die of COPD (although a significant proportion will 
die from COPD).  Because of this fact, the use of all-cause mortality, as opposed to 
disease specific mortality would be appropriate within a modelling framework: the 
numbers of people with COPD dying from COPD would mean that a focus on COPD 
mortality may miss important benefits of treatment. 
The extension of the Hole et al paper to include COPD mortality reinforced the 
importance of impaired lung function as a major indicator of COPD mortality.  This 
concept was further examined in the diagnostic criteria section.  It is important not to 
underestimate the importance of diagnostic criteria.  As previously shown in Chapter 2 
large variations in prevalence rates are seen when using different diagnostic criteria.  
NICE criteria were found to identify a group of COPD patients at higher risk of all-
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cause and COPD mortality, than the COPD population identified using GOLD criteria.  
Applied to a modelling scenario and looking at treatment in moderate disease, using 
NICE criteria to diagnose moderate COPD would identify a cohort at higher risk of 
mortality and possibly events than a GOLD diagnosed moderate group.  This is 
important to note because COPD treatments are often only licensed to specific disease 
severity groups so it is important at the outset to identify COPD cases accurately.  Of 
note is that pharmaceutical companies employ tight disease criteria for entry into their 
RCTs which tend to be similar to the diagnostic criteria recommended by NICE and the 
closer the profile of study participants is to the diseased population, the more likely that 
values obtained within the study will be externally valid.   
Where there is a range of data options for eliciting inputs to the model, it is important 
that the appropriate dataset is used for answering the question being asked.  For 
example a RCT may be more useful for eliciting information on exacerbations because 
information on minor and major exacerbations, lung function and HRQoL are collected 
over time.  Epidemiological data can be useful to inform the design and inputs into an 
economic model for COPD and as seen in this chapter, the Renfrew/Paisley 
(MIDSPAN) observational dataset can provide important information, particularly 
around survival and also on identifying the patient population.  For an economic model, 
it is desirable to also use data that has been collected repeatedly over time so that data 
on aspects that cannot be derived from an observational study are obtained.  The 
following chapter investigates a different type of dataset, a RCT and looks at deriving 
an important component of cost utility studies, utilities. 
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Chapter 6. Utilities 
The effectiveness of a new drug in relation to current treatment is an important element 
in demonstrating its cost effectiveness.  It has already been shown (Chapter 3) that there 
is a wide range of outcome measures that can be used within an economic evaluation 
and the most appropriate for ease of comparison across disease areas is a utility based 
HRQoL measure such as the EQ-5D, which can be employed to derive QALYs.  
Analyses within this chapter are focused on deriving values for utilities and QALYs. 
Within the context of economic modelling, the utility parameter can be derived from 
RCTs because trials provide accurate patient level information on the effectiveness of 
treatment over time.  Where a utility based measure such as the EQ-5D has been 
routinely collected it is relatively straightforward to generate QALYs from these scores.  
Another option for obtaining QALYs from within a trial is to develop a prediction 
equation that predicts QALY score based on patient characteristics.  Ultimately QALYs 
are used by decision makers in order to compare treatments in different disease areas on 
the same scale (discussed in detail in Chapter 3). 
Because the primary aim of the investigators who develop RCTs is drug registration 
rather than cost effectiveness, few of the COPD RCTs have included a utility based 
measure for HRQoL, instead choosing a disease specific measure, usually the SGRQ 
(see section 2.3.1).  Where economic evaluation of these RCTs is required, a mapping 
algorithm can be used to link the disease specific measure to a utility based measure, 
and then this predicted utility score can be used to derive QALYs.   
The dataset that was used within this chapter was a large, multinational, multi-site RCT 
called the Towards a Revolution in COPD Health (TORCH) trial (and was introduced in 
Chapter 2).  The TORCH clinical trial data are described below and issues around 
missing data discussed.  An example of how to obtain QALYs in the face of missing 
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data are presented followed by a statistical section containing details of the methods that 
are employed within this chapter.   
Summary utility values were derived from the TORCH trial by disease severity and 
QALYs from the trial data were calculated by treatment group.  A number of 
multivariate regression models were developed to predict: EQ-5D utility scores and 
QALYs using patient characteristics, so that the utility/QALY scores could be adjusted 
to take into account patient to patient heterogeneity.  The final section of the chapter 
develops a mapping equation which generates EQ-5D utility scores, for use when a 
utility based measure is not collected within a clinical trial. 
6.1 Data and Modelling Methods 
The TORCH trial assessed the efficacy of the combination product 
salmeterol/fluticasone compared to salmeterol, fluticasone and placebo in 6112 COPD 
patients over the course of three years.(49)  Inclusion criteria included that the subject 
had to have at least 10 pack years and FEV1 60 % predicted.  Of particular importance 
was that the EQ-5D was collected at regular time periods throughout the three years of 
the trial, the only major COPD trial to have done so.  Because of this, data from this 
RCT are of use in informing the QALY parameter of economic evaluation for COPD 
treatments. 
Other outcome measures included: the SGRQ, rate of exacerbations and post 
bronchodilator FEV1.(49)  Measures were repeatedly collected throughout the trial 
period with full follow up being achieved if the subject had full responses from seven 
different study days.  Due to translations of the EQ-5D questionnaire being unavailable 
in some languages, the EQ-5D was administered to 4237 out of the 6112 respondents.  
Therefore the base case dataset for the analyses conducted within this chapter contained 
those 4237 participants.  Attrition occurred over the three years of the trial with fewer 
observations taken at every successive session as individuals ceased to participate in the 
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study, or missed a session date.  All analyses were carried out using the TORCH 
dataset. 
The EQ-5D was developed in the late 1980s.  The EQ-5D defines health in terms of five 
dimensions: mobility, self care, usual activities, pain/discomfort and anxiety/depression 
and three possible responses: no problem, a moderate problem or an extreme problem 
(see appendix for details).(48)  This gives 243 different health states.(205)  An 
additional two states of unconscious and dead are included in the final number of health 
states and bring the total to 245 states.(206)  From the EQ-5D score, EQ-5D utility is 
calculated from a scoring mechanism that uses values that have been derived from the 
elicitation of population preferences.  Originally this elicitation of population 
preferences was carried out for 42 EuroQoL health states using time trade off methods 
and then a tariff was developed for all the 245 health states.(207;208)  For all EQ-5D 
scores, the tariff is employed to get the utility value; a utility of one indicates perfect 
health and a value of zero represents a health state equal to death.  Sometimes the EQ-
5D drops below 0 and these states indicate a health state worse than death.  Within the 
TORCH study, the EQ-5D scores were transformed into utilities based on the UK tariff, 
which was developed using responses from a sample of 3000 members of the UK 
population. 
The SGRQ is used to record health status on patients with chronic airflow limitation 
(including COPD and asthma).  Published in 1992, the SGRQ provides a self-
administered HRQoL questionnaire for patients, designed to improve upon the original 
interview administered, non-standardised Chronic Respiratory Disease Questionnaire, 
by being comparable across different studies and patient populations and contains 
questions which are used to inform three health domains of: symptoms, activity and 
impact upon daily life, and a total score (see appendix for details).(121)  The total score 
ranges from 100 which is the worst possible health state, to zero, which is considered 
the best possible health state.   
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There are 50 questions in the SGRQ and each questionnaire response has a unique 
empirically derived 'weight'.  The lowest possible weight is zero and the highest is 100.   
Each domain of the SGRQ (symptoms, activity and impact) is worked out separately in 
three steps: first the weighted values for all the items are summed; the weights for 
missed items are then subtracted from the maximum possible weight for each 
component.  The score for the domain is then calculated using the formula: 
Score = Sum of weights from positive items in the domain  x 100 
         Sum of weights for all items in the domain 
 
The total score is calculated using the same formula, but based on the entire 
questionnaire rather than any specific domain within it.  Each domain carries a different 
weight when the total score is calculated: approximately one sixth of the total score 
comes from the symptoms domain (weight = 662.5), one third from activity (weight = 
1209.1) and half from impacts (weight = 2117.8).   The total score has a weight of 
3989.4.  The symptoms domain can handle two items of missing data, the activity 
domain, four and the impact domain six.  For this reason the total score and domain 
scores may be available even when some items are missing. 
6.1.1 Missing Data 
In this section the issue of missing data is described before the TORCH dataset is 
examined for patterns of missingness around the EQ-5D and SGRQ variables.  
Missing data are a feature of applied analyses and whilst there are various ways of 
dealing with the problem of missing data, including dropping observations with missing 
values, imputation, last observation carried forward and inserting the mean value, the 
issue of missing data nevertheless should be considered.  
There are three different types of missingness: Missing Completely At Random 
(MCAR), Missing at Random (MAR) and Missing Not At Random (MNAR).  MCAR 
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is said to occur when the probability of an observation being missing is unrelated to 
either observed or unobserved variables.  Consistent results can be obtained using the 
same analyses that would have been used had there been no missing data.  Analysing 
data in which the missingness is MCAR leads to valid inferences.(209)  Missing at 
Random (MAR) occurs when given the observed data, the missingness mechanism does 
not depend on the unobserved data, and for example missing data may be related to 
gender, with men more likely to miss study day appointments than women.  When 
working with a regression model with missing observations that are MAR, as long as 
the variables predictive of missing responses are included as independent variables 
within regression equations, the analysis will be valid.(209)  Missing Not At Random 
(MNAR) occurs when neither MCAR or MAR hold. This means that even accounting 
for all the available observed information, the reason for the missing observations is 
dependent on unobserved observations.   
Checking for Patterns of Missingness 
Three sets of the TORCH data were compared for patterns of missing data: datasets 1, 2 
and 3. 
Dataset 1 used all the data on participants to whom an EQ-5D was administered (minus 
one subject who had missing FEV1 and FVC values and who was dropped from all 
analyses).  Dataset 1 contained 4236 participants and 22 532 observations.  
Dataset 2, a subset of dataset 1, contained observations with complete data on EQ-5D 
and SGRQ total score, comprising 3854 participants and 18 503 observations. 
Dataset 3, a subset of dataset 2, contained observations with complete data on EQ-5D 
index, SGRQ total score, SGRQ domain scores and SGRQ item scores and was 
comprised of 3640 subjects and 14 612 observations.   
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Figure 6.1 Percentage of missingness within each SGRQ question, datasets 1 and 2 
 
Figure 6.1 above illustrates the degree of missingness for each item score in datasets 1 
and 2.  Before dropping any observation with missing SGRQ item scores to form 
dataset 3, it was observed that questions 6, 8, 10 and 50 each had a large proportion of 
missing responses (clearly illustrated in figure 6.1) and that responses were either 
conditional or optional (see figure 6.2).  Because of this, these questions were excluded 
within dataset 3.  This act was justified on the grounds that not only can the total score 
and the domain scores deal with missing responses for up to 12 items within the SGRQ, 
but dropping questions 6,8,10 and 50 prevented the subsequent loss of even more 
observations in dataset 3 and aimed to minimise any potential bias.  If question 50 were 
not removed then the total study population for dataset 3, which contains only complete 
cases, would amount to one person.  As questions 6, 8, and 10 were predominantly 
related to more severe disease, the result of dropping observations where answers to 
these questions were not recorded would bias the resulting dataset towards people with 
worse health. 
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Figure 6.2 Questions omitted from the dataset because of a high degree of missingness  
and the conditionality of the question 
 
Table 6.1 presents summary statistics from the three datasets in order to aid 
identification of any differences between the datasets.  The proportion of men in each of 
the three datasets was the same at 71% and there was no difference in age with 27% of 
participants aged less than 60 years, 41% were aged 60-69 and 32/33% were 70 years or 
older.  BMI slightly increased from dataset 1 to datasets 2 and 3, though was not 
statistically significant.  Most of the participants in the TORCH study were Caucasian 
(93-94%) with few people from Black, Asian and ‘other’ races recruited, and this was 
the same for all three datasets.  The number of deceased participants after the three 
years was the same in each dataset at 13% of the total study population.  
Fewer of the subjects withdrew in dataset 2 (40%) and dataset 3 (38%) compared to 
dataset 1 (42%), suggesting that subsequent withdrawers were more likely to provide 
incomplete data during study visits than non-withdrawers during their study visits.  The 
proportion of mild COPD participants was slightly less in dataset 3 than in dataset 1 and 
there were more participants with severe disease in dataset 3 than in dataset 1, 
suggesting some potential correlation between disease severity and missingness.   
 
 
 
Q6: How long did the worst attack of chest trouble last? (go 
to Q6 if you had no severe attacks) 
 
Q8: If you have a wheeze, is it worse in the morning? 
 
Q10: If you ever had paid employment… 
 
Q50: Please write down any other important activities that your 
chest trouble may stop you doing 
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Table 6.1 Patterns of missingness, summary statistics by dataset % (n)  
 Dataset 1 Dataset 2 Dataset 3 
N 4236 3854 3640 
N observations 22 532 18 503 14 612 
Men, % (n) 71(2994) 71(2735) 71(2586) 
<60yrs, % (n) 27(1134) 27(1026) 27(979) 
60-69yrs, % (n) 41(1733) 41(1573) 41(1498) 
70yrs +, % (n) 32(1369) 33(1255) 32(1163) 
BMI (sd) 25.95(5.21) 26.01(5.28) 26.04(5.30) 
Caucasian, % (n) 94(3973) 93(3603) 93(3402) 
American Hispanic, % 
(n) 
3(113) 3(105) 3(102) 
Black , % (n) 2(91) 2(57) 1(53) 
Other, % (n) 1(59) 1(89) 2(83) 
Dead, % (n) 13(555) 13(505) 12(451) 
Withdrew, % (n) 42(1760) 40(1546) 38(1366) 
Mild COPD, % (n) 38(8541) 37(6896) 36(1298) 
Moderate COPD, % (n) 50(11175) 50(9243) 50(1822) 
Severe COPD, % (n) 12(2696) 12(2263) 14(497) 
 
The three datasets were found to give very similar summary statistics, datasets 1 and 2 
were almost identical and dataset 3 was only slightly different.  The largest disparities 
between the datasets were for disease severity and for withdrawing.  The reason for 
missingness may be explained by disease severity and/or by withdrawing, or it could be 
explained by some unobserved variable.  Within this chapter, datasets 2 and 3 are used.  
It was assumed that withdrawal was related to disease severity and that missingness can 
be explained by disease severity, therefore an assumption that the data are MAR was 
made.  Therefore analyses contain, where possible, a variable for adjusting by disease 
severity.  
6.1.2 Calculating QALYs 
The EQ-5D can be used within a RCT to measure HRQoL and where used, the 
instrument is usually administered to each participant at pre-scheduled intervals 
throughout the duration of the trial.  Within the TORCH trial, the EQ-5D was 
administered every six months.  The EQ-5D scores over time can be combined in order 
to derive QALYs.  QALYs are easily calculated for each participant using the method 
of Area Under the Curve (AUC) using data on utility over time.  For example, in a RCT 
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lasting for three years, subject X was administered the EQ-5D seven times at pre 
scheduled intervals.  To calculate QALYs for subject X, for each observation, the date 
of the assessment day, (d) was subtracted from the date of the previous assessment date, 
(d-1) and this was divided by 365.25 to get a value between 0 and 1 representing the 
proportion of one year between assessments.  The average utility value between the two 
observations was calculated by adding the EQ-5D score from the current observation, 
(e) to the EQ-5D score from the previous observation (e-1) and dividing the value by 
two.  The two differences are multiplied together to give a time weighted QALY score.  
The time weighted QALY scores are summed to get a QALY score out of 3 (for 3 
years). 
To further illustrate this, a worked example is shown in table 6.2.  The duration of 
follow up between the first and second observations is calculated as 169-1 to give 168 
and is divided by 365.25 to get 0.46 (A in table 6.2), representing the duration of time in 
years between the first and second observation.  At baseline, the participant had an EQ-
5D utility of 0.796 and in the second observation, had a score of perfect health, or 1.  To 
estimate the average utility between the two study days, 0.796 is added to 1 to give 
1.796.  This is divided by two to give 0.898 (B).  To weight this value by time, the 
utility is multiplied by the value previously derived for the duration of time between the 
first and second observation to give 0.413 (A*B).  All the weighted utilities are summed 
together for the duration of the trial to give a within trial QALY score.  In this example, 
patient X had a QALY score of 2.526 from a maximum of 3.  
Table 6.2 QALY calculation for a hypothetical patient over a three year trial 
Follow 
up day 
EQ-5D utility Diff in date/ 
365.25 (A) 
Difference in 
EQ-5D/2 (B) 
(A*B) 
1 0.796 / /  
169 1 0.460 0.898 0.413 
337 0.725 0.460 0.863 0.397 
505 0.883 0.460 0.804 0.370 
673 0.848 0.460 0.866 0.398 
841 1 0.460 0.924 0.425 
1093 0.516 0.690 0.758 0.523 
   QALYs 2.526 
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To calculate mean QALYs for the TORCH trial, the process described above is carried 
out for each participant.  Mean QALYs by treatment group can be compared to 
determine if a treatment is effective in terms of improving quality and quantity of life. 
Missing Data and Deriving QALYs 
Where the participant is followed up at every pre-scheduled time point for the duration 
of the RCT, complete information is available for this person.  In real life however some 
values are missing and it is necessary to use imputation methods in order to create a full 
three year follow up history for each participant.  The TORCH dataset had missing 
observations on EQ-5D utilities because some of the participants were not observed on 
the first study day, others were not observed on the last study visit (they were lost to 
follow up) and a large number had missing study days in between.  The problem of 
missing study visits between the first and last observation was solved by finding the 
AUC between each observation and summing together as previously described.  
Imputation for missing first observations was achieved by using first observation carried 
backwards.  Missing observations where participants withdrew from the trial or were 
lost to follow up had EQ-5D index values inputted using last observation carried 
forwards.  Participants who died during the trial were given an EQ-5D value of 0 from 
the date of death for the remainder of the trial.  Whilst this method of imputation may 
not be regarded quite as highly as other methods such as multiple imputation, the aim of 
the analyses on QALYs was to develop a multivariate regression equation to predict 
QALY scores, rather than the precise estimation and comparison of QALYs by 
treatment group per se.  Where the ultimate aim is to accurately predict relative 
treatment gains, a variety of imputation methods may be attempted in order to improve 
the reliability of results.    
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6.1.3 OLS and GLM modelling 
Within this section, different structures for developing regression equations that predict 
utility values are described.  Because utility data (like cost data) are likely to be heavily 
skewed, the appropriateness of Ordinary Least Squares (OLS) in particular which relies 
upon the normal distribution, should be considered.  A more flexible approach such as 
the Generalised Linear Model (GLM) may be more appropriate.    
OLS Models 
OLS is frequently used to model relationships between variables.  The classic normal 
multiple regression model can be written as: 
 ++= ijiji XY εβα  
( )2,0: σε NIDi   ni ,...1=  
Where the error term is normally and independently distributed (NID).  The OLS 
estimators,  and β , are chosen to get the ‘best fit’ in terms of minimising the sum of 
the squared residuals: 
( ) ( )[ ] +−= 2,...,1, jijjii XykS βαββα  
For OLS modelling, several important assumptions about the property of estimators are 
made.  
• The model is linear in parameters, that is, the model can be written as described 
above with  and β as unknown parameters, and the error term is an 
unobservable random error. 
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• There is a random sample of observations from the population. 
• The error term has a zero conditional mean, so that given any values of the 
explanatory variables the error has an expected value of zero. 
• There is no perfect collinearity between any of the explanatory variables, in 
other words, none of the explanatory variables is constant and there is no exact 
linear relationship among the explanatory variables.  
If these assumptions hold then the OLS estimators are unbiased estimators of the 
population parameters.(210) 
Homoscedasticity, which refers to the variance of each error term being constant, 
conditional on the explanatory variables, is necessary for OLS to be efficient.  If all 
these assumptions hold in the analysis then the OLS estimators are regarded as being 
the Best Linear Unbiased Estimators (BLUE).  For inference, normality is also assumed.  
The condition of BLUE is important because where all these assumptions hold, for 
determining unbiased estimators, OLS will do as well, or better than any other method.  
Any breaches of the assumptions will lead to the condition of BLUE failing.  There are 
circumstances in which OLS may no longer be ‘best’ which refers to the smallest 
variance, but may still give unbiased estimators, for example including irrelevant 
variables in a regression model will have no effect on the unbiasdness of the estimators, 
but can cause the variances of the OLS estimators to increase because of multi 
collinearity.  Sample size is important to achieve the ‘best’ condition because the larger 
the total variation in X, the smaller the variance of β will be.  It is desirable therefore to 
gain as much sample variation as possible ,which is achieved through a large sample 
size.  
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If the assumption of homoscedasticity fails so that there is heteroskedasticity; for 
example where the error term varies, this will result in unbiased coefficients but 
inefficient estimates.  Excluding a relevant variable can cause the estimators to be 
biased as the expected value of β (E(β)) will not equal β.  The assumption of 
independence of the error term may be violated if there are multiple observations from 
the same subject. 
Utility data are negatively skewed and because OLS operates assuming a normal 
distribution, predicted values from OLS may not be suitable for working with utility 
data, in this case it may be useful to explore other methods. 
GLM Models 
An alternative approach is GLM modelling.  A feature of the GLM is that the OLS 
model is a special example of the GLM in which the family is Gaussian and the link, 
identity.  Thus the OLS model can be identified within the GLM framework if it is 
found to fit the data well.  GLM modelling has advantages over OLS because GLM 
directly models the mean and variance function on the original scale of EQ-5D.  The 
GLM is based on the following equation: 
( ){ } ,βxyEg =       y   F 
With covariates x, g() is the link function and F is the distributional family.(211)  The 
link function specifies the relationship between the mean (E(y|x)) and the linear 
specification of the covariates (x).  Link functions include, but are not limited to: 
identity, log and square root links.  The family used within the GLM should be one that 
fits the distribution of the data.  Families include: Gaussian, Poisson and gamma.  The 
GLM model with a Gaussian family and an identity link takes the form: 
( ) ,βxyE =        y       Normal 
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Which is the equation for the OLS model.(211) 
The family and a link function are selected, based on outcomes from statistical tests.  
Testing for distributional family is done using the Parks test,(212) using a GLM model 
with any link and family.  Once the test is run, the family is identified based on the 
lowest Chi2 value and is inputted into the model, at which point the Parks test is re-run 
to check whether the chosen family still gives the lowest Chi2 value.  Once the family is 
determined, tests are carried out to identify link using the Pearson correlation test,(213) 
the Pregibon link test,(214) and the modified Hosmer–Lemeshow test.(215)  Where all 
three tests yield non-significant p-values, the link function is said to fit well.(99)  The 
appropriate trade-off between the three links is currently unknown.  A decision rule was 
used so that if any power function dominates in two or more tests then it is the chosen 
link function to take forward.  
6.2 Utilities and QALYs from Trial Data 
Utility data are an important component in a cost utility analysis, for reasons previously 
explained within Chapter 3.  Therefore it is important to derive utility values from an 
appropriate patient population such as TORCH.  Within this section EQ-5D utility 
scores were summarised from the data.  OLS and GLM multivariate modelling were 
used to derive equations that predict EQ-5D utility and the predicted results were 
compared to the observed results of EQ-5D utility by disease severity.  Using the AUC 
method, QALYs over three years were obtained for each subject and were summarised 
by treatment group.  A multivariate analysis was developed in order to predict within 
trial QALY scores.  
6.2.1 Methods 
Subjects within TORCH were classified into COPD disease severity groupings 
according to the following spirometry classifications, which are consistent with the 
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NICE diagnostic criteria, given the inclusion criteria of the trial.  COPD cases were 
identified where airflow obstruction was FEV1/FVC<0.7 and FEV1<80% predicted.  For 
each COPD case, mild COPD was defined as 50 FEV1< 80 % predicted, moderate 
COPD as 30 FEV1< 50 % predicted and severe COPD as FEV1<30 % predicted.  
Because the spirometry inclusion criteria was FEV1 60 % predicted for the trial, in 
practice the mild group contained, in the most part, subjects with a lung function 
capacity of 50 FEV1 60 % predicted.  The TORCH dataset 2 was used for all 
analyses because it was important that there was complete data on EQ-5D, which 
entered the equation as the dependent variable.  Mean EQ-5D utility by disease severity 
was derived from the data.  
A prediction equation for EQ-5D utility using patient specific variables was developed 
using OLS and GLM models.  Utility decrement (ud) scores were used to conduct the 
analyses in order to bind the distribution to a positive scale.  This was achieved by 
subtracting the index scores from 1 (ud=1-index).  The advantage of using ud rather 
than utility is that standard methods (particularly GLM models) can be used to deal with 
skewed data by constraining values onto a positive scale.  Multivariate analysis was 
conducted rather than univariate analysis because it enables subgroup analyses to be 
carried out.  Exploratory analysis identified a number of candidates for inclusion within 
the model to predict EQ-5D utility and these were included within the regression 
models; COPD severity group, sex, ex-smoker, BMI and country.  Because the utility 
scores of interest are those for the UK population, a dummy variable for UK was 
included within the list of covariates.  Statistical tests previously described were used to 
identify family and link functions. 
QALYs were derived from the TORCH dataset using the method of AUC (as described 
in section 6.1.3).  QALYs were derived for each participant and mean QALYs by 
treatment group were compared.  A multivariate analysis was developed to predict 
QALYs using the QALY scores estimated from the AUC method. 
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Once the best fitting model had been identified, the method of recycled predictions was 
used to estimate average EQ-5D values, by treatment group.  Glick et al argue that on 
the transformed scale the effect of the treatment group is estimated holding all else 
equal but retransformation in order to estimate EQ-5D can reintroduce covariate 
imbalances and so the method of recycled predictions gets around this problem by 
creating an identical covariate structure for each treatment group, by coding everyone as 
if they were in the first treatment group (1) and predicting QALYs for each subject, then 
coding everyone in the other treatment groups in turn (2, 3 or 4) and predicting QALYs 
for each person.  The difference in the arithmetic mean between the treatments, predicts 
QALYs holding all else equal during model estimation and retransformation.(99) 
The best fitting GLM equation and the method of recycled predictions were replicated 
1000 times using bootstrapping to obtain 1000 average QALY scores in each of the four 
treatment groups.  These average scores were ordered from lowest to highest where the 
26th and the 975th values represent the 95% CIs.  Non parametric tests such as 
bootstrapping of arithmetic means may be more suitable for tests of significance,(99) 
than standard parametric tests such as the t test which assume that the data are normally 
distributed.  QALY data are likely to have a skewed distribution which potentially 
invalidates the assumptions underlying the use of parametric tests.  
6.2.2 Results 
EQ-5D utility values from dataset 2 are illustrated in figure 6.3 which shows that the 
EQ-5D utility values are not normally distributed and are negatively skewed.  The 
distribution is tri-modal, with almost 3800 of the observations taking the value 1.  Only 
8% of the responses fall below 0.50.  The distribution of utility scores, particularly the 
apparent gaps, represents an artefact of the scoring algorithm; it is well known that the 
scoring algorithm does not generate values above 0.88 but below 1. 
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Figure 6.3 Distribution of EQ-5D responses 
 
The study population comprised of 3854 subjects and 18 503 observations of whom, as 
shown in table 6.3, 2735 (71%) were male and 1119 (29%) were female.  Mean age at 
the first observation was 64.8 (62.7) for men (women).  Of the men and women, 39% 
and 42% respectively withdrew from the trial and 14% of the men died during the three 
years of the trial compared to 10% of the women. 
Table 6.3 Summary statistics, dataset 2 
n=3854, n observations= 18 503 
  Men Women 
Number in study, n (%) 2735 (71) 1119 (29) 
Age, mean (sd) 64.8 (8.3) 62.7 (8.7) 
BMI, mean (sd) 26.2 (4.9) 25.5 (6.0) 
Withdrew, n(%) 1072 (39) 474 (42) 
Dead, n(%) 391 (14) 114 (10) 
 
EQ-5D utility by disease severity was 0.773 (SD=0.22) for mild COPD, 0.713 (0.23) for 
moderate COPD patients and 0.650 (0.23) for severe COPD patients. 
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Utilities from the Prediction Equation 
An OLS and GLM were developed during exploratory analyses.  The GLM model 
identified that a Poisson family (Chi2=0.96, p=0.33) with an identity link was 
appropriate for the data, rather than the Gaussian family (OLS) and so the GLM model 
was taken forward and is described here.  The GLM model had ud as the dependent 
variable with: BMI, UK, ex-smoker and COPD disease severity group as independent 
variables.  Based on three statistical tests, the identity link was found to perform 
relatively well (Pearson correlation test=0.87, Pregibon link test=0.44 and Modified 
Hosmer and Lemeshow=0.61).  Table 6.4 contains the coefficients, standard errors and 
p-values for the prediction equation for EQ-5D utility with Poisson family and identity 
link.  
Table 6.4 Prediction equation for EQ-5D ud  
with independent variables, coefficients, SEs and p values from a GLM regression with 
Poisson family and identity link  
Variable Coefficient SE P 
BMI (range12-57) 0.0016 0.0007 0.03 
UK (0=no 1=yes) 0.0907 0.0264 0.00 
Ex-smoker(0=no 1=yes) -0.0292 0.0080 0.00 
Moderate (0=no 1=yes) 0.0613 0.0083 0.00 
Severe (0=no 1=yes) 0.1268 0.0139 0.00 
Cons 0.1974 0.0204 0.00 
 
Gender was originally included within the list of coefficients and was removed due to 
statistical insignificance.  The variable on ex-smoker shows that ex-smokers had a small 
but statistically significant, larger utility compared to smokers.  COPD moderate and 
severe disease severity was statistically significant compared to mild disease.     
Because the regression was developed on the ud scale, transformation of the resulting 
ud values to EQ-5D utility was conducted (1-ud), in order to compare against observed 
utility, and for reporting purposes.  Predicted EQ-5D utility by disease severity was 
calculated using the prediction equation described above and is shown in table 6.5 
alongside mean EQ-5D utility by disease severity as recorded in the trial. 
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Table 6.5 Observed and predicted EQ-5D utility by COPD disease severity 
Disease severity Predicted Observed 
Mild 0.773 0.773 
Moderate 0.713 0.713 
Severe 0.649 0.650 
 
As can be seen in table 6.5, utility was highest for people with mild disease and lowest 
for those with severe disease, suggesting HRQoL deteriorates as the disease progresses.  
The prediction equation was found to perform well in predicting EQ-5D utility by 
disease severity when compared to the observed results.  The predictions matched the 
observed scores, accurate to 2 decimal places.   
QALYs from Trial Data 
QALY scores were derived for each subject using the AUC method.  QALYs by 
treatment group were: 1.988, 1.980, 2.019 and 2.087 for treatment groups 1, 2, 3 and 4 
respectively.  The histogram of QALYs, reproduced in figure 6.4, shows that the QALY 
data were left skewed with over 80% of scores between 1.5 and 3.  The distribution was 
characterised by a long left tail and for a minority of subjects, QALY scores were less 
than 0  
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Figure 6.4 Distribution of QALYs  
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QALYs from Modelling 
GLM regression models were developed to predict QALY decrement ((3-QALY) and 
were retransformed to QALYs for reporting).  Explanatory variables of: treatment 
group; COPD disease severity; sex; BMI; UK and ex-smoker were used.  
The Poisson family was identified using the Parks test with a Chi2 of 3.37 (p=0.07).  
The GLM on ud with Poisson family was run with a number of different link functions 
and the outputs of the resulting statistical tests are reproduced in table 6.6.  Table 6.6 
shows that for the identity link (where power=1), the p-value from the Pregibon link test 
was 0.3214 and 0.8887 for the modified Hosmer and Lemeshow test.  It is clearly seen 
in the table that these numbers are the largest within each test, and based on the a priori 
decision rule, the identity link is said to fit the data well.  
Table 6.6 P-values from statistical tests 
Results from the Pearson Correlation, Pregibon link and Modified Hosmer and 
Lemeshow tests applied to a GLM on QALY decrement with a Poisson family and 
different link functions 
Power Pearson Correlation 
test 
Pregibon Link test Modified Hosmer and 
Lemeshow test 
0 0.8837 0.1716 0.1398 
0.25 0.8653 0.1953 0.1555 
0.50 0.8526 0.2278 0.2505 
0.65 0.8478 0.2518 0.4825 
0.75 0.8458 0.2698 0.4426 
1 0.8447 0.3214 0.8887 
-1 1.0000 0.1500 0.6853 
-2 0.8707 0.2407 0.0724 
 
The GLM model for QALY decrement with Poisson family and identity link is shown 
in table 6.7 below.  BMI was not found to be statistically significant and so was 
removed from the analysis.  Disease severity, sex, UK and ex-smoker were all found to 
be statistically significant in the prediction of QALY decrement.  Treatments 2 and 3 
were not found to be statistically significant, but the p value for treatment 4 suggested 
some QALY gain arising from this treatment. 
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Table 6.7 Prediction equation for QALY decrement  
with independent variables, coefficients, SEs and p values from a GLM regression with 
Poisson family and identity link  
Variable Coefficient SE P 
Tmt 2 (0=no 1=yes) -0.0195 0.0500 0.695 
Tmt 3 (0=no 1=yes) -0.0455 0.0495 0.358 
Tmt 4 (0=no 1=yes) -0.0924 0.0487 0.058 
Sex (0=women 1=men) -0.0889 0.0390 0.023 
UK (0=no 1=yes) 0.2670 0.1242 0.032 
Ex-smoker(0=no 1=yes) -0.0759 0.0353 0.032 
Moderate (0=no 1=yes) 0.1884 0.0370 0.000 
Severe (0=no 1=yes) 0.4199 0.0598 0.000 
Cons 0.9702 0.0519 0.000 
 
Using the resulting GLM model as described, with the identity link and Poisson family 
together with the method of recycled predictions, gave predicted QALY scores: 1.981, 
1.991, 2.021 and 2.081 for treatments 1,2,3 and 4 respectively as shown in table 6.8 
below.  The predicted means were similar to those from the dataset.  Bootstrapping 
1000 times with replacement gave 95% CIs around the predicted mean QALYs and the 
results from this analysis are presented in table 6.8.   Analyses from the bootstrapped 
results suggested that treatment 4 has a higher mean QALY than the other 3 treatments 
(p<0.001 vs. treatment 1, p=0.008 vs. treatment 2, p=0.070 vs. treatment 3), and there is 
no evidence of differences between treatments 1 to 3 (all p>0.2). 
Table 6.8 Predicted QALYs and bootstrapped 95% CIs 
Treatment Observed Predicted 95% CI 
1 1.988 1.981 1.935-2.030 
2 1.980 1.991 1.946-2.036 
3 2.019 2.021 1.978-2.063 
4 2.087 2.081 2.036-2.123 
 
6.2.3 Discussion 
Previous studies have used a range of utility scores within their COPD models.  As 
discussed in Chapter 3, all of the COPD models currently published are structured on a 
Markov framework and within the Markov model; many authors have presented the 
disease in terms of COPD disease severity based on FEV1 % predicted.  Table 6.9 
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illustrates the array of utility values used within these models, alongside the results from 
the current study, which are consistent with those previously estimated.   
Table 6.9 Utilities used in economic models, by COPD disease severity 
 >80% 
predicted 
Mild 
50-80 
Moderate 
30-50 
Severe 
<30 
Rutten van Molken 
(2007) 0.81 0.81 0.76 0.66 
Borg et al (2004(138)) 
(sd) 
0.8971 
(0.1117) 
0.7551 
(0.2747) 
0.7481 
(0.2991) 
0.5493 
(0.3129) 
Spencer (2005)(144) 
(se) 
0.81(0.02) 
0.81(0.02) 0.72(0.03) 0.67(0.05) 
Sin (2004)(141) 1.00 1.00 0.92 0.84 
Observed  0.773 0.713 0.649 
Predicted  0.773 0.713 0.650 
 
QALYs derived from the TORCH trial using means and predicted means, by treatment 
group were found to be similar.  Deriving QALYs directly from the dataset may have 
limited usage because the resulting QALYs cannot take account of, amongst other 
things, age, sex or disease severity.  The use of regression models to predict QALYs 
allows these variables to be explicitly accounted for.  
A prediction equation for QALYs using a GLM model with Poisson family and the 
identity link was found to fit the data well. Non-parametric tests of statistical 
significance were preferred and a bootstrap was carried out to determine the 95% CIs 
around the predicted mean scores. 
The methods described above to estimate and predict utilities can be applied in exactly 
the same way to cost data.  Extensions to this study on utilities would be to use the same 
methods on costs, which would lead to costs and QALY estimates being available for 
each treatment group.  The differences between the treatment groups would be 
calculated to derive ICERs.  Uncertainty around the ICER would be established using 
the method of bootstrapping as previously described. 
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6.3 Utilities and QALYS Indirectly from Trial Data 
For reasons previously described in Chapter 3, for cost utility analyses, data on a utility 
based measure such as the EQ-5D is necessary in order to assess the cost effectiveness 
of an intervention.  However, clinical studies assessing the effectiveness of new drugs 
or treatments for COPD often only employ the SGRQ (section 2.3.1), a disease specific 
HRQoL instrument, in order to examine changes in HRQoL: of the major COPD RCTs, 
only TORCH has collected information on EQ-5D.  Therefore, in order to use the 
HRQoL data gathered within trials where EQ-5D was not collected, it is useful to 
employ a mapping algorithm in order to predict utility from the SGRQ.  NICE have 
recently approved of mapping and have stated:  
“Where EQ-5D data are not available, other methods should be used to 
estimate EQ-5D utility data.  Consideration will be given to mapping EQ-
5D utility data from other HRQL measures included in the relevant clinical 
trial(s) where an adequate mapping function can be demonstrated and 
validated.” (87) 
Responses to the SGRQ questionnaire and the EQ-5D questionnaire were routinely 
collected within the three years of the TORCH trial and these measures have previously 
been described at the start of this chapter.   
6.3.1 Literature Review 
This section reviews the literature on both existing SGRQ to EQ-5D mappings and on 
other mappings more generally. 
Two mapping algorithms already exist that map the SGRQ to utilities, and are available 
in abstract form only.(216;217)  The first by Meguro et al derives utilities directly from 
a COPD patient population using the TTO method (this method is described in Chapter 
3).  The states were created using a combination of nine of the questions/statements 
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within the SGRQ in order to simulate different levels of disease severity for a small 
number of sample states.(216)  A multiple regression model was developed to impute 
values for the other possible states.  A few issues exist about the study results, 
including: that of the patients recruited, fewer than 50% provided reliable data (69 out 
of 150); an adjustment factor is required to normalise the resulting utility estimate; and 
the algorithm is currently restrictive in that it only applies to 65 year old males.  
The second mapping by Vardeva et al models the relationship between the SGRQ and 
EQ-5D utilities using a regression model.(217)  OLS regression was used for the 
mapping.  Various alternatives were also investigated, including Tobit regression and 
logarithm transformation of the dependent variable.  A validation sample was used 
based upon health status at the end of the study.  Predictive ability by COPD severity 
was estimated.  R2 and Root Mean Squared Error (RMSE) were used to assess the 
model with regards to fit and predictive ability.  The preferred model (OLS no log 
transformation) combined domain scores and individual item scores, resulting in some 
element of double-counting.  The model has been shown to be problematic (GSK 
statisticians, Stockley Park) when applied to a recent dataset, particularly at the upper 
and lower extremes of self-reported HRQoL.  There is therefore room for a soundly 
developed and thoroughly validated mapping algorithm from the SGRQ to the EQ-5D. 
Structured Review 
There has been an increase in the literature on mapping within recent years.  A literature 
search in OVID was carried out using the terms “utility” “mapping” “health” since 1996 
until January 2008 which identified 50 papers.  Of these, 24 abstracts were read and of 
these 10 were found to be relevant.  Reference lists were also searched in order to 
identify potentially relevant papers.  Five additional papers were identified via this 
search.  The inclusion criterion was ‘HRQoL questionnaires mapped to utility’ and the 
exclusion criterion was ‘mapping based upon VAS or SG studies’.  
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In total, 14 papers were identified and table 6.10 below provides a summary of each of 
these papers, including for each study: the HRQoL measures used to carry out the 
mapping; the statistical model(s) used; how missing data was dealt with; the various 
coefficients that were included within the model; details of the validation sample used; 
how goodness of fit and predictive ability compared; the final model; and the method 
chosen for each study. 
Table 6.10 illustrates that whilst there is much variability in the HRQoL measures used 
to conduct the mapping, the methods used are similar.  Without exception, all of those 
papers published before 2005 solely employed OLS in order to develop regression 
equations.  A number of other methods have been employed more recently including 
Generalised least squares, Random Effects, Generalised Estimating Equations, and 
Tobit models.  
Where stated within the studies, only complete case data were used on which to run the 
analyses, thus removing all missing data.  Different combinations of explanatory 
variables were investigated, particularly around options with total, domain or individual 
item scores.  Some analyses included squared coefficients and/or interaction terms.  The 
majority included demographic terms but these were found to differ between the studies 
(most used as a minimum age and gender).  
The validation samples used were usually internal following a random split within the 
dataset: either 1/2 fitting and 1/2 validation or 2/3 fitting and 1/3 validation.  Other 
studies used an external clinical trial, or bootstrapping from the original dataset.  R2 was 
the usual method used to measure goodness of fit; ranging from 0.34 to 0.69.  RMSE 
was most frequently used for testing predictive ability and ranged from 0.09 to 0.21.  
 
 197 
Brazier et al Systematic Review 
A systematic literature review by Brazier et al,(218;219) identified 28 mapping studies, 
representing 119 models, including studies from so called ‘grey’ literature’.  The 
Brazier et al review had similar findings to those previously outlined. 
Brazier at al found that most of the studies employed OLS, though some used more 
complex techniques including GLM with random effects, adjusted least squares, Tobit, 
censored least absolute deviation and non-linear models.  
The most popular measure to map to was the EQ-5D Index (16 out of 28 studies).  The 
sample size used within the studies varied from 98 to 23 547.  Regression models were 
usually additive, with total/dimension/item scores as independent variables (some 
including the item scores as categorically as well as continuous).  Of the 119 models, 34 
included personal characteristics such as age, sex and race, 33 included interaction 
terms and 19 used squared transformations of the dependent variable.  Increasing the 
complexity of the model was found to often achieve only negligible improvements in 
predictive ability. 
  
Table 6.10 Summary of the mapping papers 
First 
author
, ref 
Dataset, 
n 
HRQoL 
measure Model 
missin
g data Coefficients validation 
validation 
stat Mapping algorithm 
Wu 
(220) 
Obs 
study, 
270 
FACT-P 
and the 
EORTC 
QLQ-C30 
to EQ-5D 
Index 
1) OLS              
2) OLS for 
EQ-5D 
scores <1 3) 
median 
regression 
Baselin
e 
measur
es  
1) FACT-P score, EORTC QLQ-C30 component scores, demographics   2) 
FACT-P score, EORTC QLQ-C30 component scores, demographics and 
interaction terms 3)  FACT-P component scores, EORTC QLQ-C30 
component scores, demographics   4) FACT-P component scores, EORTC 
QLQ-C30 component scores, demographics and interaction terms. 
Split into 10: 90% 
used to fit, 10% 
validation. Each 
group of 10% used 
successively to 
test  
R2 and SSE 
Absolute 
deviation 
OLS with FACT-P 
component scores, 
EORTC QLQ-C30 
component scores and 
demographics (R2=0.58)  
Yang, 
(221)  
MOS 
study, 
2825 and 
2 RCTs 
199, 124  
MOS 
sleep 
scale to 
SF-6D 
non 
parametric 
and OLS 
/ 1) non parametric regression 2) SLP9 3) SLP9, SLP9 squared 4) SLP9, 
SLP9 squared, gender, age 5) slp9, slp9 squared, disease status 6) SLP9, 
SLP9 squared, gender, age, disese status 
random split  R2, 
observed vs 
predicted 
SF-6D 
linear regression: SLP, 
SLP squared (R2=0.34) 
Buxton 
(222) 
Two 
RCTs, 
905 
IBDQ, 
CDAI, 
EQ-5D 
Index and 
SF-6D 
Index 
GLS not 
stated 
1) IBDQ to SF-6D 2) IBDQ to EQ-5D 3) CDAI to SF-36 4) CDAI to EG-5D 
plus for the IBDQ mappings, squared IBDQ and demographics 
external RCT R2, MA% 
Error. 
Comparison
s of means  
IBDQ with the inclusion of 
IBDQ squared to SF-6D 
(R2=0.69). And IBDQ to 
EQ-5D (R2=0.45). Both 
with no demographics 
Groote
ndorst 
(223) 
RCT 255 WOMAC 
and HUI-
3 
OLS 
RE 
Comple
te 
cases. 
1) WOMAC individual items (cat) 2) WOMAC domain scores 3) WOMAC 
Domain scores plus interaction terms 4)WOMAC total + total^2 + 
demographics for each 
Random split: 2/3 
training, 1/3 
validation 
MAE, 
RMSE,  ICC 
WOMAC domain scores + 
interactionn + 
demographics. (R2= 0.39) 
(RMSE= 0.21) 
(MAE=0.16) 
Bansba
ck 
(224) 
Survey, 
319 CAN, 
151 UK 
HAQ, SF-
36 and 
EQ-5D 
Index 
GEE / Each to EQ-5D and SF-6D: 1) Total HAQ 2) HAQ domain scores (cont) 3) 
HAQ individual items (cont) 4) HAQ domain scores (ca) 5) HAQ individual 
items (cat) + patient demographics 
Random split. 2/3 
training, 1/3 
validation.  
RMSE, R2 SF-6D: Models 2 and 4 
performed well, no 
demographics 
(RMSE=0.089) EQ-5D: 
All with marginal R2>0.5 
Brenna
n (225) 
Survey, 
375 
OHIP to 
EQ-5D 
Index 
Tobit / individual items (categorical and continuous) plus age and sex, nonlinear 
(age2) and inclusion of interaction terms 
Random split: 2/3 
fitting 1/3 validation 
forecast 
errors.  
continuous model + age 
and sex (R2=0.62) 
Sullivan 
(226) 
MEPS 
2000 14 
286 & 
2002, 23 
647 
SF-12 to 
EQ-5D 
Index 
CLAD, 
Tobit,  
OLS 
complet
e cases 
PCS-12, MCS-12, PCS-12*2 MCS-12*2 + demographics (age, sex, 
ethnicity, income, education, no of chronic conditons) 
MEPS 2002 for 
fitting, MEPS 2000 
for validation 
T PE, mean 
PE 
CLAD PCS-12, MCS-12 + 
demographics  
Longwo
rth 
(227) 
Survey, 
510 
CCS, 
Breathles
sness 
grade to 
EQ-5D 
Index 
OLS complet
e cases 
CCS score, breathlessness score, gender, age, treatment centre, 
type/number of revascularisation experiences, no current medications and 
interaction terms is statistically significant 
/ R2 OLS with CCS(cat) 
Breathlessness 
score(cat), No of drugs 
Franks 
(228) 
Survey, 
12 998 
SF-12 to 
EQ-5D 
Index (UK 
pref) 
OLS complet
e cases 
SF-12 domain scores, with and without inclusion of squared domain scores 
and interaction terms, up to 4th degree polynomials and using linear splines 
of each domain (dividing each into 20 equally saced intervals and 
demographics  
Bootstrap and 
external validation 
on a dataset of 240 
R2. A second degree 
polynomial without 
demographics (R2=0.62). 
  
Brazier 
(229) 
survey, 
RCTs, 
surgery 
cand, 
1972 
IWQOL-
Lite to 
SF-6D 
OLS complet
e cases 
1) IWQOL-Lite total score 2) IWQOL-Lite domain scores 3) IWQOL-Lite 
individual scores (cont) 4) IWQOL-Lite individual scores (cat) 5) the best 
from above + age, gender, bmi  
Random split: 
50:50 
RMSE and 
R2 
Model 4 plus age and bmi 
(R2= 0.521) 
(RMSE=0.0946) 
Lawren
ce 
(230) 
MEPS 
(2000), 
14 580 
SF-12 to 
EQ-5D 
OLS complet
e case 
1) PCS-12, MCS-12, 2) PCS-12, MCS-12, PCS-12*MCS-12 3) PCS-12, 
MCS-12, PCS-12*MCS-12, PCS-12^2, MCS-12^2, PCS-12^3   
Random split: 
50:50 
R2  PCS-12, MCS-12 (R2= 
0.612) 
Sengup
ta (231) 
Survey, 
6923 
SF-12 to 
the HUI3 
and VAS  
OLS complet
e case 
1) SF-12 individual items (cat) 2 SF-12 individual items (cont) 3) MCS-12, 
PCS-12, MCS-12^2, PCS-12^2, PCS-12*MCS-12 + age and gender 
Random split: 
50:50 
R2 MAD, 
mean 
deviation2 
1) SF-12 individual items 
+ demographics (cont) 
(HUI3 R2= 0.47) (VAS 
R2= 0.55) 
Franks 
(232) 
Survey, 
240 
SF-12, 
HUI3 to 
EQ-5D 
OLS complet
e case 
PCS-12 and MCS-12, squared and interaction terms, demographics and 
clinical variables 
Bootstrapping with 
1000 replications 
R2 EQ-5D: PCS-12, MCS-12, 
PCS-12^2, MCS-12^2, 
PCS-12*MCS-12 
(R2=0.59)  HUI: PCS-12, 
MCS-12, MCS-12^2 (R2 
= 0.51) 
Nichol 
(233) 
Survey, 
6921 
SF-36 to 
HUI2 
OLS complet
e case 
SF-36 domain scores, interaction terms, age and gender / R2 SF-36 domain scores + 
age (R2=0.51) 
MOS = Medical outcomes study, FACT-P = Functional Assessment of Cancer Therapy - Prostate, EORTC-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, 
AQoL = Assessment of quality of life, IBDQ = Inflammatory Bowel Disease Questionnaire, CDAI = Crohn's Disease Activity Index, WOMAC=Western Ontario and McMaster University Osteoarthristis Index, FACT-
G = Functional Assessment of Cancer Therapy - General, HAQ=Health Assessment Questionnaire, OHIP = Oral Health Impact Profile, MEPS= Medical Expenditure Panel Survey, CCS = Canadian 
Cardiovascular Society score 
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R2 and/or adjusted R2 were usually reported.  For models mapping from a generic to a 
generic measure (such as the SF-12 to EQ-5D), the studies achieved an R2/adjusted R2 of 
greater than 0.5.  However, for those studies mapping from a condition specific to a generic 
measure, R2 was lower, with a range of 0.17-0.51.  Brazier et al question the use of the R2 
statistic by stating that: 
“Measures of explanatory power, for example R2 and adjusted R2, are not a 
useful basis for assessing model performance of mapping functions as they 
focus upon how well the model explains the dataset it was estimated on…  A 
better method for assessing mapping functions is to examine the difference 
between predicted and observed values by calculating Mean Error (ME), Mean 
Absolute Error (MAE) or Root Mean Squared Error (RMSE).  These can 
provide an indication of the size of the prediction errors.”(234) 
Within the studies, ME ranged from 0.0007 to 0.042, MAE ranged from 0.0011 to 0.19 and 
RMSE ranged from 0.084 to 0.2.  Overall, the level of error was found to be far greater 
when predicting more severe health states.  Scatter plots in several of the studies found that 
there is a tendency for the predicted EQ-5D values to over-predict observed values at the 
lower end and under-predict at the upper end of the EQ-5D utility scale. 
It has been seen that whilst previous studies have mapped disease specific measures to the 
EQ-5D, the extent to which these algorithms are developed and tested varies and is often 
limited.  Most studies have employed and stop at using OLS to derive a prediction equation 
for the mapping.  Where validation has been attempted, the majority of studies used a 
random split of the data on which to test their resulting algorithm.  Here it is argued that 
such a split is inappropriate, with preference made for a non-random split of the data.  
Within this section, a rigorous approach to the development and validation of a prediction 
model using a dataset in which both the EQ-5D and the SGRQ were routinely collected in 
COPD patients was carried out.   
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6.3.2 Methods 
The methods used to develop and validate a mapping algorithm from the SGRQ to the EQ-
5D are described below. 
The TORCH dataset 3 (as previously described) was used to conduct all the analyses within 
this dataset, complete data were available on EQ-5D utility and on all SGRQ responses.  It 
was important to only use the complete cases because it was the relationship between the 
SGRQ variable(s) and the EQ 5D variable that was of interest and imputing missing values 
for these variables potentially risks blurring the relationship between them.  Within the 
TORCH study, SGRQ and EQ-5D were collected at baseline and every 24 weeks over three 
years.  Data were split non-randomly into a ‘fitting’ sample (all non-USA subjects, 67% of 
study sample) and a ‘validation’ sample (all USA subjects, 33% of study sample).  Splitting 
the dataset in this way ensures a more robust validation than would be provided using a 
random split.  
During earlier exploratory analyses, the dataset was randomly split into two to give a fitting 
dataset and a validation dataset.  Two thirds of the data went to the fitting dataset (6987 
observations on 2098 participants) and the remainder to the validation dataset (3727 
observations on 1082 participants).  However, following a conference discussion as to the 
usefulness of this approach, this method was reconsidered.  If the data were randomly split 
so that there was a fitting and a validation dataset, it is expected that these groups would be 
almost identical in terms of population characteristics.  Therefore a prediction equation 
developed in one of these groups should predict well in the other group, precisely because 
the two groups are similar.  Thus when comparing the actual to predicted values in the 
validation dataset, the model should predict well.  Therefore it was decided to split the data 
non-randomly.  In deciding how to split the data, ‘country’ came out as a reasonable choice 
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as the country variable was found to be statistically insignificant within exploratory 
analyses of the dataset.  The number of USA individuals within the trial equalled about 1/3 
of the complete case dataset.  Therefore the data were split into two, with the data from all 
of the countries, apart from the USA, going in the fitting dataset and just those USA 
participants’ data making up the validation dataset.  The prediction dataset was used to 
conduct all the analyses.  The validation dataset was used to test the predictive ability of the 
mapping algorithm. 
Basic summary statistics were derived from the dataset.  COPD disease severity states were 
used for comparing the prediction equations, and were classified in terms of degree of 
airway restriction as previously described in section 6.2.1.  As before, EQ-5D utility values 
were transformed onto a ud scale so that commonly used distributions could be fit to the 
(right) skewed data.  
Model Development 
Models were developed with increasing complexity, in terms of explanatory variables.  As 
previously described, the SGRQ contains three levels of questions: item scores 
corresponding to individual questions, domain scores (symptoms, activity and impact) and 
a total score.  Together with demographic variables of gender, age and BMI, each of these 
levels in turn were offered to the model, to give a general algorithm for the prediction of 
EQ-5D ud of: 
EQ-5D ud =  + (SGRQ(total/domain/questions)) +age + BMI + gender 
All models were developed in the fitting sample.  Fractional polynomial analysis was used 
to identify non-linear terms for SGRQ within the above model, for equations where either 
total SGRQ score or the SGRQ domain scores were the independent variable(s).  As the 
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starting point, OLS was used to develop the prediction algorithms using the algorithm 
described above.  Significant terms that arose when employing fractional polynomials were 
used to develop additional prediction equations.  For example fractional polynomials can 
identify if total0.5, total2 and total3 are statistically significant in the model that predicts EQ-
5D index, with SGRQ total as the primary independent variable.  Backwards stepwise 
selection was used on all models to identify statistically significant variables.  
The following algorithms were developed: 
EQ-5D ud =SGRQ total score + age + gender + BMI 
EQ-5D ud = impact + activity + symptoms  + age + gender + BMI 
EQ-5D ud = SGRQ individual item scores (continuous variables) + age + gender + BMI 
EQ-5D ud = SGRQ individual item scores (categorical variables) + age + gender + BMI 
 
Models were developed using in turn: OLS, GLM and two part models.  The GLM model 
used the same methods as previously set out in 6.1.4 in order to identify family and link.  
The two part model,(235) provided an alternative approach to modelling skewed data.  Of 
the EQ-5D ud scores, a large proportion of values were zero, corresponding to a full health 
status.  The first part of the two part model uses a logistic regression to determine the 
probability of a non-zero value.  The second part uses a GLM regression to predict EQ-5D 
from each SGRQ value.  A GLM model for the second part of the two part model was 
found in exactly the same way as previously described: using fractional polynomials, 
backwards stepwise selection and then the modified Parks test and link tests to identify 
family and link.(99)  However, because it is the non zero values that are of interest, only 
data with positive values for EQ-5D ud were used to develop the model.  The predicted 
EQ-5D ud score from the two part model was found by multiplying the predicted values 
from the first part of the model by the predicted values from the second part.   
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Validation 
The OLS, GLM and two part prediction models developed within the previous section were 
used to predict EQ-5D index scores within the validation sample.  The maximum and 
minimum predicted EQ-5D scores values are presented to illustrate the predictive ability of 
the resulting models.  A summary measure of model fit; RMSE was calculated,(236) using 
each mapping equation in turn to predict EQ-5D values within the validation sample.  Fit 
was decided based on lowest RMSE.  Predicted scores from the OLS, GLM and two part 
procedure were compared to observed EQ-5D score by disease severity. 
Recommended Model 
The best fitting model from the validation exercise was identified, based on the lowest 
RMSE.  In cases where RMSEs were very similar, the decision criterion was to select the 
simplest model.  The selected model structure with associated explanatory variables was 
refit onto as much of the data as possible in order to determine the best fitting model.  For 
example, if the model containing SGRQ total score was selected, then only variables with 
missing total and missing EQ-5D utility would be excluded from the dataset (ie dataset 2 
would be used).  The model was fit using all of the resulting dataset.  The resulting 
prediction equation is referred to as the recommended model.  
QALYs 
In order to further validate the prediction equation within the context in which it could 
ultimately be used, ie the generation of QALYs within a cost utility analysis, QALY scores 
by treatment group were calculated.  The recommended model was used to predict EQ-5D 
utility within the dataset.  QALYs were estimated for each subject in the whole study 
population, by treatment arm: 1, 2, 3 or 4.  For both the observed and the predicted values, 
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QALYs were calculated using the AUC method using EQ-5D scores over a three year 
history.  Where missing values occurred, the last observation was carried forward and/or 
the first observation carried backwards in order to create a full follow up history of three 
years for each subject as described earlier in 6.1.3.  
6.3.3 Results 
As previously described, the TORCH study consisted of 6112 participants (4236 with EQ-
5D administered) of whom 3855 (Obs=18 505) had data on both the EQ-5D index score 
and the SGRQ total score.  For this analysis, dataset 3 was used (described in section 6.1.2) 
which contained observations with complete responses on any of the SGRQ individual 
responses, the SGRQ domain scores, the SGRQ total score and/or in the EQ-5D index 
score to give a study sample containing 3640 subjects (2586 men, 1054 women), and 14 
612 observations, and is summarised in table 6.11.  To minimise loss due to missing data, 
as previously explained, four of the SGRQ questions (6, 8, 10 and 50) were removed 
because of high proportions of missing data.  The fitting dataset consisted of 9724 
observations and the validation dataset, 4888. 
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Table 6.11 Summary statistics, TORCH study 
Number in study 3640 
Observations, n  14 612 
Validation sample, n (%) 1278 (33) 
Men 2586 (71) 
Age, mean (sd) 64.7 (8.4) 
3yr survival, n (%) 3189 (88) 
Withdrawal, n (%) 1366 (38) 
Mild COPD, n (%) 1315 (36) 
Moderate COPD, n (%) 1828 (50) 
Severe COPD, n (%) 497 (14) 
EQ-5D utility, mean (SD) 0.73 (0.23) 
SGRQ Total score, mean (SD) 46.5 (17.9) 
SGRQ Impact score, mean (SD) 34.3 (19.5) 
SGRQ Activity score, mean (SD)   61.5 (20.6) 
SGRQ Symptom score, mean (SD) 58.3 (21.3) 
SGRQ= St George’s respiratory questionnaire 
 
The mean age of subjects was 65 years as can be seen in table 6.11.  After three years of 
follow-up, 88% of the study population were still alive and 38% had withdrawn from the 
study.  Most of the participants had either mild (36%) or moderate (50%) disease with a 
smaller proportion of the study in the severe group (14%).  Mean (SD) EQ-5D utility score 
was 0.73 (0.23).  SGRQ Impact scores were lower than the activity and symptom scores for 
both men and women, suggesting that the impact domain was the least affected compared 
to the domains of activities and symptoms. 
The scatter graph of EQ-5D responses against SGRQ total score in figure 6.5 shows that 
there is some correlation between the two measures and the overlaid histogram illustrates 
the tri-modal nature of the responses to the EQ-5D: 3068 observations were at 1 (full 
health), 10 372 were between 0.5-0.88 and 1172 observations were lower than 0.5.  
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Figure 6.5. Scatter of SGRQ total and EQ-5D utility together with the distribution of EQ-5D 
utility responses 
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Model Development 
Models that mapped to the EQ-5D ud scale from the SGRQ were developed using 
increasingly more explanatory variables leading to a more complex structure.  Fractional 
polynomial analysis found SGRQ total2 was statistically significant in the model with 
SGRQ total as the primary independent variable and within the regression with SGRQ 
domains as the independent variables, symptoms2 was found to be statistically significant.  
Using backwards stepwise selection, gender was the only non SGRQ variable that was 
found to be statistically significant (p<0.05).   
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The following six models were developed in the fitting dataset: 
1. EQ-5D ud =SGRQ total score + gender 
2. EQ-5D ud =SGRQ total score + SGRQ total score2 + gender 
3. EQ-5D ud = impact + activity + symptoms + gender  
4. EQ-5D ud = impact + activity + symptoms + symptoms2 + gender 
5. EQ-5D ud = SGRQ individual item scores (continuous variables) + gender  
6. EQ-5D ud = SGRQ individual item scores (categorical variables) + gender  
 
OLS was used for each of the six models in order to predict EQ-5D ud using SGRQ.  GLM 
modelling was used for the six models and included additional steps of selecting the chosen 
family based on the results from the modified Parks test and the link was identified using 
the link function tests: the Pearson correlation test, the Pregibon link test and the modified 
Hosmer–Lemeshow test.  Based on these results, the Poisson family with the square root 
link were identified as appropriate for modelling each of the six models. 
In order to build up a two part model, for each of the six models described above, a 
corresponding logistic regression and GLM were identified.  The logistic regression used 
statistically significant explanatory variables (determined by backward stepwise selection) 
to predict the probability of non-zero EQ-5D ud values.  The GLM was fit onto positive 
EQ-5D ud values.  Results from the modified Parks test and the three link tests found that 
for three of the six models (1,3 and 4), the Poisson family with a log link fit well, for 
models 5 and 6, a gamma family with a log link was chosen and for model 2, a gamma 
family with an identity link.  The predicted values from the logistic regression and the 
GLM predicted values for each algorithm were multiplied together to give predicted values 
for the two part model.  
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Validation 
The 18 models (six using each of OLS, GLM and two part) were used to predict EQ-5D 
scores within the validation sample, from the SGRQ.  Summary statistics from the different 
models are presented in table 6.12.  Predicted mean EQ-5D scores for all 18 models 
performed well, predicting either the same value as was observed of 0.72, else 0.71.  The 
range of predicted values was found to be generally wider when using the GLM models 
compared to OLS and wider still when using the two part model.  OLS model 2 was the 
only OLS based model to predict scores within the possible range of EQ-5D utility (1), 
with all other OLS models predicting values of greater than 1.  All the GLM and two part 
models predicted scores of less than 1.   
Table 6.12 Observed utility compared to predicted utility scores using the 18 models  
in terms of mean scores, minimum and maximum values and RMSE for each of the model, 
validation sample (number observations=4888). 
  Mean Min Max RMSE 
Observed  0.72 -0.43 1.00  
OLS1 0.71 0.30 1.14 0.1746 
OLS 2 0.71 0.13 0.98 0.1723 
OLS 3 0.72 0.28 1.11 0.1740 
OLS 4 0.72 0.27 1.09 0.1739 
OLS 5 0.71 0.24 1.01 0.1726 
OLS 6 0.72 0.22 1.02 0.1746 
GLM 1 0.71 0.13 0.99 0.1724 
GLM 2 0.71 0.11 0.99 0.1724 
GLM 3 0.72 0.13 0.99 0.1722 
GLM 4 0.72 0.13 0.99 0.1722 
GLM 5 0.71 0.14 0.97 0.1724 
GLM 6 0.72 0.14 0.98 0.1728 
2 part 1 0.71 0.15 0.99 0.1725 
2 part 2 0.71 0.11 0.98 0.1723 
2 part 3 0.72 0.11 0.99 0.1722 
2 part 4 0.72 0.12 0.99 0.1720 
2 part 5 0.71 0.10 0.97 0.1737 
2 part 6 0.71 0.07 0.97 0.1741 
RMSE= root mean squared error 
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Based on RMSE it was seen in table 6.12 that algorithm 2 using OLS, algorithm 3 and 4 
with the GLM and algorithm 4 from the two part model performed well, with RMSE values 
of: 0.1723, 0.1722 and 0.1720 respectively.  RMSE within the 18 models ranged from 
0.1720-0.1746.  Algorithms 2 (OLS) and 4 (GLM and two part) were compared in terms of 
predictive ability for utility scores by disease state.  The predicted scores were very close to 
the observed scores, irrespective of model employed.  
Table 6.13 Mean (SD) observed EQ-5D utility compared to mean predicted EQ-5D 
utility scores by disease severity using the best fitting OLS, GLM and two part models, 
validation sample 
Disease severity Model Mild Moderate Severe 
Obs, n 1681 2380 827 
Observed 0.752 (0.22) 0.708 (0.23) 0.672 (0.22) 
Pred -OLS  0.752 (0.14) 0.704 (0.15) 0.667 (0.15) 
Pred-GLM 0.754 (0.15) 0.705 (0.15) 0.667 (0.14) 
Pred-2 part 0.755 (0.15) 0.706 (0.15) 0.666 (0.14) 
 
As seen in tables 6.12 and 6.13, algorithm 2 using OLS, predicted as well as the algorithms 
developed using more complex model structures.  The 0.0003 difference between the 
RMSE of the OLS model and the RMSE of the best fitting two part model (calculated from 
table 6.12), was small and the mean score and range of minimum maximum values were 
comparable with the best fitting models using either GLM or two part, as seen in table 6.12.  
Table 6.13 shows that all the algorithms predicted utility scores close to observed scores by 
disease severity.  On the grounds of parsimony, OLS algorithm 2 was seen to have a good 
fit for mapping the EQ-5D from the SGRQ and was taken through for further validation. 
Recommended Model 
OLS equation 2 was refit onto dataset 2, where observations had complete EQ-5D and 
SGRQ total scores (n=3855, Obs=18 505), to give a best fit mapping algorithm for 
predicting EQ-5D index scores from SGRQ which is described below: 
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EQ-5D utility = 0.9617 – 0.0013 SGRQ Total – 0.0001 SGRQ Total2 + 0.0231M 
M= male 
QALYs 
Within the full dataset, QALYs derived using observed utility scores were compared to 
QALYs derived from utility scores predicted using the algorithm described above, by 
disease severity and by treatment arm.  Results by disease severity are presented in table 
6.14 and show that whilst predicted QALY scores were slightly larger than the observed 
values, the absolute difference between QALYs from the mild to moderate groups was the 
same at 0.17.  However, the difference between the moderate and severe groups was larger 
in the observed than the predicted values (0.24 compared to 0.21).  Mean QALY scores by 
treatment group were slightly larger for the predicted QALY scores than for observed 
scores.   
Table 6.14 Mean (SD) QALY scores by COPD disease severity group, 
using the observed utility scores compared to the predicted utility scores to generate QALY 
scores in the full dataset 
 Mild Moderate Severe 
Observed 2.16 (0.68) 1.99 (0.74) 1.75 (0.75) 
Predicted 2.18 (0.52) 2.01 (0.57) 1.80 (0.58) 
 
The absolute difference between treatment 1 and treatment 2 was the same (0.07) using 
observed and predicted scores and the difference between the most and least effective 
treatments in terms of QALY gain was equivalent at 0.11.  However, using the predicted 
utility scores to derive QALYs gave a different relative ordering of treatments in terms of 
QALY gain, than using the observed utility scores.  This is demonstrated in table 6.15 
where subjects taking treatment 3 had a marginally larger QALY gain than those on 
treatment 4 within the observed data, but when using predicted scores, treatment 4 was 
associated with more QALY gain than treatment 3.  These differences are slight. 
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Table 6.15 Mean (SD) QALY scores by treatment group, full dataset 
using the observed utility scores compared to the predicted utility scores to generate QALY 
scores 
Treatment  Study result Predicted 
1  2.09 (0.69) 2.11 (0.54) 
2 2.02 (0.73) 2.04 (0.57) 
3 1.99 (0.74) 2.00 (0.59) 
4 1.98 (0.75) 2.02 (0.56) 
 
6.3.4 Discussion 
A wide range of potential model structures were considered to ensure that a systematic and 
robust approach was taken in identifying an appropriate model.  Most previous studies on 
mapping stop after developing an algorithm based on OLS.  This paper went beyond OLS 
and carried out a rigorous approach to model fitting using not only OLS but GLM and two 
part models.  Use of fractional polynomials in the development stage of the study identified 
significant squared terms to include within the models.  Fitting the GLM models employed 
a number of statistical tests to determine the appropriate family and link function for each 
algorithm.  A two part model was developed based on a logistic regression and GLM in 
order to better fit the distribution of the data, with the intention of improving predictive 
accuracy.  The predictive ability of each of the models was validated using RMSE in the 
validation sample.  A prediction equation developed using OLS was found to perform as 
well as more complex model structures in terms of RMSE within the validation sample, 
with RMSE values comparable to RMSE from other mapping studies.(218)  The finding 
that increasing the complexity of the model only achieved slight improvements in 
predictive ability was consistent with that reported elsewhere.(218)  The chosen model 
predicted a range of values that remained within the possible range for EQ-5D utility scores 
(1).  The equations were not made to take account of multiple observations per participant 
on the grounds that it was the relationship between the SGRQ and the EQ-5D that was of 
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interest.  There was no reason to assume that this relationship would change if there was 
more than one observation per participant. 
Validation occurred in a sample that was not used to develop the model.  Importantly, the 
validation sample was identified from a non random split of the data.  If the data were 
randomly split into a fitting and a validation dataset, these groups would be almost identical 
in terms of population characteristics, therefore a prediction equation developed in one of 
the groups should predict well in the other group.  A non random split was chosen based on 
country, because country was found to be statistically insignificant within exploratory 
analyses of the dataset and the number of USA subjects within the trial totalled about 1/3 of 
the complete case dataset so non-USA/USA country was an appropriate candidate on which 
to split the data.  Using a non-random split as opposed to a random split did not affect the 
final choice of model: during exploratory analyses in which a random dataset was used, the 
final equation included both a total and a total2 term. 
The prediction equation was refit onto the whole dataset and was used to predict QALYs 
using the AUC method.  Predicted QALY scores were compared against QALY scores 
obtained from observed utility data, derived using the same AUC method.  Applying the 
prediction equation was found to produce slightly higher QALY scores than using observed 
utility data by disease severity and by treatment group, but the absolute differences between 
disease severity groups were similar using either observed or predicted values to derive 
QALYs.   These inflated QALY scores may have been due to rounding error in the 
coefficient for the SGRQ total2 term.  A way to improve the accuracy of the prediction 
equation might be to rescale the SGRQ onto a scale of -1 to +1, and is of interest for future 
research.   
The relative treatment ordering of the four treatments was different using observed utility 
scores to generate QALYs compared to using predicted utility scores.  Whilst the resulting 
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prediction equation appears to perform well, given the size of QALY gains to be had 
between treatments, small differences in QALY scores can lead to large impacts on cost 
effectiveness outcomes.  Therefore it is important to measure utility scores as accurately as 
possible and the best way of doing this is to routinely value the impact of treatment on 
HRQoL using a utility based measure, such as the EQ-5D within the clinical trial.  A 
mapping algorithm such as the one developed here can be used to predict EQ-5D utility 
scores from the SGRQ and may be useful in some situations, however for use within a 
HTA submission where precision of estimation is important, it is recommended that utility 
scores are directly derived from the clinical trial population and that mapping is used as a 
second best solution only.  This conclusion differs from an earlier study which reported on 
a mapping between a different HRQoL measure and the EQ-5D in estimating QALYs.(237)   
Missing data was dealt with by using complete cases for the development of the algorithm 
because it was the relationship between the SGRQ variable and the EQ-5D variable that 
was of interest, and this was not thought to be affected by reasons for missingness (in 
contrast to if the focus of the study was to accurately estimate EQ-5D utility scores), rather 
is was thought that if imputation methods were used, this might blur the relationship 
between the variables.  Imputation of missing values was used for the estimation of QALYs 
and this was achieved using last observation carried forward and first observation carried 
backwards in order to create full follow up of SGRQ total and EQ-5D utility scores.   
A recent study has shown the impact that 10 different imputation methods for inputting 
missing quality of life scores had on the resulting ICER.  ICER values for the same 
procedure were between $178 000 and $433 000 depending on the imputation method used.  
The frequently used method of last value carried forward resulted in an ICER in the middle 
of these estimates at $292 000 and restriction to a complete case analysis resulted in the 
largest ICER of $433 000.  Because of the large difference in results, the authors 
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recommend using two imputation methods, one of which to always include multiple 
imputation.(152)  An extension to this current study would be to assess different imputation 
methods for utility, for the purpose of deriving QALYs from clinical trial data in order to 
assess the impact on the QALY estimates. 
6.4 Conclusion 
Utility data are integral to economic evaluation in health care.  Within this chapter, two 
strategies for deriving utilities and QALYs were employed.  The first strategy was to derive 
utility data directly from a relevant clinical trial in which a utility based measure, the EQ-
5D, was routinely collected.  Deriving utility based values directly from trial data can either 
be simple, as was initially carried out such that mean EQ-5D utility scores are summarised 
by disease severity, or alternatively, deriving utility values can be more complex.  More 
complex techniques are appropriate when, for example, it is important to account for 
subject heterogeneity in utility scores.  Within this chapter, a GLM model with a Poisson 
family and identity link with independent variables of treatment group, disease severity, 
sex, BMI and race was developed to generate EQ-5D utility scores.  The derivation of 
QALYs by treatment group is frequently the next step after deriving utility scores.  Mean 
QALY scores by treatment group were estimated using the method of AUC.  A GLM 
model was used to derive predicted QALY scores, by treatment group and the results were 
compared.  
Eliciting utilities from trial data becomes a problem when utility based measures such as 
the EQ-5D have not been collected within a trial and instead only disease specific 
questionnaires such as the SGRQ have been employed.  For reimbursement decisions, it is 
necessary to show value for money in terms of effectiveness, preferably using a generic 
effectiveness measure based on utility.  The second strategy employed within this chapter 
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was to elicit utilities and QALYs for application where a utility based HRQoL measure 
such as the EQ-5D has not been routinely collected, by developing a mapping equation so 
that where a utility based measure has not been collected, a mapping equation can be used 
to predict EQ-5D utility from a disease specific HRQoL measure.  However, the 
development and validation of a prediction equation is only an option where both measures 
have been collected, such as in the TORCH study. 
In applying the resulting mapping equation it was found that in some situations, such as 
predicting mean EQ-5D utility scores, the mapping predicts well.  Therefore if the use of 
the algorithm was to derive simple EQ-5D scores by disease severity, then the use of such 
an equation is likely to give a fairly accurate mean score.  In other situations the prediction 
equation should be used with caution.  The algorithm was used to derive QALY scores by 
treatment group and found that by employing the prediction equation to predict utility 
scores and then to work out AUC led to a slight underestimation of the relative treatment 
effect and a difference in the relative ordering of treatments.  Mapping is only advisable 
when no utility data have been collected and where there is no alterative, as it is regarded as 
a second best solution.  As EQ-5D was routinely collected within the TORCH dataset, 
utility values can be derived directly from trial data and this is the approach used in the 
following chapter on modelling. 
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Chapter 7. A New Economic Model for COPD 
Resource allocation decisions for healthcare are made with respect to opportunity cost: 
decision makers need to know what the impact of a new treatment will be in terms of 
impact on health and impact on cost in comparison to the costs and effects of current 
treatment or current best practice.  The real system is highly complex and Health 
Economists use economic modelling in order to combine information on the natural history 
of the disease and the effect of treatment in a potentially useful and meaningful way.   
There are many challenges in developing an economic model, some of which can be 
overcome early on in the process by clear conceptualisation.  During conceptualisation, it is 
useful to consider how the disease could be modelled and to identify key aspects of the 
disease that affect disease progression and impact upon HRQoL and/or cost.  Following 
conceptualisation, an appropriate modelling structure can be selected which allows for 
these components to be included within the model.  With structural decisions made, the 
model can be developed using available and relevant data sources.  
This chapter presents the development and results of a new concept in economic modelling 
for COPD.  The model employs a series of regression equations to parameterise key drivers 
of cost effectiveness: lung function, symptoms and exacerbations and from these, informs 
regression equations for cost and effectiveness that predict cost and effect values per cycle.  
Values for a current treatment arm and a comparator arm are calculated separately and for 
each arm, costs and effects are summed over time to give cost effectiveness statistics.  This 
chapter is focussed on conceptualising and developing an economic model and is split into 
three sections. 
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In the first section, a conceptual framework for an economic model of COPD is developed 
which considers incorporating the natural history of the disease (as studied within the 
thesis) into the model.  The section principally considers the major components that are 
likely to bring about an impact on either cost or HRQoL, or both.  Based on this, an 
economic structure is selected and the rationale for preferring the chosen economic 
structure, a regression based model, for modelling the disease area is explained.  The first 
section also contains information pertaining to all economic models, including use and 
perspective, timeframe, discounting and uncertainty, and draws on the experience gained 
from the published literature on COPD economic models as described in Chapter 4.    
The second section describes the methods used in developing the model, starting with the 
generation of individual regression equations for each of: lung function; exacerbations; 
symptoms; EQ-5D utility; cost; and survival probability.  For each regression equation, the 
rationale for the selection of the dataset within which the equations were developed, the 
type of regression model used and choice of explanatory variables, as well as the resulting 
model and interpretation of the results, is given.  These regression equations are combined 
to form an economic model for COPD, representing current treatment.   
In the final section, potential effects of treatment on each component are considered in 
relation to the model so that a treatment arm can be developed.  Exploratory analyses 
around a hypothetical treatment for COPD are presented and resulting ICERs produced. 
7.1 Conceptual framework 
The conceptual framework presented within this section is important within the model 
development process as it enables various known components of the disease to be 
considered and pieced together, in a structured way, before the model is built.   
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7.1.1 Use and Perspective 
In developing a new economic model it is important to decide at the outset what the end use 
of the model will be: what it will assess and who it is for.  The aim is to develop a model 
that represents the natural history of the disease for a range of COPD patients, and on top of 
that, layer in a treatment effect.  This new COPD model will be flexible with regards to the 
type of intervention it will be employed for and the treatment effect will be dependent upon 
the intervention’s mechanism of action.  It will also be able to incorporate heterogeneity in 
the disease population.  Comparing costs and utilities in the population receiving current 
treatment, to those receiving the new treatment, will give cost effectiveness statistics.  
Primary interest lies in the UK market and because the UK is one of a small number of 
countries that requires HTA for treatments, the NICE guidelines for HTA are followed, 
which recommend that the most appropriate provider perspective is the UK NHS (see 
Chapter 3).  NICE also recommends that all economic evaluations should be based on UK 
population preferences and this was adopted within the chapter.  
7.1.2 Key Components of the Model 
Within cost utility analysis the aim is to determine the cost effectiveness of one treatment in 
comparison to another.  A case for promoting one treatment over another, especially in 
COPD, has historically been based on improvements in effectiveness rather than a 
reduction in cost.   
It is important to bear in mind the role of treatment for COPD as this has a bearing as to 
how manufacturers target their products and subsequently provides an insight into the 
potential effects of treatment.  The role of treatment for COPD:  
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“…in the absence of a disease cure, is to prevent and control symptoms, reduce 
the frequency and severity of exacerbations, improve health status and improve 
exercise tolerance.”(2)   
Different treatments have different mechanisms of action, targeting any one or more of the 
factors identified in the quote above.  Through the treatment action there is an element of 
causality whereby, for example, treatment eases symptoms and as a result HRQoL 
improves and impacts upon QALYs.  In the same way, cost is impacted on through (other 
than cost of the specific treatment), the benefits (or side effects) of taking a particular 
treatment.  For example, if treatment causes an absolute reduction in the rate of 
exacerbations requiring hospitalisation, the financial burden should be less than otherwise. 
As described in the quote above, and as has been seen throughout this thesis, there are three 
important factors that impact quality and quantity of life, affect costs and influence 
mortality risk for people with COPD.  These are: exacerbations, symptoms and lung 
function.  The statements reproduced below, extracted from the NICE COPD guidelines, 
further illustrate that each of these elements are tied up in the effectiveness of treatment: 
 “The effectiveness of bronchodilator therapy should not be assessed by lung 
function alone but should include a variety of other measures such as 
improvement in symptoms, activities of daily living, exercise capacity, and 
rapidity of symptom relief.”(7) 
“[The aim of treatment with] inhaled corticosteroids…is to reduce exacerbation 
rates and slow the decline in health status and not to improve lung function per 
se.”(7) 
“The clinical effectiveness of combined treatments can be assessed by 
improvements in symptoms, activities of daily living, exercise capacity and 
lung function.”(7) 
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Most of the published models, as described in Chapter 4, have used lung function as the 
driver of progression through the model, with episodes of exacerbations occurring at a pre-
defined rate within each health state, with increased frequency as disease severity worsens.  
Symptoms have not previously been modelled explicitly.  Nevertheless, because these three 
elements are each important components for the treatment of COPD, it is desirable that they 
are all included within the model because of their individual impact on costs and effects.   
In the following sections, further details are given that support the use of each component 
for modelling COPD. 
Lung Function 
FEV1 naturally declines over time and is frequently used to define disease severity 
groupings for COPD based on FEV1 % predicted (as seen in Chapter 2).  These groupings 
are also used for treatment allocation; with more treatments being prescribed the more 
severe the disease (see section 2.3).  The more severe the disease, generally the more 
exacerbations occur (Chapters 2 and 5) and the worse symptoms are.  The majority of 
existing models have chosen lung function as the key driver of movement through the 
model (see literature review on published COPD models in Chapter 4) with the use of 
Markov states representing disease severity groups based on FEV1 % predicted. 
Costs increase substantially as disease severity moves from (GOLD) moderate to 
severe.(24;27-32)  One study estimated the average direct cost for a mild COPD patient to 
be €232 (£207) for moderate disease, €477 (£427) and for severe disease €2026 
(£1812).(33)  As FEV1 deteriorates, a general shift from outpatient care to hospitalisation, 
an increase in the use of oxygen therapy and a subsequent increase in total costs, especially 
in the most advanced stages of the disease has been shown to occur.(33)  
 222 
Symptoms 
The majority of people with COPD suffer from respiratory symptoms including 
breathlessness, phlegm (and cough) and wheeze, and some treatments work explicitly on 
improving symptoms.  Symptoms have not previously been incorporated into an economic 
model for COPD despite the obvious detrimental HRQoL effects of respiratory symptoms.  
Ignoring symptoms, an important element of HRQoL, within an economic model, risks 
excluding a major target area for some COPD treatments. 
Symptoms are a more subjective outcome measure of treatment for COPD than either 
COPD exacerbations or disease progression and the impact of symptoms on HRQoL is 
more difficult to capture within an economic model in a meaningful way and is perhaps 
why to date it has largely been ignored within economic models.  Nonetheless it is known 
with certainty that a treatment that reduces symptoms will have a beneficial impact upon 
HRQoL for that person.  Therefore it is important to capture this effect in the disease 
model.  The following quote illustrates the importance of symptom control from the 
perspective of the patient and how this can conflict with the more commonly used approach 
of disease measurement of lung function.    
“From a physician standpoint the Holy Grail of COPD disease modification is 
to halt, or at least slow down, the rate of decline of FEV1. However, from a 
patient perspective the Holy Grail is simply to be able to breathe easier.”(1) 
One of the aims of this new model is to bring together these components of the disease. 
Exacerbations 
As discussed in Chapter 2, exacerbations are the leading driver of cost in COPD.  
Exacerbations account for between 35-40% of the total per capita health care costs for 
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COPD.(36)  Treatment which acts to reduce or prevent disease progression and/or an 
exacerbation (particularly severe exacerbations) will have a direct effect on the total cost 
for COPD.(38)  The cost of exacerbations increases with the severity of exacerbations. An 
exacerbation is the main reason why a COPD patient would attend hospital.  In England 
and Wales, it has been calculated that for every exacerbation-related hospital admission 
avoided, a total saving of approximately £1200 would be made.(37)  The prevention of a 
minor exacerbation would reduce costs by avoiding a visit to the GP. 
In addition to COPD exacerbations being a major driver of cost for the disease, they also 
negatively impact HRQoL.  Treatments for COPD that reduce the frequency of 
exacerbations and/or the intensity of the exacerbation will improve the HRQoL for the 
person involved.  
Survival 
In economic models for COPD it is important to incorporate mortality, and within the 
literature review this was identified as a weakness in several published economic models 
(see Chapter 4).  It is known that disease severity (as defined by FEV1 % predicted) is 
related to mortality and that as the disease worsens, mortality risk increases (see Chapter 5).  
It is also known that whilst some people with COPD die of COPD, many die of other 
causes (Chapter 5), therefore it is important to incorporate mortality, but to incorporate 
mortality in a way that it is a function of disease severity and also to model all-cause 
mortality as opposed to disease-specific mortality.  Within economic models, survival 
probability can be used to represent the risk of mortality, which was seen for some of the 
models reviewed in Chapter 4.   
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Cost and Utility 
Costs and utilities are a function of disease so that, a priori, as disease worsens, costs 
would be expected to increase and utility worsen.  Throughout this section it has been 
argued that the natural history of COPD can be represented in terms of the three 
components of: lung function, symptoms and exacerbations, and within the model it is 
these components that should be incorporated and combined in a way in which cost and 
utility are elicited.  The risk of mortality and the resulting impact on costs and utilities 
needs to be accounted for within the model.  The way in which these strands are interwoven 
is dependent upon the chosen model structure. 
7.1.3 Model Structure 
Economic evaluation in COPD has traditionally been carried out either alongside a clinical 
trial or through decision analytic modelling (as described in detail within Chapter 4) with 
all published economic models adopting a Markov structure, with one exception.(153)  The 
overriding difference between the aim of this model and previously published models is 
that a main aim is to describe the natural history of disease within a modelling framework, 
before layering on top (potentially any) COPD treatment effect.  This contrasts with usual 
approaches of modelling one pre-specified treatment against another.  
The Markov approach to modelling is limited in a number of ways.  First that in order to 
incorporate each of the components (lung function, exacerbations and symptoms) into the 
model, there would be an increase in the size and complexity of the Markov model 
compared to previously described models.  For any different set of combinations of 
components, a health state representing that combination would be required.  For example, 
one could imagine a health state in which the subject had moderate COPD, with severe 
 225 
respiratory symptoms and who had a severe exacerbation in the space of one year.  Another 
person could have moderate COPD, moderate respiratory symptoms and have had no 
exacerbations over one year and yet another could have moderate COPD, mild respiratory 
symptoms and an exacerbation.  These states would have different utilities and different 
costs associate with them and should be represented by different health states, or by 
incorporating an additional exacerbating state.  Ultimately there could be a large number of 
different states in the model.  Even with a large number of states, the resulting model may 
be insufficiently flexible to account for population heterogeneity in the way that would 
meet the aim of the new economic model, as was set out earlier in this chapter. 
A second limitation is that lung function, which is usually employed as the key driver 
through the model, is forced into discrete states, and once in those states the model is 
memoryless, there is no count of how long somebody has spent in the state.  As COPD is a 
progressive disease, people who have just entered a disease state are less likely to enter a 
worse state than somebody who has remained in that state for a period of time.  The 
Markov model cannot treat these two scenarios differently where they are grouped in the 
same Markov state.  
A third reason why a Markov structure may be limited is that as one of the aims of the 
model is to incorporate a treatment effect that is dependent upon the intervention’s 
mechanism of action, it is important that the model can incorporate outcomes of COPD 
clinical trials.  In a Markov structure it is difficult to model the impact of, for example, 
absolute improvements in lung function into the model.  Often this effect has been 
modelled by assuming a blanket reduction in the transition probabilities to the next state.  
However of particular interest is how to incorporate the reported gains in FEV, for example 
a 100ml improvement over one year, into a model framework.  
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An alternative to Markov modelling that has been used in asthma and once in COPD 
(summarised in Chapter 4) is regression based modelling,(238;239).  As previously 
described within Chapter 3, the regression based model operates through a series of 
regression equations that predict values for key components.  The published regression 
based model for COPD directly predicts costs and effects using similar methods to those 
described in the utilities chapter.(153)  However, a regression based model does not need to 
be limited to just cost and effectiveness equations.  Taking this a step further, a regression 
based model structure could be more flexible because the key components identified 
previously: lung function, exacerbations and symptoms, can be individually modelled and 
then separate equations for cost and effect can be developed that employ the predicted 
values from the various component regression equations.  This approach can account for 
patient level heterogeneity and relationships between the components.  Like a Markov 
model, the regression equation based model can be extrapolated to take up to a lifetime 
perspective so every year, as the cohort ages, the outcome values of each regression 
equation change.  
A limitation of the regression based approach is the necessity to have access to large and 
relevant datasets through which regression equations can be developed in order to model 
the disease.  The Renfrew/Paisley (MIDSPAN) dataset and the TORCH RCT are suitable 
datasets on which regression equations can be developed, therefore a regression based 
structure was employed for the COPD model and was developed around the key 
components of COPD as previously identified, namely lung function, exacerbations and 
symptoms. 
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7.1.4 Generic Modelling Considerations 
Some additional considerations for the model, as set out in the NICE reference case 
(Chapter 3) are described below, including the rationale for the exclusion of productivity 
costs and side effects, the timeframe of the model and discounting.  
Productivity Costs 
Days lost from work due to illness, representing productivity costs to the economy, are a 
financial cost of illness to society.  Productivity costs for COPD represent a significant 
burden on society as COPD is a major cause of absenteeism from work.(24;240)  As 
previously discussed in Chapter 2, people with COPD have a “substantially shortened’ 
work life compared to the population average,(41) and within the UK, 44% of COPD 
patients were below retirement age.  Productivity costs were found to be almost equivalent 
in size to direct costs.(24)  
Whilst days lost from work represent a substantial burden on the individual and on society, 
their use in cost effectiveness analyses is dependent upon the perspective adopted for the 
study, as discussed in Chapter 3.  NICE limits its perspective to the health service and 
personal social services perspective and explicitly excludes the use of productivity costs in 
its evaluations.  As the economic model that will be developed is focussed in the UK, for 
potential use for submissions to regulatory bodies such as NICE, productivity costs are 
mentioned here, but are not of primary concern for inclusion within the model developed in 
this chapter.  
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Side Effects 
Major side effects occurring from COPD treatment are relatively few in number compared 
to other disease areas.  For example, the economic model by Jubran et al,(97) considered the 
toxicity of theophylline compared to ipratropium and found toxicity rates of 8% and 0% 
respectively.(97)  Theophylline has been on the market for a long time and is unlikely to be 
considered as a comparator in an economic analysis; whereas ipratropium is frequently 
used within economic evaluations (see Chapter 4).  It is assumed that side effects for COPD 
treatments are relatively insignificant and that there is little between treatment variation in 
side effects.  Therefore side effects were not included within the model.    
Timeframe and Discounting 
The timeframe of the model was lifetime (to a maximum of 90 years or at the point where 
S(t) 0.05, whichever occurs sooner) because of the reasons previously outlined in section 
3.2.7.  Cycle length was set at one year, and is consistent with cycle lengths used in 
published COPD models (refer to Chapter 4 for details).  A discount rate of 3.5% for costs 
and effects was applied, as recommended by NICE (see section 3.2.8).  
7.1.5 The Conceptual Model 
A conceptual model was developed in order to piece together the relationship between the 
individual components, and the relationship between the components and costs and 
QALYs.  The paths of effect between the components and HRQoL and cost are unlikely to 
be completely independent from one another: a degree of interdependence is likely to exist.  
For example, is has already been seen in Chapter 5 that there is a relationship between lung 
function and symptoms, so that if lung function worsens, symptoms will usually 
deteriorate, and as a result, the expectation is that HRQoL score would decrease.    
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Another relationship is between lung function and exacerbation severity; that as lung 
function becomes more limited, the severity and frequency of exacerbations tends to 
increase,(36;241;242) which in turn affects HRQoL.  The relationship between the 
components and HRQoL is difficult to untangle, however one of the benefits of a 
regression based model is that this interdependence can be modelled explicitly because 
predicted scores from one regression equation such as lung function, can be used as 
explanatory variables in regression equations that predict symptoms and exacerbation rates.  
Within figure 7.1, FEV1 has been conceptualised as the key component of the disease that 
drives symptoms and exacerbations, and this is an assumption used throughout this chapter.  
The rationale for this assumption is that previously lung function impairment (as defined by 
FEV1 % predicted) was shown to be related to the number of exacerbations experienced 
and to the severity of respiratory symptoms (Chapter 5).  The links between FEV1 and 
exacerbations and FEV1 and symptoms are assumed to be unidirectional, so exacerbations 
are a function of lung function but lung function is not a function of exacerbations, and 
symptoms are a function of FEV1 but FEV1 is not a function of symptoms.   
So far the conceptualisation of a mechanism for modelling the natural history of the disease 
has been presented, which will represent the baseline non-treated/current treatment 
population.  For the treated population, treatment effects are layered on top of the natural 
history model in a comparator arm.  Figure 7.1 illustrates ways in which treatment (Tx) 
effects may occur that influence HRQoL.  Costs are assumed to be affected by similar 
relationships, but are not presented here.  Treatment that instantly and directly affects 
HRQoL (first line of figure 7.1) has already been ruled out, and the second to the fourth 
treatment effects shown in figure 7.1 are simple relationships, so that treatment which: 
improves symptoms; or reduces exacerbations; or increases lung function, should improve 
HRQoL.  In previous models and in RCT reports, some of the relationships between the 
 230 
components may have been overlooked.  For example, trials report absolute change in 
FEV1 and change in exacerbation rates separately, yet it may be that the effect of treatment 
on FEV1 is responsible, at least in part, for the change in the rate of exacerbations, as 
illustrated by the second to last relationship in figure 7.1.  Another possibility is that the 
treatment reduces exacerbations with a knock on effect on symptoms as shown in the last 
line of figure 7.1, which jointly improves HRQoL.  Figure 7.1 is purely illustrative and 
other relationships between treatment and the three components are possible. 
Tx FEV1 HRQoL
Tx FEV1 Exacs HRQoL
Tx FEV1 Symp HRQoL
Tx HRQoL
Tx Exacs HRQoL
Tx Symp HRQoL
Tx Exacs Symp HRQoL
 
Figure 7.1 Possible treatment effects 
 
Of those treatments assessed with regards to mortality gain in RCTs; the existing evidence 
around treatment extending life is not statistically significant, therefore the effect of 
treatment on the regression equation for survival will not be considered within this model, 
though extensions to the model could be made to incorporate this. 
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Figure 7.2 Conceptual model for COPD 
 
Figure 7.2 above illustrates how four different interventions may work on the different 
components of COPD and how in turn these may impact upon costs and QALYs.  As 
previously noted, the effect of treatment on each of the components is dependent upon the 
treatment’s mechanism of action.  For example, a LABA such as salmeterol has a 
mechanism of action that relaxes the bronchial passageways, which in turn has an impact 
upon symptoms; the airways open and breathing becomes easier.  A different product like 
an ICS such as fluticasone, has an anti-inflammatory effect that reduces the number of 
exacerbations and may also slow disease progression.  A dual product such as Seretide 
(salmeterol plus fluticasone) combines the effects of the LABA and the ICS, essentially 
working on all three of the components.  
Smoking cessation impacts directly on disease progression by slowing the decline in lung 
function,(3) as depicted in figure 7.2.  Smoking cessation is a non-pharmacotherapy 
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intervention that has been shown to effectively slow the deterioration in FEV1 and return 
the trajectory of lung function to one consistent with that of a non smoker.(3)  This model 
could be used for the economic evaluation of smoking cessation, in order to inform 
decisions about public health interventions for a COPD population.  This is outside the 
scope of this thesis but is of interest for further application of the model. 
7.1.6 The Prediction Model 
Turning the conceptual model into an economic model within a regression based structure 
is relatively straightforward and is described here in terms of a two phase process.  The first 
phase is the development phase in which the regression equations are determined and the 
second phase refers to how the model is populated. 
The development of the prediction equations was carried out in either the TORCH or the 
Renfrew/Paisley (MIDSPAN) dataset depending on suitability (see section 7.2 for details), 
and the selected study is referred to as the ‘dataset’ within figure 7.3.  Phase one is split 
into seven steps.  In step 1, potential explanatory variables are identified within the 
‘dataset’, including: age, sex, disease severity at baseline, presence of symptoms and 
smoking.  These are used to develop the equation for lung function (step 2), and to inform a 
Weibull survival model that is used to represent survival probability, as shown in step 3.  
Step 4 uses explanatory variables from step 1 and a continuous variable for FEV1 in a 
regression equation for exacerbation rate.  Step 5 uses explanatory variables from step 1, a 
continuous variable for FEV1 and a variable for exacerbations (from the equation in step 4) 
to generate a prediction equation for symptoms   Explanatory variables of: symptoms, 
exacerbations and lung function from the dataset (step 6) together with some of those from 
step 1 are used in order to determine the coefficients on an equation for cost and on an 
equation for EQ-5D utility as seen in step 7.  
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Figure 7.3 Phase 1, development of the model
 234 
 
Phase 2 refers to how the model is populated and is split into eight steps and is 
illustrated in figure 7.4.  The model is populated in cycles.  Each cycle represents one 
year (see sections 3.2.7 and 7.1.4 for details on timeframe) and for the first cycle, the 
model runs as shown in figure 7.4.  User defined patient characteristics (described in 
detail in section 7.2), are entered into the model as explanatory variables for FEV1 (step 
1).  Predicted values for FEV1 and values for patient characteristics are inputted as 
explanatory variables into the equation for exacerbations as shown in step 3.  Step 4 
uses the exacerbation rate from the model in step 3 with predicted values for FEV1 and 
values for patient characteristics as explanatory variables into the equation for 
symptoms.  Predicted values from these equations (step 5) are used as explanatory 
variables for the cost and EQ-5D utility equations (step 6) to allow for the 
interdependence of the various components of the disease on one another.  The cost 
equation, and the EQ-5D utility equation are each multiplied by the survival probability 
(step 7) to give survival-adjusted cost and survival adjusted utility for the cycle (step 8).  
In subsequent cycles, the model is populated in a similar way to the first cycle with the 
prerequisite that that the user defined patient characteristics remain the same as for the 
first cycle, with the exception of age which increases by one each cycle.  As time 
increases, the survival probability, which is a function of time, decreases.  Section 7.2 
presents detailed information on how the economic model was developed.  
To get costs and QALY estimates, the survival-adjusted cost and utility from each cycle 
are summed and the mean value derived (once discounting has occurred).  Once all 
these steps are completed, a fully operational model exists that represents the natural 
history of COPD for a defined patient population on current treatment.  A treated 
population is developed in exactly the same way as described above except that a 
treatment effect is incorporated into the model.  The treatment effect is dependent upon 
the treatment’s mechanism of action and the modeller specifies which component(s) is 
affected by the treatment being modelled.  Details of treatment effects are contained in 
section 7.3.  The ICER is found by calculating the difference between the costs and 
QALYs in the new treatment group to those in the current treatment group.  
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   Figure 7.4 Phase 2, population of the model
 236 
 
7.1.7 Uncertainty 
Each of the prediction equations predicts a value based on selected patient characteristics.  
Each coefficient within the equations has a confidence interval attached representing the 
uncertainty attached to its value.  These measures of uncertainty were included within the 
model and can be used to examine uncertainty by selecting values within the distribution 
(assumed to be normal) on that variable.  
The benefit of the regression based modelling approach used here, in terms of uncertainty, 
is that a wide range of user defined patient characteristics can be inputted and the impact of 
this on costs and QALYs can be assessed.  In this way, uncertainty around patient level 
heterogeneity is diminished.  The other side of this flexibility is that an average ICER is not 
immediately available.  For example potential populations in which a new treatment could 
be assessed could be the different disease severity groups, as defined at baseline.  To 
calculate cost effectiveness statistics by disease severity group, one method would be to 
enter mean values into the model as user defined patient characteristics for each disease 
severity at baseline.  Alternatively, Monte Carlo simulation could be employed in order to 
select (with replacement) user defined patient characteristics from distributions. 
7.2 Model Development: the Natural History of 
COPD 
Within this section, the methods and results from the development of each regression 
equation are presented.  A range of different statistical models were employed to develop 
the regression equations for use within the economic model, in order that when combined 
create a model that represents the natural history of COPD.  All analyses were carried out 
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on either the observational dataset, Renfrew/Paisley (MIDSPAN) or on the TORCH RCT, 
which have previously been described in full in chapters 5 and 6 respectively.  
In order to piece together the economic model using each of the prediction equations, the 
software package, Microsoft Excel™ was used.  Following the development of each 
regression equation, examples of how each regression equation predicts within the 
economic model for men aged 55 years at baseline, with NICE diagnosed mild and 
moderate COPD, are presented.  An example of the full economic model in these groups, 
which represents current treatment, is presented at the end of the section.  In brief, each 
new row of the model represents an additional year of age/time and each column contains 
predicted values from each regression equation.  Column headings include: age, time, lung 
function, exacerbations, symptoms, cost, utility, survival, survival adjusted cost and 
survival adjusted utility.  The model was run with a lifetime perspective and costs and 
utility were summed over the duration of the study.  A discount rate of 3.5% was applied to 
both costs and utility.  
7.2.1 User Defined Patient Characteristics 
The model was designed so that different user defined patient characteristics could be 
offered to the model to enable the cost effectiveness of treatment within different subgroups 
to be assessed and therefore to minimise uncertainty due to heterogeneity. 
Depending upon the specific regression equation, the user defined explanatory variables (at 
baseline) could include any of the following: age, sex, height, FEV1 % predicted, 
respiratory symptoms, UK, disease severity, smoker/ex-smoker and greater than or less 
than a 10 pack year history, as described in table 7.1 below.  Age is entered into the model 
in years and is restricted to people aged over 45 years, which represents the typical 
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minimum age of a COPD patient and also the patient population within both the 
Renfrew/Paisley (MIDSPAN) study and the TORCH RCT.  Height can be entered into the 
model as any feasible value but the mean height in England, which is 175cm for men and 
162 for women was employed within this chapter.(243)  Disease severity at baseline was 
split into four groups: 0, 1, 2 and 3, defined by FEV1 % predicted, where group 0 is the 
baseline group which represents people with FEV1≥ 80% predicted, group 1 contains 
people with mild COPD (50 FEV1< 80 % predicted), group 2 with moderate COPD (30 
FEV1< 50 % predicted) and group 3 people with severe COPD (FEV1<30 % predicted).  
The rest of the user defined characteristics are dummy variables, taking the value of 0 or 1.  
Sex is 0 for men and 1 for women, the variable ex-smoker is 0 for not an ex-smoker and 1 
for ex-smoker, over 10 pack years is 0 for less than 10 pack years and 1 for more than 10 
pack years. When using the TORCH dataset, because the RCT was multinational and 
because country-to-country variances are known to exist, a UK variable was also offered to 
the model where 0 was non-UK and 1 was UK.  
Table 7.1 Baseline user defined patient characteristics applied within the modelling 
Patient characteristics Description Example 
Age years (>45 yrs) 60 
Height cm 162 
Disease severity FEV1 % predicted (0-1 scale) possible (0): 
>=0.80, mild (1): 0.50-0.79, moderate (2): 
0.30-0.49, severe (3) <0.30 
3 
Sex 0: men, 1: women 1 
Ex-smoker 0: not ex-smoker 1: ex-smoker 1 
Over 10 pack years 0: <10 1: ≥10 1 
Respiratory symptoms 0: no symptoms 1: symptoms 1 
UK 0: no 1: yes 1 
FEV1= Forced Expiratory Volume in one second.  
  
For respiratory symptoms, where the MIDSPAN dataset was employed, a dummy variable 
for symptoms as previously described in Chapter 5 (where 0 represents no symptoms and 1 
presence of respiratory symptoms), was used.  When using the TORCH dataset, the same 
 239 
 
respiratory symptoms classification was not available, so responses to the MRC dyspnea 
scale questionnaire were used to identify symptomatic breathless patients.  Subjects 
answering yes to statements 3, 4 or 5 (see figure 7.7) were considered as having 
breathlessness.  Coding for the breathless variable was 0 for no breathless and 1 for 
breathless.  
An example of a specific patient group that could be modelled is presented in table 7.1 
which represents a cohort containing 60 year old women, with mean height of 162 cm, ex-
smokers, with more than 10 pack years, respiratory symptoms, (therefore NICE diagnosed) 
severe COPD at baseline and who live in the UK.  Characteristics offered to the model can 
take on any value from the range presented in the description column of table 7.1. 
 
Each regression equation described in this section on model development, contains slightly 
different explanatory variables depending on the statistical significance for predicting the 
dependent variable, and on a valid rationale for including or excluding explanatory 
variables.  Specific details of explanatory variables contained within each regression 
equation are included in the relevant sections. 
As seen previously, the populations within the TORCH and the MIDSPAN datasets differ.  
TORCH contains a COPD population only and MIDSPAN is a general population study 
that includes but is not limited to COPD patients.  Because it is the natural history of the 
COPD population that is of interest, it was important to only use data from people with 
COPD in developing the regression equations within the MIDPSAN population.  As 
discussed in Chapters 2 and 5, there are a number of different COPD diagnostic criteria 
which when applied, identify differing COPD populations.  The results from the study on 
diagnostic criteria (see Chapter 5) revealed that employing the NICE criteria identified a 
population at higher risk of all cause and COPD mortality than a population identified 
 240 
 
using the GOLD criteria.  Nevertheless because there is widespread use of the GOLD 
criteria and to keep the model as flexible as possible, the regression equations were 
developed within datasets containing GOLD defined COPD, with options for specifying 
risk factors of over 10 pack years and respiratory symptoms so that either a GOLD COPD 
group, a GOLD II COPD group or a NICE COPD group (or different combinations of risk 
factors and lung function) can be modelled, depending on the patient group of interest.  In 
the following sections on the development of each regression equation, summaries of the 
patient populations within each dataset are not presented on the grounds that they have 
previously been described in detail within Chapters 5 and 6. 
Lung function was assumed to be the primary driver of the model affecting: the rate of 
exacerbations, symptoms, mortality, QALYs (through EQ-5D utility) and cost.  In practical 
terms this means that the prediction equations for each of these components could 
potentially contain lung function as an explanatory variable.  
7.2.2 Lung function 
This section describes how the equation that predicts lung function was developed. It has 
been seen in previous chapters that both the TORCH and the Renfrew/Paisley (MIDSPAN) 
study have collected information on lung function, particularly FEV1 and FVC.  This is 
because these measures give a clear indication as to the respiratory health of an individual 
and are relatively easy to collect.  For developing the lung function equation, the 
Renfrew/Paisley dataset was chosen in preference to the TORCH dataset because of the 
wider range of lung function values recorded in the Renfrew/Paisley study: the TORCH 
trial excluded subjects with a FEV1 % predicted > 60%, whereas the Renfrew/Paisley study 
did not.  Because one of the aims of this model was flexibility in terms of the population 
who could be assessed, it is desirable that the model could be used to represent patients 
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with less severe disease, where FEV1 % predicted is greater than 60.  An equation that 
predicts lung function values outside of the range in which it was originally developed, 
could give unreliable estimates, therefore using the Renfrew/Paisley dataset in the 
development phase is appropriate as it allows for a full range of lung functions to be 
predicted when the model is operationalised.  In addition, because the Renfrew/Paisley 
(MIDSPAN) study was comprised of a general population group, the COPD cases are more 
likely to be representative of a general COPD population than those identified in the 
TORCH trial, which had tight inclusion and exclusion criteria. 
RCTs for COPD, including TORCH, usually report improvement in lung function in terms 
of FEV1, rather than FEV1 % predicted.  However, as seen in Chapter 2, COPD cases are 
frequently classified into disease severity groups according to FEV % predicted in order to 
inform treatment decisions.  Therefore when modelling the disease, a question arises: 
should FEV1 or FEV1 % predicted be used, or both?  On the one hand, employing FEV1 in 
its own right within an economic model may be useful: it is known that FEV1 values are 
reported as primary outcomes from clinical trials and that pharmaceutical companies are 
looking for a way of incorporating FEV1 improvement explicitly into an economic 
evaluation for COPD (Helen Rudge, GSK, personal communication).  However COPD 
disease severity is almost always defined in terms of FEV1 % predicted and so the inclusion 
of FEV1 % predicted into the model is useful for consistency and is important for face 
validity.  One solution, and the one which is adopted here, is to develop and employ 
equations for both FEV1 and for FEV1 % predicted within the model.   
The Renfrew/Paisley dataset are used for developing an equation that predicts FEV1 given 
defined explanatory variables.  As previously described in Chapter 5, to calculate FEV1% 
predicted from FEV1, a reference equation is used that predicts expected FEV1 for a 
‘healthy person’ based on age and height.  There are a number of reference equations for 
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determining predicted FEV1, including the reference equations previously derived in 
Chapter 5 for use within the MIDSPAN dataset and a different set for use within the 
TORCH trial and there are always different reference equations for men and women.  The 
explanatory variables within the MIDSPAN and TORCH reference equations are the same, 
namely age and height.  The coefficients on the explanatory variables are similar in the 
male equations, however for the female equations, the coefficients differ, particularly in 
respect to the constant term.  In exploratory analysis, the impact of this difference in the 
reference equations was that the equations used in TORCH were found to give subjects 
comparatively lower FEV1 % predicted scores than when applying the MIDSPAN 
equations on the same population.  Because the Renfrew/Paisley dataset was selected for 
developing the FEV1 equation, the reference equations from the Renfrew/Paisley 
(MIDSPAN) population were used to generate predicted FEV1, on the grounds that they 
were more likely to be valid for the MIDSPAN population than an externally generated set 
of equations.  
Methods 
This section on lung function sets out the methods used to develop an equation for FEV1 
and how the predicted values resulting from this equation were converted into FEV1 % 
predicted scores.  Equations from this section were taken forward to inform the economic 
model for COPD. 
The analyses to derive a FEV1 equation were carried out within the Renfrew/Paisley 
(MIDSPAN) study using subjects satisfying the GOLD defined COPD criteria (as 
previously described in Chapter 5) for reasons outlined in section 7.2.1.  To develop the 
regression equation for FEV1, the method of OLS was used with FEV1 (litres) as the 
dependent variable, adjusted for user defined patient characteristics of: respiratory 
symptoms, over 10 pack years, being an ex-smoker, height, age and sex, with a categorical 
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variable for disease severity at baseline in terms of: 0) FEV180% predicted (used as the 
reference case); 1) 80<FEV50% predicted; 2) 50<FEV30% predicted; and 3) FEV1% 
predicted <30%.  Given the user defined patient characteristics, the resulting equation 
predicts a corresponding lung function value as FEV1 in litres. 
The reference equations that were used for converting FEV1 to FEV1 % predicted are 
reproduced below from Chapter 5: 
FEV1 (l) in men = -1.859 (0.532)- 0.029 (0.003) x age(yrs) + 0.037 (0.003) x height(cm) 
FEV1 (l) in women = -0.225 (0.230)- 0.029 (0.001) x age(yrs) + 0.024 (0.001) x height(cm) 
 
The estimated FEV1 as determined by the OLS regression equation was divided by the 
predicted FEV1 (for the same baseline characteristics) derived from the reference equations 
above and multiplied by 100, to get a FEV1 % predicted value for each cycle within the 
model. 
Results 
The coefficients and standard errors for the OLS regression equation on FEV1 are 
reproduced in table 7.2.  As seen in the last column of the table, all of the explanatory 
variables were found to be statistically significant (p<0.001) with the exception of over 10 
pack years and ex-smoker, which had large p-values of 0.610 and 0.383 respectively 
(R2=0.89).  Whilst statistically insignificant, these explanatory variables were retained so 
that a NICE COPD cohort could be defined.  
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Table 7.2 Prediction equation for FEV1  
Variable name Coefficient SE P 
Constant -0.016 0.109 0.885 
Height 0.022 0.001 0.000 
Age -0.022 0.001 0.000 
Sex -0.381 0.010 0.000 
Over 10 -0.005 0.009 0.610 
Ex-smoker 0.009 0.011 0.383 
Symptoms -0.050 0.008 0.000 
Mild COPD -0.594 0.008 0.000 
Moderate COPD -1.173 0.012 0.000 
Severe COPD -1.610 0.020 0.000 
 
The table shows that for each year that passes, and as age increases by one, FEV1 declines 
by 20ml.  Women have a lower lung function than men by, on average 380ml, ceteris 
paribus.  People with respiratory symptoms have, on average, 50ml less lung capacity than 
those without respiratory symptoms.  
By incorporating disease severity at baseline as a categorical value (rather than producing 
separate equations for each disease severity group), the assumption was that the rate of 
FEV1 decline (in other words the slope of the curve) was the same, regardless of disease 
severity.  Starting lung function capacity was seen to differ by disease severity so that FEV1 
score was higher for subjects with less severe disease (indicating larger lung capacity) and 
smaller for people with more severe disease (more impaired lung function).  As disease 
severity worsens, a downward shift in FEV1 score is seen.  The results presented in table 
7.2 show that compared to the group with possible COPD which contains patients with 
FEV1 % predicted ≥80, those with mild COPD had a lung function with 0.6 litres less, 
those with moderate COPD 1.2 litres less and those with severe COPD, 1.6 litres less 
capacity.  
Tables 7.3 illustrates how FEV1, predicted FEV1, and FEV1 % predicted enter into the 
model for a hypothetical cohort containing men with mild and men with moderate NICE 
diagnosed COPD with a starting age of 55 years.  Age increases by one year at every cycle 
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within the model as shown in the first column of the table.  FEV1 scores predicted from the 
FEV1 regression equation were inputted into the FEV1 columns in the table.  Predicted 
FEV1 values were calculated from the reference equations based on information on height, 
age and sex and are shown in the predicted (pred) FEV1 columns.  FEV1 % predicted values 
are presented in the FEV1 % predicted columns (where FEV1 % predicted is equal to FEV1 
divided by predicted FEV1 multiplied by 100).  
Table 7.3 An example of the decline in FEV1 in men aged 55  
with mild and moderate NICE diagnosed COPD at baseline  
 Mild COPD Moderate COPD 
Age FEV1 Pred FEV1 FEV1% pred FEV1 Pred FEV1 FEV1% pred 
55 2.00 3.02 0.66 1.42 3.02 0.47 
56 1.98 2.99 0.66 1.40 2.99 0.47 
57 1.96 2.96 0.66 1.38 2.96 0.46 
58 1.93 2.93 0.66 1.36 2.93 0.46 
59 1.91 2.91 0.66 1.33 2.91 0.46 
60 1.89 2.88 0.66 1.31 2.88 0.46 
FEV1= Forced Expiratory Volume in one second. 
 
Table 7.3 shows that the predicted FEV1 % predicted for men in this mild cohort is 66% 
and in the moderate group is 47% which are consistent with expected FEV1 % predicted 
values in the corresponding COPD disease severity groups.  Table 7.3 shows that FEV1 has 
a steady decline of 20ml per year regardless of disease severity group.    
Fewer data were available for developing the regression equations for people with severe 
COPD and this caused inconsistencies when predicting lung function in this population.  In 
particular, FEV1 % predicted scores were slightly higher in men than expected.  For men 
aged 55 with severe disease, FEV1 % predicted was 33%, when it was expected to be less 
than 30% predicted.  In women aged 55 years with severe disease, FEV1 % predicted scores 
were as expected (below 30% predicted) at 25% predicted.  
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7.2.3 Exacerbations 
Within this section, prediction equations for the rate of exacerbations are developed and the 
resulting equations are incorporated into the economic model.  There are a number of 
different definitions of an exacerbation.  Consistent with other definitions used in economic 
modelling for COPD (see Chapter 4), exacerbations were said to occur when there is a 
worsening of respiratory symptoms requiring treatment with oral corticosteroids and/or 
antibiotics.(10)  There were assumed to be two types of exacerbation:  minor and major 
exacerbations.  A minor exacerbation is considered present when a subject is managed 
exclusively in primary care.  A major exacerbation occurs when the worsening of 
symptoms require that the subject is hospitalised.(144)  
The TORCH dataset reports on both minor and major exacerbations whereas the 
MIDSPAN dataset contains details of major COPD exacerbations only (through the linked 
hospitalisation data which were described and analysed in Chapter 5).  Therefore whilst the 
MIDSPAN dataset could be used to derive the rate of major exacerbations from a number 
of explanatory variables, because data on minor and major exacerbations is available in 
TORCH, TORCH was considered to be the most suitable dataset in which to develop the 
predication equations for the rate of minor and the rate of major exacerbations.  
Furthermore in TORCH, data on lung function and exacerbations were repeatedly collected 
over the three year study and hospitalisation was carefully followed.  This contrasts with 
the MIDSPAN dataset in which measurement of lung function was made at baseline and 
information on exacerbations came in the form of COPD recorded hospitalisation records 
that in Chapter 5 were assumed to represent major exacerbations.  Therefore as lung 
function is, a priori, expected to influence the rate of exacerbations, it is important to 
determine this relationship as accurately as possible, which is more likely within the 
TORCH dataset.   
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With reference to the conceptual model, it was assumed that the rate of exacerbations was 
related to lung function, which in turn was expected to affect symptoms, QALYs (via EQ-
5D utility) and cost.  Exacerbations are incorporated into the model as an annual rate. 
Methods 
The TORCH dataset was used to derive the prediction equations for rates of mild and rates 
of major exacerbations. Patients were dropped from the TORCH dataset where follow up 
time was less than 3 months in order to avoid biases introduced due to situations in which 
an event was observed over a short follow up period and then the patient left the study.  
These subjects would contribute a high event rate even though, if they had full follow up, it 
would be unlikely that the actual number of events would be close to the event rate 
estimated.   
Because the exacerbation data in the TORCH study are count data, the Poisson distribution 
was employed.  A goodness of fit test was used to check for over-dispersion (where the 
sample variance is greater than the sample mean) in order to decide whether a Poisson 
regression model or a negative binomial model was appropriate for modelling the data. 
In developing the regression model for rate of major exacerbations, an assumption was 
made that previous exacerbations have no impact on future exacerbations.  Explanatory 
variables included: age, FEV1 % predicted, ex-smoker, sex and a UK variable.  FEV1 % 
predicted was calculated for each observation within the TORCH dataset, using the 
prediction equation developed within the MIDSPAN population (section 5.2.2) the 
rationale for use within the MIDSPAN study has been previously described, but use within 
the TORCH study was done on the grounds of consistency. 
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The resulting equations for major and for minor exacerbations were incorporated into the 
economic model as previously described in figure 7.4, so that as age and FEV1 % predicted 
change over time, the rate of exacerbations also change over time, dependent upon the user 
defined patient characteristics. 
Results 
Major Exacerbations 
 
Testing was carried out to assess the appropriateness of the Poisson model to model major 
exacerbations.  It was found that the probability these data would be observed conditional 
on alpha being 0 (assumption for Poisson model) is close to zero with a 2= 193.87, and an 
alpha value within the equation of 3.4, which suggests that the negative binomial model is 
more appropriate for modelling this type of data, than the Poisson model.    
The coefficients and standard errors from the negative binomial model are reproduced 
below in table 7.4. The variables ex-smoker and sex were not statistically significant in 
predicting the rate of major exacerbations and were therefore excluded from the analyses.  
As seen in the last column of table 7.4, the explanatory variables: age, breathless, FEV1 % 
predicted and UK, were statistically significant and formed the prediction equation for rate 
of major exacerbations.  
Table 7.4 The prediction equation for rate of major exacerbations  
Variable name Coefficients SE P 
Age 0.023 0.006 0.000 
Breathless 0.599 0.109 0.000 
FEV % predicted -1.524 0.391 0.000 
UK 0.621 0.237 0.009 
Constant -5.286 0.448 0.000 
Time (offset)    
Offset=log(time). Cycle lengths = 1yr. Therefore the offset term is one. FEV1= Forced Expiratory Volume in one 
second. 
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This prediction equation was entered into the economic model using the algorithm below 
which gives the mean rate of exacerbation from the negative binomial model based on the 
explanatory variables and coefficients described in table 7.4.  The rate of exacerbations 
from the negative binomial model is equal to the exponential of the linear equation plus the 
offset term.  As the cycle lengths are one year, the value for the offset term is one.   
( )offsetUKUKpredfevpredFEVbreathbreathageageconseRma +++++= ββββ ****  
Minor Exacerbations 
The prediction equation for minor exacerbations was developed in the same way and using 
the same dataset as the prediction equation for major exacerbations.  In this equation, age 
was found to be statistically insignificant in the prediction of minor exacerbations and so 
was excluded.  The remaining explanatory variables: breathless, FEV1% predicted and UK 
were seen to be statistically significant (p<0.001) as shown within table 7.5 below.  
Table 7.5 The prediction equation for rate of minor exacerbations 
Variable name Coefficient SE P 
Breathless 0.451 0.062 0.000 
FEV1 % predicted -1.552 0.220 0.000 
UK 0.880 0.143 0.000 
Constant -1.983 0.121 0.000 
Time (offset)    
FEV1= Forced Expiratory Volume in one second. 
 
The prediction equation from table 7.5 was incorporated into the economic model using the 
formula described below for the negative binomial model:  
( )offsetUKUKpredfevpredFEVbreathbreathconseRmi ++++= βββ ***  
Mild and moderate exacerbation rates were incorporated into the model.  As an example, 
the predicted rates for men aged 55 years with mild or moderate NICE diagnosed COPD at 
baseline are shown in table 7.6, for the first six years of the model. 
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Table 7.6 An example of rate of major and minor exacerbations in men aged 55 
with mild and moderate NICE diagnosed COPD at baseline 
 Mild COPD Moderate COPD 
Age Minor  Major Minor Major 
55 0.51 0.06 0.68 0.08 
56 0.51 0.06 0.69 0.08 
57 0.51 0.06 0.69 0.09 
58 0.51 0.06 0.69 0.09 
59 0.51 0.07 0.69 0.09 
60 0.51 0.07 0.70 0.09 
 
Tables 7.6 show that exacerbation rates generally increase over time and that minor 
exacerbations are more frequent than major exacerbations, irrespective of disease severity. 
For mild COPD, the rate of major exacerbations increased from 0.06 at baseline to 0.07 at 
60 years.  In the moderate COPD group, the rate of major exacerbations was higher than for 
the mild group at 0.08 per year at age 55 and increasing to 0.09 at age 60.  Rate of minor 
exacerbations stayed constant over the first six years in the mild cohort, at 0.51 per year 
whereas the minor exacerbation rate for those with moderate COPD at baseline increased 
from 0.68 at 55 years to 0.70 at 60 years.      
7.2.4 Symptoms 
A prediction model for symptoms was developed within this section and the methods and 
results are presented.    
Measuring symptoms and incorporating this measure in a meaningful way into an 
economic model is not without difficulty.  One commonly used measure for breathlessness 
is the MRC dyspnea questionnaire which is shown in figure 7.5.  Changes in breathlessness 
occur over time as lung function deteriorates and the disease progresses.  The differences 
between the five levels of the MRC questionnaire are large and realistically anything other 
than a successful surgical intervention (or perhaps significantly increased exercise capacity) 
is unlikely to impact the patient so considerably that there would be an upward movement 
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to a less impaired level.  The MRC questionnaire is limited to breathlessness and is to all 
intents and purposes, a way of classifying the degree of (im)mobility in a patient.  
Respiratory symptoms can however include sputum production, cough and wheeze, in 
addition to breathlessness.  
1 I only get breathless with strenuous exercise  
2 I get short of breath when hurrying on the level or walking up a slight hill  
3 I walk slower than people of the same age on the level because of breathlessness, or I have 
to stop for breath when walking at my own pace on the level 
4 I stop for breath after walking about 100 yards or after a few minutes on the level  
5 I am too breathless to leave the house or I am breathless when dressing or undressing  
Figure 7.5 MRC dyspnea scale 
 
A frequently used method for measuring symptoms is to ask the respondent to answer a 
questionnaire.  An example is the self-reported questionnaire within the Renfrew/Paisley 
study which contained specific questions on symptoms and which are stated in figure 7.6 
below, where responses are either yes or no (the full questionnaire is reproduced in full 
within the appendix).  As with the MRC scale, the improvement in symptoms needed to, 
for example, move from answering ‘yes’ to the question, ‘do you get short of breath with 
people your own age on level ground?’, to then answer ‘no’ following treatment, is unlikely 
to occur because it is a very large jump.  Instead a more sensitive tool is required for the 
purposes of modelling.  
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Figure 7.6 Symptoms questions within the Renfrew/Paisley study 
 
As seen in Chapter 2, the SGRQ is routinely collected within COPD RCTs and has three 
domains of symptoms, activity and impact which are used to give a total score (see Chapter 
6 for further details).  Questions 1 to 8 of the SGRQ (as shown in the appendix), ask about 
symptoms experienced over the past year and form the symptoms domain of the SGRQ.  
Therefore the topics covered within the symptoms part of the questionnaire are likely to be 
sensitive to changes in symptoms experienced and fits in with the time frame of the model.  
As such, the symptoms domain of the SGRQ is a feasible option for measuring changes in 
the symptoms of COPD.    
As described within section 7.1, there is likely to be a link between exacerbations and 
symptoms because of the definition of an exacerbation, which is a worsening of respiratory 
symptoms requiring treatment.  The respiratory symptoms that occur as a result of an 
exacerbation are acute, rather than chronic, which is what this section is primarily referring 
to.  Nevertheless, because of the nature of the questions asked within the SGRQ, the 
measure is likely to be sensitive to both types.  In order to account for this possible 
relationship, a variable for exacerbation is included within the regression equation on 
symptoms.  
Presence of a self-reported respiratory symptom was considered if the participant answered 
positively to one or more of: 
 
“Do you get short of breath walking with people of your own age on level ground?” 
OR 
“Does your chest sound wheezy or whistling on most days (or nights)?” 
OR 
“Do you usually bring up any phlegm from your chest first thing in the morning in the winter?” 
plus, yes to either: “do you bring up phlegm like this on most days for as much as three 
months in the winter each year?” or “in the past three years have you had a period of 
increased cough and phlegm lasting for three weeks or more?”  
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Methods 
The TORCH dataset was used to develop the prediction equation for symptoms, using the 
same population used in the previous section on exacerbations.  The SGRQ symptoms 
domain was used as a surrogate measure for measuring symptoms experienced by COPD 
patients, and was the dependent variable in the regression equation.  The prediction 
equation for SGRQ symptoms was adjusted for a range of explanatory variables including: 
sex, age, ex-smoker and breathless at baseline.  Because symptoms were a priori, expected 
to be influenced over time by exacerbations and by lung function, variables for major 
exacerbation rate and FEV1 % predicted were also included within the model.  GLM 
regression models were used as previously described in Chapter 6, in order to identify a 
model that fit the data well. 
The resulting prediction equation on symptoms was employed within the economic model.  
For each cycle, the values from the FEV1 % predicted and major exacerbation prediction 
equations were used as explanatory variables, in addition to values for baseline user defined 
patient characteristics. 
Results 
The SGRQ symptoms scores were seen to approximately fit a normal distribution as shown 
in figure 7.7, with a mean (SD) of 57 (21), a minimum value of 0 and a maximum value of 
100, where 0 represents no symptoms.  
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Figure 7.7 Frequency of SGRQ symptoms scores in the TORCH study 
 
Given the distribution of the data, a GLM model with Gaussian family and identity link 
(OLS) was found to fit the data well.  The prediction equation from the regression is shown 
in table 7.7 and shows that major exacerbations, sex, FEV1 % predicted, being an ex-
smoker, based in the UK and having breathlessness at baseline were all statistically 
significant in the prediction of SGRQ symptoms score.   
Table 7.7 shows that: a major exacerbation increases the symptoms score by 6.1 points; a 
1% increase in FEV1% predicted lowers the SGRQ total score by -0.21; females have a 
higher symptoms score by on average 2.4; being an ex-smoker compared to a smoker 
lowers the symptoms score by 7.9 and a person with breathlessness has a higher SGRQ 
score by 7.4, compared to somebody without breathlessness.  Age was assessed for 
inclusion within the prediction equation; however, whilst statistically significant, it was 
removed from the analyses on the grounds that increasing age was found to be associated 
 255 
 
with better symptoms, rather than worse, as was originally expected.  This relationship with 
age is explained by changing expectations of health as age increases, in that people expect 
their health to be worse as they get older and adjust their expectations accordingly, with a 
greater tolerance of their ailments.  There is no evidence to suggest that symptoms per se 
improve with age.  
Table 7.7 Prediction equation for symptoms 
Variable name Coefficients SE p 
Major exac 6.100 0.788 0.000 
Sex 2.382 0.686 0.001 
FEV1 % predicted -0.213 0.023 0.000 
Ex-smoker -7.041 0.613 0.000 
UK 7.870 1.554 0.000 
Breathless 7.365 0.625 0.000 
Constant 68.435 1.246 0.000 
FEV1= Forced Expiratory Volume in one second.  
 
The prediction equation for symptoms was included within the economic model as 
described earlier.  Predicted symptoms scores from the model for a male cohort aged 55 
years with mild and moderate NICE diagnosed COPD at baseline are shown in table 7.8 
below.   
Table 7.8 Symptoms scores for men aged 55  
with mild and moderate NICE diagnosed COPD at baseline  
Age Mild Moderate 
55 62.9 67.1 
56 62.9 67.2 
57 62.9 67.2 
58 63.0 67.3 
59 63.0 67.4 
60 63.0 67.5 
 
Table 7.8 shows that symptoms marginally worsen over time as the disease progresses.  
The cohort with moderate COPD has higher symptoms scores than those with mild disease, 
indicating worse respiratory symptoms.  With reference to table 7.8, symptoms scores were 
62.9 in the mild group at baseline, rising to 63.0 by 60 years.  The corresponding symptoms 
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scores in the moderate group were 67.1 rising to 67.5, indicating that symptoms worsen at a 
faster rate in people with more severe disease than those with less severe disease.   
7.2.5 EQ-5D Utility 
Within the section, an equation that predicts expected EQ-5D utility, given: lung function, 
exacerbations and symptoms, is developed and the results presented. 
Two prediction equations for EQ-5D utility were developed in Chapter 6.  The first used 
explanatory variables of: height, age, sex, over 10 pack years, ex-smoker and disease 
severity, and the second used explanatory variables of sex and the SGRQ (total, domain or 
item) scores.  In these equations it was seen that the SGRQ symptoms domain and disease 
severity were statistically significant in the prediction of utility.  The prediction models 
presented in Chapter 6 form the starting point for this equation, with two key differences, 
which came to light following the conceptualisation of the model:  exacerbations were 
included as an explanatory variable within the prediction equation, and rather than the 
SGRQ total score being an explanatory variable, the SGRQ symptoms domain alone was 
used.  The TORCH dataset was used to derive the prediction equation for EQ-5D utility as 
no HRQoL data were collected in the Renfrew/Paisley (MIDSPAN) study. 
Methods 
The TORCH dataset was used to develop the prediction equation for EQ-5D utility.  EQ-
5D utility at one year time periods were used together with information on events and 
experiences occurring within the previous year to predict EQ-5D utility.  Explanatory 
variables assessed for incorporating into the EQ-5D utility prediction model included: 
SGRQ symptoms; FEV1 % predicted; breathless at baseline, sex, UK, ex-smoker, age and 
major exacerbations within the last year (where 0=no, 1=yes).  The prediction equation for 
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EQ-5D utility was developed using GLM models, using the same methods as previously 
applied within Chapter 6 (the equations did not adjust for multiple observations per 
participant for reasons previously described in Chapter 6).  The equation was estimated on 
the utility decrement scale (1-EQ-5D utility), in order to allow greater flexibility in 
identifying the appropriate family for the GLM model, and converted back for reporting.   
The resulting EQ-5D utility equation was applied within the economic model using the 
predicted values from the regressions on lung function, exacerbations and on symptoms 
(where statistically significant) plus user defined patient characteristics in order to predict 
EQ-5D scores for every cycle.  
Results 
The GLM prediction equation for EQ-5D was fit with a Gaussian family and identity link.  
Table 7.9 shows the resulting model.  Major exacerbations within the last year, FEV1 % 
predicted, SGRQ symptoms scores, breathlessness at baseline, UK and sex were all found 
to be statistically significant in the prediction of EQ-5D utility.  Age and being an ex-
smoker at baseline were not found to be statistically significant and were excluded from the 
regression model. 
Table 7.9 Prediction equation for EQ-5D decrement score 
Variable name Coefficients SE P 
Major 0.053 0.010 0.000 
FEV1 % predicted -0.056 0.020 0.006 
SGRQ Symptoms 0.004 0.000 0.000 
UK 0.049 0.017 0.004 
Breathless 0.087 0.006 0.000 
Sex 0.031 0.006 0.000 
Constant -0.003 0.013 0.829 
FEV1= Forced Expiratory Volume in one second. SGRQ= St George’s respiratory questionnaire.  
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Because the analysis was conducted using EQ-5D decrement, in order to generate EQ-5D 
scores, the predicted score was subtracted from 1.  The table shows that for each major 
exacerbation, EQ-5D utility decreases by 0.053, people with respiratory symptoms at 
baseline have worse EQ-5D utility and that women tend to have worse utility scores than 
men. 
Using this equation, EQ-5D utilities were predicted within the economic model for men 
aged 55 years with mild and moderate COPD at baseline and the results are shown in table 
7.20.  The model shows that over this short time frame, EQ-5D utility is relatively stable.  
As seen in the table, moderate COPD was associated with lower EQ-5D utility than mild 
COPD, with a utility value of 0.61 in the moderate group compared to 0.64 in the mild 
group.  
Table 7.10 EQ-5D utility for men aged 55  
with mild and moderate NICE diagnosed COPD at baseline Age Mild Moderate 
55 0.64 0.61 
56 0.64 0.61 
57 0.64 0.61 
58 0.64 0.61 
59 0.64 0.61 
60 0.64 0.61 
 
7.2.6 Cost 
The economic model developed in this section represents current treatment practice and it 
is assumed that there are costs accruing to the NHS as a result of the disease.  Costs can be 
split into two types: treatment costs and all ‘other costs’, which includes the cost of 
hospitalisation, GP contacts and costs associated with adverse events.  In this section, both 
types are considered but are dealt with in different ways.   
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As previously described in Chapter 2, current practice is to treat COPD based on disease 
severity with therapies added as the disease worsens.  In order to use a relevant value for 
treatment costs, the treatment pathway as described in table 2.5 and treatment costs as 
estimated in table 2.6 (Chapter 2) were used to derive costs for a person with mild and 
moderate COPD before the ‘new’ COPD therapies entered the market (Seretide, Spiriva 
and Symbicort).  It was assumed that a person with mild (NICE diagnosed) COPD would 
be prescribed ipratropium and salbutamol at an annual cost of £102 ($167) and for treating 
people with moderate COPD, that beclomethasone would been added to the treatment mix, 
so to include beclomethasone, ipratropium and salbutamol with a one year cost of treating 
this group of £183 ($299).   
As pharmacological costs are fixed, given the quantity prescribed, they are entered into the 
model as a user defined value that occurs every cycle and does not have any uncertainty 
surrounding it.  If instead incremental treatment costs were of interest as opposed to 
specific costs, the model allows for the treatment costs in the base case to be left empty 
(entered as zero into the model) and the incremental treatment cost to be added to the 
treatment costs within the new treatment arm of the economic model.  
A different option for estimating treatment costs is to use the TORCH dataset to derive a 
prediction equation.  However, this method was not pursued because the aim of this new 
economic model is to produce a general model for COPD, rather than looking at the cost 
effectiveness of any drug treatment from TORCH.  Any new treatments that come onto the 
market for COPD would be priced differently to treatments in TORCH and so this 
approach would lack external generalisability. 
For ‘other costs’, summary statistics were derived by type of exacerbation, before a 
regression equation was developed to predict cost based on patient events and experiences.  
The cost equation for ‘other costs’ was developed within the TORCH dataset because the 
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study collected detailed information on all treatment and disease related costs over six 
monthly time frames and the Renfrew/Paisley (MIDSPAN) dataset did not contain any cost 
data.  The TORCH dataset measured costs in American dollars. 
The cost equation was estimated using GLM regression methods as used within this chapter 
and previously described and applied in Chapter 6.  ‘Other costs’ was the dependent 
variable and explanatory variables offered to the model included: major exacerbations, 
minor exacerbations, SGRQ symptoms, sex, UK, FEV % predicted, breathless at baseline, 
age and ex-smoker. 
Results 
‘Other costs’ were found to be higher in people who had had an exacerbation compared to 
those people who hadn’t had an exacerbation, with costs highest in people who had 
experienced a major exacerbation.  In people who had had a major and a minor 
exacerbation in the previous year, the mean cost was  £1976 (SD=3498), where there was a 
major but no minor exacerbation, cost was £1929 (2670), where there was a minor and no 
major exacerbation cost was £339 (814).  This compares to where there was neither a minor 
nor a major exacerbation, when ‘other cost’ was found to be £97 (388).  The large standard 
deviations show the extent to which there was variability in other costs within the dataset.  
The Gaussian family and identity link were found to fit the data well.  Details of the 
resulting regression coefficients are presented in table 7.11 and the table shows that major 
exacerbations, minor exacerbations, age, SGRQ symptoms score, FEV % predicted were all 
found to be statistically significant in the prediction of ‘other costs’.  From the table it can 
be seen that a major exacerbation is estimated to cost $2498 and a minor exacerbation, 
$330.  On average, increasing age was associated with an increasing cost burden of $5 year 
on year.  For every one point increase in symptoms score (associated with deterioration in 
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health) an extra $1.50 is added to the cost burden.  A 1% increase in FEV1% predicted is 
seen to be associated with a $267 reduction in ‘other costs’. 
Table 7.11 Prediction equation for ‘other costs’ 
Variable name Coefficient SE P 
Major exac 2497.836 178.266 0.000 
Minor exac 330.223 36.7009 0.000 
Age 5.376 1.2448 0.000 
SGRQ symptoms 1.480 0.672 0.028 
FEV1 % predicted -267.176 90.409 0.003 
Constant -150.835 100.960 0.135 
 
The application of the prediction equation for ‘other costs’ is shown in table 7.12 for the 
male cohort aged 55 years at baseline with mild or moderate COPD.  Mild and moderate 
treatment costs are $167 and $299 respectively and are assumed to be constant over time as 
illustrated in table 7.12. 
Table 7.12 Treatment and ‘other costs’ for men aged 55 years  
with mild and moderate NICE diagnosed COPD at baseline ($)  Mild COPD Moderate COPD 
Age Tx  Other Tx Other 
55 167 379 299 545 
56 167 388 299 558 
57 167 398 299 571 
58 167 408 299 584 
59 167 418 299 597 
60 167 428 299 611 
 
Table 7.12 shows that ‘other costs’ increase from the mild to the moderate groups and that 
‘other costs’ increase over time as the disease progresses.  ‘Other costs’ start at $379 at age 
55 years in the mild group and $545 in the moderate group, and rise over time to $428 and 
$611 for the mild and moderate group respectively by 60 years of age.   
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7.2.7 Survival 
In Chapter 5 it was shown that those meeting NICE diagnostic criteria, which includes 
people with respiratory symptoms, airflow obstruction and over 10 pack years, had a higher 
mortality risk than people with no COPD, or people with GOLD defined COPD.  It was 
also seen that people with more severe disease had a higher mortality risk than those with 
less severe disease, for all cause and COPD mortality.  In addition, age is a well known 
driver of mortality risk, so that as the cohort ages, the probability of survival in the next 
period, decreases.  Within this section, a model that predicts survival probability, that 
incorporates all of these factors, is described and developed before being applied within the 
economic model for COPD. 
A traditional way of incorporating mortality into an economic model is to use life tables.  
However because within Chapter 5 more factors than age alone have been shown to affect 
mortality risk, the use of life tables would be inappropriate within this context as only 
information on mortality rates for the general population, by age are available within 
lifetables.  A regression model predicting survival given the presence of respiratory 
symptoms, over 10 pack years, COPD disease severity and age would be more suitable for 
representing mortality in a COPD population given the earlier findings of this thesis.   
The Renfrew/Paisley (MIDSPAN) dataset was used in Chapter 5 in order to investigate 
mortality and for the same reason, the MIDSPAN dataset is used here in preference to the 
TORCH dataset.  Within the dataset, only those meeting the GOLD COPD criteria were 
used, for reasons explained earlier in section 7.2.1.  As seen in Chapter 5 there are a range 
of causes of mortality for COPD patients and cause of mortality is not limited to COPD 
mortality.  Therefore, the survival model was developed using data on all-cause mortality 
from the MIDSPAN study, rather than on COPD specific mortality. 
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Methods 
The GOLD COPD cases of the MIDSPAN dataset were used to develop the regression 
model on survival.  Explanatory variables included sex, FEV % predicted at baseline, age at 
baseline and dummy variables for: fewer than/over 10 pack years, ex-smoker and 
respiratory symptoms.  The survival function was modelled using a Weibull regression 
where the survival function is given by:  
( ) ( )γλtEXPtS −=  
The resulting equation gives the gamma variable within the output () and ln  is the linear 
predictor of covariates, such that: 
+= ijj Xβαλln  
The survival function was used within the model to predict the probability of survival at 
each cycle using user defined patient characteristics at baseline, with the exception of FEV1 
% predicted score which was obtained from the prediction of FEV1 % predicted from the 
model in the first time period.   
Results 
The explanatory variables from the Weibull model are shown in table 7.13 together with 
the coefficients, standard errors and p values for each.  Supporting the previous findings on 
the importance of these factors on mortality risk within Chapter 5, respiratory symptoms, a 
smoking history and FEV1 % predicted, along with age, sex and ex-smoker were all found 
to be statistically significant in the prediction of survival (p<0.001). 
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Table 7.13 The prediction equation for survival 
Variable Coefficient SE P 
Constant -9.700 0.241 0.000 
Sex -0.362 0.039 0.000 
FEV1 % pred -0.008 0.001 0.000 
Age 0.078 0.003 0.000 
Over10 0.455 0.047 0.000 
Ex-smoker -0.276 0.053 0.000 
Symptoms 0.263 0.038 0.000 
Gamma 1.827 0.028 0.000 
 
The survival curves plotted in figure 7.8 show how all-cause mortality within the male 
cohort of the MIDSPAN study is affected by COPD disease severity at baseline and shows 
real data.  This figure is a replication of figure 5.4 in Chapter 5 with the exception that 
figure 7.8 presents survival probability by disease severity with time in study along the x 
axis as opposed to age in study.  Figure 7.9 demonstrates how the survival function 
described above predicts for the mean male population for 55 year old men (mean age in 
MIDPSAN study) and different disease severities. 
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Figure 7.8 Survival curves for all cause mortality for men by COPD disease severity 
within the MIDSPAN dataset 
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Figure 7.9 An example of the modelled survival function applied to 55 yr old males,  
FEV1  80% predicted assumed a smoking history and no symptoms and the other lung 
function groups were assumed to have a smoking history and respiratory symptoms 
 
The top line in each figure illustrates the survival probability of the cohort with FEV1 80% 
predicted with a smoking history of greater than 10 pack years.  The other lines restrict the 
population to those with respiratory symptoms.  The red line corresponds to the NICE mild 
group, the green line to moderate COPD and the orange line to severe disease.  The 
modelled curves in figure 7.9 are smooth over time in comparison to the jagged lines seen 
in the observed data in figure 7.8.   
The figures capture different patient groups, the observed data represent all men with 
GOLD defined COPD, whereas the modelled curves represent survival of men aged 55 
years at the start of follow, as such the curves are expected to be slightly different.  
Nevertheless, the two groups can be roughly compared and it can be seen that the survival 
probabilities are similar between the observed male patients and the average modelled male 
cohort, particularly in the least severe cohort where median survival is approximately 20 
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years.  The biggest difference between the groups is seen in the severe COPD group, and 
the spread of the curves is less in the modelled than in the observed curves.  
Table 7.14 Survival probability for men aged 55 years 
with mild and moderate NICE diagnosed COPD at baseline 
Age S(t) mild S(t) mod 
55 1.00 1.00 
56 0.99 0.98 
57 0.97 0.97 
58 0.95 0.94 
59 0.93 0.92 
60 0.90 0.89 
 
The mild and moderate disease populations plotted in figure 7.9 match those in table 7.14.  
The survival probabilities in table 7.14 show that probability of survival decreases with 
disease severity, so that moderate COPD patients are at higher risk of all-cause mortality 
than mild COPD patients.  At age 60, survival probabilities for men in the mild and 
moderate groups are 0.90 and 0.89 respectively.   
7.2.8 Survival Adjusted EQ-5D Utility and Cost 
Survival adjusted EQ-5D utility and total costs were estimated using the Kaplan-Meier 
sample average estimator.(156)  For each interval (one year within the model) the estimator 
calculates the mean cost and the mean EQ-5D utility for patients alive at the beginning of 
the interval, weighted by the probability of surviving to the beginning of the interval and 
sums these values over all the time intervals.(130)  Survival adjusted total cost was 
calculated for each time period by multiplying the cost by the survival function, and EQ-5D 
utility was calculated in the same way.     
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7.2.9 The Economic Model for Current Treatment 
Snapshots of the deterministic economic model representing current treatment for 55 year 
old men with mild NICE diagnosed COPD and moderate COPD at baseline have been 
presented above for individual sections of the model.  Within tables 7.15 and 7.16 below, 
the model for these two groups is presented in full over a lifetime perspective with 
specified patient characteristics including: ex-smoker, over 10 pack years, presence of 
respiratory symptoms and based in the UK.  The model combines the individual regression 
equations developed earlier, to predict values for lung function, exacerbations and 
symptoms and from these to predict costs and utility, which are weighted by survival and 
are discounted. 
From tables 7.15 and 7.16 it can be seen that as age increases, FEV1 decreases year on year 
in both cohorts, as does predicted FEV1 and FEV1 % predicted and lung function is more 
impaired in the moderate than in the mild group.  Whilst the incremental change in FEV1 is 
the same for the two cohorts, FEV1 % predicted deteriorates quicker in the moderate cohort 
than in the mild cohort.  Symptoms are seen to worsen over time with a deterioration that is 
quicker in the moderate group compared to the mild COPD group.  The rate of minor 
exacerbations was comparatively steady over time for the mild cohort, whereas in the 
moderate group, the rate of minor exacerbations increased over time.  The rate of major 
exacerbations in the mild and moderate cohort more than doubled.  EQ-5D utility was 
almost constant over time for the modelled mild cohort, whereas in the moderate group, 
EQ-5D utility at baseline was lower and worsened at a quicker rate than in the mild group.  
Treatment costs are assumed to be constant over time.  ‘Other costs’ are seen to increase 
over time and are higher in the moderate cohort than the mild.  Total costs are equal to the 
sum of treatment cost and ‘other costs’.  The survival probability is higher for the mild 
group than the moderate group. 
  
 
Table 7.15 Economic model for current treatment, men aged 55 yrs with mild COPD 
Time Age FEV pred 
FEV1 
FEV1% 
pred 
Symp Exac 
minor 
Exac 
major 
EQ-5D 
utilitys 
Tmt 
cost 
Other 
cost 
Total 
cost 
S(t) S(t)* 
utility 
S(t)*total 
cost 
1 55 2.00 3.02 0.66 62.9 0.51 0.06 0.64 167 379 546 1.00 0.62 525 
2 56 1.98 2.99 0.66 62.9 0.51 0.06 0.64 167 388 555 0.99 0.59 511 
3 57 1.96 2.96 0.66 62.9 0.51 0.06 0.64 167 398 565 0.97 0.56 495 
4 58 1.93 2.93 0.66 63.0 0.51 0.06 0.64 167 408 575 0.95 0.53 477 
5 59 1.91 2.91 0.66 63.0 0.51 0.07 0.64 167 418 585 0.93 0.50 457 
6 60 1.89 2.88 0.66 63.0 0.51 0.07 0.64 167 428 595 0.90 0.47 436 
7 61 1.87 2.85 0.66 63.1 0.51 0.07 0.64 167 438 605 0.87 0.44 414 
8 62 1.85 2.82 0.66 63.1 0.51 0.07 0.64 167 448 615 0.84 0.41 392 
9 63 1.83 2.79 0.65 63.1 0.51 0.07 0.64 167 459 626 0.80 0.38 369 
10 64 1.80 2.76 0.65 63.2 0.51 0.07 0.64 167 469 636 0.77 0.35 347 
11 65 1.78 2.73 0.65 63.2 0.51 0.08 0.64 167 480 647 0.73 0.32 324 
12 66 1.76 2.70 0.65 63.2 0.52 0.08 0.64 167 490 657 0.69 0.29 301 
13 67 1.74 2.67 0.65 63.3 0.52 0.08 0.64 167 501 668 0.65 0.27 279 
14 68 1.72 2.64 0.65 63.3 0.52 0.08 0.64 167 512 679 0.61 0.24 258 
15 69 1.70 2.62 0.65 63.3 0.52 0.08 0.64 167 524 691 0.58 0.22 237 
16 70 1.67 2.59 0.65 63.4 0.52 0.09 0.64 167 535 702 0.54 0.20 217 
17 71 1.65 2.56 0.65 63.4 0.52 0.09 0.64 167 546 713 0.50 0.18 199 
18 72 1.63 2.53 0.64 63.5 0.52 0.09 0.64 167 558 725 0.46 0.16 181 
19 73 1.61 2.50 0.64 63.5 0.52 0.09 0.63 167 570 737 0.43 0.14 164 
20 74 1.59 2.47 0.64 63.5 0.52 0.10 0.63 167 582 749 0.39 0.13 148 
21 75 1.56 2.44 0.64 63.6 0.52 0.10 0.63 167 594 761 0.36 0.11 133 
22 76 1.54 2.41 0.64 63.6 0.52 0.10 0.63 167 607 774 0.33 0.10 119 
23 77 1.52 2.38 0.64 63.7 0.53 0.10 0.63 167 619 786 0.30 0.09 107 
24 78 1.50 2.35 0.64 63.7 0.53 0.11 0.63 167 632 799 0.27 0.08 95 
25 79 1.48 2.33 0.64 63.8 0.53 0.11 0.63 167 645 812 0.25 0.07 84 
26 80 1.46 2.30 0.63 63.8 0.53 0.11 0.63 167 658 825 0.22 0.06 75 
27 81 1.43 2.27 0.63 63.9 0.53 0.11 0.63 167 671 838 0.20 0.05 66 
28 82 1.41 2.24 0.63 63.9 0.53 0.12 0.63 167 685 852 0.18 0.04 58 
29 83 1.39 2.21 0.63 64.0 0.53 0.12 0.63 167 699 866 0.16 0.04 51 
30 84 1.37 2.18 0.63 64.0 0.53 0.12 0.63 167 713 880 0.14 0.03 44 
31 85 1.35 2.15 0.63 64.1 0.54 0.13 0.63 167 727 894 0.12 0.03 38 
32 86 1.33 2.12 0.62 64.1 0.54 0.13 0.63 167 742 909 0.11 0.02 33 
33 87 1.30 2.09 0.62 64.2 0.54 0.13 0.63 167 757 924 0.10 0.02 29 
34 88 1.28 2.06 0.62 64.2 0.54 0.14 0.63 167 772 939 0.09 0.02 25 
35 89 1.26 2.04 0.62 64.3 0.54 0.14 0.63 167 787 954 0.07 0.01 21 
             7.72 7710 
  
 
Table 7.16 Economic model for current treatment, men aged 55 yrs with moderate COPD 
Time Age FEV pred 
FEV1 
FEV1% 
pred 
Symp Exac 
minor 
Exac 
major 
EQ-5D 
utility 
Tmt 
cost 
Other 
cost 
Total 
cost 
S(t) S(t)* 
utility 
S(t)*total 
cost 
1 55 1.42 3.02 0.47 67.1 0.68 0.08 0.61 299 545 844 1.00 0.59 812 
2 56 1.40 2.99 0.47 67.2 0.69 0.08 0.61 299 558 857 0.98 0.56 787 
3 57 1.38 2.96 0.46 67.2 0.69 0.09 0.61 299 571 870 0.97 0.53 758 
4 58 1.36 2.93 0.46 67.3 0.69 0.09 0.61 299 584 883 0.94 0.50 726 
5 59 1.33 2.91 0.46 67.4 0.69 0.09 0.61 299 597 896 0.92 0.47 692 
6 60 1.31 2.88 0.46 67.5 0.70 0.09 0.61 299 611 910 0.89 0.44 655 
7 61 1.29 2.85 0.45 67.6 0.70 0.09 0.61 299 625 924 0.85 0.41 618 
8 62 1.27 2.82 0.45 67.6 0.70 0.10 0.61 299 639 938 0.81 0.37 580 
9 63 1.25 2.79 0.45 67.7 0.71 0.10 0.61 299 653 952 0.77 0.34 541 
10 64 1.23 2.76 0.44 67.8 0.71 0.10 0.61 299 668 967 0.73 0.31 503 
11 65 1.20 2.73 0.44 67.9 0.71 0.11 0.60 299 683 982 0.69 0.29 465 
12 66 1.18 2.70 0.44 68.0 0.72 0.11 0.60 299 698 997 0.65 0.26 428 
13 67 1.16 2.67 0.43 68.1 0.72 0.11 0.60 299 713 1012 0.61 0.23 392 
14 68 1.14 2.64 0.43 68.2 0.73 0.12 0.60 299 729 1028 0.56 0.21 358 
15 69 1.12 2.62 0.43 68.3 0.73 0.12 0.60 299 745 1044 0.52 0.19 325 
16 70 1.09 2.59 0.42 68.4 0.73 0.12 0.60 299 761 1060 0.48 0.17 294 
17 71 1.07 2.56 0.42 68.5 0.74 0.13 0.60 299 778 1077 0.44 0.15 265 
18 72 1.05 2.53 0.42 68.6 0.74 0.13 0.60 299 795 1094 0.40 0.13 238 
19 73 1.03 2.50 0.41 68.7 0.75 0.13 0.60 299 813 1112 0.37 0.11 213 
20 74 1.01 2.47 0.41 68.8 0.75 0.14 0.60 299 831 1130 0.33 0.10 189 
21 75 0.99 2.44 0.40 68.9 0.76 0.14 0.60 299 849 1148 0.30 0.09 168 
22 76 0.96 2.41 0.40 69.0 0.76 0.15 0.60 299 868 1167 0.27 0.08 148 
23 77 0.94 2.38 0.40 69.1 0.77 0.15 0.59 299 887 1186 0.24 0.07 130 
24 78 0.92 2.35 0.39 69.2 0.77 0.15 0.59 299 907 1206 0.22 0.06 114 
25 79 0.90 2.33 0.39 69.4 0.78 0.16 0.59 299 927 1226 0.19 0.05 99 
26 80 0.88 2.30 0.38 69.5 0.78 0.16 0.59 299 948 1247 0.17 0.04 86 
27 81 0.86 2.27 0.38 69.6 0.79 0.17 0.59 299 969 1268 0.15 0.03 75 
28 82 0.83 2.24 0.37 69.8 0.79 0.17 0.59 299 991 1290 0.13 0.03 65 
29 83 0.81 2.21 0.37 69.9 0.80 0.18 0.59 299 1014 1313 0.11 0.02 55 
30 84 0.79 2.18 0.36 70.0 0.81 0.19 0.59 299 1037 1336 0.10 0.02 47 
31 85 0.77 2.15 0.36 70.2 0.81 0.19 0.59 299 1060 1359 0.09 0.02 40 
32 86 0.75 2.12 0.35 70.3 0.82 0.20 0.58 299 1085 1384 0.07 0.01 34 
33 87 0.72 2.09 0.35 70.5 0.83 0.20 0.58 299 1110 1409 0.06 0.01 29 
34 88 0.70 2.06 0.34 70.7 0.83 0.21 0.58 299 1136 1435 0.06 0.01 25 
35 89 0.68 2.04 0.33 70.8 0.84 0.22 0.58 299 1162 1461 0.05 0.01 21 
             6.91 10 977 
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Costs and QALYs after costs and EQ-5D utilities have been discounted and survival 
adjusted, are shown in bold in the bottom right hand corner of table 7.15 and 7.16, and are: 
7.72 QALYs and $7710 for the mild cohort and 6.91 QALYs and $10 977 for those with 
moderate COPD at baseline.  As expected, mild disease is associated with more favourable 
health outcomes and lower cost than moderate COPD.  
7.3 Model Development: Treatment Effects 
In the previous section, a model representing the natural history of COPD was created and  
was assumed to represent the current treatment arm of the model.  In order to produce a 
comparator arm for the model, treatment effects need to be incorporated.  In this section, 
methods for building in a treatment effect are considered and an example of a treatment 
effect on lung function is applied to the model. 
7.3.1 Introduction 
Treatments have different courses of action that may impact on one or more of the 
components of COPD (lung function, exacerbations, symptoms) and potential effects of 
treatment on the components are described in this introduction.  It is important to bear in 
mind that an effect of a treatment whose mechanism of action is to treat one component 
may have spill over effects onto the other components, so that a treatment that improves, 
for example, lung function may also reduce exacerbations and/or improve symptoms as 
described earlier in figures 7.1 and 7.2.  Therefore when identifying treatment effects from 
data, it is useful to understand whether a treatment effect is independent, ie once controlling 
for all other components, a statistically significant effect on one component is seen, or 
whether it is a dependent effect.  
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Exacerbations 
In this section, ways in which a treatment effect on exacerbations can be incorporated into 
the model are considered, with reference to the published literature from RCTs.  The 
regression equations developed within section 7.2 which predict rates of mild and major 
exacerbations, given user defined patient characteristics, represent the rate of mild and 
major exacerbations over time, given current treatment.  In line with what is known about 
the natural history of the disease (Chapter 5) and as was seen within tables: 7.6, 7.15 and 
7.16, the rate of exacerbations is expected to increase over time.  As illustrated earlier in 
figures 7.1 and 7.2, treatment for COPD can affect the rate of exacerbations.  The effect of 
treatment on rate of exacerbations can take a number of forms including: 1) no effect, such 
that the rate of exacerbations is the same in the new treatment arm as in the current 
treatment arm and is represented in figure 7.10 by the navy line (with diamond markers).  
Alternatively treatment could; 2) reduce the rate of exacerbations such that the curve shifts 
downwards as illustrated by the pink line (square markers) in figure 7.10; 3) cause a change 
in the slope of the curve which represents a slowing down in the increasing rate of 
exacerbations over time as shown in the green line (triangle markers) or; 4) treatment may 
cause the rate of exacerbations to shift downwards and to change slope as represented by 
the pale blue curve (cross markers).  In order to apply treatment effects to the model, the 
starting point is to look to the exacerbation rates from RCTs in order to inform the size of 
the treatment effect. 
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Figure 7.10 Effect of treatment on exacerbations over time 
 
Table 7.17 reports on outcomes of the TORCH trial with respect to rates of exacerbations 
according to resource utilisation by treatment group.  The placebo group were found to 
have a higher rate of unscheduled health care contacts than the other groups, particularly 
the combination therapy and rates for Accident and Emergency visits were almost double 
that of the combination therapy group (143 per 1000 person year vs 72 per 1000).   
In a 2003 paper, describing outcomes of a RCT, Calverley et al reported that when treated 
with placebo, the mean rate of total exacerbations (minor plus major) per patient year was 
1.30 compared to a rate of 0.97 for the treatment group who were prescribed the 
combination therapy of salmeterol and fluticasone.(50)   
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Table 7.17 Rates of healthcare contacts within the TORCH trial.  
 Placebo 
(N=1524) 
SAL 50 
(N=1521) 
FP 500 
(N=1534) 
SFC 50/500 
(N=1533) 
Unscheduled Healthcare 
contacts, n(%) 
949 (62%) 918 (60%) 937 (61%) 896 (58%) 
Rate/1000 years of exposure     
ER/A & E Visits 143 75 81 72 
Out-patient clinic visits 245 196 197 209 
GW admissions 200 172 195 180 
ICU admissions 18 15 16 17 
GW and/or ICU admissions 208 179 201 187 
GP office/practice visits 593 450 603 426 
ER = Emergency Room A & E = Accident and Emergency ICU = Intensive Care Unit GP = General Practitioner GW= General Ward 
Table adapted from the TORCH study report.(244) 
 
In a more recent paper (2009) Calverley et al describe exacerbation event rates within two 
one year clinical trials (M2-124 and M2-125) which compare roflumilast to placebo.  Mean 
(95% CI) severe exacerbation rates in M2-124 were 0.11 (0.07-0.15) per patient year for 
treatment compared to 0.12 (0.09-0.16) for placebo.  For the M2-125 trial these rates were 
0.14 (0.10-0.20) and 0.18 (0.13-0.25) respectively.  Moderate exacerbation rates per patient 
year were: 0.94 (0.83-1.06) and 1.11 (1.00-1.25) in the M2-124 trial and 1.04 (0.92-1.18) 
and 1.27 (1.13-1.42) in the M2-125 trial.(245)    
To incorporate treatment effects on exacerbations, the relative difference in the rates 
between the treated population and a relevant comparator within the trial could be 
determined and then this effect applied onto exacerbations in the new treatment arm of the 
model.   
Treatment effects may cause a permanent change (improvement) to the curve, which 
continues over time, or over time treatment effects may diminish such that the trajectory 
attenuates to the baseline curve, or even to a different trajectory.  Scenario analysis could 
be conducted in order to test various possibilities for the effect of treatment over time on 
exacerbation rate, and should be informed by observed effects from studies.  Scenario 
analysis can be used to examine the impact of different durations of effect on the cost 
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effectiveness statistic, for example by limiting the effect of treatment to the duration of the 
trial, such as one year. 
Symptoms 
Some treatments for COPD work explicitly on alleviating symptoms, for example LABAs 
relax the bronchial passageways and through this action, breathing becomes easier for the 
patient.  As seen in tables 7.15 and 7.16, over time symptoms scores gradually worsen as 
the disease progresses (symptoms scores get closer to 100).  In much the same way as has 
been described in figure 7.10, treatment for symptoms can have a number of effects: 1) 
there may be no effect on symptoms such that the symptoms scores remain unchanged 
between the current treatment population and the new treatment arm (as in the blue line in 
figure 7.10).  Alternatively, 2) an immediate and constant improvement in symptoms 
following treatment could occur, which would be modelled by a downward shift in the 
curve for symptoms over time (such as is illustrated by the pink line), 3) the change in 
symptoms score over time such that the rate at which symptoms worsen slows down, as 
shown by the green line in figure 7.10, or 2) and 3) could both occur such that symptoms 
immediately improve and continue to improve over time relative to the non treated arm 
(pale blue line).  Over time, the treatment curve may attenuate to the baseline curve for 
symptoms if the effectiveness of treatment is assumed to diminish with continued exposure.  
Or, the shifted curve could remain over time.  Scenario analysis could be employed in order 
to investigate the impact of treatment duration on the outcomes of the model.  SGRQ total 
score rather than SGRQ symptoms scores are generally reported in the clinical trial reports, 
as such these data are not as readily available as data on exacerbations and on lung 
function.   
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Mortality Risk 
Little information is available on the effect of COPD treatment on mortality and it is an 
area of contention.  The TORCH trial reported on mortality and found that the absolute risk 
reduction for death in the combination therapy group compared to the placebo group was 
2.6% (12.6% vs 15.2%).  The corresponding HR for all-cause mortality for the combination 
product compared to placebo (HR=1) was 0.825 (95% CI 0.681-1.002) and was fractionally 
non-significant.  The corresponding reduction in the risk of mortality between the two 
treatments was found to be 17.5%.  Secondary analysis using Cox proportional-hazards 
gave a significant HR of  0.811 (95% CI 0.670-0.982).(49)   
Because of this uncertainty, treatments directly affecting survival per se are not 
incorporated into this model, nonetheless it would be relatively simple to incorporate a 
direct survival effect by applying a HR to the survival curve of the current treatment arm to 
elicit the survival curve for the new treatment arm, if this were of interest.  The way this 
model is set up, an impact on survival could be experienced indirectly as a result of 
improved lung function, by multiplying the treatment adjusted FEV1 % predicted, observed 
within the first year, with the coefficient on FEV1 % predicted from the survival equation.  
Lung Function  
This section considers how treatment may affect lung function and how this could be 
incorporated into the model.  
Effects of treatment on FEV1 include: 1) no effect on FEV1.  As seen earlier in figures 7.1 
and 7.2, different COPD treatments have different paths of effect and treatment may affect 
rate of exacerbations, symptoms or mortality rather than lung function, or could be 
ineffective in the patient.  If there is no effect on FEV1, then FEV1 would necessarily be the 
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same in the treated group as in no treatment/current treatment arm of the model and is 
illustrated by the navy curve in figure 7.11.  Alternatively, treatment could: 2) cause an 
outward shift in the curve of FEV1, for example, to the pink line as shown in figure 7.11. 
which shows that whilst FEV1 declines at the same rate regardless of treatment, the 
treatment group has a comparatively higher FEV1, 3) the rate of change in FEV1 could be 
altered by treatment, illustrated by the green line in figure 7.11 so that FEV1 declines at a 
slower rate than the non-treatment group or; 4) a shift in the curve could occur changing the 
rate of FEV1 decline as seen in the light blue curve. 
 
Figure 7.11 Effect of treatment on FEV1 rate of decline  
 
Some treatments for COPD have been shown to affect the decline in lung function.(246)  In 
two recently reported roflumilast clinical trials (M2-127 and M2-128) the primary endpoint 
was change in prebronchodilator FEV1.  Study M2-127 found that combining salmeterol 
with roflumilast improved mean FEV1 (SE) by 39 (9) ml compared to salmeterol with 
placebo in which FEV1 worsened by 10 (9) ml.  Study M2-128 examined the combination 
of tiotropium with roflumilast and reported a 65 (12) ml improvement in lung function 
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compared to the tiotropium plus placebo arm where lung function dropped by 16 (12) ml 
over the 24 weeks of the trial.(247)  In terms of the effect of treatment on lung function, the 
trials showed that following treatment, lung function increased, such that a shift in the 
curve for FEV1 was seen, peaking at around 12 weeks before a decline, with a similar rate 
of decline in the treatment in the placebo group.  A similar trajectory is captured by the 
pink line in figure 7.11.  Calverley et al reported similar shifts in the FEV curve as a result 
of treatment, including a 10% increase in pre-bronchodilator FEV1 (150ml) over a one 
year trial,(248) and Celli et al reported on an outward shift in FEV1 within the TORCH 
study following treatment.(246)  Therefore a curve for FEV1 which shifts outwards 
following treatment, as illustrated by the pink curve in figure 7.11 appears to represent the 
mechanics of the situation well and is applied to the model within this section. 
Duration of effect is an important consideration as this affects the duration for which the 
curves would be separated.  An analysis of the TORCH dataset has shown that treatment 
effects occur as shown by the pink line in figure 7.11, for the duration of the three year 
trial.(246)  As to date, TORCH is the longest trial within COPD, the duration of treatment 
effect beyond three years is unknown.  A conservative analysis of the economic model 
would use the same duration of effect as observed within the RCT, after which time a 
return to the curve for the baseline FEV1 may be modelled.  Another scenario would be to 
keep the shift constant as long as treatment is continued.  Scenario analysis can be used to 
investigate the implications on CE of different durations of effect.   
If treatment improves FEV1, a HRQoL gain and a reduction in costs would be expected. 
Mean QALYs are higher for people with larger lung functions (as defined by disease 
severity, see Chapter 6) and as the disease progression slows compared to the current 
treatment arm, exacerbation rates (and associated costs of hospitalisation) and symptoms 
should reduce.  
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7.3.2 Methods 
The ‘new treatment’ arm of the model was developed based on the current treatment arm as 
described previously and is demonstrated applied to the same cohort: men aged 55 years 
with mild and moderate (NICE diagnosed) COPD at baseline.  There are two differences 
between the ‘new treatment’ and the current treatment arms, the first is the incorporation of 
a treatment effect on lung function using the new treatment and the second is different 
treatment costs are applied to the different arms.  
In order to assess the impact of an improvement in lung function on the cost effectiveness 
estimate, a one off increase in lung function of 150ml (as found by Calverley et al, see 
previous section) was incorporated into the ‘new treatment’ arm of the model as a dummy 
variable into the equation for FEV1.  This improvement was assumed to be sustained for the 
duration of the model or as long as treatment was continued.   
With reference to section 7.2.6,  in order to use a relevant value for new treatment costs, the 
treatment pathway as described in table 2.5 and treatment costs as estimated in table 2.6 
(Chapter 2) were used to derive costs for a person with mild and moderate COPD after the 
‘new’ COPD therapies entered the market (Seretide, Spiriva and Symbicort).  Following 
the introduction of the ‘new’ therapies, it is anticipated that tiotropium has largely replaced 
the use of ipratropium, so that a person with mild COPD, is likely to be prescribed 
salbutamol plus tiotropium at a yearly cost of £493 ($808) and treatment for moderate 
COPD would be likely to include salbutamol, tiotropium and Seretide at an annual cost of 
£1240 ($2032).  These treatment costs were used in the ‘new treatment’ arm of the model.  
Cost effectiveness statistics (ICERs) were calculated for the cohort containing men aged 55 
years with mild COPD, and men with moderate COPD at baseline by taking the difference 
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between costs and QALYs in the current treatment arm as calculated in section 7.2 and 
those in the ‘new treatment’ arm.  
Analyses were conducted around the user defined characteristics of: age, sex, symptoms 
and treatment duration, keeping all else the same and for each, ICERs were calculated.  In 
further detail: age entering the model was changed from 55 years to 65 years; the effect of 
no respiratory symptoms at baseline, as opposed to presence of respiratory symptoms was 
assessed by changing the user defined input on symptoms from one to zero; the effect of 
changing the patient population to women instead of men was assessed and accordingly 
height was changed from 175 cm to 162 cm to reflect the difference in mean height 
between men and women; and the impact of a three year treatment duration was looked at 
by incorporating the treatment dummy variable for the first three years and then taking it 
out, different treatment costs were also assumed to occur for the first three years only, after 
which time they became the same as in the current treatment arm.     
Results 
A snap shot of the economic model representing the new treatment for 55 year old men 
with mild and moderate NICE diagnosed COPD is presented in tables 7.18 and 7.19 and 
combines all the individual regression equations developed in section 7.2 plus a treatment 
effect on lung function, to predict costs and effect, which are weighted by survival and are 
discounted.   
The costs and QALYs over the modelled lifetime for the new treatment are shown in the 
bottom right hand corner of tables 7.18 and 7.19 and are £10 233 ($15 164) and 7.94 for the 
cohort with mild COPD at baseline, and £20 667 ($30 617) and 7.10 for those starting with 
moderate COPD.  This compares to the cost and QALYs from current treatment, which 
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were £5204 ($7709) and 7.77 for mild disease and 7408 ($10 975) and 6.91 for moderate 
disease, as shown in tables 7.15 and 7.16. 
Therefore, a new treatment which improves and sustains lung function by 150ml compared 
to current treatment leads to improved HRQoL in that more QALYs are gained compared 
to current treatment, but at higher cost.  Corresponding ICERs are £22 888 ($34 300) per 
QALY in the mild group and £63 396 ($95 004) per QALY in the moderate group, 
compared to current treatment.  Based on these ICERs, it is likely that the treatment would 
be accepted for use in the UK NHS for the management of mild (NICE diagnosed) COPD 
but not for the management of moderate COPD. 
  
 
Table 7.18 Economic model for new treatment, men aged 55 yrs with mild COPD 
Time Age FEV pred 
FEV1 
FEV1% 
pred 
Symp Exac 
minor 
Exac 
major 
EQ-5D 
utility 
Tmt 
cost 
Other 
cost 
Total 
cost 
S(t) S(t)* 
utility 
S(t)*total 
cost 
1 55 2.15 3.02 0.71 61.8 0.47 0.06 0.65 808 341 1149 1.00 0.62 1106 
2 56 2.13 2.99 0.71 61.8 0.47 0.06 0.65 808 350 1158 0.99 0.60 1066 
3 57 2.11 2.96 0.71 61.8 0.47 0.06 0.65 808 359 1167 0.97 0.57 1023 
4 58 2.08 2.93 0.71 61.9 0.47 0.06 0.65 808 368 1176 0.95 0.54 977 
5 59 2.06 2.91 0.71 61.9 0.47 0.06 0.65 808 377 1185 0.93 0.51 929 
6 60 2.04 2.88 0.71 61.9 0.47 0.06 0.65 808 386 1194 0.91 0.48 880 
7 61 2.02 2.85 0.71 61.9 0.47 0.06 0.65 808 395 1203 0.88 0.45 829 
8 62 2.00 2.82 0.71 61.9 0.47 0.07 0.65 808 405 1213 0.85 0.41 779 
9 63 1.98 2.79 0.71 62.0 0.47 0.07 0.65 808 414 1222 0.81 0.38 728 
10 64 1.95 2.76 0.71 62.0 0.47 0.07 0.65 808 424 1232 0.78 0.36 679 
11 65 1.93 2.73 0.71 62.0 0.47 0.07 0.65 808 434 1242 0.74 0.33 630 
12 66 1.91 2.70 0.71 62.0 0.47 0.07 0.65 808 444 1252 0.70 0.30 582 
13 67 1.89 2.67 0.71 62.0 0.47 0.07 0.65 808 454 1262 0.67 0.27 537 
14 68 1.87 2.64 0.71 62.1 0.47 0.08 0.65 808 464 1272 0.63 0.25 493 
15 69 1.85 2.62 0.71 62.1 0.47 0.08 0.64 808 474 1282 0.59 0.23 451 
16 70 1.82 2.59 0.71 62.1 0.47 0.08 0.64 808 484 1292 0.55 0.20 411 
17 71 1.80 2.56 0.70 62.1 0.47 0.08 0.64 808 495 1303 0.51 0.18 373 
18 72 1.78 2.53 0.70 62.1 0.48 0.08 0.64 808 505 1313 0.48 0.17 338 
19 73 1.76 2.50 0.70 62.2 0.48 0.09 0.64 808 516 1324 0.44 0.15 305 
20 74 1.74 2.47 0.70 62.2 0.48 0.09 0.64 808 527 1335 0.41 0.13 274 
21 75 1.71 2.44 0.70 62.2 0.48 0.09 0.64 808 538 1346 0.38 0.12 245 
22 76 1.69 2.41 0.70 62.2 0.48 0.09 0.64 808 549 1357 0.34 0.10 219 
23 77 1.67 2.38 0.70 62.3 0.48 0.09 0.64 808 560 1368 0.31 0.09 195 
24 78 1.65 2.35 0.70 62.3 0.48 0.10 0.64 808 572 1380 0.29 0.08 173 
25 79 1.63 2.33 0.70 62.3 0.48 0.10 0.64 808 583 1391 0.26 0.07 153 
26 80 1.61 2.30 0.70 62.3 0.48 0.10 0.64 808 595 1403 0.24 0.06 135 
27 81 1.58 2.27 0.70 62.4 0.48 0.10 0.64 808 607 1415 0.21 0.05 119 
28 82 1.56 2.24 0.70 62.4 0.48 0.11 0.64 808 619 1427 0.19 0.05 104 
29 83 1.54 2.21 0.70 62.4 0.48 0.11 0.64 808 631 1439 0.17 0.04 91 
30 84 1.52 2.18 0.70 62.5 0.48 0.11 0.64 808 644 1452 0.15 0.03 79 
31 85 1.50 2.15 0.70 62.5 0.48 0.11 0.64 808 656 1464 0.14 0.03 69 
32 86 1.48 2.12 0.70 62.5 0.48 0.12 0.64 808 669 1477 0.12 0.03 59 
33 87 1.45 2.09 0.69 62.6 0.48 0.12 0.64 808 682 1490 0.11 0.02 51 
34 88 1.43 2.06 0.69 62.6 0.48 0.12 0.64 808 695 1503 0.09 0.02 44 
35 89 1.41 2.04 0.69 62.6 0.48 0.13 0.64 808 708 1516 0.08 0.02 38 
             7.94 15 162 
  
 
Table 7.19 Economic model for new treatment, men aged 55 yrs with moderate COPD 
Time Age FEV pred 
FEV1 
FEV1% 
pred 
Symp Exac 
minor 
Exac 
major 
EQ-5D 
utility 
Tmt 
cost 
Other 
cost 
Total 
cost 
S(t) S(t)* 
utility 
S(t)*total 
cost 
1 55 1.57 3.02 0.52 66.0 0.63 0.07 0.62 2032 499 2531 1.00 0.59 2435 
2 56 1.55 2.99 0.52 66.1 0.63 0.08 0.62 2032 511 2543 0.98 0.57 2337 
3 57 1.53 2.96 0.52 66.1 0.64 0.08 0.62 2032 523 2555 0.97 0.54 2230 
4 58 1.51 2.93 0.51 66.2 0.64 0.08 0.62 2032 535 2567 0.95 0.51 2116 
5 59 1.48 2.91 0.51 66.3 0.64 0.08 0.62 2032 547 2579 0.92 0.48 1997 
6 60 1.46 2.88 0.51 66.3 0.64 0.09 0.62 2032 560 2592 0.89 0.45 1876 
7 61 1.44 2.85 0.51 66.4 0.65 0.09 0.62 2032 572 2604 0.86 0.41 1753 
8 62 1.42 2.82 0.50 66.5 0.65 0.09 0.61 2032 585 2617 0.82 0.38 1631 
9 63 1.40 2.79 0.50 66.5 0.65 0.09 0.61 2032 598 2630 0.78 0.35 1511 
10 64 1.38 2.76 0.50 66.6 0.65 0.10 0.61 2032 612 2644 0.74 0.32 1393 
11 65 1.35 2.73 0.50 66.7 0.66 0.10 0.61 2032 625 2657 0.70 0.29 1278 
12 66 1.33 2.70 0.49 66.7 0.66 0.10 0.61 2032 639 2671 0.66 0.27 1168 
13 67 1.31 2.67 0.49 66.8 0.66 0.10 0.61 2032 653 2685 0.62 0.24 1063 
14 68 1.29 2.64 0.49 66.9 0.67 0.11 0.61 2032 668 2700 0.58 0.22 963 
15 69 1.27 2.62 0.48 67.0 0.67 0.11 0.61 2032 682 2714 0.54 0.20 869 
16 70 1.24 2.59 0.48 67.1 0.67 0.11 0.61 2032 697 2729 0.50 0.17 781 
17 71 1.22 2.56 0.48 67.1 0.67 0.12 0.61 2032 713 2745 0.46 0.16 699 
18 72 1.20 2.53 0.48 67.2 0.68 0.12 0.61 2032 728 2760 0.42 0.14 623 
19 73 1.18 2.50 0.47 67.3 0.68 0.12 0.61 2032 744 2776 0.38 0.12 553 
20 74 1.16 2.47 0.47 67.4 0.68 0.13 0.61 2032 760 2792 0.35 0.11 489 
21 75 1.14 2.44 0.47 67.5 0.69 0.13 0.61 2032 777 2809 0.32 0.09 431 
22 76 1.11 2.41 0.46 67.6 0.69 0.13 0.61 2032 793 2825 0.29 0.08 378 
23 77 1.09 2.38 0.46 67.7 0.70 0.14 0.60 2032 811 2843 0.26 0.07 331 
24 78 1.07 2.35 0.45 67.8 0.70 0.14 0.60 2032 828 2860 0.23 0.06 288 
25 79 1.05 2.33 0.45 67.9 0.70 0.14 0.60 2032 846 2878 0.21 0.05 250 
26 80 1.03 2.30 0.45 68.0 0.71 0.15 0.60 2032 865 2897 0.18 0.04 216 
27 81 1.01 2.27 0.44 68.1 0.71 0.15 0.60 2032 883 2915 0.16 0.04 186 
28 82 0.98 2.24 0.44 68.2 0.72 0.16 0.60 2032 903 2935 0.14 0.03 160 
29 83 0.96 2.21 0.44 68.3 0.72 0.16 0.60 2032 923 2955 0.13 0.03 136 
30 84 0.94 2.18 0.43 68.5 0.73 0.17 0.60 2032 943 2975 0.11 0.02 116 
31 85 0.92 2.15 0.43 68.6 0.73 0.17 0.60 2032 964 2996 0.10 0.02 99 
32 86 0.90 2.12 0.42 68.7 0.74 0.18 0.60 2032 985 3017 0.08 0.02 83 
33 87 0.87 2.09 0.42 68.8 0.74 0.18 0.60 2032 1007 3039 0.07 0.01 70 
34 88 0.85 2.06 0.41 69.0 0.75 0.19 0.59 2032 1029 3061 0.06 0.01 59 
35 89 0.83 2.04 0.41 69.1 0.75 0.19 0.59 2032 1053 3085 0.05 0.01 49 
             7.12 30 618 
 283 
 
Although the improvement was applied purely to FEV1, knock on effects are seen to the 
majority of the components within the model, reflecting the interdependence between lung 
function, symptoms, exacerbations and mortality, and how these impact on costs and 
QALYs as previously described in section 7.1.  Comparing the mild COPD cohort 
receiving the new treatment (table 7.18) to those receiving current treatment (table 7.15), at 
89 years of age, symptoms scores are more favourable (62.6 instead of 64.3), there are 
fewer minor and fewer major exacerbations (0.48 minor exacerbations and 0.13 major 
exacerbations as opposed to 0.54 minor exacerbations and 0.14 major exacerbations), EQ-
5D utility is marginally higher (0.65 compared to 0.64) and other costs are lower (£478 
($708) instead of £531 ($787)), but treatment costs are higher (£545 ($808) rather than 
£113 ($167)).  There is a slight survival advantage in the new treatment arm at age 89 years 
(0.08 instead of 0.07).  Similar improvements in symptoms, exacerbations rates, QALYs 
and other costs are seen in the modelled moderate COPD cohort receiving new treatment, 
in comparing table 7.16 to table 7.19, but there was no difference seen in survival between 
the groups.  
Table 7.20 Results from analyses on heterogeneity, mild and moderate COPD 
Costs and QALYs represent average costs over the model timeframe 
   Current treatment New treatment 
  ICER $ (£) Cost ($) QALYs Cost ($) QALYs 
Mild Base case 34 300 (22 888) 7710 7.72 15 162 7.94 
 Aged 65 yrs  27 529 (18 371) 6334 5.61 11 784 5.81 
 Women 24 429 (16 302) 9180 8.04 17 214 8.37 
 No symptoms 34 125 (22 773) 6305 10.10 15 575 10.34 
 Tx for 3yrs 13 268 (8854) 7710 7.72 9506 7.86 
Moderate Base case 95 004 (63 396) 10 977 6.91 30 618 7.12 
 Aged 65 yrs  77 786 (51 909) 8756 4.89 22 829 5.07 
 Women 68 377 (45 630) 14 466 6.81 35 736 7.12 
 No symptoms 92 820 (61 943) 9404 9.18 31 194 9.42 
 Tx for 3 yrs 37 384 (24 948) 10 977 6.91 15 820  7.04 
 
Analyses were conducted around the user defined patient characteristics analysis for 
treatment on lung function.  As seen from table 7.20, there were considerable differences in 
the cost effectiveness of the same treatment, dependent on user defined patient 
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characteristics.  In general, the use of this treatment on a moderate COPD cohort is less 
likely to be cost effective than in a mild COPD cohort, with the ICERs for the mild cohort 
in the range of £9000 to £23 000 per QALY and those for the moderate population between 
£25 000 and £63 000 per QALY.  The analyses on women with mild COPD gave lower 
ICERs than for men, with an ICER of £16 302 compared to £22 888 for the mild COPD 
cohort and £45 630 compared to £63 396 for the moderate COPD group.  Using a cohort 
with no reported respiratory symptoms at baseline slightly reduced the ICERs compared to 
the base case in both the mild and the moderate cohort.  Restricting treatment duration to 
three years reduced the ICER per QALY by more than half, from £22 888 to £8854 in the 
mild group and from £63 396 to £24 948 in the moderate group.  
7.4 Discussion 
In this chapter an economic model for COPD was developed, based around the key 
components of COPD that were identified within the thesis.  The focus of the chapter was 
the conceptualisation of an economic model for COPD, which was successfully 
accomplished.  From that, a working model developed and operationalised, which works 
and predicts sensible results.   
This model is unique within COPD and breaks the mould for modelling the disease as 
Markov models are usually employed as opposed to regression based models.  It has a 
number of advantages over earlier models, including: the incorporation of patient level 
heterogeneity; it can be used to assess a wide range of treatments; the explicit inclusion of 
symptoms into the model; and allowing for interdependence.  These advantages are 
described in detail below. 
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A variety of people with COPD can be modelled with the model developed in this chapter, 
including those with: mild, moderate and severe disease; presence/absence of respiratory 
symptoms; and different smoking histories at baseline.  A range of different ages can be 
modelled and men and women enter the model separately.  Therefore the uncertainty 
pertaining to patient level heterogeneity is minimised.  Because of this flexibility the 
resulting model can assist with the identification of subgroups in which a product is cost 
effective.   
The model can be used to assess the cost effectiveness of different types of treatments, 
which is important because as was seen in Chapter 4, if different treatments can be assessed 
on the same platform then decisions around cost effectiveness can be standardised.   
An important advantage of this model over other models for COPD is that this is the first to 
include a specific component for symptoms.  Symptoms have a major impact on HRQoL 
for people with COPD and many treatments for COPD have mechanisms of action that 
work specifically on alleviating respiratory symptoms.  Thus it is important to incorporate 
symptoms explicitly into the model.   
The model developed in this chapter allows interdependence to exist between the different 
components of COPD and is novel in modelling COPD.  Lung function, symptoms, 
exacerbations, survival, costs and utility are all intertwined so that a treatment which 
specifically works on one component, can have a knock on effect on the other components 
and this interdependence was clearly demonstrated in the final section of this chapter where 
treatment effects were incorporated into the model.    
The country variable for UK was highly significant for both major and minor 
exacerbations.  This is more likely to be explained by a higher propensity to hospitalise in 
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the UK and/or to seek treatment/support for the exacerbation, than the absolute risk of 
experiencing an exacerbation being higher in the UK than in other countries.   
This type of model is demanding in terms of the need for good quality real data on which to 
derive the regression equations.  The availability of the TORCH and the MIDSPAN 
datasets was of huge importance in enabling this type of model to be pursued and to be 
developed.  The MIDSPAN observational study and the TORCH RCT are complementary 
types of dataset each with their own strengths and limitations.  The benefit of using both 
types to develop the model is that where one dataset may not provide the information 
required, such as on long term survival, the other does, so that the resulting model is built 
on reliable data and is well supported.  Because of this, the use of observational data 
together with RCT data can enhance the external validity of the cost effectiveness 
study.(162)  For model building, the combined usage of such datasets is the gold standard 
for developing economic models. 
The regression models within this chapter are developed using data from each of the 
treatment groups within the TORCH trial, not just the placebo group.  This means that data 
from the treatment group (those randomised to Seretide) in TORCH were included to 
develop equations for the current treatment arm.  Whilst it may be argued that only patients 
receiving the placebo should form the current treatment arm, this goes against the 
recommendation that it is current treatment that forms the comparator.  It is argued here 
that whilst at the present time, Seretide may be one of the newest products on the market, it 
is anticipated that newer products, particularly triple combination therapies, will soon 
supersede this.  In which case, benefits of new treatment will need to be compared to 
products currently on the market, which this model represents.   
The Renfrew/Paisley (MIDSPAN) dataset, which recruited study participants between 1972 
and 1976, was used for developing the equations on lung function and on survival.  The use 
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of longitudinal data is important for accurately predicting long-term survival but by the 
very nature of the data, it will always be ‘out of date’.  Nonetheless, because no treatments 
for COPD have shown a clear survival benefit, it is likely that the equations presented here 
represent the natural history of COPD, even within the current treatment arm of the model.  
The component regression equations would benefit from further research into model fit and 
validation; using methods similar to those demonstrated in Chapter 6, in order to ascertain 
whether the regression equations represent the natural history of the disease well.  For 
example, the 20ml annual decline in FEV1 that was predicted by the regression equation on 
lung function was consistent with some studies on lung function decline, however other 
studies have reported larger declines in lung function of around 50ml per year, as such it 
may be beneficial to conduct further research on the FEV1 equation.  One avenue for 
further research is around the type of dataset used.  It might be that the use of cross-
sectional data to predict longitudinal change in FEV1 has underestimated the decline.  One 
possible explanation is that because the population in MIDSPAN are those who survived 
long enough to participate in the study, a selection bias exists as those who died prior to the 
survey are likely to be in worse health with poorer lung function.  As described in Chapter 
5, there are a number of longitudinal datasets that exist such as the GPRD QRESEARCH, 
LINK and Mediplus databases.  These datasets could be used to derive an equation for 
FEV1, though they also have limitations.  For example, because they only contain data 
taken in GP surgeries, the resulting equations are unlikely to be generalisable to a wider 
COPD population.    
Fine-tuning the equations is relatively straightforward to execute and was not pursued 
further in this chapter due to both time constraints and the fact that such methods were 
previously described and applied within Chapter 6.  Potential study around each equation 
may include, but is not limited to: the use of fractional polynomials to identify any power 
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terms, the use of interaction terms to identify any relationships between the explanatory 
variables, the incorporation of treatment effects, the selection of best fitting explanatory 
variables and thorough testing of relationships between the components.  Extensions to the 
survival model may include producing separate models by baseline disease severity and 
exploring the exponential model as an alternative to the Weibull model.  Currently, because 
of the inconsistencies in predicting FEV1 for men with severe COPD, as identified in the 
section on lung function in this chapter, and on survival, caution should be taken if the 
model is to be used to assess the cost effectiveness of treatment in people with severe 
(NICE diagnosed) COPD.  Further work in the severe group would be of benefit.  
This chapter focused on one kind of uncertainty; patient level heterogeneity, but as 
described in Chapter 3 there are others, including parameter uncertainty and structural 
uncertainty.  It would be interesting to compare the outcomes of this modelling approach 
with that of another approach, such as a Markov model, so that the costs and outcomes 
could be compared between different methods.  This would give some indication as to the 
degree that structural uncertainty has on the cost effectiveness estimate.  Each of the 
coefficients in each of the equations within the model has a standard error attached to it.  
Fitting distributions to these coefficients and re-running the model whilst sampling from 
within those distributions in a probabilistic sensitivity analysis would address parameter 
uncertainty (maintaining the covariance structure between coefficients in the regression 
equations may be achieved using the Cholesky decomposition).  Net benefit statistics can 
easily be calculated from the model by taking the value of the threshold, for example £20 
000 and multiplying it by the change in QALYs, then subtracting the difference in costs 
between the current and new treatment arms of the model.  A treatment is considered cost 
effective if the net benefit statistic is greater than zero.   
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This model was designed for the economic evaluation of different treatments for supporting 
reimbursement decisions to the UK NHS.  However, there are a number of applications of 
this model in addition to establishing the cost effectiveness of treatment.  One possible use 
of the model is in the ‘early modelling’ arena.  At the early stages of a products life, there is 
uncertainty about the products efficacy and whether that product is worth the initial 
investment to try and take it to launch.  Because of the flexibility to incorporate measurable 
outcomes within this model, such as absolute reduction in FEV1 (something that could be 
predicted at the early stages of a products life), the cost effectiveness of such an 
improvement could be assessed.  Taking it one step further, the model could be used to 
estimate a UK price for the treatment in order to bring it in under the UK threshold.  
Another possible use of this model would be for public health decisions relating to the 
COPD population, such as how much of an investment should be given over to smoking 
cessation programme, where one arm would consider current smokers and the treated arm 
would contain ex-smokers.  Different smoking cessation costs could then be assessed to 
determine how much investment would bring the intervention under and over the UK 
threshold for cost effectiveness.  These different uses of the model are all of interest and 
could be taken further in future research.  
7.5 Conclusion 
Within this chapter, data from an observational study and a RCT were used in a 
complementary manner in order that equations predicting lung function, exacerbations, 
symptoms, cost, EQ-5D utility and survival could be obtained.  The resulting equations 
were combined so that an economic model representing the natural history of COPD under 
current treatment was built.  A hypothetical treatment effect was combined into a second 
arm of the economic model to give a new treatment comparator arm.  Costs and effects of 
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current treatment were compared to those from the new treatment to obtain cost 
effectiveness statistics. 
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Chapter 8. Discussion 
The broad aim of this thesis on ‘Health Economic aspects in the management of COPD’ 
was to combine information on the natural history of the disease with health economics in 
order to inform an economic model.  The resulting model is a generic model that has the 
potential to facilitate better decision making, as different COPD therapies can be appraised 
on the same platform.  The methods and principles used are generalisable to modelling 
other disease areas. 
This thesis has shown that when observational and RCT datasets are used in partnership, 
the result is a unique and powerful body of evidence that can be and was successfully 
explored in order to develop a different kind of economic model than has previously been 
presented.  The novelty has come through the harmonious use of two large and powerful 
data sets, TORCH and MIDSPAN.  In Chapter 5, using the Renfrew/Paisley (MIDSPAN) 
study, the natural history of COPD was studied, including: an assessment of risk factors for 
mortality, the investigation of different diagnostic criteria for COPD, how disease severity 
affects hospitalisation rates and the rate and causes of mortality for people with COPD.  
Within Chapter 6, patient level data on EQ-5D utility from TORCH were used and 
particular attention was paid to predicting utility and the calculation of QALYs from the 
utility data.  All of this information was brought together in order to inform the 
conceptualisation of a model for COPD and the data were used to develop a series of 
regression equations that when combined, formed a model representing the natural history 
of COPD as seen within Chapter 7. 
A second aim of the thesis was to improve upon existing models for COPD.  In this way, 
published models were reviewed and critiqued and within Chapter 4, desirable 
characteristics of cost effectiveness studies were identified, namely: the use of economic 
modelling, the need for a model to extend to a lifetime timeframe, the role of the 
comparator to be current practice rather than placebo, the importance of the QALY as the 
HRQoL outcome measure and the incorporation of capturing uncertainty.  All these aspects 
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were used in order to guide the conceptualisation of a new economic model for COPD, as 
lessons learned, to avoid the same limitations being repeated in the new model. 
This body of research is unique in a number of ways, which are described below:  
The review of the published economic evaluations for COPD in Chapter 4, which 
highlights the weaknesses of current studies and suggesting ways in which a new model 
could improve upon existing ones has not previously been seen before. 
The update of the Hole et al paper at the beginning of Chapter 5, not only replicated and 
validated existing analyses, but presented new results on the relationship between COPD 
and lung function.  Analyses were conducted using both the traditional time along the x 
axis of the survival curve and, age on the x axis and found that the two ways of analysing 
survival data give similar results but that for presenting the data, age along the x axis is 
perhaps more useful for representing longitudinal observational data.   
No other research is known of that compares the use of the NICE diagnostic criteria 
compared to the GOLD diagnostic criteria in order to identify people with COPD as was 
carried out in Chapter 5.  This was made possible because of the relevance of the questions 
asked at the start of the Renfrew/Paisley (MIDSPAN) study and the lengthy follow-up of 
mortality. 
The mapping algorithm developed in Chapter 6 goes beyond the scope of previous mapping 
equations which often start and stop with the use of OLS to develop the mapping equation.  
The use of the GLM and the two part models to develop the equation is a new idea in the 
area of mapping equations.  The resulting model has been shown to predict well, in 
comparison to other mapping equations for COPD and this has been recognised in a study 
within the updated full NICE guidelines for COPD (anticipated publication date is June  
2010),(249) which employs the algorithm developed in Chapter 6 in order to predict EQ-
5D utility.  Validation of the resulting mapping equation using QALYs in four different 
treatment groups has not been done before.   
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Within COPD and as far as is known, within health economics, the economic model that 
was developed is unique.  Other models have used regression analyses to inform parts of 
their model and the Briggs et al model,(153) used a regression based model to do a within 
trial analysis on costs and effects.  None have used regression models to predict values for 
each component of the disease and then combine these values into equations for cost and 
effect.  The development of a baseline cohort representing current treatment, is rather 
different than a group taking a placebo treatment, or a specified comparator.   
Access to such data is a privilege and by no means a right.  The PhD Industrial 
Collaborative studentship that funded this research gave an advantageous position from 
which to access data held by both the pharmaceutical industry and by academia, the likes of 
which may be difficult in other situations.  From the pharmaceutical perspective, clinical 
trials are expensive and potential income from successful drugs, very lucrative.  As such, 
pharmaceutical companies must be very careful with their data.  Observational studies such 
as the MIDSPAN dataset, developed within a university setting are incredibly valuable 
from a research perspective and it is essential that the integrity of the data is maintained.  In 
both cases it is important that results are consistent with previous outcomes of the studies 
and that they are analysed and reported on with sensitivity and that the data are kept safe.  
Because of these issues, model building of this nature in which both types of data are 
employed, is perhaps best placed to occur within an academic setting. 
This work confirms and/ or challenges the research previously been seen in that: 
The methodologies used within some of the existing economic models for COPD were 
challenged in terms of the rationale for not including a death state within the model, the 
chosen timeframe being less than lifetime, no consideration given to uncertainty and the 
choice of outcomes, with support given to the use of the QALY as the appropriate measure 
for use in COPD.  
The analyses replicating and building on the Hole et al study in Chapter 5 confirmed the 
earlier published results, including the reference equation as the updated results were found 
to be very similar to those reported.  It has been confirmed that people with COPD die of 
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different causes, including but not exclusively from COPD mortality.  This outcome has 
previously been documented, however within Chapter 5, causes of mortality by disease 
severity were also examined and it was found that whilst mortality from all other major 
causes of mortality decreases, mortality from respiratory disease increases.  Whilst perhaps 
intuitive, from a modelling perspective these findings are important because they support 
and confirm the use of all-cause mortality as opposed to COPD mortality within economic 
models for the disease.  The study on diagnostic criteria for COPD challenged the use of 
the GOLD diagnostic criteria, suggesting the NICE criteria in its place, but confirms that 
applying the GOLD criteria does identify people at higher risk of mortality than a non 
COPD defined population.  The study supports the use of GOLD II diagnostic criteria to 
identify a COPD population, as has been used for the reporting in the BOLD study.  
Whilst challenging the sole reliance of OLS in order to develop a mapping algorithm, the 
study confirmed the view that increasingly complex structures may only slightly improve 
the predictive ability of the model: a simple model developed using OLS was selected on 
the grounds that a complex structure such as the two-part model only offered a 0.0003 
improvement in RMSE.  In the past, where internal validation has been conducted on the 
same dataset, the data have been split randomly.  This study dismissed this as an option in 
favour of a random split of the data for reasons previously described.  The mapping study 
was cautious in its conclusions about overly promoting the use of mapping, and confined it 
as a second best solution, which is a more conservative approach than others have made.  
The research within this thesis has confirmed the use of lung function as an important risk 
factor for COPD and the application of it in order to define disease severity groupings from 
which summary statistics can be compared.  The model developed in Chapter 8 rejected the 
use of lung function to define Markov states, in favour of a more flexible approach where 
lung function continually changes over time.  Previously symptoms have not been included 
within an economic model for COPD.  However, it has been seen that symptoms are an 
important component of disease and that therefore they should be captured within an 
economic model.  This study has shown that a regression based approach is feasible and 
can be used to model COPD. 
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As well as being the first COPD model to use a proxy for symptoms, this model improves 
upon other models in COPD by allowing for the incorporation of absolute changes to lung 
function, exacerbation rates and symptoms scores directly into the model.  In addition, the 
model has a flexible yet standard framework that permits the cost effectiveness of 
alternative COPD treatment strategies to be established for different patient populations, 
such as by disease severity, which is of use for decision-making. 
Another benefit of this new approach in terms of decision-making is that the model 
attempts to match the disease population more closely than traditional models have been 
able to do.   As a result, uncertainty associated with heterogeneity is reduced, whilst none 
of the functionality of more traditional approaches in dealing with parameter uncertainty is 
lost. 
From a theoretical standpoint, this model has opened up a new dimension in model 
building, with a strong focus on longitudinal data on the natural history of the disease to 
inform the model.  The model was built from the bottom up, based by an understanding of 
the epidemiology of the disease as a result of analyses conducted on a wealth of data.  The 
methods and principles used are generalisable to developing and modelling other disease 
areas, particularly to chronic conditions where there are large amounts of data, such as in 
arthritis and cancer.    
There is scope for further development of the research conducted and presented within this 
PhD thesis.  The list below represents those areas in which further research would be both 
of interest and of use, in the order in which they would be approached. 
The modelling chapter represents the area in which the most research would be beneficial, 
in particular, further development and validation of the individual regression equations that 
make up the economic model. This would be the priority for future research.  Chapter 6 
illustrates ways in which equations can be developed and validated.  Methods for further 
development of each regression equation would follow the methods used in Chapter 6 and 
have been described previously in Chapter 7.  For validation, the dataset could be split into 
two to form a fitting and a validation dataset, where fit would be determined using RMSE 
 296 
 
as used within Chapter 6.  An alternative approach for external validation is to compare the 
results from an alternative dataset.  For example by comparing the results from the equation 
predicting FEV1, or predicted survival probability from the Weibull model, which were 
developed within the MIDSPAN dataset, and validating them using the TORCH dataset. 
Once the prediction equations have been further developed and validated, in order to 
support an application of this model for example, within a HTA submission, then analysis 
of parameter uncertainty, involving the employment of the standard errors around the 
coefficients of each equation should be assessed.  
Further work arising from Chapter 6 would include an analysis of a complete case cohort to 
predict QALYs, based on: observed EQ-5D data, and predicted EQ-5D scores from 
employing the mapping equation.  The results of this analysis would be compared to the 
results presented in Chapter 6, in which QALYs were predicted using a dataset in which 
there were missing data. 
A variety of analyses could be conducted on the Renfrew/Paisley (MIDSPAN) dataset in 
order to further study COPD.  For example, research into different diagnostic criteria could 
be undertaken, particularly with regards to alternative diagnostic methods such as the 
Lower Limit of Normal classification, instead of FEV1/FVC.    
This thesis has contributed to knowledge in a number of ways.  The new mapping equation 
for COPD is the first to predict plausible results and can be used to generate EQ-5D utility 
where only data on the SRGQ were collected.  
The NICE COPD criteria identified a group at higher risk of all-cause and COPD mortality 
compared to the more frequently used GOLD diagnostic criteria, and importantly the 
resulting COPD population is much smaller when the NICE criteria are applied compared 
to when using the GOLD criteria.   
It has been shown that observational and RCT data can be combined in a meaningful and 
useful way in order to model disease.  The published economic models for COPD were 
critically appraised and the results used to inform the new economic model for COPD as 
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presented in Chapter 7.  It is thought that no other model for COPD exists where results 
from RCTs can be directly plugged into the model, such as an improvement in FEV1 of x 
ml per year.  The model developed in Chapter 7 is based on a series of regression equations 
that predict outcomes for key components of disease: lung function, respiratory symptoms 
and exacerbations.  This is an entirely new concept and approach for modelling COPD. 
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SGRQ (250) 
 
These questions are about how much chest trouble you have had over the past year. Please tick one box in 
response to each question. 
 
1. Over the last year, I have coughed: 
• Most days a week 
• Several days a week 
• A few days a week 
• Only with chest infections 
 
2. Over the last year, I have brought up phlegm (sputum): 
• Most days a week 
• Several days a week 
• A few days a week 
• Only with chest infections 
 
3. Over the last year, I have had shortness of breath: 
• Most days a week 
• Several days a week 
• A few days a week 
• Only with chest infections 
 
4. Over the last year, I have had attacks of wheezing: 
• Most days a week 
• Several days a week 
• A few days a week 
• Only with chest infections 
 
5. During the last year, how many severe or very bad unpleasant attacks of chest trouble have you had? 
• More than three attacks 
• 3 attacks 
• 2 attacks 
• 1 attack 
• No attacks 
 
6. How long did the worst attack of chest trouble last? (if you had no severe attacks go to question 7) 
• A week or more 
• 3 or more days 
• 1 or 2 days 
• Less than a day 
 
7. Over the last year, in an average week, how many good days (with little chest trouble) have you had? 
• None 
• 1 or 2 
• 3 or 4 
• Nearly every day 
• Every day 
 
8. Do you have a wheeze? 
• No 
• Yes 
 
      If yes, is it worse in the morning? 
• No 
• Yes 
 
9. How would you describe your chest condition? 
• The most important problem I have 
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• Causes me quite a lot of problems 
• Causes me a few problems 
• Causes no problem 
 
10.  If you have ever had paid employment: 
• My chest trouble made me stop work 
• My chest trouble interferes with my work 
• Or made me change my work 
• My chest trouble does not affect my work 
 
11. Questions about what activities usually make you feel breathless. Please tick one box in response to each question as 
it applies to you recently: 
a) Sitting or lying 
• True 
• False 
 
b) Getting washed or dressed 
• True 
• False 
 
c) Walking around the home 
• True 
• False 
 
d) Walking outside on the level 
• True 
• False 
 
e) Walking up a flight of stairs 
• True 
• False 
 
f)   Walking up hills 
• True 
• False 
 
g) Playing sports or games 
• True 
• False 
 
12. More questions about your cough and breathlessness. Please tick one box in response to each question as it applies to 
you recently: 
a) My cough hurts 
• True 
• False 
 
b) My cough makes me tired 
• True 
• False 
 
c) I get breathless when I talk 
• True 
• False 
 
d) I get breathless when I bend over 
• True 
• False 
 
e) My cough or breathing disturbs my sleep 
• True 
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• False 
 
f)    I get exhausted easily 
• True 
• False  
 
13. Questions about other effects your chest trouble may have on you. Please tick one box in response to each question 
as it applies to you recently: 
a) My cough or breathing is embarrassing in public 
• True 
• False 
 
b) I get afraid or panic when I cannot get my breath 
• True 
• False 
 
c) I feel that I am not in control of my chest problem 
• True 
• False 
 
d) I do not expect my chest to get any better 
• True 
• False 
 
e) I have become frail or an invalid because of my chest 
• True 
• False 
 
f)    Exercise is not safe for me 
• True 
• False  
 
g) Everything seems too much of an effort 
• True 
• False  
 
14. Questions about your medication (if you are not receiving medication for your chest trouble, go to question 15). 
Please tick one box in response to each question as it applies to you recently: 
a) My medication does not help me very much 
• True 
• False 
 
b) I get embarrassed using my medication in public 
• True 
• False 
 
c) I have unpleasant side effects from my medication  
• True 
• False 
 
d) My medication interferes with my life a lot 
• True 
• False 
 
15.  Questions about how activities may be affected by your breathing. Please tick one box in response to each question 
as it applies because of your breathing: 
 
a) I take a long time to get washed or dressed 
• True 
• False 
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b) I cannot take a bath or shower, or I take a long time 
• True 
• False 
 
c) I walk more slowly than other people, or I stop for rests 
• True 
• False 
 
d) Jobs such as housework take a long time, or I have to stop for rests 
• True 
• False 
 
e) If I walk up one flight of stairs, I have to go slowly or stop 
• True 
• False 
 
f)   If I hurry or walk fast, I have to stop or slow down 
• True 
• False 
 
g) My breathing makes it difficult to do things such as walk up hills, carry things up stairs, light gardening such as 
weeding, dance, play bowls or play golf. 
• True 
• False 
 
h) My breathing makes it difficult to do things such as carry heavy loads, dig the garden or shovel snow, jog or walk 
at 5 mile per hour, play tennis, or swim. 
• True 
• False 
 
i)  My breathing makes it difficult to do things such as very heavy manual work, run, cycle, swim fast or play 
competitive sports. 
• True 
• False 
 
16.  We would like to know how your chest trouble usually affects your daily life, Please tick one box for each question 
as it applies because of your chest trouble: 
 
a) I cannot play sports or games 
• True 
• False 
 
b) I cannot go out for entertainment or recreation 
• True 
• False 
 
c) I cannot go out of the house to do the shopping 
• True 
• False 
 
d) I cannot do housework 
• True 
• False 
 
e) I cannot move far from my bed or chair 
• True 
• False 
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Here is a list of other activities that your chest trouble may prevent you from doing (You do not have to tick 
these, they are just examples of ways in which breathlessness may affect you) 
• Going for walks or walking the dog 
• Doing things in the home or in the garden 
• Sexual intercourse 
• Going out to church, pub or place of entertainment 
• Going out in bad weather or into smokey rooms 
• Visiting family or friends or playing with the children 
  
Please write down any other important activities that your chest trouble may            
stop you doing: …………………………………………………………………. 
 
17. Tick the statement which you think best describes how your chest affects you. Please tick only one box: 
• It does not stop me doing anything I would like to do 
• It stops me doing one or two things I would like to do 
• It stops me doing most of the things I would like to do 
• It stops me doing everything I would like to do 
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EQ-5D (251) 
 
1. Mobility: 
 
• No problems walking about (1) 
• Some problems walking about (2) 
• Confined to bed (3) 
 
2. Self care 
• No problems with self-care (1) 
• Some problems washing or dressing myself (2) 
• Unable to wash or dress myself (3) 
 
 
3. Usual activities 
• No problems with performing usual activities (eg work, study, housework, family or leisure 
activities) (1) 
• Some problems with performing usual activities (2) 
• Unable to perform usual activities (3) 
 
4. Pain/discomfort 
• No pain or discomfort (1) 
• Moderate pain or discomfort (2) 
• Extreme pain or discomfort (3) 
 
5. Emotions 
• Not anxious or depressed (1) 
• Moderately anxious or depressed (2) 
• Extremely anxious or depressed (3) 
 310 
 
References 
(1)  Brines R, Thorne M. Clinical consensus on COPD. Respiratory Medicine 2007; 
COPD update 3:42-48. 
 
(2)  GOLD. Global Initiative for Chronic Obstructive Lung Disease: global strategy for 
the diagnosis, management, and prevention of chronic obstructive pulmonary 
disease.  2007.  
 
(3)  Fletcher C, Peto R. The natural history of chronic airflow obstruction. British 
Medical Journal 1977; 1:1645-1648. 
 
(4)  British Thoracic Society. BTS guidelines for the management of Chronic 
Obstructive Pulmonary Disease. Thorax 1997; 52(S1):S28. 
 
(5)  Celli BR, MacNee W, Augusti A, Anzueto A, Berg M, Buist AS et al. Standards for 
the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS 
position paper. European Respiratory Journal 2004; 23(932):946. 
 
(6)  Siafakas N, Vermeire P, Pride NB, Paoletti P, Gibson P, Howard JC et al. Optimal 
assessment and management of chronic obstructive pulmonary disease (COPD). 
European Respiratory Journal 1995; 8(1398):1420. 
 
(7)  National Collaborating Centre for Chronic Conditions for the National Institute of 
Health and Clinical Excellence. Chronic obstructive pulmonary disease. National 
clinical guideline on management of chronic obstructive pulmonary disease in 
adults in primary and secondary care. Thorax 2004; 59 Suppl 1:1-232. 
 
(8)  National Institute of Health and Clinical Excellence. Diagnosing COPD. Chronic 
obstructive pulmonary disease: national clinical guideline on management of 
chronic obstructive pulmonary disease in adults in primary and secondary care. 
Thorax 2004; 59:27-38. 
 
(9)  Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. 
European Respiratory Journal Suppl 2003; 41:46s-53s. 
 
(10)  Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA et al. Randomised, 
double blind, placebo controlled study of fluticasone propionate in patients with 
moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. 
British Medical Journal 2000; 320:1297-1303. 
 
(11)  European Respiratory Society, European Lung Foundation. Chronic Obstructive 
Pulmonary Disease. European Lung White Book. Huddersfield: ERSJ, 2003. 
 
 311 
 
(12)  Calverley PM, Bellamy D. The challenge of providing better care for patients with 
chronic obstructive pulmonary disease: the poor relation of airways obstruction? 
Thorax 2000; 55:78-82. 
 
(13)  Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T et al. 
COPD in Japan: The Nippon COPD Epidemiology study. Respirology 2004; 9(4). 
 
(14)  Zielinski J, Bednarek M, Gorecka D, Viegi G, Hurd SS, Fukuchi Y et al. Increasing 
COPD awareness. European Respiratory Journal 2006; 27:833-852. 
 
(15)  IMS disease analyzer-Mediplus UK. IMS, editor.  2006.  
 
(16)  Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for 
the future. The International Journal of COPD. 2008; 3(1): 71-88. 
 
(17)  Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 
year follow up study of the general population. Thorax 2006; 61:935-939. 
 
(18)  Mackay J, Eriksen M. The Tobacco Atlas.  World Health Organization. 2002.  
 
(19)  Anthonisen N, Skeans MA, Wise RA, Manfeda J, Kanner RE, Connett JE. The 
effects of a smoking cessation intervention on 14.5 year mortality. Annals of 
Internal Medicine 2005; 142(4):233-239. 
 
(20)  Murray Christopher JL, Lopez AD, Mathers CD, Stein C. The Global Burden of 
Disease 2000 project: aims, methods and data sources. World Health Organization.  
2001.   
 
(21)  US Department of Health and Human Services. Summary Health Statistics for US 
Adults: National Health Interview Survey, 2004.  2004.  
 
(22)  Department of Health. Improving Chronic Disease Management.[Online] 2004. 
Available from 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicy
AndGuidance/DH_4075214 [Accessed 18th July 2010].  
 
(23)  Calverley PM. The burden of obstructive lung disease in the UK - COPD and 
asthma. Thorax 1998; 53 Suppl 4. 
 
(24)  Britton M. The burden of COPD in the U.K.: results from the Confronting COPD 
survey. Respiratory Medicine 2003; 97 Suppl C:S71-S79. 
 
(25)  Guest JF. The annual cost of chronic obstructive pulmonary disease to the UK's 
National Health Service. Disease Management & Health Outcomes 1999; 5(2):93-
100. 
 
 312 
 
(26)  Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 
117(2 Supplement S):5-9. 
 
(27)  Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results 
from the Confronting COPD survey. Respiratory Medicine 2003; 97 Suppl C:S81-
S89. 
 
(28)  Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD 
survey. Respiratory Medicine 2003; 97 Suppl C:S61-S69. 
 
(29)  Wouters EF. The burden of COPD in The Netherlands: results from the Confronting 
COPD survey. Respiratory Medicine 2003; 97 Suppl C:S51-S59. 
 
(30)  Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the 
Confronting COPD survey. Respiratory Medicine 2003; 97 Suppl C:S43-S50. 
 
(31)  Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from 
the Confronting COPD survey. Respiratory Medicine 2003; 97 Suppl C:S23-S31. 
 
(32)  Piperno D, Huchon G, Pribil C, Boucot I, Similowski T. The burden of COPD in 
France: results from the Confronting COPD survey. Respiratory Medicine 2003; 
97(Suppl C):S33-S42. 
 
(33)  Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B et al. Costs 
of COPD in Sweden according to disease severity. Chest 2002; 122(6):1994-2002. 
 
(34)  Lung and Asthma Information Agency. Trends in COPD.  2003.  
 
(35)  Department of Health. NHS reference costs 2005-2006.  2006. London, Department 
of Health.  
 
(36)  Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C et al. The costs 
of exacerbations in chronic obstructive pulmonary disease (COPD). Respiratory 
Medicine 2002; 96(9):700-708. 
 
(37)  McGuire A, Irwin DE, Fenn P, Gray A, Anderson P, Lovering A et al. The excess 
cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in 
England and Wales. Value Health 2001; 4(5). 
 
(38)  Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for 
the future. International Journal of COPD 2008; 3(1):71-88. 
 
(39)  Pritchard C, Sculpher M. Productivity costs: principles and practice in economic 
evaluation. London: Office of Health Economics, 2000. 
 
 313 
 
(40)  Halpin DM. Health economics of chronic obstructive pulmonary disease. 
Proceedings of the American Thoracic Society. 2006; 3(3):227-233. 
 
(41)  Yelin E, Katz Patricia, Balmes J. Work life of persons with asthma, rhinits, and 
COPD: A study using a national, population based sample. Journal of Occupational 
Medicine and Toxicology 2006; 1(2). 
 
(42)  Calverley PM, Sondhi S. The burden of obstructive lung disease in the UK - COPD 
and Asthma. Thorax 1998; 53 Suppl 4:A83. 
 
(43)  Adelphi Group. Asthma/COPD DSP V USA & Europe COPD.  21-11-2006.  
 
(44)  British Thoracic Society standards of care subcommittee on pulmonary 
rehabilitation. Pulmonary rehabilitation. Thorax 2001; 56(827):834. 
 
(45)  Pelletier-Fleury N, Lanoe JL, Fleury B, Fardeau M. The cost of treating COPD 
patients with long-term oxygen therapy in a French population. Chest 1996; 
110:411-416. 
 
(46)  Meyers BF, Patterson GA. Chronic obstructive pulmonary disease v 10: 
Bullectomy, lung volume reduction surgery, and transplantation for patients with 
chronic obstructive pulmonary disease. Thorax 2003; 58:634-638. 
 
(47)  Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of 
health status for chronic airflow limitation. American Review of Respiratory 
Disease 1992; 145(1321):1327. 
 
(48)  EuroQol group. EuroQol - a new facility for the measurement of health-related 
quality of life. Health Policy 1990; 16:199-208. 
 
(49)  Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al. 
Salmeterol and Fluticasone proprotionate and survival in Chronic Obstructive 
Pulmonary Disease. New England Journal of Medicine 2007; 356(8):775-789. 
 
(50)  Calverley PM, Pauwels R, Vestbo, Jones P, Pride N, Gulsvik A et al. Combining 
salmeterol and fluticasone in the treatment of chronic obstructive pulmonary 
disease. Lancet 2003; 361:449-456. 
 
(51)  Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C et al. 
Clinical trial design considerations in assessing long term functional impacts of 
Tiotropium in COPD: the UPLIFT trial. COPD:Journal of Chronic Obstructive 
Pulmonary Disease 2004; 1(2):303-312. 
 
(52)  Vincken W, Van Noord JA, Greefhorst APM, Bantje ThA, Kesten S, Korducki L et 
al. Improved health outcomes in patients with COPD during 1 yr's treatment with 
tiotropium. European Respiratory Journal 2002; 19(209):216. 
 314 
 
 
(53)  Seemungal TA, Stockley R, Calverley PM, Hagan GW, Wedzicha JA. Investigating 
new standards for Prophylaxis in reduction of exacerbations - the INSPIRE study 
methodology. COPD 2007; 4(3):177-183. 
  
(54)  Aaron sD, Vandemheen K, Fergusson D, FitzGerald M, Maltais F, Bourbeau J et al. 
The Canadian Optimal Therapy of COPD Trial: Design, organization and patient 
recruitment. Canadian Respiratory Journal 2004; 11(8):581-585. 
 
(55)  Welte T, Hartman L, Polanowski T et al. Budesonide/formoterol added to 
tiotropium is well tolerated and reduces risk of severe exacerbations in COPD 
patients. Abstract presented at American Thoracic Society International Conference, 
San Diego, USA. May 2009 
 
(56)  Welte T, Miravitlles M, Hernandez P, Ericsson G, Peterson S, Polanowski T et al. 
Efficacy and tolerability of Budesonide/Formoterol added to Tiotropium in patients 
with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and 
Critical Care Medicine 2009; 180:741-750. 
 
(57)  Aaron SD, Vandemheen K, Fergusson D, Maltais F, Bourbeau J, Goldstein R et al. 
Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for 
treatment of chronic obstructive pulmonary disease. Annals of Internal Medicine 
2007; 146(545):555. 
 
(58)  Joint Formulary Committee (2007). British National Formulary. 54th edition. 
London: British Medical Association and Royal Pharmaceutical Society of Great 
Britain. British National Formulary.  
 
(59)  Department of Health. Improving Chronic Disease Management.[Online] 2004. 
Available from 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicy
AndGuidance/DH_4075214 [Accessed 18th July 2010].  
 
(60)  The Department of Health. Investing in general practice: the new general medical 
services contract.  30-12-0003. London, The NHS Confederation and the BMA.  
 
(61)  Dowson LJ, Yeung A, Allen MB. General practice spirometry in North 
Staffordshire. Monaldi Archives for Chest Disease 1999; 54(2):186-188. 
 
(62)  Ma Lwin A, McKinley RK. Management of COPD in Primary Care in 
Leicestershire. Primary Care Respiratory Journal 2005; 14(1):38-41. 
 
(63)  Cleland J, Mackenzue M, Small I, Douglas G, Gentles I. Management of COPD in 
primary care in North-East Scotland. Scottish Medical Journal 2006; 51(4):10-14. 
 
 315 
 
(64)  Dowson LJ, Yeung A, Allen MB. Most practices would use open access spirometry 
in hospitals. British Medical Journal 1998; 317(209). 
 
(65)  Jones RCM, Freegard S, Reeves M, Hanney K, Dobbs F. The role of the practice 
nurse in the management of chronic obstructive pulmonary disease (COPD). 
Primary Care Respiratory Journal 2001; 10:106-108. 
 
(66)  Bellamy D. Spirometry in Practice. 2nd Ed. 2005. London, British Thoracic Society 
(BTS) COPD Consortium.  
 
(67)  British Thoracic Society. Intermediate Care - Hospital-at-Home in Chronic 
Obstructive Pulmonary Disease. Thorax 2007; 63(3):200-210. 
 
(68)  Cotton MM, Bucknall CE, Dagg KD, Johnson MK, MacGregor G, Stewart C et al. 
Early discharge for patients with exacerbations of Chronic Obstructive Pulmonary 
Disease: a randomised controlled trial. Thorax 2000; 55:902-906. 
 
(69)  Mannino D. COPD: epidemiology, prevalence, morbidity and mortality and disease 
heterogeneity. Chest 2002; 121:121S-126S. 
 
(70)  Celli BR, Halbert RJ, Schau B. Population impact of different definitions of airway 
obstruction. European Respiratory Journal 2003; 22(268):273. 
 
(71)  American Thoracic Society. Standards for the diagnosis and care of patients with 
chronic obstructive pulmonary disease. American Journal of Respiratory and 
Critical Care Medicine 1995; 152(S77):S120. 
 
(72)  American Thoracic Society. Evaluation of impairment/disability secondary to 
respiratory disorders. American Review of Respiratory Disease 1986; 133:1205-
1209. 
 
(73)  Viegi G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L et al. Prevalence 
of airways obstruction in a general population. European Respiratory Society vs 
American Thoracic Society Definition. Chest 2000; 117:339S-345S. 
 
(74)  Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E et al. 
Not 15 but 50% of smokers develop COPD? - report from the obstructive lung 
disease in northern Sweden studies. Respiratory Medicine 2003; 97:115-122. 
 
(75)  Menezes AM, Macedo S, Gigante DP, Costa JD, Olinto MT, Fiss E et al. 
Prevalence and risk factors for chronic obstructive pulmonary disease according to 
symptoms and spirometry. COPD 2004; 1(2):173-179. 
 
(76)  Shirtcliffe P, Weatherall M, Marsh S, Travers J, Hansell A, McNaughton A et al. 
COPD prevalence in a random population survey: a matter of definition. European 
Respiratory Journal 2007; 30(232):239. 
 316 
 
 
(77)  Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki T, Siafakas N. Prevalence 
of COPD in Greece. Chest 2004; 125(892):900. 
 
(78)  Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: 
what is the true burden of disease? Chest 2003; 123:1684-1692. 
 
(79)  Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AMB et al. The 
Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and design. 
COPD 2005; 2(2). 
 
(80)  Buist SA, McBurnie MA, Vollmer WM, Gillespie S. International variation in the 
prevalence of COPD (The BOLD Study): a population-based prevalence study. The 
Lancet 2007; 370(741):750. 
 
(81)  Nizankowska-Mogilnicka E, Mejza F, Buist AS, Vollmer WM. Prevalence of 
COPD and tobacco smoking in Malopolska region-results from the BOLD study in 
Poland. Polskie Archiwum Medycyny Wewnetrznej 2007; 117(9):402-409. 
 
(82)  Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, Studnicka M, Jensen RL et 
al. COPD prevalence in Salzburg, Austria. Results from the Burden of Obstructive 
Lung Disease (BOLD) Study. Chest 2007; 131:29-36. 
 
(83)  NHS. NHS core principles. [online] 2009. Available from 
http://www.nhs.uk/NHSEngland/thenhs [Accessed 18th July 2010]. 
 
(84)  Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for 
the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford University 
Press, 2005. 
 
(85)  ISPOR. Pharmacoeconomic guidelines around the world. [Online] 2007. Available 
from http://www.ispor.org/peguidelines/index.asp . [Accesssed 18th July 2010].  
 
(86)  National Institute of Health and Clinical Excellence. A guide to NICE. [Online] 
2005. Available from 
http://www.nice.org.uk/nicemedia/pdf/NewguidetoNICEApril2005.pdf [Accessed 
18th July 2010].  
 
(87)  National Institute for Health and Clinical Excellence. Guide to the methods of 
technology appraisal. 2008. London, National Institute for Health and Clinical 
Excellence.  
 
(88)  Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for 
decision-analytic modelling in Health Technology Assessment: A review and 
consolidation of quality assessment. Pharmacoeconomics 2006; 24(4):355-371. 
 
 317 
 
(89)  Drummond M, Sculpher M. Common Methodological Flaws in Economic 
Evaluations. Medical Care 2005; 43(7(S)):II-5-II-14. 
 
(90)  Sculpher M, Claxton K, Drummond M, McCabe C. Whither trial-based economic 
evaluation for health care decision making? Health Economics 2006;(15):677-687. 
 
(91)  Briggs AH, O'Brien BJ. The death of cost-minimisation analysis? Health 
Economics 2001; 10:179-184. 
 
(92)  Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic 
Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD 
patients in different countries. Value Health 2005; 8(1):32-46. 
 
(93)  Jones PW Wilson KS. Cost-effectiveness of salmeterol in patients with chronic 
obstructive pulmonary disease: an economic evaluation. Respiratory Medicine 
2003; 97(1):20-26. 
 
(94)  Gold M, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and 
Medicine. New York: Oxford University Press, 1996. 
 
(95)  National Institute for Clinical Excellence. Guide to the Methods of Technology 
Appraisal.  2004. London, National Institute for Clinical Excellence.  
 
(96)  Briggs AH, Sculpher M, Claxton K. Decision Modelling for Health Economic 
Evaluation. First ed. Oxford: Oxford University Press, 2006. 
 
(97)  Jubran A, Gross N, Ramsdell J, Simonian R, Schuttenhelm K. Comparative cost-
effectiveness analysis of theophylline and ipratropium bromide in chronic 
obstructive pulmonary disease. A three-centre study. Chest 1993; 103:678-684. 
 
(98)  Le Lay A, Despiegel N, Francois C, Duru G. Can discrete event simulation be of 
use in modelling major depression? Cost Effectiveness & Resource Allocation 
2006; 4(19). 
 
(99)  Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. 
New York: Oxford University Press Inc, 2007. 
 
(100)  Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health 
and medical practices. The New England Journal of Medicine 1977; 296(13):716-
721. 
 
(101)  Sculpher MJ. The role and estimation of productivity costs in economic evaluation. 
In: Drummond MF, McGuire A, editors. Theory and practice of economic 
evaluation in health. Oxford: Oxford University Press, 2001. 
 
 318 
 
(102)  Sullivan SD. The burden of illness and economic evaluation for COPD. European 
Respiratory Journal 2003; 22(Suppl 43):7S-8S. 
 
(103)  Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P et al. Optimal 
assessment and management of Chronic Obstructive Pulmonary Disease (COPD). 
European Respiratory Journal 1995; 8:1398-1420. 
 
(104)  Feeny D, Furlong W, Boyle M, Torrance G. Multi-attribute health status 
classifications systems: health utilities index. Pharmacoeconomics 1995; 
7(490):502. 
 
(105)  Brazier J. The SF-36 Health Survey Questionnaire - a tool for economists. Health 
Economics 1993; 2:213-215. 
 
(106)  Ware JE, Kosinski M, Keller SD. A 12 item short-form health survey: construction 
of scales and preliminary tests of reliability and validity. Medical Care 1996; 
34:220-233. 
 
(107)  Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of 
health from the SF-36. Journal of Health Economics 2002; 21:271-292. 
 
(108)  Goldberg DP. Manual of the general health questionnaire. Windsor, England: NFER 
Publishing, 1978. 
 
(109)  Nelson EC, Landgraf JM, Hays RD, Wasson JH, Kirk JW. The functional status of 
patients: how can it be measured in physicians' offices? Medical Care 1990; 
28(12):1111-1126. 
 
(110)  Hunt SM, McEwan J. The development of a subjective health indicator. Sociology 
of Health and Illness 1983; 2:231-245. 
 
(111)  Kaplan RM, Anderson J. A general health policy model: update and application. 
Health Services Research 1988; 23:203-235. 
 
(112)  Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: 
development and final revision of a health status measure. Medical Care 1981; 
19(8):787-805. 
 
(113)  Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). 
Medical Care 1992; 30(6):473-483. 
 
(114)  Larson JL, Kapella MC, Wirtz S, Covey MK, Berry J. Reliability and validity of the 
functional performance inventory in patients with moderate to severe chronic 
obstructive pulmonary disease. Journal of Nursing Measurement 1998; 6(1):55-73. 
 
 319 
 
(115)  Guyatt G, Berman LB, Townsend M. A measure of quality of life for clinical trials 
in chronic lung disease. Thorax 1987; 42:773-778. 
 
(116)  Hyland ME, Bott J, Singh S, Kenyon CAP. Domains, constructs and the 
development of the breathing problems questionnaire. Quality of Life Research 
1994; 3(4):245-256. 
 
(117)  Tu SP, NcDonell MB, Spertus JA, Steele BG, Fihn SD. A new self-administered 
questionnaire to monitor health-related quality of life in patients with COPD. Chest 
1997; 112:614-622. 
 
(118)  Piccirillo JF, Merritt MG, Richards ML. Psychometric and clinimetric validity of 
the 20 item sino-nasal outcome test (SNOT-20). Otolaryngology - head and neck 
surgery 2002; 126:41-47. 
 
(119)  Fletcher C. Standardised questionnaire on respiratory symptoms: a statement 
prepared and approved by the MRC Committee on the aetiology of chronic 
bronchitis (MRC breathlessness score). British Medical Journal 1960; 2:1665. 
 
(120)  Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: 
contents, inter-observer agreement, and physiologic correlates of two new clinical 
indexes. Chest 1984; 85(751):758. 
 
(121)  Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of 
health status for Chronic Airflow Limitation. The American review of respiratory 
disease 1992; 145(6):1321-1327. 
 
(122)  Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome 
measures for use in clinical trials. Vol 2 No 14. 1998. Basingstoke, Core Research 
on behalf of The National Coordinating Centre for Health Technology Assessment. 
Health Technology Assessment.  
 
(123)  von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. 
Princeton,NJ: Princeton University Press, 1947. 
 
(124)  Garber AM. Advances in cost-effectiveness analysis of health interventions. In: 
Culyer A, Newhouse J, editors. Handbook of Health Economics. Amsterdam: 
Elsevier BV, 2000: 181-221. 
 
(125)  Claxton K, Sculpher M, McCabe C, Briggs AH, Akehurst R, Buxton M et al. 
Probabilistic sensitivity analysis for NICE technology assessment: not an optional 
extra. Health Economics 2005; 14:339-347. 
 
(126)  Briggs AH. Probabilistic Analysis of Cost-Effectiveness odels: Choosing between 
Treatment Strategies for Gastroesophageal Reflux Disease. Medical Decision 
Making 2002; 22:290-308. 
 320 
 
 
(127)  Baker CB, Johnsrud MT, Lynn Crismon JM, Rosenheck RA, Woods SW. 
Quantitative analysis of sponsorship bias in economic studies of antidepressants. 
British Journal of Psychiatry 2003; 183:498-506. 
 
(128)  Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D et al. Bias in 
published cost effectiveness studies: systematic review. British Medical Journal 
2006; 332:699-703. 
 
(129)  Friedman MSCM. Pharmacoeconomic evaluation of a combination of ipratropium 
plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 
1999; 115(3):635-641. 
 
(130)  Ramsey SD, Patrick DL, Albert RK, Larson EB, Wood DE. The cost-effectiveness 
of lung transplantation. A pilot study. University of Washington medical centre lung 
transplantation study group. Chest 1995; 108:1594-1601. 
 
(131)  Rutten-van Molken M, Van Doorslaer EK, Jansen MC, Kerstjens HA, Rutten FF. 
Costs and effects of inhaled corticosteroids and bronchodilators in asthma and 
chronic obstructive pulmonary disease. American Journal of Respiratory and 
Critical Care Medicine 1995; 151(4):975-982. 
 
(132)  Al MJ, Koopmanschap NA, van Enckevort PJ, Geertsma A, Van der Bij W, de Boer 
WJ et al. Cost-effectiveness of lung transplantation in the Netherlands. Chest 1998; 
113:124-130. 
 
(133)  van den Boom GR. The cost effectiveness of early treatment with fluticasone 
propionate 250 microg twice a day in subjects with obstructive airway disease. 
Results of the DIMCA program. American Journal of Respiratory and Critical Care 
Medicine 2001; 164(11):2057-2066. 
 
(134)  Anyanwu AC, McGuire A, Rogers CA, Murday AJ. An economic evaluation of 
lung transplantation. The Journal of Thoracic and Cardiovascular Surgery 2002; 
123(3):411-420. 
 
(135)  Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE et al. Cost 
effectiveness of lung-volume-reduction surgery for patients with severe 
emphysema. New England Journal of Medicine 2003; 348(21):2092-2102. 
 
(136)  Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the 
treatment of chronic obstructive pulmonary disease: a double-blind randomized, 
placebo-controlled trial. Respiratory Medicine 2003; 97(3):212-220. 
 
(137)  Hogan TJ, Geddes R, Gonzalez E. An economic assessment of inhaled formoterol 
dry powder versus ipratropium bromide pressurized metered dose inhaler in the 
 321 
 
treatment of chronic obstructive pulmonary disease. Clinical Therapeutics 2003; 
25(1):285-297. 
 
(138)  Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson GC et al. A 
Computer Simulation Model of the Natural History and Economic Impact of 
Chronic Obstructive Pulmonary Disease. Value in Health 2004; 7(2). 
 
(139)  Groen H, van der BW, Koeter GH, TenVergert EM. Cost-effectiveness of lung 
transplantation in relation to type of end-stage pulmonary disease. Am J Transplant 
2004; 4(7):1155-1162. 
 
(140)  Oostenbrink JB, Rutten-van Molken MPMH, Al MJ, Van Noord JA, Vincken W. 
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic 
obstructive pulmonary disease. European Respiratory Journal 2004; 23(2). 
 
(141)  Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids 
for chronic obstructive pulmonary disease according to disease severity. American 
Journal of Medicine 2004; 116(5):325-331. 
 
(142)  Gagnon YM, Levy AR, Spencer MD, Hurley JS, Frost FJ, Mapel DW et al. 
Economic evaluation of treating chronic obstructive pulmonary disease with inhaled 
corticosteroids and long-acting beta2-agonists in a health maintenance organization. 
Respiratory Medicine 2005; 99(12):1534-1545. 
 
(143)  Lofdahl CG, Ericsson A, Svensson K, Andreasson E. Cost effectiveness of 
budesonide/formoterol in a single inhaler for COPD compared with each 
monocomponent used alone. Pharmacoeconomics 2005; 23(4):365-375. 
 
(144)  Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic 
model to assess the cost-effectiveness of treatment interventions for chronic 
obstructive pulmonary disease. Pharmacoeconomics 2005; 23(6):619-637. 
 
(145)  Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS. 
Estimating the cost-effectiveness of fluticasone propionate for treating chronic 
obstructive pulmonary disease in the presence of missing data. Value in Health 
2006; 9(4):227-235. 
 
(146)  Maniadakis N, Tzanakis N, Fragoulakis V, Hatzikou M, Siafakas N. Economic 
evaluation of tiotropium and salmeterol in the treatment of chronic obstructive 
pulmonary disease (COPD) in Greece. Current Medical Reseacrh Opinion 2006; 
22(8). 
 
(147)  Ramsey SD, Shroyer AL, Sullivan SD, Wood DE. Updated evaluation of the cost-
effectiveness of Lung Volume Reduction Surgery. Chest 2007; 131(3):823-832. 
 
 322 
 
(148)  Rutten-van Molken MPMH, Oostenbrink JB, Miravitlles M, Monz BU. Modelling 
the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the 
treatment of chronic obstructive pulmonary disease in Spain. European Journal of 
Internal Medicine 2007; 8:123-135. 
 
(149)  Chuck A, Jacobs P, Mayers I, Marciniuk D. Cost-effectiveness of combination 
therapy for Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal; 
2008; 15(8):437-443. 
 
(150)  Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R et al. 
Cost effectiveness of fluticasone propionate/ salmeterol (500/50mg) in the treatment 
of COPD. Respiratory Medicine 2008; 103:12-21. 
 
(151)  Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL 
et al. Cost effectiveness of therapy with combinations of long acting 
bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008; 63:962-
967. 
 
(152)  Blough DK, Ramsey S, Sullivan SD, Yusen R. The impact of using different 
imputational methods for missing quality of life scores on the estimation of the cost 
effectiveness of lung volume reduction surgery. Health Economics 2009; 18:91-
101. 
 
(153)  Briggs A, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW et al. 
Is treatment with ICS and LABA cost-effective for COPD? Multinational economic 
analysis of the TORCH study. European Respiratory Journal 2010; 35: 532-539 
 
(154)  Oba Y. Cost effectiveness of long term oxygen therapy for Chronic Obstructive 
Pulmonary Disease. The American Journal of Managed Care 2009; 15(2):97-104. 
 
(155)  Dahl R, Greefhorst LA, Nowak D. Inhaled formoterol dry powder versus 
ipratropium bromide in chronic obstructive pulmonary disease. American Journal of 
Respiratory and Critical Care Medicine 2001; 164(5):778-784. 
 
(156)  Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete 
follow-up data. Biometrics 1997; 53(2):419-434. 
 
(157)  Sin DD, Stafinski T, Ng YC. The impact of chronic obstructive pulmonary disease 
on work loss in the United States. Critical Care Medicine 2002; 165:704-707. 
 
(158)  Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision tress 
with multiple branches: the use of the Dirichlet distribution in a Bayesian 
framework. Medical Decision Making 2003; 23:341-350. 
 
 323 
 
(159)  Calverley PM, Pauwels R, Vestbo, Jones P, Pride N, Gulsvik A et al. Combined 
salmeterol and fluticasone in the treatment of chronic obstructive pulmonary 
disease: a randomised controlled trial. Lancet 2003; 361:449-456. 
 
(160)  Oba Y. Cost-Effectiveness of salmeterol, fluticasone and combination therapy for 
COPD. American Journal of Managed Care 2009; 15(4):226-232. 
 
(161)  Rutten-van Molken M, Lee TA, Authors FN, Lee TA. Economic modelling in 
chronic obstructive pulmonary disease. Proceedings of the American Thoracic 
Society 2006; 3(7):630-634. 
 
(162)  Baltussen R, Leidl R, Ament A. Real World Designs in Economic Evaluation: 
Bridging the gap between Clinical Research and Policy-Making. 
Pharmacoeconomics 1999; 16(5 (1)):449-458. 
 
(163)  Halpin DM, Authors FN. Health economics of chronic obstructive pulmonary 
disease. Proceedings of the American Thoracic Society 2006; 3(3):227-233. 
 
(164)  Claxton K, Sculpher M, Drummond M. A rational framework for decision making 
by the National Institute for Clinical Excellence (NICE). The Lancet 2002; 
360:711-715. 
 
(165)  Gross N. Outcome measures for COPD Treatments: A critical Evaluation. COPD 
2004; 1(1):41-57. 
 
(166)  Hole DJ, Watt GCM, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. 
Impaired lung function and mortality risk in men and women: findings from the 
Renfrew and Paisley prospective population study. British Medical Journal 1996; 
313:711-715. 
 
(167)  Hart CL, MacKinnon PL, Watt GCM, Upton MN, McConnachie A. The Midspan 
studies. International Journal of Epidemiology 2005; 34:28-34. 
 
(168)  GPRD Division of the Medicines and Healthcare products Regulatory Agency 
(MHRA). The General Practice Research Database. www.gprd.com . 2007.  
 
(169)  The University of Nottingham, EMIS National User Group, EMIS. Qresearch. 
www.qresearch.org . 2007.  
 
(170)  THIN.  The Health Improvement Network website. [Online]. Available from: 
www.thin-uk.com [Accessed 15th June 2010].  2010.  
 
(171)  IMS. A brief description of IMS databases. http://research.imhhealth.com/databases 
. 2002.  
 
 324 
 
(172)  Raza Z, Holdworth RJ, McCollum PT. Accuracy of the recording of operative 
events by the Scottish morbidity record 1 (SMR1) for a teaching hospital vascular 
unit. Journal of the Royal College of Surgeons of Edinburgh 1999; 44(96):98. 
 
(173)  The Information Centre for health and social care by the National Centre for Health 
Outcomes Development. Clinical and Health Outcomes Knowledge base: Scottish 
Morbidity Record 1. [Online]. Available from: www.nchod.nhs.uk . [Accessed on 
24th September 2007]. 2003  
 
(174)  The Information Centre for health and social care by the National Centre for Health 
Outcomes Development. Clinical and Health Outcomes Knowledge base: Hospital 
Episode Statistics.  [Online]. Available from: www.nchod.nhs.uk . [Accessed on 
24th September 2007].2003.  
 
(175)  North East Public Health Observatory. Hospital Episode Statistics. [Online]. 
Available from: www.nepho.org.uk . [Accessed on 24th September 2007]. 2004.  
 
(176)  ISD Scotland. The Scottish Health Surveys. [Online]. Available from: 
www.isdscotland.org. [Accessed on 24th September 2007]. 2006.  
 
(177)  General Register Office. Classification of Occupations. London: HMSO, 1966. 
 
(178)  Hanlon P, Walsh D, Whyte BW, Scott SN, Lightbody P, Gilhooly LM. Hospital use 
by an ageing cohort: an investigation into the association between biological, 
behavioural and social risk markers and subsequent hospital utilization. Journal of 
Public Health Medicine 1998; 20(4):467-476. 
 
(179)  Predicted Forced Expiratory Volume in 1 second (FEV1). [Online]. Available from: 
http://www.medal.org/visitor/www%5CActive%5Cch8%5Cch8.01%5Cch8.01.01.a
spx . [Accessed on 10th October 2007]. 2008.  
 
(180)  Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R et al. 
Interpretative strategies for lung function tests. European Respiratory Journal 26, 
948-968. 2005.  
 
(181)  Stocks J, Quanjer PH. Reference values for residual volume, functional residual 
capacity and total lung capacity. ATS workshop on lung volume measurements. 
Official statement of the European Respiratory Society. European Respiratory 
Journal 8, 492-506. 1995.  
 
 
(182)  Stata Statistical Software: Release 10.0. College Station, TX: StataCorp LP, 2008. 
 
(183)  Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. 
Journal of the American Statistical Association 1958; 53(282):457-481. 
 
 325 
 
(184)  Ahmed FE, Vos PW, Holbert D. Modeling survival in colon cancer: a 
methodological review. Molecular Cancer 2007; 6(15). 
 
(185)  Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part 1: basic 
concepts and first analyses. British Journal of Cancer 2003; 89:232-238. 
 
(186)  Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-
up of a survey: choice of the time scale. American Journal of Epidemiology 1997; 
145:72-80. 
 
(187)  Kirkwood BR, Sterne JAC. Essential Medical Statistics. 2nd ed. Blackwell 
Publishing, 2006. 
 
(188)  Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: 
multivariate data analysis - an introduction to concepts and methods. British Journal 
of Cancer 2003; 89:431-436. 
 
(189)  Kay R. An explanation of the hazard ratio. Pharmaceutical Statistics 2004; 3:295-
297. 
 
(190)  Concato J, Feinstein AR, Holford TR. The risk of determining risk with 
multivariable models. Annals of Internal Medicine 1993; 118(201):210. 
 
(191)  Shepherd BE. The cost of checking proportional hazards. Statistics in Medicine 
208; 27:1248-1260. 
 
(192)  Schoenfeld D. Partial residuals for the proportional hazards regression  model. 
Biometrika 1982; 69(1):239-241. 
 
(193)  Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part III: 
multivariate data analysis-choosing a model and assessing its adequacy and fit. 
British Journal of Cancer 2003; 89:605-611. 
 
(194)  Christensen E. Multivariate survival analysis using Cox's regression model. 
Hepatology 1987; 7(6):1346-1358. 
 
(195)  Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG et al. 
FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of 
age. Chest 2006; 130:200-206. 
 
(196)  GOLD. Global Initiative for Chronic Obstructive Lung Disease home page. 
[Online]. Available from: http://www.goldcopd.com. [Accessed on 28th August 
2008]. 2008  
 
(197)  Lindberg A, Jonsson A-C, Ronmark E, Lundgren R, Larsson LG, Lundback B. 
Prevalence of Chronic Obstructive Pulmonary Disease according to BTS, ERS, 
 326 
 
GOLD and ATS criteria in relation to Doctor's diagnosis, age, gender, and smoking 
habits. Respiration 2005; 72:471-479. 
 
(198)  Lindberg A, Bjerk-Backlund A, Ronmark E, Larsson LG, Lundback B. Prevalence 
and under diagnosis of COPD by disease severity and the attributable fraction of 
smoking. Report from the Obstructive Lung Disease in Northern Sweden studies. 
Respiratory Medicine 2006; 100:264-272. 
  
(199)  Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and 
mortality in the United States: Examination Survey follow up study data from the 
First National Health and Nutrition. Thorax 2003; 58:388-393. 
 
(200)  Currie GP, Legg JS. Diagnosis. British Medical Journal 2006; 332:1261-1263. 
 
(201)  Starkie HJ, Briggs AH. OHE Commission on NHS Productivity. Outcome measures 
for the assessment of treatment results in Chronic Obstructive Pulmonary Disease.  
2007.  
 
(202)  Rodriguez-Roisin R, Authors FN. Toward a consensus definition for COPD 
exacerbations. Chest 2000; 117(5 Suppl 2):398S-401S. 
 
(203)  Rutten van-Molken MP, Feenstra TL, Authors FN, Feenstra TL. The burden of 
asthma and chronic obstructive pulmonary disease: data from The Netherlands. 
Pharmacoeconomics 2001; 19 Suppl 2:1-6. 
 
(204)  Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of 
causes of death from COPD. European Respiratory Journal. 2006; 28:781-785. 
 
(205)  Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: 
results from a United Kingdom national questionnaire survey. British Medical 
Journal 1998; 316:736-741. 
 
(206)  Kind P, Hardman G, Leese B. Measuring health status: information for primary care 
decision making. Health Policy 2005; 71:303-313. 
 
(207)  Dolan P. Modelling valuations for EuroQol health states. Medical Care 1997; 
35(11):1095-1108. 
 
(208)  Williams A. The measurement and valuation of health: a chronicle.  1995. York, 
Centre for Health Economics.  
 
(209)  Carpenter J, Kenward M. Missing Data. [Online]. Available from: 
www.missingdata.org.uk . [Accessed on 4th February 2009].2009.  
 
(210)  Wooldridge JM. Introductory Econometrics: a modern approach. 2E ed. Ohio: 
South western, 2003. 
 327 
 
 
(211)  StataCorp. STATA base reference manual A-J. Release 9 ed. 2005. 
 
(212)  Manning WG, Mullaly J. Estimating log models: to transform or not to transform? 
Journal of Health Economics 2001; 20:461-494. 
 
(213)  Pearson ES, Please NW. Relationship between the shape of population distribution 
and the robustness of four simple test statistics. Biometrika 1975; 62:223-241. 
 
(214)  Pregibon D. Goodness of link tests for generalized linear models. Applied Statistics 
1980; 29(15):24. 
 
(215)  Hosmer Jn.D.W, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: 
John Wiley & Sons, Inc, 2000. 
 
(216)  Meguro M, Jones PW. Elicitation of utility weights for a COPD specific preference 
measure. [unpublished]  2007.  
 
(217)  Vardeva K, Spencer MD, Punekar Y. Development of preference based EQ-5D 
utility values for the St George's Respiratory Questionnaire - chronic obstructive 
pulmonary disease (SGRQ-COPD). Value in Health 10[6], A311. 2007.  
 
(218)  Brazier J, Yang Y, Tsuchiya A. Review of methods for mapping between condition 
specific measures onto generic measures of health.  2007. www.ohe.org, OHE 
Commission.  
 
(219)  Brazier J, Yang Y, Tsuchiya A, Rowen D. A review of studies mapping (or cross 
walking) non-preference based measures of health to generic preference-based 
measures. European Journal of Health Economics 2009; 11(2): 215-225. 
 
(220)  Wu E, Mulani P, Farrell MH, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to 
patient health status measured by EQ-5D metastatic hormone-refractory prostate 
cancer patients. Value in Health 2007; 10(5):408-414. 
 
(221)  Yang M, Dubois D, Kosinski M, Sun X, Gajria K. Mapping MOS Sleep Scale 
scores to SF-6D utility index. Current Medical Research Opinion 2007; 23(9):2269-
2282. 
 
(222)  Buxton MJ, Lacey LA, Feagan BG, Niecko T, Miller DW, Townsend RJ. Mapping 
from disease-specific measures to utility: an analysis of the relationships between 
the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index 
in Crohn's disease and measures of utility. Value in Health 2007; 10(3):214-220. 
 
(223)  Grootendorst P, Marshall D, Pericak D, Bellamy N, Feeny D, Torrance G. A Model 
to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index 
 328 
 
Scores in Patients with Osteoarthritis of the Knee. Journal of Rheumatology 2007; 
34:534-542. 
 
(224)  Bansback N, Marra CTA, Anis A, Guh D, Hammond T, Brazier J. Using the Health 
Assessment Questionnaire to Estimate Preference-Based Single Indices in Patients 
With Rheumatoid Arthritis. Arthritis & Rheumatism (Arthritis Care & Research) 
2007;(963):971. 
 
(225)  Brennan DS, Spencer AJ. Mapping oral health realted quality of life to generic 
health state values. BMC Health Services Research 2006; 6(Art. no. 96). 
 
(226)  Sullivan P, Ghushchyan V. Mapping the EQ-5D Index from the SF-12: US General 
Population Preferences in a Nationally Representative Sample. Medical Decision 
Making 2006; 26(4):401-409. 
 
(227)  Longworth L, Buxton MJ, Sculpher M, Smith DH. Estimating utility data from 
clinical indicators for patients with stable angina. European Journal of Health 
Economics 2005; 6:347-353. 
 
(228)  Franks P, Lubetkin EL, Gold MR, Tancredi DJ, Jia H. Mapping the SF-12 to the 
EuroQol EQ-5D Index in a National US Sample. Medical Decision Making 2004; 
24(3):247-254. 
 
(229)  Brazier J, Kolotkin RD, Crosby RD, Williams R. Estimating a Preference-Based 
Single Index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) 
Instrument from the SF-6D. Value in Health 2004; 7(4):490-498. 
 
(230)  Lawrence WF, Fleishman JA. Predicting EuroQoL EQ-5D Preference Scores from 
the SF-12 Health Survey in a Nationally Representative Sample. Medical Decision 
Making 2004; 24(2):160-169. 
 
(231)  Sengupta N, Nichol MB, Wu J, Globe D. Mapping the SF-12 to the HUI3 and VAS 
in a managed care population. Medical Care 2004; 42(9):927-937. 
 
(232)  Franks P, Lubetkin EL, Gold MR, Tancredi DJ. Mapping the SF-12 to preference-
based instruments: convergent validity in a low-income, minority population. 
Medical Care 2003; 41(11):1277-1283. 
 
(233)  Nichol NB, Sengupta N, Globe D. Evaluating Quality-Adjusted Life Years. Medical 
Decision Making 2001; 21(2):105-112. 
 
(234)  Brazier J, Yang Y, Tsuchiya A, Rowen D. A review of studies mapping (or cross 
walking) non-preference based measures of health to generic preference-based 
measures. The European Journal of Health Economics 2010; 11(2):215-225. 
 
 329 
 
(235)  Lachenbruch PA. Analysis of data with excess zeros. Statistical Methods in Medical 
Research 2002; 11:297-302. 
 
(236)  Lipscomb J, Ancukiewicz M, Parmigiani G, Hasselblad V, Samsa G, Matchar DB. 
A comparison of alternative models applied to stroke. Medical Decision Making 
1998; 18(2):S39-S66. 
 
(237)  McKenzie L, van der Pol M. Mapping the EORTC QLQ C-30 onto the EQ-5D 
Instrument: The potential to estimate QALYs without Generic Preference Data. 
Value in Health 2009; 12(1):167-171. 
 
(238)  Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJH, Pederson SE et al. 
Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. 
Allergy: European Journal of Allergy and Clinical Immunology 2006; 61(5):531-
536. 
 
(239)  Briggs A, Glick HA, Lozano-Ortega G, Spencer M, Calverley PM, Jones PW et al. 
Is treatment with ICS and LABA cost-effective for COPD? Multinational economic 
analysis of the TORCH study. European Respiratory Journal 2010; 35(532):539. 
 
(240)  Halpin DM. Health economics of chronic obstructive pulmonary disease. 
Proceedings of the American Thoracic Society 2006; 3(3):227-233. 
 
(241)  Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between 
exacerbation frequency and lung function decline in Chronic Obstructive 
Pulmonary Disease. Thorax 2002; 57(847):852. 
 
(242)  Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Lois Segu 
J. Factors associated with increased risk of exacerbation and hospital admission in a 
cohort of ambulatory COPD patients: a multiple logistic regression anlaysis. 
Respiration 2000; 67:495-501. 
 
(243)  Joint Health Surveys Unit. Health Survey for England 2007 Latest Trends.  16-12-
2008.  
 
(244)  TORCH steering Committee. TORCH Study report. GlaxoSmithKline  2006.  
 
(245)  Calverley PM, Rabe KF, Goehring U-M, Kristiansen S, Fabbri LM, Martinez F. 
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised 
clinical trials. The Lancet 2009; 374:685-694. 
 
(246)  Celli B, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW et al. 
Effect of pharmacotherapy on rate of decline of lung function in Chronic 
Obstructive Pulmonary Disease. American Journal of respiratory and Critical Care 
Medicine 2008; 178:332-338. 
 
 330 
 
(247)  Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, 
Martinez FJ et al. Roflumilast on moderate to severe chronic obstructive pulmonary 
disease treated with long acting bronchodilators: two randomised clinical trials. The 
Lancet 2009; 374:695-703. 
 
(248)  Calverley PM, Pauwels R, Vestbo, Jones P, Pride N, Gulsvik A et al. Combined 
salmeterol and fluticasone in the treatment of chronic obsructive pulmonary disease: 
a randomised controlled trial. Lancet 2003; 361:449-456. 
 
(249) National Clinical Guideline Centre. (2010) Chronic obstructive pulmonary disease: 
management of chronic obstructive pulmonary disease in adults in primary and 
secondary care. London: National Clinical Guideline Centre. Available from: 
http://guidance.nice.org.uk/CG101/Guidance/pdf/English 
 
(250)  Health Status Research Team. St George's respiratory Questionnaire population 
survey.[Online] 2007. Available from: www.healthstatus.sgul.ac.uk . [Accessed on 
20th July 2010].  
 
(251)  Brazier J, Roberts J, Tsuchiya A, Busschbach J et al. A comparison of the EQ-5D 
and SF-6D across seven patient groups. Health Economics 2004; 13(9):873-884. 
 
 
